
<html lang="en"     class="pb-page"  data-request-id="8c7ef8b4-da46-4392-9c9e-781cdc890ed6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00854;issue:issue:10.1021/jmcmar.2018.61.issue-16;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176)" /></meta><meta name="dc.Creator" content="Alicia  Regueiro-Ren" /></meta><meta name="dc.Creator" content="Jacob J.  Swidorski" /></meta><meta name="dc.Creator" content="Zheng  Liu" /></meta><meta name="dc.Creator" content="Yan  Chen" /></meta><meta name="dc.Creator" content="Ny  Sin" /></meta><meta name="dc.Creator" content="Sing-Yuen  Sit" /></meta><meta name="dc.Creator" content="Jie  Chen" /></meta><meta name="dc.Creator" content="Brian L.  Venables" /></meta><meta name="dc.Creator" content="Juliang  Zhu" /></meta><meta name="dc.Creator" content="Beata  Nowicka-Sans" /></meta><meta name="dc.Creator" content="Tricia  Protack" /></meta><meta name="dc.Creator" content="Zeyu  Lin" /></meta><meta name="dc.Creator" content="Brian  Terry" /></meta><meta name="dc.Creator" content="Himadri  Samanta" /></meta><meta name="dc.Creator" content="Sharon  Zhang" /></meta><meta name="dc.Creator" content="Zhufang  Li" /></meta><meta name="dc.Creator" content="John  Easter" /></meta><meta name="dc.Creator" content="Brett R.  Beno" /></meta><meta name="dc.Creator" content="Vinod  Arora" /></meta><meta name="dc.Creator" content="Xiaohua S.  Huang" /></meta><meta name="dc.Creator" content="Sandhya  Rahematpura" /></meta><meta name="dc.Creator" content="Dawn D.  Parker" /></meta><meta name="dc.Creator" content="Roy  Haskell" /></meta><meta name="dc.Creator" content="Kenneth S.  Santone" /></meta><meta name="dc.Creator" content="Mark I.  Cockett" /></meta><meta name="dc.Creator" content="Mark  Krystal" /></meta><meta name="dc.Creator" content="Nicholas A.  Meanwell" /></meta><meta name="dc.Creator" content="Susan  Jenkins" /></meta><meta name="dc.Creator" content="Umesh  Hanumegowda" /></meta><meta name="dc.Creator" content="Ira B.  Dicker" /></meta><meta name="dc.Description" content="GSK3532795, formerly known as BMS-955176 (1), is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. The careful design, sele..." /></meta><meta name="Description" content="GSK3532795, formerly known as BMS-955176 (1), is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. The careful design, sele..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 1, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00854" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00854" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00854" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00854" /></link>
        
    
    

<title>Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00854" /></meta><meta property="og:title" content="Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0014.jpeg" /></meta><meta property="og:description" content="GSK3532795, formerly known as BMS-955176 (1), is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. The careful design, selection, and evaluation of substituents appended to the C-3 and C-17 positions of the natural product betulinic acid (3) was critical in attaining a molecule with the desired virological and pharmacokinetic profile. Herein, we highlight the key insights made in the discovery program and detail the evolution of the structure–activity relationships (SARs) that led to the design of the specific C-17 amine moiety in 1. These modifications ultimately enabled the discovery of 1 as a second-generation MI that combines broad coverage of polymorphic viruses (EC50 &lt;15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00854"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00854">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00854&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00854&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00854&amp;href=/doi/10.1021/acs.jmedchem.8b00854" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7289-7313</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00807" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00900" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Alicia Regueiro-Ren</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alicia Regueiro-Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><span class="conrtib-corresp"><strong>*</strong>A.R-R.: phone, (609)466-5035; E-mail, <a href="/cdn-cgi/l/email-protection#43022f2a202a226d31262436262a312c31262d03212e306d202c2e"><span class="__cf_email__" data-cfemail="95d4f9fcf6fcf4bbe7f0f2e0f0fce7fae7f0fbd5f7f8e6bbf6faf8">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alicia++Regueiro-Ren">Alicia Regueiro-Ren</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2991-719X" title="Orcid link">http://orcid.org/0000-0003-2991-719X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacob J. Swidorski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacob J. Swidorski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+J.++Swidorski">Jacob J. Swidorski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zheng Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zheng Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Liu">Zheng Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Chen">Yan Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ny Sin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ny Sin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ny++Sin">Ny Sin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sing-Yuen Sit</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sing-Yuen Sit</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sing-Yuen++Sit">Sing-Yuen Sit</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Chen">Jie Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian L. Venables</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian L. Venables</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+L.++Venables">Brian L. Venables</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Juliang Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juliang Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Synthesis, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juliang++Zhu">Juliang Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Beata Nowicka-Sans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beata Nowicka-Sans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beata++Nowicka-Sans">Beata Nowicka-Sans</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tricia Protack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tricia Protack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tricia++Protack">Tricia Protack</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zeyu Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zeyu Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zeyu++Lin">Zeyu Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian Terry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian Terry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Terry">Brian Terry</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Himadri Samanta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Himadri Samanta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Himadri++Samanta">Himadri Samanta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sharon Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sharon Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sharon++Zhang">Sharon Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhufang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhufang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhufang++Li">Zhufang Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Easter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Easter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Easter">John Easter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brett R. Beno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brett R. Beno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brett+R.++Beno">Brett R. Beno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vinod Arora</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vinod Arora</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vinod++Arora">Vinod Arora</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaohua S. Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaohua S. Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohua+S.++Huang">Xiaohua S. Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandhya Rahematpura</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandhya Rahematpura</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandhya++Rahematpura">Sandhya Rahematpura</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dawn D. Parker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dawn D. Parker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dawn+D.++Parker">Dawn D. Parker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roy Haskell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roy Haskell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roy++Haskell">Roy Haskell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenneth S. Santone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenneth S. Santone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+S.++Santone">Kenneth S. Santone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark I. Cockett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark I. Cockett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+I.++Cockett">Mark I. Cockett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Krystal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Krystal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Krystal">Mark Krystal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicholas A. Meanwell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicholas A. Meanwell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+A.++Meanwell">Nicholas A. Meanwell</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8857-1515" title="Orcid link">http://orcid.org/0000-0002-8857-1515</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan Jenkins</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan Jenkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><span class="conrtib-corresp"><strong>*</strong>S.J.: E-mail, <a href="/cdn-cgi/l/email-protection#176462647679397a397d72797c7e796457617e7e617f72767b637f747665723974787a"><span class="__cf_email__" data-cfemail="21525452404f0f4c0f4b444f4a484f5261574848574944404d5549424053440f424e4c">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Jenkins">Susan Jenkins</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Umesh Hanumegowda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Umesh Hanumegowda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Umesh++Hanumegowda">Umesh Hanumegowda</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ira B. Dicker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ira B. Dicker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ira+B.++Dicker">Ira B. Dicker</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00854&amp;href=/doi/10.1021%2Facs.jmedchem.8b00854" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7289–7313</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 1, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 May 2018</li><li><span class="item_label"><b>Published</b> online</span>1 August 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 August 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00854" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00854</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7289%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlicia%2BRegueiro-Ren%252C%2BJacob%2BJ.%2BSwidorski%252C%2BZheng%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D16%26contentID%3Dacs.jmedchem.8b00854%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BSAR%2Bof%2BC-3%2BBenzoic%2BAcid%252C%2BC-17%2BTriterpenoid%2BDerivatives.%2BIdentification%2Bof%2Bthe%2BHIV-1%2BMaturation%2BInhibitor%2B4-%2528%25281R%252C3aS%252C5aR%252C5bR%252C7aR%252C11aS%252C11bR%252C13aR%252C13bR%2529-3a-%2528%25282-%25281%252C1-Dioxidothiomorpholino%2529ethyl%2529amino%2529-5a%252C5b%252C8%252C8%252C11a-pentamethyl-1-%2528prop-1-en-2-yl%2529-2%252C3%252C3a%252C4%252C5%252C5a%252C5b%252C6%252C7%252C7a%252C8%252C11%252C11a%252C11b%252C12%252C13%252C13a%252C13b-octadecahydro-1H-cyclopenta%255Ba%255Dchrysen-9-yl%2529benzoic%2BAcid%2B%2528GSK3532795%252C%2BBMS-955176%2529%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7313%26publicationDate%3DAugust%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00854"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1514</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00854" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Alicia&quot;,&quot;last_name&quot;:&quot;Regueiro-Ren&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;J. Swidorski&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Ny&quot;,&quot;last_name&quot;:&quot;Sin&quot;},{&quot;first_name&quot;:&quot;Sing-Yuen&quot;,&quot;last_name&quot;:&quot;Sit&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;L. Venables&quot;},{&quot;first_name&quot;:&quot;Juliang&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Beata&quot;,&quot;last_name&quot;:&quot;Nowicka-Sans&quot;},{&quot;first_name&quot;:&quot;Tricia&quot;,&quot;last_name&quot;:&quot;Protack&quot;},{&quot;first_name&quot;:&quot;Zeyu&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Terry&quot;},{&quot;first_name&quot;:&quot;Himadri&quot;,&quot;last_name&quot;:&quot;Samanta&quot;},{&quot;first_name&quot;:&quot;Sharon&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zhufang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Easter&quot;},{&quot;first_name&quot;:&quot;Brett&quot;,&quot;last_name&quot;:&quot;R. Beno&quot;},{&quot;first_name&quot;:&quot;Vinod&quot;,&quot;last_name&quot;:&quot;Arora&quot;},{&quot;first_name&quot;:&quot;Xiaohua&quot;,&quot;last_name&quot;:&quot;S. Huang&quot;},{&quot;first_name&quot;:&quot;Sandhya&quot;,&quot;last_name&quot;:&quot;Rahematpura&quot;},{&quot;first_name&quot;:&quot;Dawn&quot;,&quot;last_name&quot;:&quot;D. Parker&quot;},{&quot;first_name&quot;:&quot;Roy&quot;,&quot;last_name&quot;:&quot;Haskell&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;S. Santone&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;I. Cockett&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Krystal&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;A. Meanwell&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Jenkins&quot;},{&quot;first_name&quot;:&quot;Umesh&quot;,&quot;last_name&quot;:&quot;Hanumegowda&quot;},{&quot;first_name&quot;:&quot;Ira&quot;,&quot;last_name&quot;:&quot;B. Dicker&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;7289-7313&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00854&quot;},&quot;abstract&quot;:&quot;GSK3532795, formerly known as BMS-955176 (1), is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. The careful design, selection, and evaluation of substituents appended to the C-3 and C-17 positions of the natural product betulinic acid (3) was critical in attaining a molecule with the desired virological and pharmacokinetic profile. Herein, we highlight the key insights made in the discovery program and detail the evolution of the structure–activity relationships (SARs) that led to the design of the specific C-17 amine moiety in 1. These modifications ultimately enabled the discovery of 1 as a second-generation MI that combines broad coverage of polymorphic viruses (EC50 &lt;15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00854&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00854" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00854&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00854" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00854&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00854" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00854&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00854&amp;href=/doi/10.1021/acs.jmedchem.8b00854" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00854" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00854" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00854%26sid%3Dliteratum%253Aachs%26pmid%3D30067361%26genre%3Darticle%26aulast%3DRegueiro-Ren%26date%3D2018%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BSAR%2Bof%2BC-3%2BBenzoic%2BAcid%252C%2BC-17%2BTriterpenoid%2BDerivatives.%2BIdentification%2Bof%2Bthe%2BHIV-1%2BMaturation%2BInhibitor%2B4-%2528%25281R%252C3aS%252C5aR%252C5bR%252C7aR%252C11aS%252C11bR%252C13aR%252C13bR%2529-3a-%2528%25282-%25281%252C1-Dioxidothiomorpholino%2529ethyl%2529amino%2529-5a%252C5b%252C8%252C8%252C11a-pentamethyl-1-%2528prop-1-en-2-yl%2529-2%252C3%252C3a%252C4%252C5%252C5a%252C5b%252C6%252C7%252C7a%252C8%252C11%252C11a%252C11b%252C12%252C13%252C13a%252C13b-octadecahydro-1H-cyclopenta%255Ba%255Dchrysen-9-yl%2529benzoic%2BAcid%2B%2528GSK3532795%252C%2BBMS-955176%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D16%26spage%3D7289%26epage%3D7313%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292035" title="Viruses">Viruses</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/jmcmar.2018.61.issue-16/20180823/jmcmar.2018.61.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">GSK3532795, formerly known as BMS-955176 (<b>1</b>), is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. The careful design, selection, and evaluation of substituents appended to the C-3 and C-17 positions of the natural product betulinic acid (<b>3</b>) was critical in attaining a molecule with the desired virological and pharmacokinetic profile. Herein, we highlight the key insights made in the discovery program and detail the evolution of the structure–activity relationships (SARs) that led to the design of the specific C-17 amine moiety in <b>1</b>. These modifications ultimately enabled the discovery of <b>1</b> as a second-generation MI that combines broad coverage of polymorphic viruses (EC<sub>50</sub> <15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Current therapies to treat human immunodeficiency virus-1 (HIV-1) infection have transformed acquired immune deficiency syndrome (AIDS) into a chronic disease for the majority of patients. Combination antiretroviral therapy (cART) consists of multiple antiviral agents with complementary mechanisms of action (MOAs) and resistance profiles that is optimally administered as part of a convenient, fixed-dose regimen that simplifies patient compliance.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, the search for medicines with novel MOAs that are capable of overcoming the resistance that could eventually emerge in response to therapy, as well as improved safety profiles that are compatible with the long-term administration of these agents, is still of vital importance.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Inhibition of the maturation step of the virus life circle for the treatment of HIV-1 infection/AIDS has been the focus of significant attention over the last 30 years.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Maturation of the HIV-1 virion is mediated by the viral protease, which sequentially cleaves the Gag polyprotein in five different places to release the structural proteins, matrix (MA), capsid (CA), nucleocapsid (NC), and p6, as well as two spacer peptides, SP1 and SP2.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> HIV-1 protease inhibitors (PIs), which act at the latter stage of the virus life cycle, impede maturation of the virus by binding to the virally encoded protease, thereby preventing all of the proteolytic cleavages from occurring. In contrast, maturation inhibitors (MIs) have been shown to bind to the virally encoded Gag polyprotein proximal to the CA-SP1 junction and specifically preclude cleavage at this site, which is the final and rate-limiting step in the virion maturation process. The advent of PIs has provided an efficacious therapy to treat AIDS, and an MI would provide an alternative approach to effect a similar therapeutic intervention while offering a complementary resistance profile. While there are 10 Federal Drug Administration (FDA)-approved HIV-1 PIs, some of which are used as an integral part of cART (although most PIs need to be coadministered with a pharmacokinetic enhancer such as ritonavir or cobicistat), only a few MIs have been advanced into clinical trials.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> GSK3532795, formerly known as BMS-955176 (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), is a second-generation HIV-1 MI with broad polymorphic virus coverage.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> The discovery program that led to the development of <b>1</b> was grounded on overcoming the limitations observed with bevirimat (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), the first compound with this MOA that was advanced into clinical trials and which established proof-of-concept for this therapeutic intervention strategy.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Administration of <b>2</b> at doses of 150 and 250 mg once a day (quaque die, QD) in a 10 day phase I/II monotherapy trial resulted in mean viral load reductions (VLRs) of 0.72 log<sub>10</sub> copies/mL.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, in a phase IIa monotherapy clinical trial conducted in highly ART-experienced patients, 55% of the individuals in the study treated with <b>2</b> did not experience a significant VLR (defined as >0.5 log<sub>10</sub> copies/mL). It was subsequently determined that all of the nonresponders were infected with viruses that expressed naturally occurring polymorphic variations proximal to the CA/SP1 cleavage site at amino acid residues Q369-V370-T371 of the Gag polyprotein.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> Mutations at position V362, which is immediately adjacent to the L363-A364 cleavage site, were subsequently identified as being involved in reducing the response to <b>2</b>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In addition, <b>2</b> displayed high human serum (HS) binding (>99%), reducing the free fraction of the drug in plasma and contributing to the need for an elevated dose, as well as poor aqueous solubility (<1 μg/mL), which limited options for formulation.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> The lack of coverage of naturally occurring polymorphic viruses and the formulation challenges prevented further development of <b>2</b> but highlighted the characteristics needed for an improved MI clinical candidate.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> A second-generation MI should demonstrate efficacy against these polymorphic viruses, be suitable for administration at a low dose, and be compatible with other agents in order to facilitate combinations as a part of a cART regimen. This manuscript describes the drug design and optimization efforts that led to the discovery and preclinical characterization of <b>1</b> as a second-generation MI with broad polymorphic virus coverage and the potential for QD dosing. Compound <b>1</b> is a derivative of <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) that incorporates a 4-substituted benzoic acid at C-3 of the triterpene core and a diamine-containing side chain installed at the C-17 position.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> GSK3532795 was examined in a phase IIb clinical trial where it proved to be efficacious, although development was terminated recently due to unacceptable rates of adverse gastrointestinal events and treatment-emergent NRTI resistance (GSK3532795 was coadministered with an NRTI).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure–activity relationship (SAR) evolution of HIV-1 maturation inhibitors from betulinic acid to GSK3532795 (BMS-955176, <b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Biological and Pharmacokinetic Profiling of Compounds</h3><div class="NLM_p">To facilitate the identification of a second-generation MI, a primary screening tier comprised of wild-type (WT) HIV-1 and two key polymorphic viruses was implemented along with monitoring of the effect of added HS on the inhibition of WT HIV-1 by compounds with promising profiles. The two polymorphic viruses that were selected for the primary screen were V370A, for which there is a high prevalence of changes (∼17% V370A/M) at this position in HIV-1 subtype-B viruses and which demonstrated a reduced clinical response to the first-generation MI <b>2</b> and ΔV370. While ΔV370 is present in only ∼1% of B-subtype viruses, it exhibits a high level of resistance (>1000-fold) to <b>2</b>, therefore representing a challenging and stringent case with which to drive the SARs. Additionally, the ΔV370 polymorph is common (>70%) in nonsubtype-B HIV-1 viruses. Newly synthesized compounds were screened for antiviral activity toward WT HIV-1, V370A, and ΔV370 polymorphic viruses in a virus replication assay in which the Nef gene was replaced with a luciferase reporter and which replicated in MT-2 cells infected for 4–5 days.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The concentration at which test compounds were half-maximally cytotoxic toward the host cell (CC<sub>50</sub>) was also determined. Selected compounds were rescreened in the WT HIV-1 cell culture assay in the presence of HS, with the results compiled in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Except where noted, all compounds exhibited high metabolic stability in vitro with <i>t</i><sub>1/2</sub> values of >120 min when incubated in rat and human liver microsomes (RLM and HLM) in the presence of NADPH, which predicted for low clearance in vivo. It was not possible to assess the in vitro membrane permeability of any of the test compounds due to their limited solubility under the assay conditions. Representative compounds were evaluated for their in vivo pharmacokinetic (PK) profile either in an abbreviated, 6 h snapshot rat PK screen or in a full, 24 h rat PK study. The compounds were dosed at 5 mg/kg PO, and the results are included in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Antiviral Potency, Cytotoxicity, and in Vivo Rat Pharmacokinetic Profiling Data for MIs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The data provided are the means of at least triplicate values with mean CVs (confidence values) of 83 ± 50% for all of the experiments, and all CV values were <200%. Where experiments were performed four or more times, the standard deviations are included.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Compounds were evaluated for serum effects in 10% FBS + 40% human serum except for <b>1</b> (10% FBS + 40% human serum +27 mg/mL human serum albumin).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Dose 5 mg/kg PO; for vehicle information see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last"><i>n</i> = 3.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Compound Synthesis</h3><div class="NLM_p">Amides <b>6</b> and <b>7</b> were prepared accordingly to previously described procedures.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> describes the synthesis of C-17 amine derivatives of C-3 benzoic acid-based betulinic acid derived MIs <b>23</b>–<b>28</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of C-17 Amine Derivatives of Triterpenoid MIs <b>23</b>–<b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TPAP, NMO, CH<sub>3</sub>CN/CH<sub>2</sub>Cl<sub>2</sub>, rt, 24 h 89%; (b) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 2-methyl-2-butene, <sup>t</sup>BuOH, H<sub>2</sub>O, rt, 1 h, quant; (c) K<sub>2</sub>CO<sub>3</sub>, BnBr, DMF, 60 °C, 3.5 h, 99%; (d) KHMDS, PhNTf<sub>2</sub>, THF, −78 °C, 4 h, 90%; (e) (4-(methoxycarbonyl)phenyl)boronic acid, Na<sub>2</sub>CO<sub>3</sub>, Pd(Ph<sub>3</sub>P)<sub>4</sub>, 1,4-dioxane/<i>i</i>-PrOH/H<sub>2</sub>O, reflux, 14.5 h, 68%; (f) TBDMSH, Pd(OAc)<sub>2</sub>, TEA, DCE, 60 °C, 2 h, 97%; (g) TBAF, H<sub>2</sub>O/1,4-dioxane, rt, 4 h, 99%; (h) DPPA, TEA, 1,4-dioxane, 100 °C, 5 h, 93%; (i) 4-(2-hydroxyethyl)thiomorpholine-1,1-dioxide, NaH, THF, rt, 18; (j) LiOH, THF/H<sub>2</sub>O, 18 h, 75 °C or NaOH, 1,4-dioxane, 78 °C, 3 h; (k) 4-(2-aminoethyl)thiomorpholine 1,1-dioxide, DIEA, THF, rt, 18 h; (l) HCl, THF, rt, 4 h, 95%; (m) RCOOH, HATU, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 18 h.</p></p></figure><div class="NLM_p">The oxidation of betulin (<b>8</b>) to betulonic acid (<b>9</b>) was accomplished in a synthetically and economically efficient manner. Exposure of <b>8</b> to TPAP/NMO concomitantly oxidized the two alcohol moieties and was followed by Pinnick oxidation of the newly formed C-28 aldehyde to afford <b>9</b> in an overall yield of 70–80%, circumventing the previously reported method which relied upon the more expensive <b>3</b> as starting material.<a onclick="showRef(event, 'ref9 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref9 ref17 ref18 ref19 ref20 ref21 ref22">(9,17−22)</a> Treatment of <b>9</b> with benzyl bromide in the presence of base protectively esterified the carboxylic acid moiety and was followed by conversion of the C-3 ketone into the corresponding enol triflate <b>10</b>. Suzuki–Miyaura coupling of <b>10</b> with (4-methoxycarbonyl)phenylboronic acid rendered <b>11</b>. Deprotection of <b>11</b> was accomplished by exposing to <i>t</i>-butyldimethylsilane in the presence of Pd(OAc)<sub>2</sub>, followed by the addition of TBAF, which afforded carboxylic acid <b>12</b> via an intermediate silyl ester, a procedure that prevented the hydrogenation of the olefins observed when using other reduction methods.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Curtius rearrangement of <b>12</b> afforded isocyanate <b>13</b>, which was treated with 4-(2-hydroxyethyl)- or 4-(2-aminoethyl)-thiomorpholine 1,1-dioxide to provide carbamate <b>23</b> or urea <b>24</b>, respectively, after hydrolysis of the methyl benzoate.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Acidic hydrolysis of isocyanate <b>13</b> provided the C-17 primary amine <b>14</b> that was converted into amides <b>25</b>–<b>28</b> by coupling with the corresponding carboxylic acid in the presence of HATU, followed by deprotection of the methyl benzoate under basic conditions.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">The synthesis of the C-17 alkylamine derivatives prepared by the direct alkylation of <b>14</b> is depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.<a onclick="showRef(event, 'ref19 ref25'); return false;" href="javascript:void(0);" class="ref ref19 ref25">(19,25)</a> Alkylation of <b>14</b> with alkyl halides in the presence of K<sub>3</sub>PO<sub>4</sub> and KI followed by deprotection of the benzoic acid afforded C-17 amines <b>1</b>, <b>30</b>, <b>34</b>–<b>36</b>, <b>38</b>, and <b>45</b> as well as the 3′-fluoro analogue <b>48</b>, a compound that required the use of (2-fluoro-4-(methoxycarbonyl)phenyl)boronic acid in the Suzuki–Miyaura reaction. Thiopyran derivative <b>33</b> was prepared from <b>14</b> via sulfide <b>15</b>, followed by oxidation with oxone and ester deprotection. Alkylation of <b>14</b> with <i>N</i>-(4-(2-chloroethyl)-1-oxido-6-thiomorpholin-1-ylidene)-4-methylbenzenesulfonamide afforded <b>16</b>, which upon treatment with Hg amalgam in the presence of base generated sulfoximine <b>47</b>.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a></div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of C-17 Alkylamino Triterpenoid MIs Prepared via Direct Alkylation of <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RCl, K<sub>3</sub>PO<sub>4</sub>, KI, CH<sub>3</sub>CN, 115–125 °C, 48 h; (b) LiOH, THF/H<sub>2</sub>O, 18 h, 75 °C or NaOH, 1,4-dioxane, 78 °C, 3 h; (c) oxone, MeOH/H<sub>2</sub>O/acetone, 0 °C, 2 h; (d) Hg(Na), NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, MeOH, reflux, 4.5 h.</p></p></figure><div class="NLM_p">Reductive amination of <b>14</b> with the corresponding aldehydes afforded intermediates <b>17</b>–<b>19</b> as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Removal of the protecting groups from <b>17</b> provided <b>32</b>. Acid hydrolysis of the Boc-protected amine <b>18</b> followed by Michael addition to vinylsulfonylethene and final deprotection rendered <b>29</b>. Alternatively, <b>36</b> was obtained via reductive amination of the primary amine generated from <b>19</b> using <i>tert</i>-butyl-3-oxopyrrolidine-1-carboxylate and 2-methylpyridine borane (Pic-BH<sub>3</sub>) followed by standard BOC deprotection, sulfonylation, and final ester deprotection.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of C-17 Alkylamino Triterpenoid MIs Prepared via Reductive Amination of <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RCHO, Ti(<sup>i</sup>PrO)<sub>4</sub>, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>ClCH<sub>2</sub>Cl, rt, 18–48 h or RCHO, NaBH(OAc)<sub>3</sub>, AcOH, EtOH/1,4-dioxane, rt, 2 h; (b) TBAF, THF, rt, 3 h; (c) LiOH, THF/H<sub>2</sub>O, 18 h, 75 °C or NaOH, 1,4-dioxane, 78 °C, 3 h; (d) HCl, 1,4-dioxane, rt, 4–17 h; (e) vinylsulfonylethene, TEA, 100 °C, 3 h; (f) <i>tert</i>-butyl-3-oxopyrrolidine-1-carboxylate, Pic-BH<sub>3</sub>, MeOH/AcOH, rt, 17 h; (g) ClSO<sub>2</sub>Me, TEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h.</p></p></figure><div class="NLM_p">Piperidine derivatives <b>31</b> and <b>37</b> and sulfonamide <b>39</b> were prepared from <b>14</b> in four steps as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Alkylation of <b>14</b> with bromoethanol followed by treatment of the alcohol with thionyl chloride rendered alkyl chloride <b>20</b>. Displacement of the terminal chloride with an amine followed by benzoate ester deprotection afforded <b>31</b>, <b>37</b>, and <b>39</b>. Conversely, the addition of <i>t</i>-butylpiperazine-1-carboxylate to <b>20</b> followed by Boc-deprotection using HCl gave the terminal piperazine <b>21</b>. Addition of isopropylsulfonyl choride to <b>21</b> followed by deprotection of the ester under standard conditions provided piperazine sulfonamide <b>40</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of C-17 Alkylamino Triterpenoid MIs Prepared via Alkylchloride <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) BrCH<sub>2</sub>CH<sub>2</sub>OH, K<sub>3</sub>PO<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, KI, CH<sub>3</sub>CN, 120 °C, 15 h, 86%; (b) SOCl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 90%; (c) 4,4-difluoropyridine, K<sub>3</sub>PO<sub>4</sub>, NaI, CH<sub>3</sub>CN, 120 °C, 19 h; (d) NaOH, 1,4-dioxane, 78–80 °C, 1–4 h; (e) R<sub>1</sub>R<sub>2</sub>NH, DIPEA, DMSO, 120 °C, 1 h; (f) <i>t</i>-butyl piperazine-1-carboxylate, DIPEA, DMSO, 120 °C, 1 h, 52%; (g) HCl, THF, rt, 18 h, 39%; (h) <sup>i</sup>PrSO<sub>2</sub>Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h.</p></p></figure><div class="NLM_p">Alkylation of <b>14</b> with 1-bromo-2-chloroethane afforded aziridine <b>22</b> in 98% yield. Nucleophilic ring opening of the aziridine by the addition of mono-Boc protected diamines followed by unmasking of the terminal amine moiety, subsequent sulfonylation, and deprotection of the benzoic acid under standard conditions afforded bicyclic sulfonamides <b>41</b>–<b>43</b> and <b>46</b><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of C-17 Alkylamine Triterpenoid MIs Prepared via Aziridine <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) BrCH<sub>2</sub>CH<sub>2</sub>Cl, K<sub>3</sub>PO<sub>4</sub>, KI, CH<sub>3</sub>CN, 120 °C, 24 h, 98%; (b) mono-Boc protected diamine, DIPEA, THF, 100 °C, 14–67 h; (c) TFA/HCl, CH<sub>2</sub>Cl<sub>2</sub>/ClCH<sub>2</sub>CH<sub>2</sub>Cl, rt; 1–3 h; (d) ClSO<sub>2</sub>Me, TEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1.5–2 h; (e) LiOH, THF/MeOH, 75 °C, 1–2 h.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have previously described the initial key structural modifications that led to the discovery of <b>1</b>.<a onclick="showRef(event, 'ref9 ref17 ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref9 ref17 ref18 ref20">(9,17,18,20)</a> The introduction of a 4-substituted benzoic acid moiety at the C-3 position of the core of <b>3</b> provided a carbon-linked motif that preserved unique aspects of the topology and topography and the relationship of the carboxylic acid moiety of <b>2</b> with the triterpenoid core.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The incorporation of basic amines at the C-28 position via an amide linker (C-28 amides) or an amine linker (C-28 amines) rendered compounds with good antiviral potency toward not only the WT virus but also toward the V370A and ΔV370 polymorphic viruses that experienced lower shifts in the presence of HS when compared with <b>2</b> (5-fold for <b>4</b>). However, with respect to pharmacokinetic properties, both C-28 amide and C-28 amine derivatives showed lower AUC values following oral dosing to rats when compared with <b>2</b>. Modulation of the overall basicity of the molecule by reducing the p<i>K</i><sub>a</sub> of the terminal amine by incorporation into a thiomorpholine-1,1-dioxide (TMD) ring, p<i>K</i><sub>a</sub> = 5.4,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> as in <b>4</b>, resulted in a modest improvement in the AUC when compared with other C-28 analogues bearing amine-containing side chains while maintaining excellent potency toward the polymorphic viruses.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> We have shown that installing a carboxylic acid moiety in the C-28 side chain can help to improve oral exposure, although the polymorphic coverage was negatively affected, as exemplified by the profile of <b>5</b>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Recognizing the potential of the sulfone moiety to act as a surrogate of the two oxygen atoms of a carboxylic acid but without the burden of charge and encouraged by the results obtained with <b>4</b>, we prepared amides <b>6</b> and <b>7</b> with the purpose of improving polymorphic coverage while preserving the advantageous PK profile associated with a carboxylic acid derivative. However, while both <b>6</b> and <b>7</b> displayed superior potency toward WT, V370A, and ΔV370 viruses when compared to <b>5</b>, the plasma AUC following oral dosing of <b>7</b> to rats was significantly lower than observed with <b>5</b> and even <b>4</b>. The SARs that emerged from the C-28 derivatives <b>4</b>–<b>7</b> clearly established the need for a side chain bearing both an amine moiety and a polar functionality in order to combine targeted polymorphic coverage with good PK properties. However, the modifications implemented in the context of the C-28 amine/amide series were not sufficient to support the further advancement of any of these compounds.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> At this point, it was postulated that positioning both the C-28 and TMD amine moieties closer to the triterpenoid core may provide an opportunity for preserving the favorable features while improving membrane permeability and, consequently, the AUC following oral dosing. This concept arose from observations made with C-28 amine derivatives where shielding of the amine moieties by installing adjacent alkyl substituents led to improved oral exposure.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Carbamate <b>23</b> and urea <b>24</b> are C-17 amine derivatives that preserve the length of the side chain present in <b>4</b>, but both compounds showed diminished potency toward all of the screening viruses when compared with <b>4</b>. The introduction of an amide moiety, as in <b>25</b> and <b>26</b>, allowed the linker to be shortened by 1 and 2 atoms, respectively. While <b>25</b> exhibited similar antiviral properties to <b>23</b> and <b>24</b>, the shorter analogue <b>26</b> displayed a much improved antiviral profile and was comparable to that of <b>4</b>. In addition, the PK properties of carbamate <b>23</b> in the rat following oral dosing represented a 1.5-fold improvement in the AUC<sub>0–24h</sub> when compared with <b>4</b>, while the AUC<sub>0–6h</sub> of <b>26</b> was 5-fold higher than that of <b>4</b> and was comparable to that of <b>2</b>. Amide <b>26</b> combined both the targeted virological and rat PK profiles but, while stable during incubation with RLM with a <i>t</i><sub>1/2</sub> value of >120 min, unfortunately suffered from unacceptably poor metabolic stability in HLM, with a <i>t</i><sub>1/2</sub> of just 9 min. The introduction of an alkyl group α- to the amide moiety had a positive effect on the human metabolic stability, extending the <i>t</i><sub>1/2</sub> to 15.2 min for the methyl derivative <b>27</b> and to 90 min for the isopropyl analogue <b>28</b>. However, these structural modifications had a detrimental impact on the inhibitory activity toward polymorphic viruses. An in vitro biotransformation study conducted with amide <b>26</b> revealed that the major metabolites were a consequence of oxidation either in the C-17 side chain or in the triterpenoid core, while no products of amide hydrolysis were detected. It was hypothesized that compounds with increased polarity might exert a positive effect on HLM stability while maintaining antiviral potency and targeted oral exposure in the rat. To that end, the C-17 amine derivatives <b>1</b> and <b>29</b> exhibited high metabolic stability in HLM (<i>t</i><sub>1/2</sub> > 120 min) and excellent potency toward both WT and polymorphic viruses as well as demonstrating significantly higher oral exposure in rats when compared with <b>4</b> (4.5- and 3-fold for <b>1</b> and <b>29</b>, respectively). In accord with previous observations, the shorter chain analogue <b>1</b>, which incorporated an ethyl linker between the two amino groups, demonstrated 2–3-fold better antiviral potency and superior oral exposure compared to amine <b>29</b>, which is configured with a propyl linker.</div><div class="NLM_p">Compound <b>1</b>, with EC<sub>50</sub> values of 1.9, 2.7, and 13 nM toward the WT, V370A, and ΔV370 viruses, respectively, represented a 5-, 200-, and >1000-fold improvement in potency toward each virus over the first generation MI, <b>2</b>. In the presence of human serum, <b>1</b> exhibited a modest ∼5-fold reduction in antiviral potency, a reflection of moderate serum protein binding (86.1% binding to human serum albumin as determined by an ultracentrifugation assay, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Furthermore, the plasma AUC<sub>0–24h</sub> for <b>1</b> following oral administration to rats was 14,198 nM·h, exposure comparable to that recorded for <b>2</b>. On the basis of the antiviral potency, polymorphic coverage, low serum shift, and good PK properties, <b>1</b> met the requirements of a potential second generation MI. However, because <b>1</b> was one of the first of two C-17 amines prepared, it was decided to further explore the SARs associated with this series in search of further modifications that might identify a candidate with an enhanced profile. The optimal ethyl linkage between the two nitrogen atoms was maintained throughout the survey. The relevance of the TMD moiety was evaluated by first replacing it with slightly more basic cyclic amines such as morpholine <b>30</b> (p<i>K</i><sub>a</sub> = 8.2) and 4,4-difluoropiperidine <b>31</b> (p<i>K</i><sub>a</sub> = 8.5).<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> In each case, there was a 3–6-fold loss of antiviral potency toward all three screening viruses. A noncyclic terminal amine was also evaluated, of which the hydroxyethylamine derivative <b>32</b> exhibited potency toward the WT virus comparable to <b>1</b> but was significantly less potent toward the polymorphic variants.</div><div class="NLM_p">Replacing the nitrogen atom in the ring of <b>1</b> with a carbon, as illustrated by tetrahydro-2<i>H</i>-thiopyran dioxide <b>33</b>, preserved potency toward the WT virus but resulted in a pronounced 10-fold shift of potency in the presence of HS. The cyclic sulfonamide variant <b>34</b> conserved potency toward the WT and V370A viruses but was a weaker inhibitor of the ΔV370 polymorphic virus. Increasing the size of the cyclic amine, as in <b>35</b>, was tolerated, but the increased lipophilicity resulted in a deleterious effect in the presence of HS, with a 9.7-fold shift in the EC<sub>50</sub> value. Moving either the terminal amine (<b>36</b>) or the sulfone (<b>37</b>) moiety outside of the ring system was well tolerated with respect to antiviral potency, which extended to the polymorphic viruses, and these modifications were associated with a modest EC<sub>50</sub> shift in the presence of HS. The promising antiviral profile of the piperidine-based sulfone <b>37</b> provided the basis for the preparation of the topologically related piperazine sufonamide <b>38</b> which exhibited potency toward WT and V370A viruses comparable to <b>1</b> but was less potent toward the ΔV370 virus.</div><div class="NLM_p">The piperazine ring of <b>38</b> facilitated the exploration of other substituents in the heterocycle but, as illustrated by ethyl derivative <b>39</b> and isopropyl analogue <b>40</b>, the larger substituents provided no specific advantage. Analogues incorporating the piperidine mimics explored by <b>41</b>–<b>44</b> displayed good antiviral potency toward both WT and the ΔV370 virus. However, in general, the sulfonamides <b>38</b> and <b>41</b>–<b>44</b> suffered from more pronounced shifts in potency in the presence of HS (7.2–14.4-fold). Interestingly, the bicyclic compounds sulfone <b>45</b> and sulfonamide <b>46</b> exhibited potency toward the WT and polymorphic viruses with HS shifts that were comparable to <b>1</b>, while the cyclic sulfoximine <b>47</b> offered a similar overall profile.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Finally, as observed previously, the introduction of a fluorine atom to the phenyl ring <i>ortho</i>- to the carboxylic acid moiety (<b>48</b>) was also well tolerated.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">In rat PK studies, sulfone <b>36</b> and bicyclic sulfonamide <b>46</b> displayed lower plasma AUC values (4243 and 7077 nM·h, respectively) than <b>1</b> (14,198 nM·h), while compounds <b>38</b>, <b>45</b>, <b>47</b>, and <b>48</b> all displayed higher AUC values (28562, 27032, 20745, and 24276 nM·h, respectively) that exceeded those of <b>1</b> following an identical dose. However, the higher plasma AUC values were accompanied by considerable inter-animal variability, as reflected by the standard deviations indicated for each of these four compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, a phenomenon that might be attributable to solubility issues compromising exposure. While all five compounds <b>1</b>, <b>38</b>, <b>45</b>, <b>47</b>, and <b>48</b> presented similar aqueous solubility with values of <1 μg/mL, the solubility in biorelevant fluids exhibited some variation. For example, the fluoro analogue <b>48</b> showed solubility values of 0.14 and 0.33 mg/mL in fasted simulated intestinal fluid (FaSSIF, pH = 6.5) and fed simulated intestinal fluid (FeSSIF, pH = 5.0), respectively.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In contrast, <b>1</b> displayed higher solubility in FaSSIF (0.28 mg/mL) and in FeSSIF (1.02 mg/mL). These solubility differences in FeSSIF and FaSSIF, although modest, are very likely underestimates because <b>48</b> was evaluated as an amorphous solid while <b>1</b> was crystalline. Difficulties in developing suitable formulations for <b>38</b>, <b>45</b>, <b>47</b>, and <b>48</b> that would address the PK variability prevented further consideration of these compounds for advancement.</div><div class="NLM_p">Compound <b>1</b> emerged as the best candidate as a result of its potent antiviral activity toward both WT and polymorphic viruses, a low fold-shift in the presence of HS, and favorable PK properties in the rat. In addition, <b>1</b> was tested for mutagenicity in a bacterial reverse mutation assay (<i>Salmonella typhimurium</i> strains TA98 and TA100) with and without metabolic activation (Aroclor 1254-induced rat liver S9). Over the concentration range of 5–5000 μg/plate, <b>1</b> was not mutagenic at concentrations up to 1600 μg/plate, conditions under which precipitation or cytotoxicity was not observed. In a micronucleus assay with evaluation by flow cytometry, <b>1</b> was not genotoxic at concentrations of 12 and 17 μg/mL in the absence and presence of metabolic activation, respectively. An in vitro safety evaluation of <b>1</b> against a broad panel of ion channels and enzyme and receptor binding assays indicated no significant off-target liabilities. Because <b>1</b> contains a basic amine, the potential for inducing phospholipidosis was explored using a predictive in silico method that indicated no potential for this potentially problematic side effect, a prediction subsequently confirmed with in vivo studies.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The promising properties of <b>1</b> led to it being subjected to extensive in vitro virological profiling and in vitro and in vivo pharmacokinetic assessment.</div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> compiles the potency of <b>1</b> against an expanded panel of common viruses with polymorphisms in the Gag protein that are resistant to <b>2</b>, with EC<sub>50</sub> values for <b>1</b> against all viruses below 15 nM. The fold difference (FD) between <b>1</b> and <b>2</b> for each virus is also noted and ranges from 3.7-fold for the Q369H variant to >770-fold for the ΔV370 virus. In addition, <b>1</b> displayed a mean IC<sub>50</sub> value of 3.9 ± 3.4 nM when tested against a selection of 87 clinically relevant isolates representative of ∼96.5% of the sequence variability existing across the 362–370 amino acid region of the Gag polyprotein in subtype B viruses.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Consistent with the profile of MIs, <b>1</b> showed reduced activity (EC<sub>50</sub> = 1.48 μM) toward the A364 V virus, which, although not found in clinical circulation, is selected by <b>2</b> both in vitro and in vivo and which compromises antiviral activity with EC<sub>50</sub> values of >10 μM.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> Adding further confirmation to the MI MOA, <b>1</b> inhibited the final step in the virus maturation process, cleavage of the capsid (CA) precursor p25 to capsid p24 and spacer peptide 1 (SP1), in a time-dependent manner in both virus-like particles (VLPs) and infected cells, a biochemical profile comparable to <b>2</b>.<a onclick="showRef(event, 'ref8 ref38'); return false;" href="javascript:void(0);" class="ref ref8 ref38">(8,38)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>1</b> demonstrated comparable binding affinity to <b>2</b> toward a WT HIV-1 viral-like particle (VLP) (uncleaved Gag polyprotein, i.e., the immature form of the HIV-1 virus) that was largely maintained for the same VLP incorporating either a V370A or a V362I sequence change. However, binding affinity was weaker toward a VLP with a single change representing the ΔV370 polymorph. In contrast, the affinity of <b>2</b> for the VLPs incorporating the V370A, V362I, and ΔV370 changes was more significantly attenuated (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Interestingly, while the affinity of <b>2</b> for the A364 V VLPs was too weak to be measured, the affinity of <b>1</b>, although attenuated, was measurable, with a <i>K</i><sub>d</sub> of 98 ± 13 nM. An assessment of the binding kinetics in VLPs revealed similar dissociation half-lives for <b>1</b> (<i>t</i><sub>1/2</sub> = 41 min) and <b>2</b> (<i>t</i><sub>1/2</sub> = 51 min) toward the WT sequence, while the dissociation kinetics of <b>2</b> from both the V370A and ΔV370 sequences were rapid (<i>t</i><sub>1/2</sub> ≤ 3 min). In contrast, the dissociation half-life of <b>1</b> from the V370A sequence was similar to WT (<i>t</i><sub>1/2</sub> = 36 min), while for the ΔV370 sequence, the <i>t</i><sub>1/2</sub> of 46 min suggested a slower association rate as the source of the more substantial difference in binding affinity (∼10-fold) measured for this VLP compared to WT. Compound <b>1</b> maintained comparable potency toward viruses resistant to antiviral agents with different MOAs, including protease, reverse transcriptase and integrase inhibitors, with EC<sub>50</sub> values that were comparable to the WT virus, indicating a lack of cross-resistance with MIs, an important clinical property.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiviral Activity (EC<sub>50</sub>)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> toward HIV-1 Viruses Containing Common Naturally-Occurring Polymorphisms in the Gag Polyprotein and Binding Affinity (<i>K</i><sub>d</sub>) toward a WT HIV-1 Viral-Like Particle (VLP)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±"><i>K</i><sub>d</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">LANL<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center" char="±"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center">FD<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±"><b>1</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>2</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.8</td><td class="colsep0 rowsep0" align="center">10 ± 11</td><td class="colsep0 rowsep0" align="center">5.2</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">5.4 ± 2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V362I</td><td class="colsep0 rowsep0" align="char" char=".">9.8</td><td class="colsep0 rowsep0" align="char" char="±">4.5 ± 2.2</td><td class="colsep0 rowsep0" align="center">74 ± 59</td><td class="colsep0 rowsep0" align="center">16.4</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Q369H</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.9</td><td class="colsep0 rowsep0" align="center">7.0 ± 2.0</td><td class="colsep0 rowsep0" align="center">3.7</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V370A</td><td class="colsep0 rowsep0" align="char" char=".">12.4</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.5</td><td class="colsep0 rowsep0" align="center">552 ± 633</td><td class="colsep0 rowsep0" align="center">204</td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">49.2 ± 12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V370M</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 1.5</td><td class="colsep0 rowsep0" align="center">1810 ± 1900</td><td class="colsep0 rowsep0" align="center">646</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ΔV370</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 11</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">>770</td><td class="colsep0 rowsep0" align="char" char="±">33.6 ± 5.9</td><td class="colsep0 rowsep0" align="char" char="±">259 ± 131</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V370A/ΔT371</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 3.9</td><td class="colsep0 rowsep0" align="center">1114 ± 119</td><td class="colsep0 rowsep0" align="center">309</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T371A</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.1</td><td class="colsep0 rowsep0" align="center">40 ± 48</td><td class="colsep0 rowsep0" align="center">20.0</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ΔV371</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 3.9</td><td class="colsep0 rowsep0" align="center">77 ± 97</td><td class="colsep0 rowsep0" align="center">10.5</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Values are means from experiments performed a minimum of three times (<i>n</i> ≥ 3).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Percent occurrence in the Los Alamos National Laboratories database.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">FD: Fold difference between EC<sub>50</sub> of <b>1</b> and <b>2</b> for each virus.</p></div></div></div><div class="NLM_p">The low aqueous solubility and high lipophilicity of <b>1</b> precluded a definitive in vitro assessment of membrane permeability; consequently, information could only be extracted from in vivo studies. The potential for CYP 3A4 induction or inhibition by <b>1</b> was low based on in vitro studies, but the compound could not be properly evaluated at higher concentrations due to poor solubility in the incubation media. Compound <b>1</b> was stable in the presence of mouse, rat, dog, and human NADPH-fortified LMs, with <i>t</i><sub>1/2</sub> values of >120 min. In cynomolgus monkey LMs, however, <b>1</b> exhibited a high metabolic turnover in the presence of added NADPH, with a short <i>t</i><sub>1/2</sub> of 11 min. An overprediction of clearance (CL) from cynomolgus monkey microsomal preparations was observed compared to the in vivo results. Similar results were also observed after incubation with suspensions of fresh primary hepatocytes, with <i>t</i><sub>1/2</sub> values of >120 min in all species with the exception of cynomolgus monkey cells (data not shown).</div><div class="NLM_p">Although the metabolism of <b>1</b> could not be quantified using in vitro systems, metabolites were identified by mass spectrometric analysis using a <sup>14</sup>C labeled analogue of <b>1</b>, [<sup>14</sup>C]-<b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). In vitro metabolism of <b>1</b> involved oxidation, <i>N</i>-dealkylation, aromatic decarboxylation, and glucuronidation of the carboxylic acid moiety. No unique metabolites were found in human-derived systems in vitro, and no GSH adducts were detected in any samples. Compound <b>1</b> was the main drug-related compound detected in plasma from rats, dogs, and monkeys following oral administration of the drug. Minor amounts of the metabolites Met1 and Met2 (mono-oxidation products), Met3 (<i>N</i>-dealkylation), and Met4 (acyl glucuronide) were also detected in rat, dogs, and monkeys. Although acyl glucuronide formation was observed in vivo, <b>1</b> was stable in liver microsomes fortified with UDPGA. CYP 3A4 is the primary enzyme involved in the oxidative metabolism of <b>1</b> based on in vitro metabolic reaction phenotyping studies using individually expressed recombinant CYP 450 enzymes (data not shown). Compound <b>1</b> was stable in fresh human plasma at 37 °C for 2 h. The blood-to-plasma concentration ratio was 0.68 in human blood and ranged from 0.65 to 0.68 in the three animal species studied. Protein binding could not be determined by equilibrium dialysis, possibly due to aggregation of compound in the media which prevented permeability through the dialysis membrane. Consequently, an ultracentrifugation method was used to determine protein binding for this compound under conditions where membrane permeability was not an issue.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In this assay, <b>1</b> (5.3 nM) was determined to be 86.1% bound to human serum proteins and 78–94% bound to the serum proteins of the four animal species studied, data that are compiled in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. This degree of protein binding to human serum is consistent with the rightward shift in antiviral potency observed in cell culture in the presence of 40% human serum.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro metabolic profiling of <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Protein Binding of <b>1</b> in Different Species As Determined by an Ultracentrifugation Assay<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">mouse</th><th class="colsep0 rowsep0" align="center" char="±">rat</th><th class="colsep0 rowsep0" align="center" char="±">dog</th><th class="colsep0 rowsep0" align="center" char="±">monkey</th><th class="colsep0 rowsep0" align="center" char="±">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% bound</td><td class="colsep0 rowsep0" align="char" char="±">89.4 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">85.9 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">84.6 ± 4.8</td><td class="colsep0 rowsep0" align="char" char="±">78.4 ± 3 0.2</td><td class="colsep0 rowsep0" align="char" char="±">86.1 ± 0.4</td></tr></tbody></table></div></div><div class="NLM_p">The pharmacokinetic parameters of <b>1</b> in different species are detailed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Following IV dosing to mouse, rat, cynomolgus monkey, and dog, the total plasma clearance (CLT<sub>p</sub>) was low (0.13 to 2.2 mL/min/kg). Extravascular distribution of <b>1</b> was observed in the mouse and rat, where the steady-state volume of distribution (<i>V</i><sub>ss</sub>) was 0.82 and 1.1 L/kg, respectively, but a lower <i>V</i><sub>ss</sub> was observed in the dog (0.36 L/kg) and cynomolgus monkey (0.43 L/kg). Compound <b>1</b> exhibited low to moderate oral bioavailability (<i>F</i>) in the animal species tested. The absolute oral bioavailability from a precipitation-resistant solution (80% 50 mM pH = 3 citrate buffer, 20% captisol) was 27% in mice (5 mg/kg), 26% in rats (5 mg/kg), 9% in dogs (2 mg/kg), and 4% in the cynomolgus monkey (2 mg/kg). <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows the concentration versus time curves for all species, with a delayed <i>T</i><sub>max</sub> following oral administration observed in the rat, a long <i>t</i><sub>1/2</sub> in the dog, and low oral exposure in the cynomolgus monkey, which can be explained by the poor metabolic stability in LMs from this species. There are several potential causes for the observed low oral bioavailability of <b>1</b>. Because <b>1</b> has low plasma clearance in vivo and is stable in LMs and hepatocytes, metabolic instability is most likely not a cause for the low bioavailability of this compound in the mouse, rat, and dog. Poor permeability with associated P-glycoprotein (P-gp) involvement is often a cause of low bioavailability in pharmaceutical compounds,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> but because <b>1</b> displays the behavioral characteristics associated with solubility-limited absorption, developing a formulation compatible with optimal absorption of <b>1</b> could improve the low oral exposure. In addition, on the basis of the different solubility of <b>1</b> in the FaSSIF and FeSSIF studies, pH or food effects may lead to a change in the absorption properties. The potential causes for the low oral bioavailability of <b>1</b> were investigated in a series of experiments conducted in mice, rats, and dogs.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vivo Pharmacokinetic Parameters for <b>1</b> in the Mouse, Rat, Dog, and Cynomolgus Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">RA<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">formulation</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–inf)</sub> (μM·h)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">CLT<sub>p</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">mouse</td><td class="colsep0 rowsep0" align="center">IV</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">21.6</td><td class="colsep0 rowsep0" align="center">8.9</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">0.82</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">solution</td><td class="colsep0 rowsep0" align="center">2.79</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">28.9</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">26.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">MDR1 a/b</td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">4.02</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">65.5</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">45.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="11" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">rat</td><td class="colsep0 rowsep0" align="center">IV</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">11.1 ± 1.4</td><td class="colsep0 rowsep0" align="center">6.6 ± 1.0</td><td class="colsep0 rowsep0" align="center">2.2 ± 0.3</td><td class="colsep0 rowsep0" align="center">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">solution</td><td class="colsep0 rowsep0" align="center">1.2 ± 0.17</td><td class="colsep0 rowsep0" align="center">6.0 ± 0.0</td><td class="colsep0 rowsep0" align="center">14.2 ± 1.1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">26 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">+ elacridar</td><td class="colsep0 rowsep0" align="center">1.8 ± 0.49</td><td class="colsep0 rowsep0" align="center">7.3 ± 1.2</td><td class="colsep0 rowsep0" align="center">47.4 ± 8.5</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">63 ± 6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">ID<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">1.7 ± 0.09</td><td class="colsep0 rowsep0" align="center">1.0 ± 0.0</td><td class="colsep0 rowsep0" align="center">19.9 ± 2.9</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">36 ± 5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="11" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">dog</td><td class="colsep0 rowsep0" align="center">IV</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">187 ± 13</td><td class="colsep0 rowsep0" align="center">31.7 ± 2.3</td><td class="colsep0 rowsep0" align="center">0.13 ± 0.01</td><td class="colsep0 rowsep0" align="center">0.36 ± 0.02</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">solution</td><td class="colsep0 rowsep0" align="center">0.56 ± 0.34</td><td class="colsep0 rowsep0" align="center">12.7 ± 9.9</td><td class="colsep0 rowsep0" align="center">29.4 ± 16.4</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">9 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">microsuspension + pentagastrin</td><td class="colsep0 rowsep0" align="center">4.43 ± 0.79</td><td class="colsep0 rowsep0" align="center">10.5 ± 9.0</td><td class="colsep0 rowsep0" align="center">276 ± 93</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">26 ± 8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">microsuspension + food</td><td class="colsep0 rowsep0" align="center">10.2 ± 1.3</td><td class="colsep0 rowsep0" align="center">10.5 ± 9.0</td><td class="colsep0 rowsep0" align="center">643 ± 140</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">67 ± 15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">microsuspension + famotidine</td><td class="colsep0 rowsep0" align="center">4.04 ± 2.17</td><td class="colsep0 rowsep0" align="center">13.5 ± 12.2</td><td class="colsep0 rowsep0" align="center">236 ± 144</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">26 ± 16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="11" align="center">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">cynomolgus monkey</td><td class="colsep0 rowsep0" align="center">IV</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">13.6 ± 4.0</td><td class="colsep0 rowsep0" align="center">8.6 ± 0.5</td><td class="colsep0 rowsep0" align="center">1.9 ± 0.5</td><td class="colsep0 rowsep0" align="center">0.43 ± 0.01</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">PO</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">solution</td><td class="colsep0 rowsep0" align="center">0.062 ± 0.014</td><td class="colsep0 rowsep0" align="center">3.3 ± 1.2</td><td class="colsep0 rowsep0" align="center">1.0 ± 0.3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">4 ± 0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Route of administration.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">ID: intraduodenal.</p></div></div></div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>1</b> IV/PO PK profile in animal species and predicted human PK properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mouse and rat in vivo studies were conducted to determine if <b>1</b> may be a P-gp substrate. In the mouse, a MDR1 a/b (P-gp) knockout model was used.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Elacridar (GF120918A), an in vivo P-gp and breast cancer resistance protein (BCRP) inhibitor that is commonly used to determine transporter involvement, was exploited for evaluation of <b>1</b> in the rat.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The results of these two studies are compiled in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Higher oral exposure was observed in both the mouse P-gp knockout animals and Elacridar-treated rats, suggesting that the absorption of <b>1</b> may be compromised by P-gp-mediated efflux in the gastrointestinal tract.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. P-glycoprotein (P-gp) substrate potential determination studies with <b>1</b>. (a) Plasma concentrations of <b>1</b> following IV administration (1 mg/kg) to P-gp knockout mice. (b) Plasma concentrations of <b>1</b> following PO administration (5 mg/kg) to P-gp knockout mice. (c) Plasma concentrations of <b>1</b> following PO administration (5 mpk) to elacridar-treated rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The dog was selected as the most appropriate model for an evaluation of different drug formulations and the effects of food and pH on intestinal absorption based on experience with this species.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Oral dosing of <b>1</b> as a microsuspension (particle size of 8 μm) to pentagastrin-treated dogs (to simulate the lower human gastric pH in this species) provided an absolute oral bioavailability of 26% from a 5 mg/kg dose, significantly higher than that achieved from solution dosing (9%).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The <i>t</i><sub>max</sub> and oral half-life values were similar to that following solution-based dosing (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). To investigate whether the increase in bioavailability was due to the effects of pentagastrin on pH, a dog PK study was conducted with <b>1</b> following pretreatment with famotidine to increase the gastric pH.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Following oral administration of <b>1</b> (5 mg/kg) as a microsuspension to fasted dogs pretreated with famotidine, similar oral exposure was observed compared to the fasted leg where drug was dosed as a microsuspension following pentagastrin pretreatment (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The results from this study with famotidine suggest that the effect of changes in gastric pH on the oral absorption of <b>1</b> is minimal.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma concentrations following PO administration of <b>1</b> (5 mpk) to dogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A food-effect study was also performed in dogs at a dose of 5 mg/kg of <b>1</b> administered as a microsuspension after pretreatment of the animals with pentagastrin and following a high-fat meal.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> This study revealed a significant difference in the PK profile between fasted and fed dogs following oral administration of a suspension of <b>1</b>. The oral bioavailability from a suspension formulation in pentagastrin-treated dogs was increased from 26% in fasted dogs to 67% in fed dogs, clearly demonstrating the potential for this compound to be well absorbed (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><div class="NLM_p">In summary, the oral bioavailability of <b>1</b> dosed as a solution varies depending on the preclinical species. In addition, the plasma exposure of <b>1</b> is influenced by formulation, improved bioavailability is observed when <b>1</b> is dosed as a suspension, demostrating the ability of <b>1</b> to be absorbed from a solid-dosage form. Absorption of <b>1</b> was also improved in the presence of food, indicating the potential for food effect.</div><div class="NLM_p">The efficacious human dose of <b>1</b> was projected such that plasma levels sufficient to inhibit 96% of subtype B polymorphs would be achieved.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> On the basis of the antiviral potency of <b>1</b> using a reverse transcriptase-based assay, a plasma concentration of 281 nM, estimated to be 3-fold above the EC<sub>90</sub> determined in the presence of HS, was projected to achieve this target. Therefore, following administration of <b>1</b> to humans, a <i>C</i><sub>min</sub> value of 281 nM should be maintained to ensure antiviral activity. The human volume of distribution (0.31 L/kg) and blood clearance (0.36 mL/min/kg) following IV administration were predicted by allometric scaling of mouse, rat, dog, and cynomolgus monkey PK parameters.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Predictions of blood clearance could not be obtained by scaling of in vitro intrinsic clearance values using HLMs or hepatocytes due to the high level of stability of <b>1</b> in these preparations. On the basis of this information and by using the average oral bioavailability of a solution dose in preclinical species (16%), an efficacious dose of 120 mg per 70 kg adult for <b>1</b> was predicted. At this dose, the trough concentration of <b>1</b> projected at 24 h following oral dosing is 281 nM, while the AUC<sub>0–24 h</sub> was estimated to be 18.8 μM·h. These predictions are based on dosing <b>1</b> as a solution formulation. Pharmaceutics studies with a microsuspension of <b>1</b> in the dog indicated the potential for solid dosage administration. Also, because the projected human <i>t</i><sub>1/2</sub> for <b>1</b> is 11.2 h, some accumulation of compound may occur following daily drug administration, but this was not taken into account in projecting the human efficacious dose.</div><div class="NLM_p last">Compound <b>1</b> was evaluated as monotherapy in a phase IIa clinical trial conducted in treatment-naive and treatment-experienced patients infected with HIV-1 subtype-B virus. Subjects received QD doses of <b>1</b> ranging from 5 to 120 mg. Compound <b>1</b> was safe and well-tolerated and demonstrated >1 log<sub>10</sub> copies/mL reduction in viral RNA for doses ≥40 mg.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In a 28 day clinical study conducted in subjects infected with HIV-1 subtypes B and C, <b>1</b> was administered as a part of a dual treatment regimen with the protease inhibitor atazanavir (ATV) ± ritonavir (RTV). The VLRs achieved for the 40–120 mg QD dose groups were independent of pre-existing polymorphisms and comparable to a control patient cohort treated with a standard-of-care (SOC) regimen comprising tenofovir disoproxil fumarate (300 mg), emtricitabine (200 mg), and ATV ± RTV (300 mg/100 mg), demonstrating the utility of <b>1</b> as an oral, QD HIV-1 MI with broad polymorphic coverage.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> However, due to gastrointestinal intolerability and treatment-emergent drug resistance observed during a 24-week dose-finding study conducted in treatment-naive-patients, the development of <b>1</b> was halted in favor of progression of newer generation MIs with further improvements to polymorphic coverage.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">GSK3532795, formerly known as BMS-955176 (<b>1</b>), is a C-3 benzoic acid-based, C-17 amine derivative of betulinic acid (<b>3</b>) shown to be a potent, orally active second-generation MI. The C-3 benzoic acid preserved the MOA observed with first-generation MIs while conferring a much lower shift in the EC<sub>50</sub> value in the presence of human serum. The introduction of basic amines in the C-28, C-17 position of the triterpenoid core broadened the polymorphic coverage of the chemotype while careful modulation of the basicity of the C-17 side chain was critical to achieving the desired pharmacokinetic profile. Allometric scaling of mouse, rat, dog, and cynomolgus monkey PK parameters was used to estimate an efficacious dose of 120 mg per 70 kg adult, which led to the evaluation of <b>1</b> in the clinical setting, where <b>1</b> demonstrated proof of concept.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55500" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55500" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry Materials and Methods</h3><div class="NLM_p last">Unless otherwise stated, solvents and reagents were used directly as obtained from commercial sources, and reactions were performed under a nitrogen atmosphere. Flash chromatography was performed by using pre-packed columns from Teledyne Isco and Biotage or using Silica Gel 60 (0.040-0.063 mm) from EM Science as stationary phase. The purity of all new compounds was determined using preparative high performance liquid chromatography (HPLC), and in each case, unless otherwise indicated, it was ≥95%. HPLC was performed using the following methods. Method 1: column, Phenomenex Luna C8, 10 μm, 50 mm × 250 mm; 90% H<sub>2</sub>O, 10% CH<sub>3</sub>CN, 0.1% TFA to 10% H<sub>2</sub>O, 90% CH<sub>3</sub>CN, 0.1% TFA; 10 min gradient; 100 mL/min flow rate. Method 2: column, Waters Xbridge Phenyl, 5 μm, 30 mm × 100 mm; 90% H<sub>2</sub>O, 10% CH<sub>3</sub>CN, 0.1% TFA to 10% H<sub>2</sub>O, 90% CH<sub>3</sub>CN, 0.1% TFA; 8 min gradient; 50 mL/min. Method 3: column, Waters Sunfire C18, 5 μm, 30 mm × 150 mm; 90% H<sub>2</sub>O:10% CH<sub>3</sub>CN, 0.1% TFA to H<sub>2</sub>O, 90% CH<sub>3</sub>CN, 0.1% TFA; 8 min gradient; 50 mL/min. Method 4: column, Waters Sunfire C18, 5 μm, 30 mm × 150 mm; 5% CH<sub>3</sub>CN:95% H<sub>2</sub>O:10 mM NH<sub>4</sub>OAc to 95% CH<sub>3</sub>CN:5% H<sub>2</sub>O:10 mM NH<sub>4</sub>OAc; 8 min gradient; 50 mL/min flow rate. Method 5: column, Waters Sunfire C18, 5 μm, 30 mm × 150 mm; 90% H<sub>2</sub>O:10% CH<sub>3</sub>CN:0.1% TFA to 10% H<sub>2</sub>O:90% CH<sub>3</sub>CN:0.1% TFA; 50 mL/min; 15 min gradient; 50 mL/min. Method 6: column, Waters Sunfire C18, 5 μm, 30 mm × 150 mm; 90% H<sub>2</sub>O:10% MeOH:0.1% TFA to 10% H<sub>2</sub>O:90% MeOH:0.1% TFA; 10 min gradient; 50 mL/min. HPLC Method 7: column, Waters Sunfire C18, 5 μm, 30 mm × 150 mm; 90% H<sub>2</sub>O:10% MeOH:0.1% TFA to 10% H<sub>2</sub>O:90% MeOH:0.1% TF; 15 min gradient; 50 mL/min. Method: column, Waters Sunfire C18, 5 μm, 30 mm × 150 mm; 90% H<sub>2</sub>O:10% CH<sub>3</sub>CN:0.1% TFA to 10% H<sub>2</sub>O:90% CH<sub>3</sub>CN:0.1% TFA; 15 min gradient; 50 mL/min. Method 9: column, Waters-YMC OBD 20 mm × 100 mm S5; 5% MeOH:95% H<sub>2</sub>O:10 mM NH<sub>4</sub>OAc to 95% MeOH:5% H<sub>2</sub>O:10 mM NH<sub>4</sub>OAc; 10 min gradient; 25 mL/min. All liquid chromatography (LC) data were recorded on a Shimadzu LC-10AS liquid chromatograph using a SPD-10AV UV–vis detector with mass spectrometry (MS) data determined using a Micromass Platform for LC in electrospray mode. LCMS analyses were performed using one of the following conditions. Method 1: column, Phenomenex Luna C18, 5 μm, 3.0 mm × 50 mm; 95% H<sub>2</sub>O, 5% MeOH, 10 mM NH<sub>4</sub>OAc to 5% H<sub>2</sub>O, 95% MeOH, 10 mM NH<sub>4</sub>OAc; 2 min gradient; 4 mL/min flow rate. Method 2: column, Phenomenex Luna C18, 3 μm, 2.0 mm × 30 mm; 95% H<sub>2</sub>O, 5% CH<sub>3</sub>CN, 10 mM NH<sub>4</sub>OAc to 5% H<sub>2</sub>O, 95% CH<sub>3</sub>CN, 10 mM NH<sub>4</sub>OAc; 2 min gradient; 1 mL/min flow rate. Method 3: column, Phenomenex Luna C18, 3 μm, 2.0 mm × 30 mm; 90% H<sub>2</sub>O, 10% MeOH, 0.1% TFA to 10% H<sub>2</sub>O, 90% MeOH, 0.1% TFA; 2 min gradient; 1 mL/min flow rate. Method 4: column, Xbridge Phenyl 2.1 mm × 50 mm 2.5 μm; 90% H<sub>2</sub>O, 10% MeOH, 0.1% TFA to 10% H<sub>2</sub>O, 90% MeOH, 0.1% TFA; 2 min gradient; 0.8 mL/min flow rate. Method 5: column, Xbridge Phenyl 2.1 mm × 50 mm 2.5 μm; 90% H<sub>2</sub>O, 10% MeOH, 0.1% TFA to 10% H<sub>2</sub>O, 90% MeOH, 0.1% TFA; 2 min gradient; 0.6 mL/min flow rate. Method 6: column, Phenomenex Luna C18, 3 μm, 2.0 mm × 30 mm; 90% H<sub>2</sub>O, 10% CH<sub>3</sub>CN, 0.1% TFA to 10% H<sub>2</sub>O, 90% CH<sub>3</sub>CN, 0.1% TFA; 2 min gradient; 1 mL/min. Method 7: column, Phenomenex-Luna 2.0 mm × 50 mm 3 μm; 90% H<sub>2</sub>O, 10% MeOH, 0.1% TFA to 10% H<sub>2</sub>O, 90% MeOH, 0.1% TFA; 1 min gradient; 0.8 mL/min flow rate. Method 8: column, Phenomenex-Luna 2.0 mm × 50 mm 3 μm; 90% H<sub>2</sub>O, 10% MeOH, 0.1% TFA to 10% H<sub>2</sub>O, 90% MeOH, 0.1% TFA; 4 min gradient; 0.8 mL/min flow rate. Method 8: column, YMC Pack Pro C18 (19 mm × 150 mm); gradient: 90% A, 0 min; 90% A 0–5 min; 90–0% A, 5–20 min; 0% A, 20–25 min; 0–90% A, 25–30 min (A = H<sub>2</sub>O, 0.1% HCl, B = CH<sub>3</sub>CN, 0.1% HCl); 15 mL/min flow rate. <sup>1</sup>H NMR spectra were recorded on a Bruker DRX-500f at 500 MHz (or a Bruker AV 400 MHz, Bruker DPX-300B or Varian Gemini 300 at 300 MHz, as stated). The chemical shifts were reported in ppm on the δ scale relative to δTMS = 0. The following internal references were used for the residual protons in the following solvents: CDCl<sub>3</sub> (δ<sub>H</sub> 7.27), CD<sub>3</sub>OD (δ<sub>H</sub> 3.30), AcOH-<i>d</i><sub>4</sub> (δ<sub>H</sub> 11.6, 2.07), and CH<sub>3</sub>CN-<i>d</i><sub>3</sub> (δ<sub>H</sub> 1.94<sub>)</sub>. Standard acronyms were employed to describe the multiplicity patterns: s (singlet), br. s (broad singlet), d (doublet), t (triplet), q (quartet), m (multiplet), b (broad), app (apparent). The coupling constant (<i>J</i>) is in hertz.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure for the C-28 Amide Formation and Hydrolysis</h3><div class="NLM_p last">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(chlorocarbonyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> in ClCH<sub>2</sub>CH<sub>2</sub>Cl or CH<sub>2</sub>Cl<sub>2</sub> (0.02–0.15 M) was added Hunig’s base (3–5 equiv), the amine (1–10 equiv), and DMAP (0.03–0.1 equiv). The mixture was stirred at rt for 2–72 h, diluted with 1 N HCl or H<sub>2</sub>O, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography or was directly used in the next step with no additional purification. Note: The same reaction conditions can be used without DMAP to successfully form the corresponding amides.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedures for Hydrolysis of the Benzoate Ester</h3><div class="NLM_p">(a) The ester was dissolved in 1,4-dioxane and aqueous 1N or 10N NaOH in excess (5–20 equiv) was added and the mixture heated to 50–85 °C. The reaction progress was monitored by LC/MS and after heating for 2–24 h, all starting material was consumed. The mixture was cooled to rt and was either purified by preparative HPLC directly or was made acidic by the dropwise addition of 1 N HCl and the product crystallized from 1,4-dioxane/H<sub>2</sub>O or 1,4-dioxane/MeOH/H<sub>2</sub>O.</div><div class="NLM_p">(b) The ester was dissolved in 1,4-dioxane and H<sub>2</sub>O (4:1 or 5:1 dioxane:H<sub>2</sub>O or THF:H<sub>2</sub>O) was added followed by LiOH·H<sub>2</sub>O (3–12 equiv). The reaction mixture was heated to 50–85 °C and was monitored by LC/MS for complete consumption of the starting material. After 2–24 h, the mixture was cooled to rt and was either purified by preparative HPLC or was made acidic by dropwise addition of 1 N HCl and the product crystallized from 1,4-dioxane/H<sub>2</sub>O or dioxane/MeOH/H<sub>2</sub>O.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((3-(1,1-Dioxido-4-thiomorpholinyl)propyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>6</b>)</h4><div class="NLM_p last">The title compound was prepared following the general procedures described above for the C-28 amide formation and hydrolysis using 4-(3-aminopropyl)thiomorpholine 1,1-dioxide as the reactant amine. The product was isolated as a white solid (27 mg, 95% HPLC purity, 0.035 mmol, 65% yield). LCMS: <i>m</i>/<i>e</i> 733.44 (M + H)<sup>+</sup>, 2.11 min (method 1). <sup>1</sup>H NMR (500 MHz, AcOH-<i>d</i><sub>4</sub>) δ ppm 8.03 (d, <i>J</i> = 8.24 Hz, 2 H), 7.30 (d, <i>J</i> = 8.24 Hz, 2 H), 5.37 (d, <i>J</i> = 4.58 Hz, 1 H), 4.78 (s, 1 H), 4.65 (s, 1 H), 3.85 (br s, 4 H), 3.60 (br s, 4 H), 3.49–3.33 (m, 2 H), 3.33–3.25 (m, 2 H), 3.15 (td, <i>J</i> = 11.06, 10 4.73 Hz, 1 H), 2.66–2.54 (m, 1 H), 2.26–2.13 (m, 2 H), 1.74 (s, 3 H), 2.03–1.09 (m, 21 H), 1.08 (s, 3 H), 1.07 (s, 3 H), 1.06 (s, 3 H), 1.01 (s, 3 H), 0.99 (s, 3 H).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1,1-Dioxido-4-thiomorpholinyl)ethyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>7</b>)</h4><div class="NLM_p last">The title compound was prepared following the general procedures described above for the C-28 amide formation and hydrolysis using <i>N</i>-(2-aminoethyl)thiomorpholine 1,1-dioxide as the reactant amine. The product was isolated as a white solid (39 mg, 95% HPLC purity, 0.052 mmol, 69%). LCMS: <i>m</i>/<i>e</i> 720.18 (M + H)<sup>+</sup>, 2.15 min (method 1). <sup>1</sup>H NMR (500 MHz, AcOH-<i>d</i><sub>4</sub>) δ ppm 8.03 (d, <i>J</i> = 8.24 Hz, 2 H), 7.30 (d, <i>J</i> = 8.24 Hz, 2 H), 5.37(d, <i>J</i> = 4.58 Hz, 1 H), 4.78 (s, 1 H), 4.65 (s, 1 H), 3.83 (br s, 4 H), 3.81–3.67 (m, 2H), 3.56 (br s, 4 H), 3.46–3.31 (m, 2 H), 3.14 (td, <i>J</i> = 10.91, 4.12 Hz, 1 H), 2.60–2.48 (m, 1 H), 2.26–2.11 (m, 2 H), 1.74 (s, 3 H), 2.03–1.09 (m, 19 H), 1.08 (s, 3 H), 1.06 (s, 3 H), 1.04 (s, 3 H), 1.01 (s, 3 H), 0.99 (s, 3 H).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>R</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carboxylic Acid (<b>9</b>)</h4><div class="NLM_p">To suspension of <b>8</b> (20 g, 45.2 mmol) in CH<sub>3</sub>CN (200 mL) and CH<sub>2</sub>Cl<sub>2</sub> (300 mL) was added 4 Å molecular sieves (5 g), and the mixture was stirred for 10 min at rt. To the mixture was added NMO (15.88 g, 136 mmol) followed by TPAP (0.794 g, 2.26 mmol). After 16 h of stirring, additional NMO (2 g) and TPAP (0.08g) were added and the mixture was stirred for an additional 7 h. It was then filtered through a pad of silica gel and Celite, which was washed sequentially with CH<sub>2</sub>Cl<sub>2</sub> and a 4:1 mixture of EtOAc:hexanes. The filtrate was concentrated under reduced pressure and the residue purified by flash chromatography using a gradient of 15–20% EtOAc in hexanes. Fractions containing the major isolate were combined and concentrated under reduced pressure to give (1R,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>R</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-3a<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carbaldehyde (17.6 g, 40.1 mmol, 89% yield) as a white foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 9.68 (d, <i>J</i> = 1.5 Hz, 1H), 4.77 (d, <i>J</i> = 2.0 Hz, 1H), 4.66–4.63 (m, 1H), 2.89 (td, <i>J</i> = 11.2, 5.8 Hz, 1H), 2.56–2.36 (m, 2H), 2.16–2.03 (m, 2H), 1.97–1.84 (m, 2H), 1.71 (s, 3H), 1.08 (s, 3H), 1.03 (s, 3H), 1.00 (s, 3H), 0.97 (s, 3H), 0.94 (s, 3H), 1.83–0.87 (m, 18H).</div><div class="NLM_p last">To a solution of (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>R</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-3a<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carbaldehyde (17.6 g, 36.1 mmol) in <i>t</i>-BuOH (100 mL) was added 2-methyl-2-butene (40 mL, 476 mmol). A solution of NaClO<sub>2</sub> (15 g, 133 mmol) and NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O (25 g, 181 mmol) in H<sub>2</sub>O (200 mL) was added dropwise over 1.25 h, and the mixture was stirred at rt for an additional 45 min, at which point all starting material had been consumed (monitored by TLC). The mixture was diluted with satd NH<sub>4</sub>Cl solution (100 mL) and extracted with EtOAc (3 × 125 mL). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography using a gradient of 10–50% EtOAc in hexanes to afford <b>9</b> (16.41 g, 36.1 mmol, 100% yield) as a white foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ = 10.02 (br s, 1H), 4.75 (d, <i>J</i> = 1.8 Hz, 1H), 4.64–4.61 (m, 1H), 3.02 (td, <i>J</i> = 10.8, 4.8 Hz, 1H), 2.55–2.36 (m, 3H), 2.33–2.19 (m, 2H), 2.08–1.86 (m, 4H), 1.70 (s, 3H), 1.08 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 0.93 (s, 3H), 1.82–0.90 (m, 15H).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>R</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-Benzyl 5a,5b,8,8,11a-Pentamethyl-1-(prop-1-en-2-yl)-9-(trifluoromethylsulfonyloxy)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carboxylate (<b>10</b>)</h4><div class="NLM_p">To a mixture of <b>9</b> (14.5 g, 31.9 mmol) and K<sub>2</sub>CO<sub>3</sub> (8.81 g, 63.8 mmol) in DMF (150 mL) was added benzyl bromide (3.98 mL, 33.5 mmol). The mixture was heated to 60 °C for 16 h, then was cooled to rt and 200 mL of H<sub>2</sub>O was added. The precipitate that formed were collected by filtration and washed with excess H<sub>2</sub>O to give (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>R</i>,13a<i>R</i>,13b<i>R</i>)-benzyl 5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carboxylate as a white solid (17.37g, 31.9 mmol, 100% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.40–7.29 (m, 5H), 5.20–5.08 (m, 2H), 4.73 (d, <i>J</i> = 1.8 Hz, 1H), 4.61 (s, 1H), 3.03 (td, <i>J</i> = 11.1, 4.7 Hz, 1H), 2.53–2.45 (m, 1H), 2.44–2.36 (m, 1H), 2.29 (dt, <i>J</i> = 12.6, 3.2 Hz, 1H), 2.26–2.19 (m, 1H), 1.95–1.84 (m, 3H), 1.69 (s, 3H), 1.07 (s, 3H), 1.02 (s, 3H), 0.96 (s, 3H), 0.91 (s, 3H), 1.76–0.86 (m, 17H), 0.80 (s, 3H).</div><div class="NLM_p last">A solution of (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>R</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-benzyl 5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carboxylate (20 g, 36.7 mmol) in THF (150 mL) was cooled to −78 °C, and a solution of KHMDS (0.5 M in toluene) (147 mL, 73.4 mmol) was added. The mixture was stirred for 20 min at −78 °C, and a solution of <i>N</i>-phenyl-bis(trifluoromethanesulfonimide) (17.22 g, 47.7 mmol) in THF (50 mL) was added via cannula over 5 min. The resulting red reaction mixture was stirred at −78 °C for 2 h, at which point TLC showed only a trace amount of starting material remaining. The ice bath was removed, and reaction mixture was quenched with H<sub>2</sub>O (200 mL) and stirred to ambient temperature. The mixture was extracted with EtOAc (2 × 150 mL) and the combined organic layers washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to give a yellow foam. The crude material was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL), and MeOH (200 mL) was added to effect a white precipitate which was collected by filtration and washed with MeOH to give <b>10</b> as a white solid. The mother liquor was concentrated and the crystallization process was repeated. The two batches of product were combined to give <b>10</b> (23.27 g, 34.4 mmol, 94% yield) as white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.39–7.36 (m, 4H), 7.36–7.32 (m, 1H), 5.56 (dd, <i>J</i> = 6.7, 1.8 Hz, 1H), 5.14 (t, <i>J</i> = 1.0 Hz, 2H), 4.74 (d, <i>J</i> = 1.8 Hz, 1H), 4.61 (dd, <i>J</i> = 2.1, 1.2 Hz, 1H), 3.04 (td, <i>J</i> = 11.0, 4.6 Hz, 1H), 2.30 (dt, <i>J</i> = 12.6, 3.2 Hz, 1H), 2.27–2.20 (m, 1H), 2.15 (dd, <i>J</i> = 17.1, 6.7 Hz, 1H), 1.96–1.83 (m, 2H), 1.77–1.70 (m, 2H), 1.69 (s, 3H), 1.62 (t, <i>J</i> = 11.3 Hz, 1H), 1.49–1.42 (m, 3H), 1.42–1.26 (m, 9H), 1.23–1.18 (m, 1H), 1.14 (d, <i>J</i> = 3.4 Hz, 1H), 1.12 (s, 3H), 1.02 (s, 3H), 0.96 (s, 3H), 0.90 (s, 3H), 0.79 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 175.7, 155.3, 150.5, 136.4, 128.5, 128.2, 128.1, 119.6, 117.1, 113.8, 109.6, 65.7, 56.5, 53.2, 49.3, 48.9, 46.9, 42.4, 40.5, 40.2, 38.2, 37.9, 36.9, 36.3, 33.2, 32.0, 30.5, 29.5, 27.4, 25.5, 21.4, 19.4, 19.4, 18.9, 16.2, 15.5, 14.6, 0.5.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-Benzyl 9-(4-(Methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carboxylate (<b>11</b>)</h4><div class="NLM_p last">To a solution of <b>10</b> (6.21 g, 9.18 mmol) in 1,4-dioxane (25 mL) was added 2-propanol (25 mL) and H<sub>2</sub>O (15 mL), followed by Na<sub>2</sub>CO<sub>3</sub>.H<sub>2</sub>O (3.42 g, 27.5 mmol), 4-methoxycarbonylphenylboronic acid (2.478 g, 13.77 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.318 g, 0.275 mmol). The flask was flushed with N<sub>2</sub> and the mixture heated at reflux overnight before being cooled to rt and diluted with H<sub>2</sub>O (75 mL). The mixture was extracted with EtOAc (3 × 75 mL) and washed with brine (75 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was adsorbed onto silica gel and the product purified by flash chromatography using a gradient of 0–20% EtOAc in hexanes to give the title compound (4.16 g, 6.28 mmol, 68% yield) as a white foam. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.92 (d, <i>J</i> = 8.24 Hz, 2 H), 7.40–7.29 (m, 5 H), 7.19 (d, <i>J</i> = 8.24 Hz, 2 H), 5.28 (dd, <i>J</i> = 6.10, 1.83 Hz, 1 H), 5.19–5.07 (m, 2 H), 4.73 (d, <i>J</i> = 1.83 Hz, 1 H), 4.60 (s, 1 H), 3.90 (s, 3 H), 3.04 (td, <i>J</i> = 10.91, 4.73 Hz, 1 H), 2.20–2.32 (m, 2 H), 2.09 (dd, <i>J</i> = 17.24, 6.26 Hz, 1 H), 1.95–1.82 (m, 2 H), 1.69 (s, 3 H), 0.97 (s, 3 H), 0.95 (s, 3 H), 0.92 (s, 3 H), 0.91 (s, 3 H), 1.75–0.87 (m, 17 H), 0.82 (s, 3 H).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(Methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carboxylic Acid (<b>12</b>)</h4><div class="NLM_p">To a solution of <b>11</b> (3.82 g, 5.76 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added Et<sub>3</sub>N (1.285 mL, 9.22 mmol), <i>tert</i>-butyldimethylsilane (1.912 mL, 11.52 mmol), and PdOAc<sub>2</sub> (0.647 g, 2.88 mmol). The mixture was heated to 60 °C under an atmosphere of N<sub>2</sub> for 2 h, cooled to rt, and filtered through a pad of Celite and silica gel to remove the solids which were washed with 25% EtOAc in hexanes. The filtrate was concentrated under reduced pressure and treated with AcOH (25 mL), THF (10 mL) and H<sub>2</sub>O (3 mL). After stirring for 1 h, the solids formed were collected by filtration and washed with H<sub>2</sub>O to give (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-<i>tert</i>-butyldimethylsilyl 9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[a]chrysene-3a-carboxylate (3.62 g, 5.27 mmol, 91% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.94 (d, <i>J</i> = 8.28 Hz, 2 H), 7.21 (d, <i>J</i> = 8.28 Hz, 2 H), 5.30 (dd, <i>J</i> = 6.15, 1.63 Hz, 1 H), 4.75 (d, <i>J</i> = 1.76 Hz, 1 H), 4.62 (s, 1 H), 3.92 (s, 4 H), 3.08 (td, <i>J</i> = 10.92, 4.27 Hz, 1 H), 2.35–2.22 (m, 2 H), 2.17–2.06 (m, 1 H), 2.02–1.84 (m, 2 H), 1.71 (s, 3 H), 1.01 (s, 6 H), 0.99 (br s, 3 H), 0.98 (s, 9 H), 0.94 (s, 6 H), 1.78–0.90 (m, 16 H), 0.32–0.28 (m, 6 H).</div><div class="NLM_p last">To a solution of (1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>, 13a<i>R</i>,13b<i>R</i>)-<i>tert</i>-butyldimethylsilyl 9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysene-3a-carboxylate (3.12 g, 4.54 mmol) in 1,4-dioxane (25 mL) was added TBAF (75% wt. in H<sub>2</sub>O) (2.375 g, 6.81 mmol), and the mixture was stirred at rt for 4 h. The reaction mixture was diluted with 1 N HCl (25 mL) and H<sub>2</sub>O (5 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and partially concentrated under reduced pressure to about 10 mL volume before adding 1 N HCl (50 mL). The solids that formed were collected by filtration and washed with H<sub>2</sub>O to give <b>12</b> (2.58 g, 4.50 mmol, 99% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 571.47 (M – H)<sup>−</sup>, 3.60 min (method 1). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 9.80 (br s, 1 H), 7.92 (d, <i>J</i> = 8.24 Hz, 2 H), 7.18 (d, <i>J</i> = 8.24 Hz, 2 H), 5.32–5.26 (m, 1 H), 4.75 (s, 1 H), 4.62 (br s, 1 H), 3.90 (s, 3 H), 3.07–2.99 (m, 1 H), 2.33–2.21 (m, 2 H), 2.10 (dd, <i>J</i> = 17.09, 6.10 Hz, 1 H), 2.06–1.94 (m, 2 H), 1.70 (s, 3 H), 1.01 (br s, 3 H), 1.00 (br s, 3 H), 0.98 (s, 3 H), 0.91 (s, 6 H), 1.79–0.89 (m, 17 H).</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-Isocyanato-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (<b>13</b>)</h4><div class="NLM_p last">To a slurry of <b>12</b> (10 g, 17.46 mmol) in 1,4-dioxane (200 mL) was added Et<sub>3</sub>N (4.38 mL, 31.4 mmol), followed by diphenyl phosphoryl azide (5.82 mL, 26.2 mmol). The resulting white slurry was heated to 100 °C. After 5 h, the reaction was allowed to cool to rt, diluted with EtOAc, and washed with 1N NaOH (2 × 70 mL). The combined aqueous layer was extracted with EtOAc (2 × 150 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to a slurry (75 mL), which was stored in a refrigerator overnight. The slurry was filtered, and the white solid product was washed with Et<sub>2</sub>O. The filtrate was concentrated to a yellow slurry, which was filtered and washed with Et<sub>2</sub>O to give additional product as a white solid. The two batches of product were combined and dried under reduced pressure to give the title compound (8.6 g, 15.09 mmol, 86% yield) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.0 (2 H, d, <i>J</i> = 8.2 Hz), 7.2 (2 H, d, <i>J</i> = 8.2 Hz), 5.3 (1 H, d, <i>J</i> = 4.6 Hz), 4.8 (1 H, s), 4.7 (1 H, s), 3.9 (3 H, s), 2.6 (1 H, td, <i>J</i> = 10.8, 5.8 Hz), 2.1–2.2 (2 H, m), 1.8–2.0 (4 H, m), 1.7–1.8 (1 H, m), 1.7 (3 H, s), 1.5–1.7 (5 H, m), 1.4–1.5 (5 H, m), 1.3–1.4 (2 H, m), 1.2–1.3 (2 H, m), 1.1 (3 H, s), 1.1–1.1 (1 H, m), 1.0 (3 H, s), 1.0 (3 H, s), 1.0 (3 H, br s), 1.0 (3 H, br s). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 14.2, 15.4, 16.2, 19.2, 19.5, 20.8, 21.0, 24.7, 27.4, 29.0, 29.2, 33.3, 36.0, 37.2, 39.0, 39.0, 40.3, 41.5, 41.8, 47.8, 49.0, 49.2, 51.7, 52.6, 66.8, 71.3, 110.2, 121.3, 123.7, 127.6, 128.2, 129.8, 146.0, 148.4, 148.6, 166.9.</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-Amino-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (<b>14</b>)</h4><div class="NLM_p last">To a mixture of <b>13</b> (5.47 g, 9.60 mmol) in THF (100 mL) was added concentrated HCl (19.83 mL, 240 mmol). The resulting homogeneous mixture was stirred at rt for 72 h before being concentrated to dryness to give the HCl salt of the title product (4.98 g, 8.58 mmol, 89% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 544.5 (M + H)<sup>+</sup>, 3.26 min (method 2). <sup>1</sup>H NMR (500 MHz, 1:1 CDCl<sub>3</sub>:MeOD, MeOD lock) δ ppm 7.9 (2 H, d, <i>J</i> = 8.5 Hz), 7.3 (1 H, t, <i>J</i> = 7.8 Hz), 7.2 (2 H, d, <i>J</i> = 8.5 Hz), 7.1 (1 H, t, <i>J</i> = 7.3 Hz), 5.3 (1 H, d, <i>J</i> = 4.6 Hz), 4.8 (1 H, s), 4.7 (1 H, br s), 3.9 (2 H, s), 3.6 (2 H, dt, <i>J</i> = 15.6, 6.6 Hz), 3.3 (1 H, dt, <i>J</i> = 3.1, 1.6 Hz), 2.6 (1 H, td, <i>J</i> = 11.0, 6.1 Hz), 2.1 (1 H, dd, <i>J</i> = 17.1, 6.4 Hz), 2.0 (1 H, d, <i>J</i> = 13.4 Hz), 1.9–2.0 (1 H, m), 1.8–1.9 (2 H, m), 1.7–1.7 (3 H, m), 1.6–1.7 (3 H, m), 1.5–1.6 (3 H, m), 1.5–1.5 (2 H, m), 1.4 (1 H, br s), 1.3–1.4 (1 H, m), 1.2–1.3 (1 H, m), 1.1–1.2 (2 H, m), 1.1–1.1 (1 H, m), 1.0 (3 H, s), 1.0 (3 H, s), 0.9 (3 H, s), 0.9 (3 H, s).</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure for the Preparation of C17 Amides</h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Step 1: Amide Formation</h4><div class="NLM_p last">To a solution of <b>14</b> (0.2–0.5 mmol, 1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added DIPEA (4–5 equiv), the corresponding carboxylic acid (1.3–1.5 equiv), and HATU (1.5–1.7 equiv). The mixture was stirred at rt overnight before being concentrated under reduced pressure. The solids formed were either crystallized from MeOH or purified by preparative HPLC to give the amide product.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Step 2: Hydrolysis of the Benzoate Ester</h4><div class="NLM_p last">To a solution of the amide product from step 1 in THF (5 mL) was added LiOH.H<sub>2</sub>O (3–4 equiv) in H<sub>2</sub>O (1 mL). The mixture was heated at 75 °C until hydrolysis was complete (usually within 4–7 h), cooled to rt, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give the benzoic acid product.</div></div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure for the Alkylation of C-17 Amines and Hydrolysis of the Benzoate Ester</h3><div class="NLM_p last">To a sealable pressure vessel containing a mixture of <b>14</b> (1 equiv), alkylating agent (5 equiv), KI (1.1 equiv), and K<sub>3</sub>PO<sub>4</sub> (5 equiv) was added CH<sub>3</sub>CN (0.02–0.1 M). The mixture was flushed with N<sub>2</sub>, then the vial was sealed and heated at 120 °C until the reaction was complete by LC/MS (typically 6–18 h). The reaction mixture was cooled to rt, diluted with H<sub>2</sub>O, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude alkylated product was dissolved in 1,4-dioxane, and 1N or 10N NaOH (10–50 equiv) was added. The mixture was heated at 75–80 °C for 3 h, cooled to rt, filtered, and the residue purified by preparative HPLC to give the title product. Alternatively, basic hydrolysis using LiOH could also be used as described above in the general procedure for the preparation of C17 amides.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedure for the Alkylation of the C-17 Amine via Alkylchoride <b>20</b></h3><div class="NLM_p">A mixture of chloroethyl intermediate <b>20</b> (1 equiv), Hunig’s Base (5 equiv), and a secondary amine (2 equiv) in DMSO (3 mL) was heated to 120 °C for 1 h. The reaction mixture was quenched with H<sub>2</sub>O (10 mL) and extracted with EtOAc (3 × 8 mL). The extracts were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography to provide the desired product. A mixture of carboxylate (1 equiv) and sodium hydroxide (10 equiv) in 1,4-dioxane (1 mL) was heated to 80 °C for 3 h. The reaction mixture was filtered, and the clear solution was purified by preparative HPLC. Fractions containing the product were combined and concentrated under reduced pressure to provide the desired product.</div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Preparation of <b>20</b></h4><div class="NLM_p">A mixture of <b>14</b> (1,500 mg, 2.76 mmol), 2-bromoethanol (1,034 mg, 8.27 mmol), K<sub>3</sub>PO<sub>4</sub> (1,756 mg, 8.27 mmol), and KI (916 mg, 5.52 mmol) in CH<sub>3</sub>CN (10 mL) was heated at 120 °C for 15 h. The reaction mixture was poured into distilled H<sub>2</sub>O (40 mL) and the white precipitate filtered off, washed with distilled H<sub>2</sub>O (100 mL), and dried under reduced pressure to provide methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-hydroxyethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (1.4 g, 86%). LCMS: <i>m</i>/<i>e</i> 588.5 (M + H)<sup>+</sup>, 2.40 min (method 3).</div><div class="NLM_p last">A mixture of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-hydroxyethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (1.40 g, 2.381 mmol) and SOCl<sub>2</sub> (1.74 mL, 23.8 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was heated at 60 °C for 2 h. The reaction mixture was concentrated under reduced pressure to provide <b>20</b> as a brown solid (1.30 g, 90%). LCMS: <i>m</i>/<i>e</i> 606.48 (M + H)<sup>+</sup>, 2.46 min (method 3).</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(((2-(1,1-Dioxido-4-thiomorpholinyl)ethoxy)carbonyl)amino)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-5a,5b,8,8,11a-pentamethyl-1-(1-methylethenyl)-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>23</b>)</h4><div class="NLM_p last">To a solution of 4-(2-hydroxyethyl)thiomorpholine 1,1-dioxide (377 mg, 2.11 mmol) in THF (5 mL) was added NaH (70 mg, 1.76 mmol). The resulting suspension was stirred at rt. After 25 min, <b>13</b> (200 mg, 0.35 mmol) was added in one portion. The resulting suspension was stirred for 20 h, then poured into 0.1 N HCl (5 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to give a white foam. The crude material was purified by reversed phase preparative HPLC (method 1) to give the title compound (74.4 mg, 95% HPLC purity, 0.08 mmol, 24% yield). LCMS: <i>m</i>/<i>e</i> 735.3 (M + H)<sup>+</sup>, 2.63 min (method 2). <sup>1</sup>H NMR (500 MHz, MeOH-<i>d</i><sub>4</sub>) δ = 7.95 (d, <i>J</i> = 8.5 Hz, 2 H), 7.25 (d, <i>J</i> = 8.5 Hz, 2 H), 5.33 (dd, <i>J</i> = 1.7, 6.3 Hz, 1 H), 4.79 (d, <i>J</i> = 1.8 Hz, 1 H), 4.66 (s, 1 H), 4.38–4.28 (m, 1 H), 4.27–4.19 (m, 1 H), 3.56–3.43 (m, 3 H), 3.31 (br s, 2 H), 3.17 (br s, 2 H), 2.71 (dt, <i>J</i> = 5.3, 11.1 Hz, 1 H), 2.57 (d, <i>J</i> = 13.4 Hz, 1 H), 2.33 (dd, <i>J</i> = 8.4, 12.1 Hz, 1 H), 2.18 (dd, <i>J</i> = 6.4, 17.1 Hz, 1 H), 2.00–1.89 (m, 2 H), 1.84–1.76 (m, 2 H), 1.75 (s, 3 H), 1.73 (d, <i>J</i> = 4.3 Hz, 1 H), 1.71–1.64 (m, 1 H), 1.62–1.56 (m, 2 H), 1.56–1.48 (m, 4 H), 1.47–1.35 (m, 4 H), 1.31 (dt, <i>J</i> = 4.0, 9.3 Hz, 2 H), 1.15 (s, 3 H), 1.12 (d, <i>J</i> = 3.1 Hz, 1 H), 1.07 (s, 6 H), 0.99 (s, 3 H), 0.97 (s, 3 H). <sup>13</sup>C NMR (101 MHz MeOH-<i>d</i><sub>4</sub><b>)</b> δ ppm 14.5, 16.2, 16.7, 19.2, 20.6, 21.3, 22.1, 26.2, 28.2, 29.7, 30.4, 34.5, 35.8, 37.1, 38.1, 38.2, 41.5, 42.5, 42.8, 46.5, 47.8, 49.3, 50.1, 50.5, 50.7, 52.1, 54.0, 56.3, 60.9, 65.0, 110.3, 124.9, 129.4, 130.9, 147.4, 149.7, 150.8, 156.2, 169.6.</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Preparation of 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(((2-(1,1-Dioxido-4-thiomorpholinyl)ethyl)carbamoyl)amino)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>24</b>)</h4><div class="NLM_p last">To a vial containing <b>13</b> (0.15 g, 0.26 mmol) was added 4-(2-aminoethyl)thiomorpholine 1,1-dioxide (0.14 g, 0.79 mmol), followed by THF (2 mL) and DIPEA (0.14 mL, 0.79 mmol). The vial was capped, and the mixture was shaken at rt for 2 h. The mixture was concentrated to half of its original volume and then diluted with MeOH and THF, filtered, and purified by preparative HPLC (method 1). The fractions containing the product were combined and concentrated to give the urea product (0.170 g, 0.196 mmol, 74% yield) as a white solid. To a vial containing the urea (120 mg, 0.14 mmol) was added LiOH·H<sub>2</sub>O (0.04 g, 0.84 mmol), H<sub>2</sub>O (1 mL), and 1,4-dioxane (2 mL). The mixture was heated at 75 °C for 1 h before being concentrated under a stream of N<sub>2</sub>. The crude material was dissolved in THF and MeOH, filtered, and purified by preparative HPLC (method 2) to give the title product (121 mg, 98% HPLC purity, 0.14 mmol, 100% yield) as a white solid. LCMS: <i>m</i>/<i>z</i> 734 (M + H<sup>+</sup>), retention time 2.49 min (method 3). <sup>1</sup>H NMR (500 MHz, 1:1 mixture of CDCl<sub>3</sub> and MeOD, MeOD lock) δ ppm, 7.93 (m, <i>J</i> = 8.24 Hz, 2 H) 7.21 (m, <i>J</i> = 8.24 Hz, 2 H), 5.29 (d, <i>J</i> = 4.58 Hz, 1 H), 4.75 (d, <i>J</i> = 1.22 Hz, 1 H), 4.63 (s, 1 H), 3.69 (br s, 4 H), 3.39–3.52 (m, 6 H), 3.20 (br s, 2 H), 2.52–2.63 (m, 2 H), 2.35 (dd, <i>J</i> = 12.05, 8.39 Hz, 1 H), 2.13 (dd, <i>J</i> = 17.24, 6.26 Hz, 1 H), 1.86–2.00 (m, 1 H), 1.63–1.82 (m, 8 H), 1.21–1.60 (m, 11 H), 1.11–1.17 (m, 2 H), 1.10 (s, 3 H), 1.03 (br s, 3 H), 1.02 (br s, 3 H), 0.95 (s, 3 H), 0.94 (s, 3 H).</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((3-(1,1-Dioxido-4-thiomorpholinyl)-1-oxopropyl)amino)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-5a,5b,8,8,11a-pentamethyl-1-(1-methylethenyl)-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>25</b>)</h4><div class="NLM_p last">The title compound was prepared following the general procedure for the preparation of C-17 amides using 3-(1,1-dioxidothiomorpholino)propanoic acid in step 1. The crude material was purified by reversed phase preparative HPLC (method 3) to give the title compound as a white solid (115 mg, 96% HPLC purity, 0.13 mmol, 70% yield over 2 steps). <i>m</i>/<i>e</i> 719.5 (M + H)<sup>+</sup>, 1.88 min (method 2). <sup>1</sup>H NMR (500 MHz, 2:1 MeOH-<i>d</i><sub>4</sub>:CDCl<sub>3</sub>) δ = 7.93 (d, <i>J</i> = 7.9 Hz, 2 H), 7.25 (br s, 1 H), 7.21 (d, <i>J</i> = 7.9 Hz, 2 H), 5.30 (d, <i>J</i> = 6.1 Hz, 1 H), 4.78 (s, 1 H), 4.66 (s, 1 H), 3.47 (br s, 4 H), 3.36 (br s, 4 H), 3.19 (br s, 2 H), 2.72–2.59 (m, 4 H), 2.40 (dd, <i>J</i> = 8.9, 11.9 Hz, 1 H), 2.15 (dd, <i>J</i> = 6.3, 17.2 Hz, 1 H), 1.98–1.86 (m, 2 H), 1.80 (d, <i>J</i> = 13.1 Hz, 1 H), 1.73 (s, 3 H), 1.71–1.66 (m, 1 H), 1.63–1.43 (m, 8 H), 1.42–1.23 (m, 5 H), 1.22–1.13 (m, 2 H), 1.12 (s, 3 H), 1.05 (br s, 3 H), 1.04 (br s, 3 H), 0.97 (br s, 3 H), 0.95 (br s, 3 H). <sup>13</sup>C NMR (101 MHz 2:1 MeOH-<i>d</i><sub>4</sub>:CDCl<sub>3</sub>) δ ppm 15.0, 16.5, 17.1, 19.6, 20.7, 21.6, 22.3, 26.3, 28.3, 29.5, 30.0, 30.5, 33.1, 34.5, 35.6, 37.2, 38.4, 38.5, 41.6, 42.6, 42.9, 48.1, 50.2, 50.4, 50.5, 51.8, 53.8, 53.9, 66.3, 110.9, 124.9, 129.3, 129.6, 131.0, 147.4, 149.7, 150.4, 169.9, 172.2.</div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(((1,1-Dioxido-4-thiomorpholinyl)acetyl)amino)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-5a,5b,8,8,11a-pentamethyl-1-(1-methylethenyl)-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl) benzoic Acid (<b>26</b>)</h4><div class="NLM_p last">The title compound was prepared following the general procedure for the preparation of C-17 amides using 2-(1,1-dioxidothiomorpholino)acetic acid in step 1. The crude material was purified by reversed phase preparative HPLC (method 3) to give the title compound as a white solid (90.3 mg, 100% HPLC purity, 0.11 mmol, 61% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 704.5 (M + H)<sup>+</sup>, 1.90 min (method 2). <sup>1</sup>H NMR (500 MHz, 2:1 MeOD:CDCl<sub>3</sub>) δ = 7.93 (d, <i>J</i> = 8.2 Hz, 2 H), 7.23 (br s, 1 H), 7.21 (s, 2 H), 5.31 (dd, <i>J</i> = 1.7, 6.0 Hz, 1 H), 4.78 (d, <i>J</i> = 1.2 Hz, 1 H), 4.67 (s, 1 H), 3.29 (d, <i>J</i> = 5.2 Hz, 4 H), 3.24 (d, <i>J</i> = 5.2 Hz, 4 H), 2.67–2.60 (m, 1 H), 2.53 (dt, <i>J</i> = 5.5, 10.8 Hz, 1 H), 2.47 (dd, <i>J</i> = 8.1, 12.7 Hz, 1 H), 2.16 (dd, <i>J</i> = 6.3, 17.2 Hz, 1 H), 1.94–1.78 (m, 3 H), 1.76 (d, <i>J</i> = 2.1 Hz, 1 H), 1.74 (s, 3 H), 1.62–1.49 (m, 7 H), 1.47–1.33 (m, 4 H), 1.31–1.25 (m, 1 H), 1.21–1.13 (m, 2 H), 1.12 (s, 3 H), 1.07 (s, 3 H), 1.05 (s, 3 H), 0.97 (s, 3 H), 0.96 (s, 3 H). <sup>13</sup>C NMR (101 MHz, 2:1 MeOH-<i>d</i><sub>4</sub>:CDCl<sub>3</sub>) δ ppm 15.0, 16.3, 17.1, 19.5, 20.7, 21.6, 22.2, 26.2, 28.2, 29.5, 30.0, 30.5, 34.4, 35.3, 37.2, 38.3, 39.3, 41.5, 42.6, 42.9, 49.7, 50.1, 50.4, 51.1, 52.4, 53.9, 60.2, 65.9, 79.0, 111.1, 124.9, 129.4, 129.6, 131.0, 147.4, 149.7, 150.1, 169.8, 169.9.</div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1,1-Dioxido-4-thiomorpholinyl)-1-oxopropyl)amino)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-5a,5b,8,8,11a-pentamethyl-1-(1-methylethenyl)-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl) benzoic Acid (<b>27</b>)</h4><div class="NLM_p last">The title compound was prepared following the general procedure for the preparation of C-17 amides using 2-(1,1-dioxidothiomorpholin-4-yl)-propionic acid in step 1. The crude material was purified by reverse phase preparative HPLC (method 3) to give the title compound as a white solid (127 mg, 96% HPLC purity, 0.15 mmol, 44% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 719.5 (M + H)<sup>+</sup>, 2.03 min (method 2). <sup>1</sup>H NMR (500 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ = 7.92 (d, <i>J</i> = 8.2 Hz, 2 H), 7.54 (s, 1 H), 7.20 (d, <i>J</i> = 7.9 Hz, 2 H), 5.29 (d, <i>J</i> = 5.2 Hz, 1 H), 4.75 (d, <i>J</i> = 10.4 Hz, 1 H), 4.66 (br s, 1 H), 3.48–3.39 (m, 1 H), 3.28–3.11 (m, 8 H), 2.69–2.55 (m, 1 H), 2.50–2.34 (m, 2 H), 2.13 (dd, <i>J</i> = 6.1, 17.1 Hz, 1 H), 1.80 (d, <i>J</i> = 11.6 Hz, 2 H), 1.72 (s, 6 H), 1.59–1.44 (m, 8 H), 1.43–1.36 (m, 2 H), 1.33 (dd, <i>J</i> = 6.9, 14.8 Hz, 4 H), 1.25 (d, <i>J</i> = 6.7 Hz, 1 H), 1.15 (d, <i>J</i> = 11.0 Hz, 2 H), 1.08 (s, 3 H), 1.03 (s, 3 H), 1.01 (s, 3 H), 0.94 (br s, 6 H).</div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(2-(1,1-Dioxidothiomorpholino)-3-methylbutanamido)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>28</b>)</h4><div class="NLM_p last">The title compound was prepared following the general procedure for the preparation of C-17 amides using 2-(1,1-dioxidothiomorpholino)-3-methylbutanoic acid in step 1. The crude material was purified by reversed phase preparative HPLC (method 3) to give the title compound. LCMS: <i>m</i>/<i>e</i> 747.5 (M + H)<sup>+</sup>, 2.29 min (method 2). <sup>1</sup>H NMR (500 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ = 7.92 (d, <i>J</i> = 8.5 Hz, 2 H), 7.20 (d, <i>J</i> = 8.2 Hz, 2 H), 6.40 (s, 1 H), 5.29 (dd, <i>J</i> = 1.5, 6.1 Hz, 1 H), 4.76 (d, <i>J</i> = 1.5 Hz, 1 H), 4.64 (s, 1 H), 3.77–3.72 (m, 1 H), 3.23–3.14 (m, 2 H), 3.13–3.06 (m, 4 H), 3.05–2.99 (m, 2 H), 2.80 (d, <i>J</i> = 10.4 Hz, 1 H), 2.74–2.67 (m, 1 H), 2.61 (dt, <i>J</i> = 5.3, 11.1 Hz, 1 H), 2.49 (dd, <i>J</i> = 8.4, 12.7 Hz, 1 H), 2.12 (dd, <i>J</i> = 6.4, 17.1 Hz, 1 H), 2.08–2.01 (m, 1 H), 1.99–1.91 (m, 1 H), 1.88 (ddd, <i>J</i> = 3.1, 3.3, 6.8 Hz, 1 H), 1.86–1.82 (m, 1 H), 1.78 (d, <i>J</i> = 11.0 Hz, 1 H), 1.72 (br s, 1 H), 1.71 (s, 3 H), 1.69 (d, <i>J</i> = 4.6 Hz, 1 H), 1.67–1.63 (m, 1 H), 1.61–1.53 (m, 2 H), 1.51 (br s, 1 H), 1.48 (br s, 2 H), 1.47–1.41 (m, 2 H), 1.12 (dd, <i>J</i> = 3.4, 13.4 Hz, 2 H), 1.07 (s, 3 H), 1.01 (br s, 3 H), 1.00 (s, 3 H), 0.99 (s, 3 H), 0.97 (d, <i>J</i> = 6.7 Hz, 3 H), 0.93 (s, 3 H), 0.93 (s, 3 H). <sup>13</sup>C NMR (101 MHz 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ ppm 172.2, 170.1, 150.3, 149.8, 147.4, 131.0, 129.7, 129.2, 124.9, 111.3, 78.7, 76.0, 68.9, 66.7, 53.9, 53.6, 50.5, 50.2, 50.0, 49.8, 49.6, 48.2, 43.0, 42.8, 41.7, 38.4, 37.3, 35.9, 34.6, 30.6, 30.2, 29.5, 28.4, 28.1, 26.5, 26.2, 22.3, 21.8, 20.7, 20.1, 19.7, 17.4, 16.7, 15.2.</div></div><div id="sec5_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((3-(1,1-Dioxidothiomorpholino)propyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>29</b>)</h4><div class="NLM_p">To a solution of <b>14</b> (40 mg, 0.07 mmol) in EtOH (1.0 mL) and 1,4-dioxane (1.0 mL) was added AcOH (0.01 mL, 0.22 mmol) and <i>tert</i>-butyl 3-oxopropylcarbamate (38.2 mg, 0.22 mmol). The reaction mixture was stirred for 2 h, NaBH(OAc)<sub>3</sub> (78 mg, 0.37 mmol) was added, and stirring continued at rt for 2 h. The mixture was quenched with satd aq NaHCO<sub>3</sub>, diluted with 0.1 N HCl, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide <b>18</b> as a pale-yellow oil (28 mg, 0.04 mmol, 54% yield). LCMS: <i>m</i>/<i>e</i> 701.5 (M + H)<sup>+</sup>, 3.92 min (method 2).</div><div class="NLM_p">To a solution of <b>18</b> (23 mg, 0.03 mmol) in 1,4-dioxane was added HCl (4 M in 1,4-dioxane) (33 μL, 0.13 mmol), the reaction mixture was stirred for 6 h at rt before being concentrated under reduced pressure to provide methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(3-aminopropylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate as a brown oil (15 mg, 0.03 mmol, 76% yield). LCMS: <i>m</i>/<i>e</i> 601.5 (M + H)<sup>+</sup>, 2.88 min (method 2).</div><div class="NLM_p">To a mixture of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(3-aminopropylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (15 mg, 0.03 mmol) in EtOH (1 mL) was added vinylsulfonylethene (5.9 mg, 0.05 mmol) and TEA (7.0 μL, 0.05 mmol). The reaction mixture was heated at 100 °C for 3 h before being concentrated under reduced pressure to provide methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((3-(1,1-dioxidothiomorpholino)propyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate as a brown solid (15 mg, 0.02 mmol, 84% yield). LCMS: <i>m</i>/<i>e</i> 719.46 (M + H)<sup>+</sup>, 3.62 min (method 2).</div><div class="NLM_p last">To a mixture of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((3-(1,1-dioxidothiomorpholino)propyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (15 mg, 0.02 mmol) in 1,4-dioxane (1 mL) was added 1 N NaOH (0.10 mL, 0.10 mmol), and the mixture was heated at 78 °C for 3 h. The mixture was cooled to rt and the product purified by preparative HPLC with a MeOH/H<sub>2</sub>O/TFA gradient to provide <b>29</b> as a white solid (9 mg, 95% HPLC purity, 0.01 mmol, 58% yield). LCMS: <i>m</i>/<i>e</i> 705.49 (M + H)<sup>+</sup>, 2.60 min (method 2). <sup>1</sup>H NMR (400 MHz, AcOH-<i>d</i><sub>4</sub>) δ ppm 7.99 (d, <i>J</i> = 8.28 Hz, 2 H), 7.25 (d, <i>J</i> = 8.28 Hz, 2 H), 5.33 (d, <i>J</i> = 4.77 Hz, 1 H), 4.82 (s, 1 H), 4.71 (s, 1 H), 3.87 (br s, 4 H), 3.56 (d, <i>J</i> = 4.27 Hz, 4 H), 3.51–3.40 (m, 2 H), 3.39–3.22 (m, 2 H), 2.86–2.69 (m, 1 H), 2.57–2.34 (m, 2 H), 2.27–1.18 (m, 22 H), 1.72 (s, 3 H), 1.16 (s, 3 H), 1.10 (s, 3 H), 1.04 (s, 3 H), 0.98 (s, 3 H), 0.96 (s, 3 H).</div></div><div id="sec5_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-(2-morpholinoethylamino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>30</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of C-17 amines and hydrolysis of the benzoate ester above using 4-(2-chloroethyl)morpholine hydrochloride as the alkylating agent. The product was isolated as a white solid (65 mg, 90% HPLC purity, 49% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 643.6 (M + H)<sup>+</sup>, 2.35 min (method 4). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ ppm 7.95 (m, <i>J</i> = 8.3 Hz, 2 H), 7.24 (m, <i>J</i> = 8.3 Hz, 2 H), 5.31 (d, <i>J</i> = 4.8 Hz, 1 H), 4.86 (s, 1 H), 4.74 (s, 1 H), 3.82–3.99 (m, 4 H), 3.37–3.58 (m, 4 H), 3.21 (d, <i>J</i> = 4.5 Hz, 2 H), 3.19 (br s, 2 H), 2.67–2.86 (m, 1 H), 2.02–2.26 (m, 5 H), 1.83–1.90 (m, 1 H), 1.64–1.81 (m, 8 H), 1.45–1.64 (m, 7 H), 1.34–1.45 (m, 2 H), 1.27–1.34 (m, 1 H), 1.15–1.27 (m, 4 H), 1.12 (s, 3 H), 1.04 (s, 3 H), 0.99 (s, 3 H), 0.93 (s, 3 H).</div></div><div id="sec5_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-(1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(2-(4,4-Difluoropiperidin-1-yl)ethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>31</b>)</h4><div class="NLM_p last">A mixture of chloroethyl intermediate (<b>20</b>) (50 mg, 0.082 mmol), 4,4-difluoropiperidine (40.0 mg, 0.330 mmol), K<sub>3</sub>PO<sub>4</sub> (77 mg, 0.363 mmol), and NaI (37.0 mg, 0.223 mmol) were combined and diluted with acetonitrile (5 mL). The tube was flushed with nitrogen, sealed, and heated to 120 °C for 19 h. The mixture was cooled to rt, diluted with water, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide the crude alkylated product. The crude alkylated product was diluted with 1,4-dioxane (1.0 mL), and 1N NaOH (1.0 mL, 1.0 mmol) was added. The mixture was heated to 70 °C for 3 h, then was cooled to rt and was purified by preparative HPLC. Fractions containing the product were combined and concentrated under reduced pressure to give <b>31</b> as a white solid (20 mg, 95% HPLC purity, 36% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 677.57 (M + H)<sup>+</sup>, 2.30 min (method 11). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.97 (d, <i>J</i> = 8.3 Hz, 2H), 7.22 (d, <i>J</i> = 8.3 Hz, 2H), 5.27 (d, <i>J</i> = 4.8 Hz, 1H), 4.82 (s, 1H), 4.70 (s, 1H), 3.32 (m, 1H), 3.19–3.05 (m, 1H), 2.94 (m, 2H), 2.83–2.68 (m, 5H), 2.36–2.21 (m, 2H), 2.15–1.90 (m, 7H), 1.74 (br s, 7H), 1.60–1.45 (m, 6H), 1.44–1.30 (m, 4H), 1.26 (s, 2H), 1.18 (s, 3H), 1.06 (s, 4H) 0.98 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H). <sup>19</sup>F NMR (376 MHz, chloroform-<i>d</i>) δ −98.39 (br s, 2F).</div></div><div id="sec5_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(2-Hydroxyethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>32</b>)</h4><div class="NLM_p">To a solution of <b>14</b> (300 mg, 0.55 mmol) in ClCH<sub>2</sub>CH<sub>2</sub>Cl (4 mL) was added (<i>tert</i>-butyldimethylsilyloxy)acetaldehyde (131 mL, 0.69 mmol) and Ti(<sup>i</sup>PrO)<sub>4</sub> (0.20 mL, 0.69 mmol). The mixture was stirred at rt for 45 min, NaBH(OAc)<sub>3</sub> (234 mg, 1.10 mmol) was added, and the mixture was stirred at rt for 23 h before an additional 0.1 mL of (<i>tert</i>-butyldimethylsilyloxy)acetaldehyde and NaBH(OAc)<sub>3</sub> (150 mg) were added. The mixture was stirred at rt for 22 h, diluted with satd NaHCO<sub>3</sub> (15 mL), and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate concentrated under reduced pressure. The residue was adsorbed onto silica gel and purified by flash chromatography using a 0–10% EtOAc in hexanes gradient to give <b>17</b> (0.21 g, 0.30 mmol, 54.5% yield) as a clear yellow film. <b>17</b> was used in the next step with no additional purification. LCMS: <i>m</i>/<i>e</i> 702.7 (M + H)<sup>+</sup>, 2.35 min (method 6).</div><div class="NLM_p">To a solution of <b>17</b> (0.21 g, 0.30 mmol) in THF (2 mL) was added TBAF (1 M in THF) (0.601 mL, 0.601 mmol). The mixture was stirred at rt for 2.75 h, diluted with H<sub>2</sub>O (10 mL), and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate concentrated under reduced pressure. The residue was adsorbed onto silica gel and purified by flash chromatography using a 0–25% EtOAc in hexanes gradient to give methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(2-hydroxyethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (93.4 mg, 0.16 mmol, 52.9% yield) as a colorless film. LCMS: <i>m</i>/<i>e</i> 588.6 (M + H)<sup>+</sup>, 1.98 min (method 6). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.91 (d, <i>J</i> = 8.24 Hz, 2 H), 7.18 (d, <i>J</i> = 8.24 Hz, 2 H), 5.27 (d, <i>J</i> = 4.58 Hz, 1 H), 4.70 (d, <i>J</i> = 1.83 Hz, 1 H), 4.59 (s, 1 H), 3.89 (s, 3 H), 3.54–3.64 (m, 2 H), 2.52–2.69 (m, 3 H), 2.09 (dd, <i>J</i> = 17.09, 6.41 Hz, 1 H), 1.68 (s, 3 H), 1.07 (s, 3 H), 0.98 (s, 3 H), 0.97 (s, 3 H), 0.93–2.05 (m, 21 H), 0.91 (s, 3 H), 0.91 (s, 3 H).</div><div class="NLM_p last">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(2-hydroxyethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (35 mg, 0.06 mmol) in 1,4-dioxane (1 mL) was added NaOH (1N) (0.3 mL, 0.3 mmol). The mixture was heated at 85 °C for 15 h, cooled to rt, and diluted with MeOH and purified by preparative HPLC to give <b>32</b> (25 mg, 0.04 mmol, 69.5% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 574.5 (M + H)<sup>+</sup>, 1.69 min (method 6). <sup>1</sup>H NMR (500 MHz, AcOH-<i>d</i><sub>4</sub>) δ ppm 8.04 (2 H, d, <i>J</i> = 8.2 Hz), 7.30 (2 H, d, <i>J</i> = 8.2 Hz), 5.37 (1 H, d, <i>J</i> = 4.6 Hz), 4.86 (1 H, s), 4.75 (1 H, s), 3.95–4.11 (2 H, m), 3.25–3.43 (2 H, m), 2.90–2.98 (1 H, m), 1.77 (3 H, s), 1.21 (3 H, s), 1.14 (3 H, s), 1.09 (3 H, s), 1.02 (3 H, s), 1.00 (3 H, s), 0.97–2.32 (22 H, m).</div></div><div id="sec5_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1,1-Dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>33</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of C-17 amines and hydrolysis of the benzoate ester described above using 2-(tetrahydro-2<i>H</i>-thiopyran-4-yl)ethylmethanesulfonate as the alkylating agent to give <b>15</b>. <b>15</b> (45 mg, 0.07 mmol) was diluted with MeOH (2 mL) and oxone (61.7 mg, 0.10 mmol) in H<sub>2</sub>O (2.0 mL) was added at 0 °C. The mixture was diluted with acetone (5 mL) and stirred at 0 °C for 2 h, diluted with 10 mL of H<sub>2</sub>O, and extracted with EtOAc. The organic layer was washed with NaHSO<sub>4</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was treated with the typical hydrolysis conditions using NaOH described above. <b>33</b> was isolated as a white solid after preparative HPLC purification (5.0 mg, 95% HPLC purity, 6.9 μmol, 17% yield over three steps). LCMS: <i>m</i>/<i>e</i> 690.45 (M + H)<sup>+</sup>, 2.76 min (method 5). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.46–9.17 (m, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 2H), 7.22 (d, <i>J</i> = 8.3 Hz, 2H), 6.22 (br d, <i>J</i> = 1.5 Hz, 1H), 5.21 (br d, <i>J</i> = 5.3 Hz, 1H), 4.83 (s, 1H), 4.69 (br s, 1H), 3.23 (br s, 1H), 3.13–2.92 (m, 5H), 2.88–2.73 (m, 1H), 1.68 (s, 3H), 1.15 (s, 3H), 1.04 (s, 3H), 1.00 (s, 3H), 0.95 (br s, 6H), 2.33–0.84 (m, 29H).</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Preparation of 2-(Tetrahydro-2<i>H</i>-thiopyran-4-yl)ethylmethanesulfonate</h3><div class="NLM_p">A solution of 2-(tetrahydro-2<i>H</i>-thiopyran-4-yl)ethanol (144 mg, 0.985 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was cooled in an ice bath, and Hunig’s base (0.429 mL, 2.46 mmol) was added followed by CH<sub>3</sub>SO<sub>2</sub>Cl (0.114 mL, 1.48 mmol). The mixture was stirred at 0 °C for 30 min and then placed in a refrigerator overnight. The mixture was diluted with H<sub>2</sub>O (2 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0–100% EtOAc in hexanes gradient to give the title compound (0.169 g, 0.753 mmol, 76% yield) as a pale oil. LCMS: <i>m</i>/<i>e</i> 225.05 (M + H)<sup>+</sup>, 2.02 min (method 8). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>-<i>d</i>) δ 4.29 (t, <i>J</i> = 6.5 Hz, 2H), 3.02 (s, 3H), 2.76–2.55 (m, 4H), 2.08–1.99 (m, 2H), 1.69 (q, <i>J</i> = 6.4 Hz, 2H), 1.61–1.48 (m, 1H), 1.47–1.34 (m, 2H).</div><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1,1-Dioxido-1,2-thiazinan-2-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>34</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of C-17 amines and hydrolysis of the benzoate ester above using 1-(2-chloroethyl)-4-(methylsulfonyl)piperazine<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> as the alkylating reagent. The product was isolated as a white solid (5.2 mg, 95% HPLC purity, 19% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 691.55 (M + H)<sup>+</sup>, 2.35 min (method 11). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (d, <i>J</i> = 8.3 Hz, 2H), 7.23 (d, <i>J</i> = 8.5 Hz, 2H), 5.27 (d, <i>J</i> = 4.5 Hz, 1H), 4.82 (s, 1H), 4.70 (s, 1H), 3.87–3.74 (m, 1H), 3.72–3.48 (m, 3H), 3.39 (br s, 2H), 3.18–3.08 (m, 2H), 2.96–2.78 (m, 1H), 2.34–1.10 (m, 26H), 1.71 (s, 3H), 1.23 (s, 3H), 1.05 (s, 3H), 0.99 (s, 3H), 0.96 (s, 3H), 0.96 (s, 3H).</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1,1-Dioxido-1,4-thiazepan-4-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>35</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of C-17 amines and hydrolysis of the benzoate ester described above using 4-(2-chloroethyl)-1,4-thiazepane 1,1-dioxide, HCl salt as the alkylating agent.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The title product was isolate as a white solid after preparative HPLC purification (4.7 mg, 95% HPLC purity, 0.006 mmol, 29% yield). LCMS: <i>m</i>/<i>e</i> 705.6 (M + H)<sup>+</sup>, 1.75 min (method 2). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.97 (d, <i>J</i> = 8.3 Hz, 2H), 7.28 (d, <i>J</i> = 8.0 Hz, 2H), 5.36–5.26 (m, 1H), 4.73 (d, <i>J</i> = 2.0 Hz, 1H), 4.59 (s, 1H), 3.27–3.18 (m, 4H), 3.06 (br dd, <i>J</i> = 7.7, 2.6 Hz, 2H), 2.95 (t, <i>J</i> = 6.1 Hz, 2H), 2.80 (td, <i>J</i> = 5.6, 2.9 Hz, 2H), 2.73–2.47 (m, 3H), 1.71 (s, 3H), 1.18 (s, 3H), 1.05 (s, 6H), 0.98 (s, 3H), 0.97 (s, 3H), 2.29–0.90 (m, 24H).</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Preparation of 4-(2-Chloroethyl)-1,4-thiazepane 1,1-dioxide<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></h3><div class="NLM_p">A mixture of 1,4-thiazepane 1,1-dioxide (200 mg, 1.340 mmol), 2-chloroacetaldehyde (295 mg, 1.877 mmol), and borane-2-picoline complex (158 mg, 1.474 mmol) in MeOH (5 mL) and AcOH (1 mL) was stirred at rt for 17 h. The reaction mixture was washed with satd aq Na<sub>2</sub>CO<sub>3</sub> (10 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide the desired product as a colorless oil. The oil was diluted with 1 M HCl in Et<sub>2</sub>O (5 mL) and concentrated under reduced pressure to give the HCl salt of the product (80 mg, 0.322 mmol, 24% yield), which was used with no additional purification. LCMS: <i>m</i>/<i>e</i> 212.1 (M + H)<sup>+</sup>, 0.28 min (method 2).</div><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-((1,1-Dioxidotetrahydrothiophen-3-yl)amino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>36</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of C-17 amines and hydrolysis of the benzoate ester described above using 3-((2-chloroethyl)amino)tetrahydrothiophene 1,1-dioxide as the alkylating agent.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The title product was isolated as a white solid after preparative HPLC purification (26 mg, 95% HPLC purity, 0.036 mmol, 39% yield). LCMS: <i>m</i>/<i>e</i> 691.46 (M + H)+, 2.24 min (method 3). <sup>1</sup>H NMR (500 MHz, AcOH-<i>d</i><sub>4</sub>) δ 8.04 (d, <i>J</i> = 8.2 Hz, 2H), 7.30 (d, <i>J</i> = 8.2 Hz, 2H), 5.37 (d, <i>J</i> = 4.9 Hz, 1H), 4.87 (s, 1H), 4.75 (s, 1H), 4.06 (quin, <i>J</i> = 7.7 Hz, 1H), 3.67–3.45 (m, 4H), 3.44–3.34 (m, 1H), 3.33–3.11 (m, 2H), 2.92–2.80 (m, 1H), 2.77–2.59 (m, 1H), 2.42–2.29 (m, 1H), 2.26–1.02 (m, 23H), 1.77 (s, 3H), 1.22 (s, 3H), 1.13 (s, 3H), 1.10 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H).</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-((2-(4-(methylsulfonyl)piperidin-1-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>37</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of the C-17 amine via alkyl choride <b>20</b> using 4-(methylsulfonyl)piperidine as the amine. The product was isolated as a white solid (200 mg, 95% HPLC purity, 32% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 719.58 (M + H)<sup>+</sup>, 2.31 min (method 3). <sup>1</sup>H NMR (500 MHz, AcOH-<i>d</i><sub>4</sub>) δ 8.04 (d, <i>J</i> = 8.5 Hz, 2H), 7.30 (d, <i>J</i> = 8.2 Hz, 2H), 5.37 (d, <i>J</i> = 4.6 Hz, 1H), 4.87 (s, 1H), 4.75 (s, 1H), 3.76–3.70 (m, 2H), 3.68–3.54 (m, 4H), 3.48–3.29 (m, 1H), 3.18–3.03 (m, 2H), 3.02 (s, 3H), 2.84 (td, <i>J</i> = 11.8, 4.7 Hz, 1H), 2.46–1.03 (m, 26H), 1.77 (s, 3H), 1.22 (s, 3H), 1.14 (s, 3H), 1.10 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H).</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-((2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>38</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of C-17 amines and hydrolysis of the benzoate ester above using using 1-(methylsulfonyl)piperazine as the alkylating reagent. The product was isolated as a white solid (15.8 mg, 95% HPLC purity, 28% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 720.58 (M + H)<sup>+</sup>, 2.25 min (method 11). <sup>1</sup>H NMR (500 MHz, AcOH-<i>d</i><sub>4</sub>) δ 8.04 (d, <i>J</i> = 8.2 Hz, 2H), 7.30 (d, <i>J</i> = 8.2 Hz, 2H), 5.37 (d, <i>J</i> = 4.6 Hz, 1H), 4.86 (s, 1H), 4.74 (s, 1H), 3.74–3.38 (m, 7H), 3.37–3.25 (m, 1H), 3.17 (br s, 4H), 2.94 (s, 3H), 2.91–2.80 (m, 1H), 2.35–1.01 (m, 22H), 1.77 (s, 3H), 1.26 (s, 3H), 1.14 (s, 3H), 1.10 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H).</div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(4-(Ethylsulfonyl)piperazin-1-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>39</b>)</h4><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of the C-17 amine via alkyl choride <b>20</b> using 1-(ethylsulfonyl)piperazine as the amine. The product was isolated as a white solid (11 mg, 95% HPLC purity, 43% yield over 2 steps). LCMS: <i>m</i>/<i>e</i> 734.56 (M + H)<sup>+</sup>, 2.28 min (method 11). <sup>1</sup>H NMR (400 MHz, AcOH-<i>d</i><sub>4</sub>) δ 7.99 (d, <i>J</i> = 8.5 Hz, 2H), 7.26 (d, <i>J</i> = 8.3 Hz, 2H), 5.34 (d, <i>J</i> = 4.5 Hz, 1H), 4.81 (s, 1H), 4.70 (s, 1H), 3.63–3.28 (m, 7H), 3.26–3.16 (m, 1H), 3.14–2.98 (m, 6H), 2.95–2.75 (m, 1H), 2.33–1.06 (m, 22H), 1.73 (s, 3H), 1.32 (t, <i>J</i> = 7.4 Hz, 3H), 1.23 (s, 3H), 1.10 (s, 3H), 1.06 (s, 3H), 0.98 (s, 3H), 0.97 (s, 3H).</div></div><div id="sec5_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(4-(Isopropylsulfonyl)piperazin-1-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>40</b>)</h4><div class="NLM_p">Following the representative procedure for the alkylation of the C-17 amine via alkyl choride <b>20</b> using <i>tert</i>-butyl piperazine-1-carboxylate as the amine, <i>tert</i>-butyl 4-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)piperazine-1-carboxylate was obtained as a white solid (150 mg, 52% yield). LCMS: <i>m</i>/<i>e</i> 756.66 (M + H)<sup>+</sup>, 2.44 min (method 3).</div><div class="NLM_p">A mixture of <i>tert</i>-butyl 4-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)piperazine-1-carboxylate (150 mg, 0.198 mmol) and 4 N HCl in 1,4-dioxane (0.25 mL, 0.99 mmol) in THF (2 mL) was stirred at rt for 18 h. The reaction mixture was concentrated under reduced pressure to provide <b>21</b> as a brown solid (120 mg, 0.17 mmol, 87% yield). LCMS: <i>m</i>/<i>e</i> 656.7 (M + H)<sup>+</sup>, 2.29 min (method 3).</div><div class="NLM_p">To a solution of <b>21</b> (20 mg, 0.030 mmol) and Hunig’s base (0.021 mL, 0.122 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added propane-2-sulfonyl chloride (6.81 μL, 0.06 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL). The reaction mixture was stirred at rt for 2 h, diluted with H<sub>2</sub>O, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(4-(isopropylsulfonyl)piperazin-1-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate as yellow solid (16 mg, 0.02 mmol, 69% yield). LCMS: <i>m</i>/<i>e</i> 762.60 (M + H)<sup>+</sup>, 2.37 min (method 3).</div><div class="NLM_p last">A mixture of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(4-(isopropylsulfonyl)piperazin-1-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (16 mg, 0.02 mmol) and 1N NaOH (0.21 mL, 0.21 mmol) in 1,4-dioxane (0.5 mL) was heated to 80 °C for 3 h. The mixture was cooled to rt and the product purified by preparative HPLC to provide <b>40</b> as a colorless oil (6.0 mg, 95% HPLC purity, 7.6 μM, 36% yield). LCMS: <i>m</i>/<i>e</i> 748.63 (M + H)<sup>+</sup>, 2.31 min (method 3). <sup>1</sup>H NMR (400 MHz, AcOH-<i>d</i><sub>4</sub>δ 7.99 (d, <i>J</i> = 8.0 Hz, 2H), 7.26 (d, <i>J</i> = 8.0 Hz, 2H), 5.33 (d, <i>J</i> = 5.3 Hz, 1H), 4.82 (s, 1H), 4.71 (s, 1H), 3.80–3.55 (m, 8H), 3.49–3.25 (m, 5H), 2.92–2.68 (m, 1H), 2.32–1.04 (m, 22H), 1.73 (s, 3H), 1.32 (s, 3H), 1.30 (s, 3H), 1.17 (s, 3H), 1.10 (s, 3H), 1.05 (s, 3H), 0.98 (s, 3H), 0.96 (s, 3H).</div></div><div id="sec5_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-((2-(6-(methylsulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>41</b>)</h4><div class="NLM_p">To a slurry of <b>14</b> (4 g, 6.9 mmol) in CH<sub>3</sub>CN (160 mL) in a sealable pressure vessel was added K<sub>3</sub>PO<sub>4</sub> (7.32 g, 34.5 mmol) and 1-bromo-2-chloroethane (6.88 mL, 83 mmol). The reaction mixture was stirred at 120 °C for 24 h and cooled to rt, and the solids formed were collected by filtration and washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 70 mL). The combined filtrates were concentrated under reduced pressure to give <b>22</b> (3.84 g, 6.74 mmol, 98% yield) as an off-white solid. LCMS: <i>m</i>/<i>e</i> 570.3 (M + H)<sup>+</sup>, 2.37 min (method 3).</div><div class="NLM_p">To a flask containing <b>22</b> (150 mg, 0.263 mmol) and <i>tert</i>-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (261 mg, 1.32 mmol) was added THF (2 mL) followed by DIPEA (0.32 mL, 1.84 mmol). The reaction mixture was heated at 100 °C for 67 h, cooled to rt, and the product purified by preparative reversed phase HPLC (method 12) to give <i>tert</i>-butyl 6-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (82 mg, 0.10 mmol, 41% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 768.6 (M + H)<sup>+</sup>, 2.47 min (method 5).</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 6-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (80 mg, 0.10 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added CF<sub>3</sub>CO<sub>2</sub>H (0.5 mL, 6.5 mmol). The mixture was stirred at rt for 1 h before being diluted with ClCH<sub>2</sub>CH<sub>2</sub>Cl (3 mL) and concentrated under reduced pressure. The residue was redissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and ClCH<sub>2</sub>CH<sub>2</sub>Cl (2 mL), treated with 2 N HCl in Et<sub>2</sub>O (0.5 mL, 1.0 mmol), concentrated, and the residue dried under vacuum to give methyl 4-((1R,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(2,6-diazaspiro[3.3]heptan-2-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (79.2 mg, 0.10 mmol, 98% yield) as an off-white solid. LCMS: <i>m</i>/<i>e</i> 668.5 (M + H)<sup>+</sup>, 4.08 min (method 7).</div><div class="NLM_p last">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(2,6-diazaspiro[3.3]heptan-2-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (77 mg, 0.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added Et<sub>3</sub>N (0.07 mL, 0.50 mmol) and CH<sub>3</sub>SO<sub>2</sub>Cl (0.02 mL, 0.29 mmol). The reaction mixture was stirred at rt for 2 h before being quenched with MeOH (0.5 mL) and concentrated under reduced pressure. To the residue was added THF (2 mL), MeOH (0.5 mL), and 3N LiOH (0.33 mL, 0.99 mmol) and the mixture heated at 75 °C for 2 h. After cooling to rt, the product was purified by preparative reversed phase HPLC (method 5) to give <b>41</b> (15.6 mg, 98% HPLC purity, 0.02 mmol, 16% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 732.5 (M + H)<sup>+</sup>, 3.92 min (method 7). <sup>1</sup>H NMR (400 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 7.90 (d, <i>J</i> = 8.6 Hz, 2H), 7.18 (d, <i>J</i> = 8.3 Hz, 2H), 5.28 (d, <i>J</i> = 4.6 Hz, 1H), 4.78 (s, 1H), 4.69 (s, 1H), 4.11–4.00 (m, 3H), 3.84 (br s, 4H), 3.79–3.74 (m, 1H), 3.13 (br s, 1H), 3.10–3.01 (m, 2H), 2.98–2.92 (m, 1H), 2.89 (s, 3H), 2.70 (dt, <i>J</i> = 11.0, 5.7 Hz, 1H), 2.12 (dd, <i>J</i> = 17.1, 6.4 Hz, 1H), 2.07–1.88 (m, 4H), 1.86–1.74 (m, 2H), 1.71 (s, 3H), 1.68 (br s, 1H), 1.64–1.30 (m, 12H), 1.25 (d, <i>J</i> = 10.0 Hz, 1H), 1.14 (s, 3H), 1.07 (s, 3H), 1.01 (s, 3H), 0.94 (s, 3H), 0.93 (s, 3H).</div></div><div id="sec5_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-((2-(2-(methylsulfonyl)-2,6-diazaspiro[3.4]octan-6-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>42</b>)</h4><div class="NLM_p">To a flask containing <b>22</b> and <i>tert</i>-butyl 2,6-diazaspiro[3.4]octane-2-carboxylate, HCl (327 mg, 1.32 mmol) was added THF (2 mL), followed by DIPEA (0.32 mL, 1.84 mmol). The reaction mixture was heated at 100 °C for 67 h and cooled to rt, and the solids that formed were removed by filtration. The filtrate was purified by preparative reversed phase HPLC (method 5) to give <i>tert</i>-butyl 6-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)-2,6-diazaspiro[3.4]octane-2-carboxylate (148 mg, 0.19 mmol, 72% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 782.6 (M + H)<sup>+</sup>, 2.48 min (method 3).</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 6-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)-2,6-diazaspiro[3.4]octane-2-carboxylate (145 mg, 0.19 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added CF<sub>3</sub>CO<sub>2</sub>H (0.5 mL, 6.49 mmol) and the mixture stirred at rt for 1 h. The mixture was diluted with ClCH<sub>2</sub>CH<sub>2</sub>Cl (3 mL), concentrated under reduced pressure, and the residue dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and ClCH<sub>2</sub>CH<sub>2</sub>Cl (2 mL), treated with 2 N HCl in Et<sub>2</sub>O (0.5 mL, 1.0 mmol), and concentrated and dried under reduced pressure to give methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(2,6-diazaspiro[3.4]octan-6-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (130 mg, 0.16 mmol, 89% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 682.6 (M + H)<sup>+</sup>, 4.09 min (method 7).</div><div class="NLM_p last">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(2,6-diazaspiro[3.4]octan-6-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (128 mg, 0.16 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added Et<sub>3</sub>N (0.11 mL, 0.81 mmol) and CH<sub>3</sub>SO<sub>2</sub>Cl (0.04 mL, 0.49 mmol). The mixture was stirred at rt for 2 h, quenched with MeOH (0.5 mL), and concentrated under reduced pressure. THF (2 mL), MeOH (0.5 mL) and 3N LiOH (0.54 mL, 1.6 mmol) were added to the residue and the mixture heated at 75 °C for 2 h. The mixture was cooled to rt and the product purified by preparative reversed phase HPLC (method 5) to give <b>42</b> (80.6 mg, 93% HPLC purity, 0.08 mmol, 47.6% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 746.5 (M + H)<sup>+</sup>, 3.91 min (method 7). <sup>1</sup>H NMR (400 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 7.90 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (d, <i>J</i> = 8.3 Hz, 2H), 5.27 (d, <i>J</i> = 4.6 Hz, 1H), 4.79 (s, 1H), 4.70 (s, 1H), 3.99–3.91 (m, 2H), 3.90–3.85 (m, 2H), 3.29 (d, <i>J</i> = 1.7 Hz, 1H), 3.25–3.14 (m, 3H), 3.08 (d, <i>J</i> = 4.6 Hz, 2H), 2.91 (s, 3H), 2.77–2.66 (m, 1H), 2.33–2.24 (m, 2H), 2.18–1.98 (m, 4H), 1.98–1.92 (m, 1H), 1.89–1.82 (m, 1H), 1.80–1.75 (m, 1H), 1.71 (s, 3H), 1.68–1.65 (m, 1H), 1.64–1.30 (m, 11H), 1.25 (d, <i>J</i> = 9.3 Hz, 1H), 1.20–1.13 (m, 1H), 1.10 (s, 3H), 1.07 (s, 3H), 1.00 (s, 3H), 0.94 (s, 3H), 0.92 (s, 3H). <sup>13</sup>C NMR (101 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 169.8, 149.4, 148.1, 147.1, 130.7, 129.4, 129.0, 124.5, 112.3, 78.5, 64.1, 61.6, 61.5, 54.3, 53.6, 52.2, 50.0, 46.4, 42.8, 42.4, 41.5, 40.4, 39.5, 38.2, 38.1, 36.9, 36.8, 36.2, 34.3, 33.1, 29.9, 28.8, 28.1, 27.1, 25.8, 21.7, 21.6, 20.4, 19.3, 17.0, 16.3, 15.0.</div></div><div id="sec5_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-((2-(6-(methylsulfonamido)-3-azabicyclo[3.1.0]hexan-3-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>43</b>)</h4><div class="NLM_p">To a flask containing <b>22</b> (150 mg, 0.26 mmol) and <i>tert</i>-butyl 3-azabicyclo[3.1.0]hexan-6-ylcarbamate (261 mg, 1.32 mmol) was added THF (2 mL) followed by DIPEA (0.32 mL, 1.84 mmol). The reaction mixture was heated to 100 °C for 67 h, cooled to rt, and the product purified by preparative reversed phase HPLC (method 5) to give methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(6-((<i>tert</i>-butoxycarbonyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (69 mg, 0.09 mmol, 34% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 768.6 (M + H)<sup>+</sup>, 2.44 min (method 3).</div><div class="NLM_p">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(6-((<i>tert</i>-butoxycarbonyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (66 mg, 0.09 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added CF<sub>3</sub>CO<sub>2</sub>H (0.5 mL, 6.49 mmol) and the mixture stirred at rt for 1 h before being diluted with ClCH<sub>2</sub>CH<sub>2</sub>Cl (3 mL) and concentrated under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and ClCH<sub>2</sub>CH<sub>2</sub>Cl (2 mL), treated with 2 N HCl in Et<sub>2</sub>O (0.5 mL, 1.0 mmol), and concentrated under reduced pressure to give 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (60.5 mg, 0.08 mmol, 91% yield) as an off-white solid. LCMS: <i>m</i>/<i>e</i> 668.5 (M + H)<sup>+</sup>, 4.01 min (method 7).</div><div class="NLM_p last">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (58 mg, 0.08 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added Et<sub>3</sub>N (0.06 mL, 0.43 mmol) and CH<sub>3</sub>SO<sub>2</sub>Cl (0.02 mL, 0.26 mmol). The mixture was stirred at rt for 2 h, quenched with MeOH (0.5 mL), and concentrated under reduced pressure. The residue was diluted with THF (2 mL), MeOH (0.5 mL), and 3N LiOH (0.29 mL, 0.87 mmol) and heated at 75 °C for 2 h. The mixture was cooled to rt and the product purified by preparative reversed phase HPLC (method 12) to give <b>43</b> (41.7 mg, 98% HPLC purity, 0.04 mmol, 57% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 732.5 (M + H)<sup>+</sup>, 3.86 min (method 18). <sup>1</sup>H NMR (400 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 7.90 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (d, <i>J</i> = 8.3 Hz, 2H), 5.28 (d, <i>J</i> = 4.9 Hz, 1H), 5.23 (s, 1H), 5.13 (s, 1H), 4.85 (s, 1H), 4.72 (br s, 1H), 3.85 (br s, 2H), 3.72 (br s, 2H), 3.48 (br s, 4H), 3.09 (br s, 1H), 3.03 (s, 3H), 2.81 (d, <i>J</i> = 10.3 Hz, 1H), 2.25–1.97 (m, 8H), 1.87 (d, <i>J</i> = 11.5 Hz, 1H), 1.79–1.60 (m, 6H), 1.53 (d, <i>J</i> = 16.1 Hz, 6H), 1.44–1.33 (m, 4H), 1.30–1.23 (m, 2H), 1.21 (br s, 3H), 1.11–1.04 (m, 3H), 1.02 (s, 3H), 0.94 (s, 3H), 0.93 (br s, 3H).</div></div><div id="sec5_7_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-((2-((1-(methylsulfonyl)pyrrolidin-3-yl)amino)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>44</b>)</h4><div class="NLM_p">To a mixture of <b>14</b> (1.00 g, 1.84 mmol) in ClCH<sub>2</sub>CH<sub>2</sub>Cl (5 mL) was added <i>tert</i>-butyl 2-oxoethylcarbamate (1.17 g, 7.4 mmol) and Ti(<sup>i</sup>PrO)<sub>4</sub> (0.70 mL, 2.4 mmol). The reaction mixture was stirred for 1 h, NaBH(OAc)<sub>3</sub> (1.17 g, 5.52 mmol) was added, and stirring was continued for 18 h. The reaction mixture was quenched with NaHCO<sub>3</sub>, extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 40 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using EtOAc and hexanes (20–100%) as the eluent to provide <b>19</b> as a pale-yellow oil (900 mg, 71%). LCMS: <i>m</i>/<i>e</i> 688.24 (M + H)<sup>+</sup>, 2.51 min (method 3).</div><div class="NLM_p">To a solution of <b>19</b> (900 mg, 1.310 mmol) in 1,4-dioxane (1 mL) was added HCl (4 M in dioxane) (4.26 mL, 17.0 mmol) and the mixture stirred for 4 h at rt. The mixture was concentrated under reduced pressure to provide methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-(2-aminoethylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate as a brown solid (769 mg, 100%). LCMS: <i>m</i>/<i>e</i> 588.08 (M + H)<sup>+</sup>, 2.44 min (method 3).</div><div class="NLM_p">A mixture of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-aminoethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (30 mg, 0.05 mmol), 2-picoline borane complex (6.6 mg, 0.06 mmol), and <i>tert</i>-butyl 3-oxopyrrolidine-1-carboxylate (10.4 mg, 0.06 mmol) in MeOH (1 mL) and AcOH (0.3 mL) was stirred at rt for 17 h. The reaction mixture was diluted with H<sub>2</sub>O (5 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide 3-((2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)amino)pyrrolidine-1-carboxylate (28 mg, 0.04 mmol, 72% yield) as a brown solid. LCMS: <i>m</i>/<i>e</i> 756.9 (M + H)<sup>+</sup>, 2.08 min (method 6).</div><div class="NLM_p">A mixture of <i>tert</i>-butyl 3-((2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)amino)pyrrolidine-1-carboxylate (22 mg, 0.03 mmol) and 4 M HCl in 1,4-dioxane (1.0 mL) was stirred at rt for 17 h. The reaction mixture was concentrated under reduced pressure to provide methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-3a-((2-(pyrrolidin-3-ylamino)ethyl)amino)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (19 mg, 0.03 mmol, 100% yield) as a brown solid. LCMS: <i>m</i>/<i>e</i> 656.8 (M + H)<sup>+</sup>, 1.76 min (method 6).</div><div class="NLM_p last">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-3a-((2-(pyrrolidin-3-ylamino)ethyl)amino)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (8 mg, 0.012 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added Et<sub>3</sub>N (1.7 μL, 0.01 mmol) and CH<sub>3</sub>SO<sub>2</sub>Cl. The reaction mixture was stirred for 1h at rt, concentrated under reduced pressure, and the residue diluted with 1,4-dioxane (0.5 mL) before adding NaOH (0.488 mg, 0.012 mmol). The reaction mixture was heated at 80 °C for 3h, cooled to rt, filtered, and purified by preparative HPLC to provide <b>44</b> (2.0 mg, 95% HPLC purity, 2.64 μmol, 22% yield) as a colorless oil. LCMS: <i>m</i>/<i>e</i> 720.7 (M + H)<sup>+</sup>, 1.67 min (method 6). <sup>1</sup>H NMR (500 MHz, CH<sub>3</sub>CN-<i>d</i><sub>3</sub>) δ 7.93–7.86 (m, 2H), 7.29–7.20 (m, 2H), 5.29 (dd, <i>J</i> = 6.2, 1.8 Hz, 1H), 4.79 (s, 1H), 4.73–4.66 (m, 1H), 3.77 (br d, <i>J</i> = 5.7 Hz, 1H), 3.62 (dt, <i>J</i> = 10.7, 7.0 Hz, 1H), 3.53–3.46 (m, 1H), 3.44–3.26 (m, 4H), 2.87 (d, <i>J</i> = 1.3 Hz, 3H), 2.80 (td, <i>J</i> = 11.2, 6.3 Hz, 1H), 2.40–2.29 (m, 1H), 1.72 (s, 3H), 1.16 (s, 3H), 2.21–1.11 (m, 25H), 1.06 (s, 3H), 1.01 (s, 3H), 0.94 (s, 3H), 0.93 (s, 3H).</div></div><div id="sec5_7_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-((1<i>S</i>,4<i>S</i>)-2,2-Dioxido-2-thia-5-azabicyclo[2.2.1]heptan-5-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>45</b>)</h4><div class="NLM_p last">To a slurry of <b>14</b> (0.350 g, 0.603 mmol) in CH<sub>3</sub>CN (5 mL) in a medium pressure flask was added K<sub>3</sub>PO<sub>4</sub> (0.56 g, 2.7 mmol) and KI (0.27 g, 1.63 mmol), followed by a solution of (1<i>S</i>,4<i>S</i>)-5-(2-chloroethyl)-2-thia-5-azabicyclo[2.2.1]heptane 2,2-dioxide (0.15 g, 0.72 mmol) in CH<sub>3</sub>CN (5 mL).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The reaction mixture was purged with N<sub>2</sub> and heated at 120 °C for 24 h before being allowed to cool to rt. The solid that was formed was collected by filtration and washed with CH<sub>2</sub>Cl<sub>2</sub>. The liquid filtrate was concentrated to a white paste. The crude material was dissolved in a mixture of THF/MeOH and purified by reversed phase prep-HPLC (method 6). The product was dissolved in a mixture of THF (5 mL) and MeOH (2 mL), and a solution of LiOH·H<sub>2</sub>O (0.01 mL, 0.51 mmol) in H<sub>2</sub>O (1 mL) was added. The reaction mixture was heated at 75 °C for 8 h, cooled to rt, and concentrated to dryness. The residue was dissolved in THF (1.75 mL) and MeOH (1 mL) and 0.25 mL of 1 N HCl and was purified by preparative HPLC (method 4). The combined HPLC fractions were concentrated and the residue dissolved in a mixture of THF (2 mL) and H<sub>2</sub>O (2 mL) and extracted with a 1:1 mixture of THF:EtOAc (2 × 20 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude product was purified by reversed phase preparative HPLC (method 4). The product was treated with 1 N HCl, concentrated, and dried under reduced pressure to give the title product (20.5 mg, 92% HPLC purity, 0.026 mmol, 4% yield over 2 steps) as a white solid. LC/MS: <i>m</i>/<i>e</i> 703.6 (M + H)<sup>+</sup>, 1.84 min (method 2). <sup>1</sup>H NMR (400 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 7.90 (d, <i>J</i> = 8.1 Hz, 2H), 7.18 (d, <i>J</i> = 8.1 Hz, 2H), 6.93 (s, 1H), 5.28 (d, <i>J</i> = 4.9 Hz, 1H), 4.85 (br s, 1H), 4.15 (br s, 1H), 3.69 (br s, 1H), 3.40 (br s, 2H), 3.25 (br s, 2H), 3.07 (d, <i>J</i> = 13.0 Hz, 3H), 2.60 (d, <i>J</i> = 12.0 Hz, 1H), 2.45 (d, <i>J</i> = 10.8 Hz, 1H), 2.22 (s, 1H), 2.12 (dd, <i>J</i> = 17.0, 6.2 Hz, 2H), 2.06–1.95 (m, 2H), 1.92–1.77 (m, 2H), 1.73 (s, 3H), 1.66–1.43 (m, 10H), 1.41–1.37 (m, 6H), 1.24 (br s, 2H), 1.15 (br s, 4H), 1.09 (s, 3H), 1.01 (s, 3H), 0.94 (br s, 3H), 0.93 (br s, 3H). <sup>13</sup>C NMR (101 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 169.8, 149.4, 148.2, 147.1, 137.8, 130.8, 129.5, 129.2, 126.0, 124.6, 112.2, 61.5, 53.8, 53.6, 50.0, 49.4, 46.2, 42.9, 42.4, 41.6, 38.2, 38.1, 37.0, 35.0, 34.4, 33.1, 30.8, 30.0, 28.9, 27.8, 26.9, 25.9, 21.8, 21.6, 21.5, 20.5, 19.6, 17.1, 16.8, 14.9.</div></div><div id="sec5_7_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-Pentamethyl-3a-((2-((1<i>S</i>,4<i>S</i>)-5-(methylsulfonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>46</b>)</h4><div class="NLM_p">To a vial containing <b>22</b> (82 mg, 0.14 mmol) and (1<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (86 mg, 0.43 mmol) was added THF (1 mL), followed by DIPEA (0.18 mL, 1.0 mmol). The mixture was heated at 100 °C for 14 h, cooled to rt, and the product purified by preparative reversed phase HPLC (method 7) to give (1<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 5-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (52 mg, 36.2% yield) as a white solid. LC/MS: <i>m</i>/<i>e</i> 768.7 (M + H)<sup>+</sup>, 2.43 min (method 3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14 (br s, 2H), 7.93 (d, <i>J</i> = 8.1 Hz, 2H), 7.19 (d, <i>J</i> = 8.3 Hz, 2H), 5.29 (d, <i>J</i> = 4.6 Hz, 1H), 4.78 (s, 1H), 4.70 (s, 1H), 4.65–4.49 (m, 1H), 4.28 (br s, 1H), 3.91 (s, 3H), 3.70 (d, <i>J</i> = 11.7 Hz, 3H), 3.55–3.35 (m, 4H), 2.78–2.62 (m, 1H), 2.23–1.97 (m, 6H), 1.94 (d, <i>J</i> = 12.0 Hz, 1H), 1.86 (t, <i>J</i> = 12.0 Hz, 1H), 1.80–1.71 (m, 2H), 1.69 (s, 3H), 1.67–1.61 (m, 2H), 1.54 (dd, <i>J</i> = 15.5, 3.5 Hz, 5H), 1.46 (s, 9H), 1.43–1.28 (m, 4H), 1.27–1.17 (m, 1H), 1.10 (s, 3H), 1.04 (s, 3H), 0.99 (s, 3H), 0.93 (br s, 3H), 0.93 (br s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.3, 148.6, 146.6, 146.3, 130.0, 128.5, 127.9, 123.8, 117.2, 114.3, 112.1, 81.5, 77.2, 73.5, 52.8, 52.0, 49.3, 48.9, 45.4, 42.0, 41.7, 40.7, 38.6, 37.5, 37.4, 36.2, 33.4, 32.4, 29.4, 28.2, 28.0, 27.5, 26.3, 25.0, 21.0, 20.8, 19.6, 18.8, 16.4, 15.4, 14.5.</div><div class="NLM_p">To a solution of (1<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 5-(2-(((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-3a-yl)amino)ethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (419 mg, 0.55 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added CF<sub>3</sub>CO<sub>2</sub>H (2 mL, 26.0 mmol), and the mixture was stirred at rt for 3 h. The reaction mixture was concentrated and the product purified by preparative reversed phase HPLC (method 8) to give methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-((1<i>S</i>,4<i>S</i>)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (75.2 mg, 12% yield) as a light-brown solid. LC/MS: <i>m</i>/<i>e</i> 668.7 (M + H)<sup>+</sup>, 2.36 min (method 3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.77 (br s, 1H), 9.49 (br s, 1H), 7.92 (d, <i>J</i> = 8.1 Hz, 2H), 7.19 (d, <i>J</i> = 8.1 Hz, 2H), 5.28 (d, <i>J</i> = 4.4 Hz, 1H), 4.76 (br s, 1H), 4.69 (br s, 1H), 4.31 (br s, 1H), 3.96 (br s, 1H), 3.90 (s, 3H), 3.66 (br s, 1H), 3.40–3.10 (m, 5H), 3.09–2.89 (m, 2H), 2.81 (br s, 1H), 2.23–2.06 (m, 4H), 2.05–1.91 (m, 3H), 1.85 (br s, 1H), 1.78–1.73 (m, 1H), 1.69 (br s, 3H), 1.65 (br s, 1H), 1.62–1.30 (m, 11H), 1.26–1.17 (m, 2H), 1.11 (br s, 3H), 1.05 (br s, 3H), 0.99 (br s, 3H), 0.93 (br s, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.2, 148.5, 147.1, 146.2, 130.0, 128.5, 127.9, 123.8, 114.8, 111.6, 77.24–77.18, 71.3, 65.8, 60.9, 57.7, 54.4, 52.7, 52.0, 49.2, 48.7, 48.62–48.49, 46.3, 45.0, 42.0, 41.6, 40.6, 37.4, 37.0, 36.2, 33.6, 32.5, 29.4, 28.0, 27.3, 25.8, 25.0, 20.9, 20.8, 19.5, 19.1, 16.3, 15.9, 15.2, 14.4.</div><div class="NLM_p">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-((1<i>S</i>,4<i>S</i>)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (75.2 mg, 0.11 mmol) and Et<sub>3</sub>N (0.08 mL, 0.56 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added CH<sub>3</sub>SO<sub>2</sub>Cl (10 μL, 0.14 mmol). The reaction mixture was stirred at rt for 1.5 h, diluted with CH<sub>2</sub>Cl<sub>2</sub> (25 mL), and washed with H<sub>2</sub>O (2 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (15 mL), and the combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to give methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-pentamethyl-3a-((2-((1<i>S</i>,4<i>S</i>)-5-(methylsulfonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate as a light-brown solid (69 mg, 78% yield). LC/MS: <i>m</i>/<i>e</i> 746.8 (M + H)<sup>+</sup>, 246 min (method 3). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.88 (d, <i>J</i> = 8.1 Hz, 2H), 7.15 (d, <i>J</i> = 8.1 Hz, 2H), 5.25 (d, <i>J</i> = 4.6 Hz, 1H), 4.71 (s, 1H), 4.57 (s, 1H), 4.26 (s, 1H), 3.86 (s, 3H), 3.69 (br s, 1H), 3.58 (d, <i>J</i> = 9.5 Hz, 1H), 3.19 (dd, <i>J</i> = 9.4, 1.8 Hz, 1H), 2.97 (dd, <i>J</i> = 9.8, 2.0 Hz, 1H), 2.85 (s, 3H), 2.80 (dd, <i>J</i> = 8.3, 4.2 Hz, 2H), 2.65 (d, <i>J</i> = 9.8 Hz, 1H), 2.61–2.44 (m, 2H), 2.07 (dd, <i>J</i> = 17.1, 6.4 Hz, 2H), 1.95–1.68 (m, 6H), 1.66 (s, 3H), 1.65–1.37 (m, 9H), 1.31–1.06 (m, 7H), 1.04 (s, 3H), 0.96 (s, 3H), 0.94 (s, 3H), 0.89 (s, 6H).</div><div class="NLM_p">To a solution of methyl 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-5a,5b,8,8,11a-pentamethyl-3a-((2-((1<i>S</i>,4<i>S</i>)-5-(methylsulfonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)amino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoate (65 mg, 0.09 mmol) in THF (2 mL) and MeOH (1 mL) was added a solution of LiOH.H<sub>2</sub>O(14.6 mg, 0.35 mmol). The reaction mixture was stirred at 75 °C for 1 h, concentrated, and the residue dissolved in a mixture of THF (1.5 mL) and MeOH (0.5 mL) and the product purified by preparative reversed phase HPLC (method 8) to give <b>46</b> (46.6 mg, 54.6% yield) as a white solid. LC/MS: <i>m</i>/<i>e</i> 732.7 (M + H)<sup>+</sup>, 2.22 min (method 3). <sup>1</sup>H NMR (400 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 7.90 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (d, <i>J</i> = 8.1 Hz, 2H), 5.27 (d, <i>J</i> = 4.9 Hz, 1H), 4.82 (s, 1H), 4.71 (br s, 1H), 4.45 (br s, 1H), 4.14 (br s, 1H), 3.72 (d, <i>J</i> = 10.5 Hz, 1H), 3.56 (dt, <i>J</i> = 9.8, 6.5 Hz, 1H), 3.41 (d, <i>J</i> = 10.0 Hz, 3H), 3.29–3.09 (m, 3H), 2.97 (s, 3H), 2.85 (td, <i>J</i> = 11.0, 5.1 Hz, 1H), 2.22–1.96 (m, 7H), 1.93–1.75 (m, 3H), 1.72 (s, 3H), 1.68 (br s, 1H), 1.66–1.47 (m, 8H), 1.47–1.32 (m, 4H), 1.26 (d, <i>J</i> = 10.5 Hz, 1H), 1.16 (s, 3H), 1.08 (s, 3H), 1.01 (s, 3H), 0.93 (br s, 3H), 0.92 (br s, 3H). <sup>13</sup>C NMR (101 MHz, 1:1 CDCl<sub>3</sub>:MeOH-<i>d</i><sub>4</sub>) δ 169.8, 149.4, 148.2, 147.2, 130.8, 129.5, 129.1, 124.6, 112.3, 78.7, 73.1, 64.9, 61.7 (br s, 1C), 60.1, 53.6, 50.1, 46.4, 42.9, 42.5, 41.6, 38.8, 38.2, 38.2, 37.0, 34.4, 33.1, 30.5, 30.0, 28.9, 27.9, 27.0, 25.9, 21.8, 21.6, 20.4, 19.4, 17.1, 16.7, 15.0.</div><div id="sec5_7_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1-Imino-1-oxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)benzoic Acid (<b>47</b>)</h5><div class="NLM_p last">The title compound was prepared following the representative procedure for the alkylation of C-17 amines and hydrolysis of the benzoate ester described above using <i>N</i>-(4-(2-chloroethyl)-1-oxidothiomorpholin-1-ylidene)-4-methylbenzenesulfonamide, HCl as the alkylating agent to give <b>16</b>. <b>16</b> was purified by flash chromatography using a 10–55% EtOAc in hexanes gradient with 0.1% TEA added to the mobile phase. Instead of using the standard hydrolysis procedure, the compound was treated with Na<sub>2</sub>HPO<sub>4</sub>, (4 equiv) and Na(Hg) (10% sodium) (15 equiv). The mixture was diluted with MeOH to 0.7 M and heated at reflux for 4.25 h, cooled to rt, and concentrated under reduced pressure. The residue was diluted with MeOH and CH<sub>2</sub>Cl<sub>2</sub> and filtered through a plug of Celite to remove the metal formed in the reaction, and the filtrate was concentrated under reduced pressure. The residue was diluted with MeOH, and H<sub>2</sub>O was added dropwise until the mixture was cloudy. The mixture was set aside until solids formed which were collected by filtration and washed with H<sub>2</sub>O. A second crop of solids formed in the mother liquor upon standing and were collected. The solids were purified by preparative HPLC (method 9) to give <b>47</b> (410 mg, 92% HPLC purity, 0.59 mmol, 43% yield over 2 steps) as a white solid. LCMS: <i>m</i>/<i>e</i> 690.6 (M + H)<sup>+</sup>, 1.60 min (method 6). <sup>1</sup>H NMR (400 MHz, AcOH-<i>d</i><sub>4</sub>) δ = 7.99 (d, <i>J</i> = 7.8 Hz, 2H), 7.26 (d, <i>J</i> = 8.0 Hz, 2H), 5.34 (d, <i>J</i> = 5.0 Hz, 1H), 4.81 (s, 1H), 4.70 (s, 1H), 3.64–3.04 (m, 12H), 2.93 (d, <i>J</i> = 4.3 Hz, 1H), 1.73 (s, 3H), 1.25 (s, 3H), 1.11 (s, 3H), 1.08 (s, 3H), 0.99 (s, 3H), 0.97 (s, 3H), 2.32–0.85 (m, 22H).</div></div></div><div id="sec5_7_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i>-(4-(2-Chloroethyl)-1-oxidothiomorpholin-1-ylidene)-4-methylbenzenesulfonamide, HCl</h4><div class="NLM_p">To a suspension of PhI = NTs (9.8 g, 26.3 mmol) in toluene (100 mL) was added vinyl sulfoxide (2.0 mL, 21.12 mmol) and copper(I)triflate toluene complex (2:1) (0.273 g, 0.528 mmol). The suspension was stirred at rt with the solids eventually dissolving to give a yellow solution. After 4 h of stirring, the mixture was filtered through a plug of Celite and partially concentrated. The product was purified by flash chromatography using a gradient of 0–60% EtOAc in hexanes as eluent to give 4-methyl-<i>N</i>-(oxodivinyl-λ<sup>6</sup>-sulfaneylidene)benzenesulfonamide (3.84 g, 11.32 mmol, 53.6% yield, 80% purity) as a light-yellow oil. LCMS: <i>m</i>/<i>e</i> 272.1 (M + H)<sup>+</sup>, 1.44 min (method 6). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.85 (d, <i>J</i> = 8.2 Hz, 2H), 7.28 (br d, <i>J</i> = 8.2 Hz, 2H), 6.76 (dd, <i>J</i> = 16.3, 9.6 Hz, 2H), 6.54 (dd, <i>J</i> = 16.2, 1.2 Hz, 2H), 6.30 (dd, <i>J</i> = 9.6, 1.4 Hz, 2H), 2.41 (s, 3H).</div><div class="NLM_p">To a solution of 4-methyl-<i>N</i>-(oxodivinyl-λ<sup>6</sup>-sulfaneylidene)benzenesulfonamide (80% purity) (3.66 g, 10.79 mmol) in ClCH<sub>2</sub>CH<sub>2</sub>Cl (100 mL) was added Et<sub>3</sub>N (4.51 mL, 32.4 mmol) and ethanolamine (3.26 mL, 54.0 mmol). The mixture was stirred at rt for 15 h before being concentrated under reduced pressure and the residue purified by flash chromatography using a gradient of 0–5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> as eluent to give <i>N</i>-(4-(2-hydroxyethyl)-1-oxidothiomorpholin-1-ylidene)-4-methylbenzenesulfonamide (1.42 g, 4.27 mmol, 39.6% yield) as an off-white solid. LCMS: <i>m</i>/<i>e</i> 333.1 (M + H)<sup>+</sup>, 1.11 min (method 6). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.85 (d, <i>J</i> = 8.2 Hz, 2H), 7.28 (br d, <i>J</i> = 8.2 Hz, 2H), 6.76 (dd, <i>J</i> = 16.3, 9.6 Hz, 2H), 6.54 (dd, <i>J</i> = 16.2, 1.2 Hz, 2H), 6.30 (dd, <i>J</i> = 9.6, 1.4 Hz, 2H), 2.41 (s, 3H).</div><div class="NLM_p last">To a solution of <i>N</i>-(4-(2-hydroxyethyl)-1-oxidothiomorpholin-1-ylidene)-4-methylbenzenesulfonamide (1.4 g, 4.21 mmol) in ClCH<sub>2</sub>CH<sub>2</sub>Cl (30 mL) was added SOCl<sub>2</sub> (7.68 mL, 105 mmol). The mixture was warmed to 50 °C for 20.5 h and then heated at 65 °C for 3 h. The mixture was cooled to rt and the solids that formed collected by filtration and washed with Et<sub>2</sub>O to give <i>N</i>-(4-(2-chloroethyl)-1-oxidothiomorpholin-1-ylidene)-4-methylbenzenesulfonamide, HCl (1.58 g, 4.08 mmol, 97% yield) as a white solid. LCMS: <i>m</i>/<i>e</i> 351.1 (M + H)<sup>+</sup>, 1.40 min (method 6). <sup>1</sup>H NMR (500 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.83–7.76 (m, 2H), 7.35 (d, <i>J</i> = 8.2 Hz, 2H), 4.00–3.92 (m, 2H), 3.88 (t, <i>J</i> = 6.1 Hz, 2H), 3.85–3.63 (m, 6H), 3.48 (t, <i>J</i> = 6.1 Hz, 2H), 2.41 (s, 3H).</div></div><div id="sec5_7_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-((1<i>R</i>,3a<i>S</i>,5a<i>R</i>,5b<i>R</i>,7a<i>R</i>,11a<i>S</i>,11b<i>R</i>,13a<i>R</i>,13b<i>R</i>)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]chrysen-9-yl)-2-fluorobenzoic Acid (<b>48</b>)</h4><div class="NLM_p last">The title product was prepared in a similar fashion to <b>1</b>, using 3-fluoro-4-(methoxycarbonyl)phenylboronic acid in place of the 4-methoxycarbonylphenylboronic acid used in step e of <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. LCMS: <i>m</i>/<i>e</i> 709.5 (M + H)<sup>+</sup>, 1.66 min (method 6). <sup>1</sup>H NMR (500 MHz, acetic acid-<i>d</i><sub>4</sub>) δ ppm 7.96 (1 H, t, <i>J</i> = 7.8 Hz), 7.09 (1 H, dd, <i>J</i> = 7.9, 1.5 Hz), 7.03 (1 H, d, <i>J</i> = 11.9 Hz), 5.43 (1 H, d, <i>J</i> = 4.6 Hz), 4.84 (1 H, s), 4.74 (1 H, s), 3.43–3.49 (1 H, m), 3.02–3.36 (11 H, m), 2.91–3.00 (1 H, m), 1.77 (3 H, s), 1.30 (3 H, s), 1.15 (3 H, s), 1.10 (3 H, s), 1.04 (3 H, s), 1.01 (3 H, s), 0.98–2.34 (22 H, m).</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> HIV Cell Culture Assay<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></h3><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Cell</h4><div class="NLM_p last">MT-2 cells were obtained from the NIH AIDS Research and Reference Reagent Program and subcultured twice a week in RPMI 1640 media supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 units/mL of penicillin G, and 100 μg/mL of streptomycin.</div></div><div id="sec5_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Viruses</h4><div class="NLM_p">NLRepRluc virus contains the <i>Renilla</i> luciferase marker in place of the viral <i>nef</i> gene. The proviral plasmid pNLRepRluc was constructed at Bristol-Myers Squibb starting from a proviral NL<sub>4–3</sub> clone (B subtype) that was obtained from the NIH AIDS Research and Reference Reagent Program. The parent recombinant wild-type virus (NLRepRlucP373S) was derived from pNLRepRluc and contained the additional substitution of P373 for serine in the Gag gene (within the SP1 spacer). A serine at position 373 is the most common variation at that position among in subtype B viruses. The other recombinant viruses were generated by site-directed mutagenesis of plasmid pNLRepRlucP373S to introduce amino acid substitutions representing important polymorphic variations in Gag. The recombinant virus DNA was then used to generate virus stocks by transfecting HEK293T cells (Lipofectamine PLUS kit, Invitrogen).</div><div class="NLM_p last">Titers of virus stocks were determined using as end points a virus infectivity assay with a luciferase end point (Dual-Luciferase Reporter Assay System, Promega, Milwaukee, WI, USA). The TCID<sub>50</sub>/mL (50% tissue culture infectious dose) was calculated by the method of Spearman–Karber.</div></div><div id="sec5_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Multiple Cycle Drug Susceptibility Assays</h4><div class="NLM_p">Pellets of MT-2 cells were infected with NLRepRlucP373S Gag site-directed strains. Initial inocula of the reporter strains in these assays were normalized using equivalent end point luciferase activity signals. Cell-virus mixtures were resuspended in medium, incubated for 1 h at 37 °C/CO<sub>2</sub>, and added to compound containing 96-well plates at a final cell density of 50000 cells per mL, a concentration found to permit exponential cell growth (total volume 200 μL). The test compounds were 3-fold serially diluted in 100% DMSO and assayed at a final DMSO concentration of 1%. After 4–5 day incubation at 37 °C/CO<sub>2</sub>, virus yields were determined by <i>Renilla</i> luciferase activity (Dual-Luciferase Reporter Assay System, Promega).</div><div class="NLM_p">Serum effects in multiple cycle drug susceptibility assays were determined by supplementing the 10% FBS medium with 15 mg/mL of HSA or 10% FBS medium plus 40% human serum and 27 mg/mL human serum albumin. The serum effect was calculated as the fold change in EC<sub>50</sub> versus the no-serum EC<sub>50</sub>.</div><div class="NLM_p last">The 50% inhibitory concentrations (EC<sub>50</sub>) were calculated by using the exponential form of the median effect equation where Percent Inhibition = 100(1/(1 + (EC<sub>50</sub>/drug conc)<sup><i>m</i></sup>)), where <i>m</i> is a parameter that reflects the slope of the concentration–response curve. Background was taken as the residual signal observed upon inhibition at the highest concentration of a control protease inhibitor, NFV (3 μM).</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Evaluation of in Vitro Metabolism Rates in Liver Microsomes</h3><div class="NLM_p last">Compound (0.5 μM) was incubated with liver microsomes (1 mg/mL) in the presence of NADPH (1.0 mM) and MgCl<sub>2</sub> (5 mM). Metabolic reaction was terminated (quenched) with MeOH and MeCN (1:3 v/v) containing an internal standard at multiple time points. Metabolism rate was determined based on the parent compound disappearance over time, as measured by LC-MS/MS.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Bioanalytical Methods</h3><div class="NLM_p last">Aliquots of test compound in biological matrices were combined with acetonitrile containing internal standard (IS) and centrifuged at 1000 rpm. Aliquots were injected onto the LC/MS/MS equipped with an electrospray ionization interface (ESI) operating in the positive ionization mode. The analysis of test compound was conducted against a standard curve ranging from 2 to 10000 nM.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Serum Protein Binding and Stability</h3><div class="NLM_p">Because of nonspecific binding of test compound to filters and other components, equilibrium dialysis could not be used to evaluate the extent of protein binding in 100% serum. Therefore, serum binding was determined using an ultracentrifugation method. Ten μL of radiolabeled test compound in DMSO was added to serum from various species (1 mL) (final concentration 53 nM). Serum was incubated at 37 °C for 1 h and centrifuged in a TLA100.3 rotor in an Optima TLX ultracentrifuge at 58K rpm for 18 h at 37 °C. Fractions (100 μL) were collected from the top of the tube, and the amount of radioactivity in each fraction was assessed through scintillation analysis. The radioactivity in fraction 2 (second fraction from the top out of 10 fractions) were taken as those in the protein-free fraction as a determination of the protein concentration in that fraction indicated it was less than 1% of the total starting protein concentration.</div><div class="NLM_p last">Percent protein binding was calculated from the ratio of measured concentration in the second fraction to the nominal serum concentration using the following equation.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_m001.gif" alt="" id="_i71" /></img></span></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Blood Cell Partitioning</h3><div class="NLM_p last">The blood to plasma concentration ratio of test compound was determined in triplicate in fresh rat, dog, monkey, and human blood. The blood hematocrit (HCT) from each species was used in data analysis. Test compound (100 μM) in acetonitrile and DMSO (95.5:0.5) was added into blood at a volume ratio of 1:100 to give a final concentration of 1 μM; the blood was then incubated at 37 °C in a shaking water bath for 1 h. Two aliquots of blood (0.25 mL each) were removed at 0 and 60 min. The first aliquot was centrifuged (10000 rpm for 10 min at rt) to obtain plasma. The second aliquot was treated with a half volume of water (125 μL) to hemolyze the blood cells. The samples were vortexed for 5 min and then centrifuged (10000 rpm for 10 min at rt). Plasma and blood samples were stored at −20 °C until analysis. The blood-to-plasma concentration ratio was calculated as drug concentrations in blood (<i>C</i><sub>b</sub>) relative to plasma (<i>C</i><sub>p</sub>). Percent blood cell distribution was calculated using the following equation.<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_m002.gif" alt="" id="_i73" /></img></span></div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Evaluation of in Vitro Metabolism Rates in Liver Microsomes and Hepatocytes</h3><div class="NLM_p last">Compound (0.5 μM) was incubated with liver microsomes (1 mg/mL) in the presence of NADPH (1.0 mM) and MgCl<sub>2</sub> (5 mM). Incubations with hepatocytes (0.83 × 10<sup>6</sup> cells/mL) were conducted in triplicate at 37 °C for 1 h with 95% humidity and 5% CO<sub>2</sub>. Metabolic reaction was terminated (quenched) with MeOH and MeCN (1:3 v/v) containing an internal standard at multiple time points. Samples were analyzed by an LC/MS/MS method, and metabolism rate was determined based on the parent compound disappearance over time, as measured by LC-MS/MS.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> In Vivo Studies</h3><div class="NLM_p last">All animal studies were performed under the approval of the Bristol-Myers Squibb Animal Care and Use Committee and in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care. Animals were dosed orally 5 mg/kg by gavage following an overnight fast. Oral solution vehicle for rat studies: <b>1</b>, <b>17</b>, <b>20</b>, <b>26</b>, <b>33</b>, and <b>35</b>, 84.5% polyethylene glycol 300 (PEG 300), 10% ethanol (EtOH), 5% 0.1 N NaOH, and 0.5% Tween-80 (TW80); <b>2</b>, <b>4</b> and <b>6</b>–<b>14</b>, 89% PEG 300, 10% EtOH, 1% TW80; <b>5</b>, 78% PEG 300, 10% EtOH, 1% 0.1 N NaOH, and 1% <span class="smallcaps smallerCapital">d</span>-α-tocopherol polyethylene glycol 1000 succinate (TPGS); <b>24</b>, 80% 50 mM citrate buffer, 20% sulfobutylether-β-cyclodextrin; <b>34</b>, 95% 50 mM citrate buffer; 5% hydroxypropyl β-cyclodextrin. The pharmacokinetic profile of <b>1</b> was characterized in male CD1 mice, male MDR1 a/b knockout mice, male Sprague–Dawley rats, male cynomolgus monkeys, and male beagle dogs. For intraduodenal dosing, rats had cannulas implanted in the duodenum. Mice were dosed IV bolus by tail-vein injection, and all other animals were dosed IV by a cannula implanted in an acceptable vein with an infusion period of 10 min for rats and 5 min for dogs and monkeys. Animals were dosed orally by gavage following an overnight fast unless specified otherwise. The vehicle for the IV study was 10% EtOH/90% PEG300 and the vehicle for the PO study was 80% 50 mM citrate buffer and 20% sulfobutylether-β-cyclodextrin. Elacridar (10 mg/kg) was administered immediately after dosing <b>1</b> using 90% PEG 400/10% EtOH (5 mL/kg) as the vehicle. Mouse samples were obtained using composite bleeding, and serial sampling was used for other species. Blood was collected via venous sampling and centrifuged to obtain plasma. Samples were treated with CH<sub>3</sub>CN containing an internal standard, centrifuged, and analyzed by LC-MS/MS. Pharmacokinetic parameters were obtained by noncompartmental analysis of plasma concentration versus time data (KINETICA software).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Single-Dose Food-Effect Studies in Dogs</h3><div class="NLM_p last">The oral pharmacokinetic profile of test compound was evaluated in the fed and fasted state in male beagle dogs.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> These studies were conducted in a crossover design (<i>n</i> = 4). There was at least a three week washout period between studies. Dogs (8.3 to 10 kg) were either fasted overnight prior to oral gavage administration and were fed 4 h after dosing or were fed a human FDA high-fat meal consisting of a 50 g homogenate estimated at ∼200 kcal (15% protein, 25% carbohydrate, and 50–60% fat) 15–30 min prior to dosing. Pentagastrin (6 μg/kg) was administered by IM injection 15–30 min prior to dosing compound. Famotidine (40 mg) was administered via capsule followed by H<sub>2</sub>O (10 mL) 1 h prior to administration of compound. Serial blood samples were collected from the saphenous vein at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 24, 30, 48, 72, and 168 h postdose. In both legs, test compound was administered by oral gavage at 2 mg/kg (2 mg/mL) suspension in 0.5% Methocel A4M, 0.1% sodium lauryl sulfate, and 99.4% H<sub>2</sub>O. Serial blood samples were collected from the saphenous vein at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 24, 30, 48, 72, and 168 h postdose. Blood samples were collected, stored, and analyzed as described previously.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00854" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05730" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05730" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00854" class="ext-link">10.1021/acs.jmedchem.8b00854</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures and characterization data for <b>[</b><sup><b>14</b></sup><b>C]-1</b>, WT EC<sub>50</sub>, V370A EC<sub>50</sub>, and ΔV370 EC<sub>50</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILE strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_001.csv">jm8b00854_si_001.csv (5.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_002.pdf">jm8b00854_si_002.pdf (165.19 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00854" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alicia Regueiro-Ren</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        A.R-R.: Bristol Myers Squibb, 350 Carter Road, Room 126, Hopewell, New Jersey 08540, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2991-719X" title="Orcid link">http://orcid.org/0000-0003-2991-719X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#71301d181218105f031416041418031e03141f31131c025f121e1c"><span class="__cf_email__" data-cfemail="5415383d373d357a26313321313d263b26313a143639277a373b39">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Jenkins</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        M.K. and S.J.: ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#067573756768286b286c63686d6f687546706f6f706e63676a726e656774632865696b"><span class="__cf_email__" data-cfemail="364543455758185b185c53585d5f584576405f5f405e53575a425e555744531855595b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob J. Swidorski</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Liu</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Chen</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ny Sin</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sing-Yuen Sit</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Chen</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian L. Venables</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juliang Zhu</span> - <span class="hlFld-Affiliation affiliation">Chemical Synthesis, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><sup>○</sup><span class="hlFld-ContribAuthor strong">Beata Nowicka-Sans</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tricia Protack</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zeyu Lin</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Terry</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Himadri Samanta</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharon Zhang</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        M.K. and S.J.: ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhufang Li</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Easter</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brett R. Beno</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinod Arora</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohua S. Huang</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandhya Rahematpura</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dawn D. Parker</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        M.K. and S.J.: ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roy Haskell</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth S. Santone</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark I. Cockett</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        M.K. and S.J.: ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Krystal</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        M.K. and S.J.: ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas A. Meanwell</span> - <span class="hlFld-Affiliation affiliation">Departments
of Discovery Chemistry and Molecular Technologies, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8857-1515" title="Orcid link">http://orcid.org/0000-0002-8857-1515</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Umesh Hanumegowda</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Candidate Optimization, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        M.K. and S.J.: ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ira B. Dicker</span> - <span class="hlFld-Affiliation affiliation">Virology, , ,  and , Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        M.K. and S.J.: ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><sup>○</sup>B.N-S.: Deceased April 8, 2016.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9640-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the support of the Bioanalytical group.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">betulinic acid</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">BVM</td><td class="NLM_def"><p class="first last">bevirimat</p></td></tr><tr><td class="NLM_term">CA</td><td class="NLM_def"><p class="first last">capsid</p></td></tr><tr><td class="NLM_term">cART</td><td class="NLM_def"><p class="first last">combination antiretroviral therapy</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">confidence value</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">methylene chloride</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FD</td><td class="NLM_def"><p class="first last">fold-difference</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">FeSSIF</td><td class="NLM_def"><p class="first last">fed simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">HS</td><td class="NLM_def"><p class="first last">human serum</p></td></tr><tr><td class="NLM_term">ID</td><td class="NLM_def"><p class="first last">intraduodenal</p></td></tr><tr><td class="NLM_term">KHMDS</td><td class="NLM_def"><p class="first last">potassium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">LANL</td><td class="NLM_def"><p class="first last">Los Alamos National Laboratory</p></td></tr><tr><td class="NLM_term">MA</td><td class="NLM_def"><p class="first last">matrix</p></td></tr><tr><td class="NLM_term">MI</td><td class="NLM_def"><p class="first last">maturation inhibitor</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">NC</td><td class="NLM_def"><p class="first last">nucleocapsid</p></td></tr><tr><td class="NLM_term">NFV</td><td class="NLM_def"><p class="first last">nelfinavir</p></td></tr><tr><td class="NLM_term">PCC</td><td class="NLM_def"><p class="first last">pyridinium chlorochromate</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">route of administration</p></td></tr><tr><td class="NLM_term">SP</td><td class="NLM_def"><p class="first last">spacer peptide</p></td></tr><tr><td class="NLM_term">TBDMSH</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilylhydride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TMD</td><td class="NLM_def"><p class="first last">thiomorpholine-1,1-dioxide</p></td></tr><tr><td class="NLM_term">TPAP</td><td class="NLM_def"><p class="first last">tetrapropylammonium perruthenate</p></td></tr><tr><td class="NLM_term">TPGS</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">d</span>-α-tocopherol polyethylene glycol 1000 succinate</p></td></tr><tr><td class="NLM_term">TW</td><td class="NLM_def"><p class="first last">Tween</p></td></tr><tr><td class="NLM_term">VLR</td><td class="NLM_def"><p class="first last">viral load reduction</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taiwo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J.</span></span> <span> </span><span class="NLM_article-title">Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1093/jac/dkq096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1093%2Fjac%2Fdkq096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=20348088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFOhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=1100-1107&author=B.+Taiwoauthor=C.+Hicksauthor=J.+Eron&title=Unmet+therapeutic+needs+in+the+new+era+of+combination+antiretroviral+therapy+for+HIV-1&doi=10.1093%2Fjac%2Fdkq096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1</span></div><div class="casAuthors">Taiwo, Babafemi; Hicks, Charles; Eron, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1100-1107</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Significant advances in outcomes were achieved with combination antiretroviral therapy (cART) in patients living with HIV.  However, several ongoing needs remain with respect to the development of new treatments.  The need for new or enhanced cART may become increasingly apparent as patients live longer with HIV and a greater proportion die from non-AIDS-related illnesses.  Immunol. response to cART is variable and immune failure occurs, despite virol. control.  Moreover, viral suppression can be incomplete due to insufficient antiviral efficacy, acquired or transmitted drug resistance, suboptimal pharmacokinetics/pharmacodynamics and lack of adherence.  Chronic immune activation may continue even when viral replication is relatively restrained.  Patients continue to experience cardiovascular and metabolic complications, due to disease, treatment and aging.  In addn., neurocognitive impairment and malignancy are important sources of ongoing morbidity despite cART.  HIV also affects immune system senescence and bone turnover.  This review discusses potential unmet needs with respect to these issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Au0uaJt3ZbVg90H21EOLACvtfcHk0lj2JWMRcY58Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFOhtrY%253D&md5=c338501700cf75a10602f178252c67ff</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkq096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkq096%26sid%3Dliteratum%253Aachs%26aulast%3DTaiwo%26aufirst%3DB.%26aulast%3DHicks%26aufirst%3DC.%26aulast%3DEron%26aufirst%3DJ.%26atitle%3DUnmet%2520therapeutic%2520needs%2520in%2520the%2520new%2520era%2520of%2520combination%2520antiretroviral%2520therapy%2520for%2520HIV-1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2010%26volume%3D65%26spage%3D1100%26epage%3D1107%26doi%3D10.1093%2Fjac%2Fdkq096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pau, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. M.</span></span> <span> </span><span class="NLM_article-title">Antiretroviral therapy</span>. <i>Infect. Dis. Clin. N. Am.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/j.idc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.idc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=25151562" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=371-402&author=A.+K.+Pauauthor=J.+M.+George&title=Antiretroviral+therapy&doi=10.1016%2Fj.idc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.idc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.idc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DPau%26aufirst%3DA.%2BK.%26aulast%3DGeorge%26aufirst%3DJ.%2BM.%26atitle%3DAntiretroviral%2520therapy%26jtitle%3DInfect.%2520Dis.%2520Clin.%2520N.%2520Am.%26date%3D2014%26volume%3D28%26spage%3D371%26epage%3D402%26doi%3D10.1016%2Fj.idc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensing, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhuis, M.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus gag and protease: partners in resistance</span>. <i>Retrovirology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">63</span>, <span class="refDoi"> DOI: 10.1186/1742-4690-9-63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1186%2F1742-4690-9-63" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=63&author=A.+Funauthor=A.+J.+Wensingauthor=J.+Verheyenauthor=M.+Nijhuis&title=Human+immunodeficiency+virus+gag+and+protease%3A+partners+in+resistance&doi=10.1186%2F1742-4690-9-63"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1186%2F1742-4690-9-63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4690-9-63%26sid%3Dliteratum%253Aachs%26aulast%3DFun%26aufirst%3DA.%26aulast%3DWensing%26aufirst%3DA.%2BJ.%26aulast%3DVerheyen%26aufirst%3DJ.%26aulast%3DNijhuis%26aufirst%3DM.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520gag%2520and%2520protease%253A%2520partners%2520in%2520resistance%26jtitle%3DRetrovirology%26date%3D2012%26volume%3D9%26spage%3D63%26doi%3D10.1186%2F1742-4690-9-63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Le, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, F. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the HIV RNA genome: high hanging fruit only needs a longer ladder</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1007/82_2015_434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1007%2F82_2015_434" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2015&pages=147-169&author=G.+Leauthor=F.+J.+Stuart&title=Targeting+the+HIV+RNA+genome%3A+high+hanging+fruit+only+needs+a+longer+ladder&doi=10.1007%2F82_2015_434"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1007%2F82_2015_434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F82_2015_434%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DG.%26aulast%3DStuart%26aufirst%3DF.%2BJ.%26atitle%3DTargeting%2520the%2520HIV%2520RNA%2520genome%253A%2520high%2520hanging%2520fruit%2520only%2520needs%2520a%2520longer%2520ladder%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2015%26volume%3D389%26spage%3D147%26epage%3D169%26doi%3D10.1007%2F82_2015_434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span> For a comprehensive
review on HIV-1 protease inhibitors see:<span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span>; <span class="NLM_string-name">Anderson, D. D.</span>; <span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">The FDA-approved HIV-1 protease inhibitors for treatment of HIV/AIDS</span>. In  <i>Burger’s Medicinal Chemistry and Drug Discovery</i>, <span class="NLM_edition">7th</span> ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D. J.</span>, <span class="NLM_string-name">Rotella, D. P.</span></span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">7</span>, pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">74</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2F0471266949.bmc224" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=1-74&author=A.+K.+Ghosh&author=D.+D.+Anderson&author=H.+Mitsuyaauthor=D.+J.+Abraham&author=D.+P.+Rotella&title=Burger%E2%80%99s+Medicinal+Chemistry+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2F0471266949.bmc224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471266949.bmc224%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DThe%2520FDA-approved%2520HIV-1%2520protease%2520inhibitors%2520for%2520treatment%2520of%2520HIV%252FAIDS%26btitle%3DBurger%25E2%2580%2599s%2520Medicinal%2520Chemistry%2520and%2520Drug%2520Discovery%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2010%26volume%3D7%26spage%3D1%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prato, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5172</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5172-5208&author=A.+K.+Ghoshauthor=H.+L.+Osswaldauthor=G.+Prato&title=Recent+progress+in+the+development+of+HIV-1+protease+inhibitors+for+the+treatment+of+HIV%2FAIDS&doi=10.1021%2Facs.jmedchem.5b01697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.; Prato, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5172-5208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 protease inhibitors continue to play an important role in the treatment of HIV/AIDS, transforming this deadly ailment into a more manageable chronic infection.  Over the years, intensive research has led to a variety of approved protease inhibitors for the treatment of HIV/AIDS.  In this review, we outline current drug design and medicinal chem. efforts toward the development of next-generation protease inhibitors beyond the currently approved drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4DisuSRbQXbVg90H21EOLACvtfcHk0ljK95VmgvrWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D&md5=e0994f3d84ab627d3ac3f757e8d11725</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01697%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26aulast%3DPrato%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520in%2520the%2520development%2520of%2520HIV-1%2520protease%2520inhibitors%2520for%2520the%2520treatment%2520of%2520HIV%252FAIDS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5172%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.5b01697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dismuke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forshey, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of HIV-1 replication by a novel mechanism: specific interference with the final step of virion maturation</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.2.922-929.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FJVI.78.2.922-929.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=14694123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=922-929&author=J.+Zhouauthor=X.+Yuanauthor=D.+Dismukeauthor=B.+M.+Forsheyauthor=C.+Lundquistauthor=K.+H.+Leeauthor=C.+Aikenauthor=C.+H.+Chen&title=Pharmacologic+inhibition+of+HIV-1+replication+by+a+novel+mechanism%3A+specific+interference+with+the+final+step+of+virion+maturation&doi=10.1128%2FJVI.78.2.922-929.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation</span></div><div class="casAuthors">Zhou, Jing; Yuan, Xiong; Dismuke, David; Forshey, Brett M.; Lundquist, Christopher; Lee, Kuo-hsiung; Aiken, Christopher; Chen, Chin Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">922-929</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Despite the effectiveness of currently available human immunodeficiency virus type 1 (HIV-1) therapies, a continuing need exists for new drugs to treat HIV-1 infection.  We investigated the mechanism by which 3-O-{3',3'-dimethylsuccinyl}betulinic acid (DSB) inhibits HIV-1 replication.  DSB functions at a late stage of the virus life cycle but does not inhibit the HIV-1 protease in vitro or interfere with virus assembly or release.  DSB specifically delays the cleavage of Gag between the capsid (CA) and p2, resulting in delayed formation of the mature viral core and reduced HIV-1 infectivity.  Replication of simian immunodeficiency virus (SIV) was resistant to DSB; however, a chimeric SIV carrying CA-p2 sequences from HIV-1 was inhibited by the drug, indicating that susceptibility to DSB maps to the CA-p2 region of the HIV-1 Gag protein.  A single point mutation at the CA-p2 cleavage site of HIV-1 conferred strong resistance to DSB, confirming the target of the drug.  HIV-1 strains that are resistant to a variety of protease inhibitors were sensitive to DSB.  These findings indicate that DSB specifically protects the CA-p2 cleavage site from processing by the viral protease during virion maturation, thereby revealing a novel mechanism for pharmacol. inhibition of HIV-1 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqINzh_nRQEVLVg90H21EOLACvtfcHk0ljK95VmgvrWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFeiug%253D%253D&md5=00be1aa7c70e20a1855418a784089da6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.2.922-929.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.2.922-929.2004%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DDismuke%26aufirst%3DD.%26aulast%3DForshey%26aufirst%3DB.%2BM.%26aulast%3DLundquist%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DAiken%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DPharmacologic%2520inhibition%2520of%2520HIV-1%2520replication%2520by%2520a%2520novel%2520mechanism%253A%2520specific%2520interference%2520with%2520the%2520final%2520step%2520of%2520virion%2520maturation%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D922%26epage%3D929%26doi%3D10.1128%2FJVI.78.2.922-929.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundquist, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kräusslich, H. G.</span></span> <span> </span><span class="NLM_article-title">HIV-1 assembly, budding, and maturation</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">a006924</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a006924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1101%2Fcshperspect.a006924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=22762019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a006924&author=W.+I.+Sundquistauthor=H.+G.+Kr%C3%A4usslich&title=HIV-1+assembly%2C+budding%2C+and+maturation&doi=10.1101%2Fcshperspect.a006924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 assembly, budding, and maturation</span></div><div class="casAuthors">Sundquist, Wesley I.; Krausslich, Hans-Georg</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">a006924/1-a006924/24</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  A defining property of retroviruses is their ability to assemble into particles that can leave producer cells and spread infection to susceptible cells and hosts.  Virion morphogenesis can be divided into three stages: assembly, wherein the virion is created and essential components are packaged; budding, wherein the virion crosses the plasma membrane and obtains its lipid envelope; and maturation, wherein the virion changes structure and becomes infectious.  All of these stages are coordinated by the Gag polyprotein and its proteolytic maturation products, which function as the major structural proteins of the virus.  Here, we review our current understanding of the mechanisms of HIV-1 assembly, budding, and maturation, starting with a general overview and then providing detailed descriptions of each of the different stages of virion morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH1Quq8ytnBrVg90H21EOLACvtfcHk0ligDReUvTumUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemtbs%253D&md5=91c7bf7383d85be14ef6f5200990f451</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a006924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a006924%26sid%3Dliteratum%253Aachs%26aulast%3DSundquist%26aufirst%3DW.%2BI.%26aulast%3DKr%25C3%25A4usslich%26aufirst%3DH.%2BG.%26atitle%3DHIV-1%2520assembly%252C%2520budding%252C%2520and%2520maturation%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26spage%3Da006924%26doi%3D10.1101%2Fcshperspect.a006924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span> <span> </span><span class="NLM_article-title">HIV-1 assembly, release and maturation</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1038/nrmicro3490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1038%2Fnrmicro3490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=26119571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFaitr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=484-496&author=E.+O.+Freed&title=HIV-1+assembly%2C+release+and+maturation&doi=10.1038%2Fnrmicro3490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 assembly, release and maturation</span></div><div class="casAuthors">Freed, Eric O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">484-496</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Major advances occurred in recent years in the authors' understanding of HIV-1 assembly, release and maturation, as work in this field has been propelled forwards by developments in imaging technol., structural biol., and cell and mol. biol.  This increase in basic knowledge is being applied to the development of novel inhibitors designed to target various aspects of virus assembly and maturation.  This Review highlights recent progress in elucidating the late stages of the HIV-1 replication cycle and the related interplay between virol., cell and mol. biol., and drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPfA3gjWasqbVg90H21EOLACvtfcHk0ligDReUvTumUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFaitr3I&md5=6eeb09143263c9ef53e385d3243323ff</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro3490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro3490%26sid%3Dliteratum%253Aachs%26aulast%3DFreed%26aufirst%3DE.%2BO.%26atitle%3DHIV-1%2520assembly%252C%2520release%2520and%2520maturation%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2015%26volume%3D13%26spage%3D484%26epage%3D496%26doi%3D10.1038%2Fnrmicro3490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">HIV protease inhibitors: a review of molecular selectivity and toxicity</span>. <i>HIV/AIDS</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.2147/HIV.S79956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.2147%2FHIV.S79956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=25897264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFChtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=95-104&author=Z.+Lvauthor=Y.+Chuauthor=Y.+Wang&title=HIV+protease+inhibitors%3A+a+review+of+molecular+selectivity+and+toxicity&doi=10.2147%2FHIV.S79956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HIV protease inhibitors: a review of molecular selectivity and toxicity</span></div><div class="casAuthors">Lv, Zhengtong; Chu, Yuan; Wang, Yong</div><div class="citationInfo"><span class="NLM_cas:title">HIV/AIDS</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-104</span>CODEN:
                <span class="NLM_cas:coden">HIVAA2</span>;
        ISSN:<span class="NLM_cas:issn">1179-1373</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Highly active antiretroviral therapy (HAART) is recognized as the most effective treatment method for AIDS, and protease inhibitors play a very important role in HAART.  However, poor bioavailability and unbearable toxicity are their common disadvantages.  Thus, the development of safer and potentially promising protease inhibitors is eagerly needed.  In this review, we introduced the chem. characteristics and assocd. side effects of HIV protease inhibitors, as well as the possible off-target mechanisms causing the side effects.  From the chem. structures of HIV protease inhibitors and their possible off-target mols., we could obtain hints for optimizing the mol. selectivity of the inhibitors, to provide help in the design of new compds. with enhanced bioavailability and reduced side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAkmF3LC4h4rVg90H21EOLACvtfcHk0ligDReUvTumUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFChtrk%253D&md5=2a28e6df087fcf50f52aa3f217c57ffe</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FHIV.S79956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHIV.S79956%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DHIV%2520protease%2520inhibitors%253A%2520a%2520review%2520of%2520molecular%2520selectivity%2520and%2520toxicity%26jtitle%3DHIV%252FAIDS%26date%3D2015%26volume%3D7%26spage%3D95%26epage%3D104%26doi%3D10.2147%2FHIV.S79956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span> <span> </span><span class="NLM_article-title">Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1177/095632020801900301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1177%2F095632020801900301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=19024627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlChur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=107-113&author=D.+E.+Martinauthor=K.+Salzwedelauthor=G.+P.+Allaway&title=Bevirimat%3A+a+novel+maturation+inhibitor+for+the+treatment+of+HIV-1+infection&doi=10.1177%2F095632020801900301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection</span></div><div class="casAuthors">Martin, David E.; Salzwedel, Karl; Allaway, Graham P.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">107-113</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  Existing antiretroviral treatments for HIV type-1 (HIV-1) disease are limited by problems of resistance and drug-drug interactions.  Bevirimat is a novel HIV-1 maturation inhibitor with a mechanism of action that is distinct from other antiretroviral agents.  Specific inhibition of the final rate-limiting step in Gag processing by bevirimat prevents release of mature capsid protein from its precursor (CA-SP1), resulting in the prodn. of immature, non-infectious virus particles.  Bevirimat inhibits replication of both wild-type and drug-resistant HIV-1 isolates in vitro, achieving similar 50% inhibitory concn. values with both categories.  Serial drug passage studies have identified six single amino acid substitutions that independently confer bevirimat resistance.  These resistance mutations occur at or near the CA-SP1 cleavage site, which is not a known target for resistance to other antiretroviral drugs.  Bevirimat has demonstrated a consistent pharmacokinetic profile in healthy volunteers and HIV-infected patients, with peak plasma concns. attained approx. 1-3 h after dosing.  Plasma concns. decrease in a log-linear manner with a mean plasma elimination half-life of 58-80 h, supporting once-daily dosing.  Animal studies suggest that elimination of bevirimat is primarily by hepatic glucuronidation and hepatobiliary excretion.  There is minimal renal elimination, with <1% of the administered dose appearing in the urine.  In responsive patients, bevirimat has demonstrated a robust dose-dependent redn. in viral load (>1.5 log10 copies/mL).  Short-term administration (≤14 days) of bevirimat is well tolerated, even when used in combination with other antiretroviral agents.  Further studies to evaluate the long-term efficacy and tolerability of bevirimat are currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGralYiuCP9_FrVg90H21EOLACvtfcHk0lgJyTy9gUOd0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlChur3L&md5=9e6c7573626ce746ef6c26b25efea756</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1177%2F095632020801900301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020801900301%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DD.%2BE.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26atitle%3DBevirimat%253A%2520a%2520novel%2520maturation%2520inhibitor%2520for%2520the%2520treatment%2520of%2520HIV-1%2520infection%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2008%26volume%3D19%26spage%3D107%26epage%3D113%26doi%3D10.1177%2F095632020801900301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilgore, N.</span>; <span class="NLM_string-name">Reddick, M.</span>; <span class="NLM_string-name">Zuiderhof, M.</span>; <span class="NLM_string-name">Stanley, D.</span>; <span class="NLM_string-name">Nitz, T.</span>; <span class="NLM_string-name">Bullock, P.</span>; <span class="NLM_string-name">Allaway, G.</span>; <span class="NLM_string-name">Martin, D.</span></span> <span> </span><span class="NLM_article-title">Characterization of PA1050040, a second generation HIV-1 maturation inhibitor</span>. In  <i>4th IAS Conference on HIV Pathogenesis, Treatment and Prevention,  July 22–25, 2007, Sydney, Australia</i>, <span class="NLM_year">2007</span>; abstract  <span class="NLM_fpage">MOPDX05</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=MOPDX05&author=N.+Kilgore&author=M.+Reddick&author=M.+Zuiderhof&author=D.+Stanley&author=T.+Nitz&author=P.+Bullock&author=G.+Allaway&author=D.+Martin&title=Characterization+of+PA1050040%2C+a+second+generation+HIV-1+maturation+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKilgore%26aufirst%3DN.%26atitle%3DCharacterization%2520of%2520PA1050040%252C%2520a%2520second%2520generation%2520HIV-1%2520maturation%2520inhibitor%26jtitle%3D4th%2520IAS%2520Conference%2520on%2520HIV%2520Pathogenesis%252C%2520Treatment%2520and%2520Prevention%252C%2520%2520July%252022%25E2%2580%259325%252C%25202007%252C%2520Sydney%252C%2520Australia%26date%3D2007%26spage%3DMOPDX05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baichwal, V.</span>; <span class="NLM_string-name">Austin, H.</span>; <span class="NLM_string-name">Brown, B.</span>; <span class="NLM_string-name">McKinnon, R.</span>; <span class="NLM_string-name">Yager, K.</span>; <span class="NLM_string-name">Kumar, V.</span>; <span class="NLM_string-name">Gerrish, D.</span>; <span class="NLM_string-name">Anderson, M.</span>; <span class="NLM_string-name">Carlson, R.</span></span> <span> </span><span class="NLM_article-title">Anti-viral characterization in vitro of a novel maturation inhibitor, MPC-9055</span>.  <i>16th Conference on Retroviruses and Opportunistic Infections, February 8–11, 2009, Montreal, Canada</i>, <span class="NLM_year">2009</span>; abstract  <span class="NLM_fpage">J-105</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=J-105&author=V.+Baichwal&author=H.+Austin&author=B.+Brown&author=R.+McKinnon&author=K.+Yager&author=V.+Kumar&author=D.+Gerrish&author=M.+Anderson&author=R.+Carlson&title=Anti-viral+characterization+in+vitro+of+a+novel+maturation+inhibitor%2C+MPC-9055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBaichwal%26aufirst%3DV.%26atitle%3DAnti-viral%2520characterization%2520in%2520vitro%2520of%2520a%2520novel%2520maturation%2520inhibitor%252C%2520MPC-9055%26jtitle%3D16th%2520Conference%2520on%2520Retroviruses%2520and%2520Opportunistic%2520Infections%252C%2520February%25208%25E2%2580%259311%252C%25202009%252C%2520Montreal%252C%2520Canada%26date%3D2009%26spage%3DJ-105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span> <span> </span><span class="NLM_article-title">A repeat dose pharmacokinetic (PK) and safety study of GSK2838232
with and without ritonavir (RTV) conducted in healthy subjects</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>; <a href="https://www.clinicaltrials.gov/ct2/show/NCT02289495?term=GSK2838232&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02289495?term=GSK2838232&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+repeat+dose+pharmacokinetic+%28PK%29+and+safety+study+of+GSK2838232%0Awith+and+without+ritonavir+%28RTV%29+conducted+in+healthy+subjects.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02289495%3Fterm%3DGSK2838232%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520repeat%2520dose%2520pharmacokinetic%2520%2528PK%2529%2520and%2520safety%2520study%2520of%2520GSK2838232%250Awith%2520and%2520without%2520ritonavir%2520%2528RTV%2529%2520conducted%2520in%2520healthy%2520subjects%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and gag polymorphic coverage</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3956</span>– <span class="NLM_lpage">3969</span>, <span class="refDoi"> DOI: 10.1128/AAC.02560-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.02560-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=27090171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=3956-3969&author=B.+Nowicka-Sansauthor=T.+Protackauthor=Z.+Linauthor=Z.+Liauthor=S.+Zhangauthor=Y.+Sunauthor=H.+Samantaauthor=B.+Terryauthor=Z.+Liuauthor=Y.+Chenauthor=N.+Sinauthor=S.+Sitauthor=J.+Swidorskiauthor=J.+Chenauthor=B.+L.+Venablesauthor=M.+Healyauthor=N.+A.+Meanwellauthor=M.+Cockettauthor=U.+Hanumegowdaauthor=A.+Regueiro-Renauthor=M.+Krystalauthor=I.+B.+Dicker&title=Identification+and+characterization+of+BMS-955176%2C+a+second-generation+HIV-1+maturation+inhibitor+with+improved+potency%2C+antiviral+spectrum%2C+and+gag+polymorphic+coverage&doi=10.1128%2FAAC.02560-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of BMS-955176, a second- generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and Gag polymorphic coverage</span></div><div class="casAuthors">Nowicka-Sans, Beata; Protack, Tricia; Lin, Zeyu; Li, Zhufang; Zhang, Sharon; Sun, Yongnian; Samanta, Himadri; Terry, Brian; Liu, Zheng; Chen, Yan; Sin, Ny; Sit, Sing-Yuen; Swidorski, Jacob J.; Chen, Jie; Venables, Brian L.; Healy, Matthew; Meanwell, Nicholas A.; Cockett, Mark; Hanumegowda, Umesh; Regueiro-Ren, Alicia; Krystal, Mark; Dicker, Ira B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3956-3969</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-955176 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor (MI).  A first-generation MI, bevirimat, showed clin. efficacy in early-phase studies, but ∼50% of subjects had viruses with reduced susceptibility assocd. with naturally occurring polymorphisms in Gag near the site of MI action.  MI potency was optimized using a panel of engineered reporter viruses contg. site-directed polymorphic changes in Gag that reduce susceptibility to bevirimat (including V362I, V370A/M/Δ, and T371A/Δ), leading incrementally to the identification of BMS-955176.  BMS-955176 exhibits potent activity (50% effective concn. [EC50], 3.9 ± 3.4 nM [mean ± std. deviation]) toward a library (n = 87) of gag/pr recombinant viruses representing 96.5% of subtype B polymorphic Gag diversity near the CA/SP1 cleavage site.  BMS-955176 exhibited a median EC50 of 21 nM toward a library of subtype B clin. isolates assayed in peripheral blood mononuclear cells (PBMCs).  Potent activity was maintained against a panel of reverse transcriptase, protease, and integrase inhibitor-resistant viruses, with EC50s similar to those for the wild-type virus.  A 5.4-fold redn. in EC50 occurred in the presence of 40% human serum plus 27 mg/mL of human serum albumin (HSA), which corresponded well to an in vitro measurement of 86% human serum binding.  Time-of-addn. and pseudotype reporter virus studies confirm a mechanism of action for the compd. that occurs late in the virus replication cycle.  BMS-955176 inhibits HIV-1 protease cleavage at the CA/SP1 junction within Gag in virus-like particles (VLPs) and in HIV-1-infected cells, and it binds reversibly and with high affinity to assembled Gag in purified HIV-1 VLPs.  Finally, in vitro combination studies showed no antagonistic interactions with representative antiretrovirals (ARVs) of other mechanistic classes.  In conclusion, BMS-955176 is a second-generation MI with potent in vitro anti-HIV-1 activity and a greatly improved preclin. profile compared to that of bevirimat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOlEXzA0wovbVg90H21EOLACvtfcHk0lgJyTy9gUOd0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyksbY%253D&md5=3a2d50795078357c62d002d2293c1852</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.02560-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02560-15%26sid%3Dliteratum%253Aachs%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSamanta%26aufirst%3DH.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DSit%26aufirst%3DS.%26aulast%3DSwidorski%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DHealy%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520BMS-955176%252C%2520a%2520second-generation%2520HIV-1%2520maturation%2520inhibitor%2520with%2520improved%2520potency%252C%2520antiviral%2520spectrum%252C%2520and%2520gag%2520polymorphic%2520coverage%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D3956%26epage%3D3969%26doi%3D10.1128%2FAAC.02560-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockett, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of BMS-955176, a second generation HIV-1 maturation inhibitor with broad spectrum antiviral activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVOhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=568-572&author=A.+Regueiro-Renauthor=Z.+Liuauthor=Y.+Chenauthor=N.+Sinauthor=S.+Y.+Sitauthor=J.+J.+Swidorskiauthor=J.+Chenauthor=B.+L.+Venablesauthor=J.+L.+Zhuauthor=B.+Nowicka-Sansauthor=T.+Protackauthor=Z.+Linauthor=B.+Terryauthor=H.+Samantaauthor=S.+Zhangauthor=Z.+F.+Liauthor=B.+R.+Benoauthor=X.+S.+Huangauthor=S.+Rahematpuraauthor=D.+D.+Parkerauthor=R.+Haskellauthor=S.+Jenkinsauthor=K.+S.+Santoneauthor=M.+I.+Cockettauthor=M.+Krystalauthor=N.+A.+Meanwellauthor=U.+Hanumegowdaauthor=I.+B.+Dicker&title=Discovery+of+BMS-955176%2C+a+second+generation+HIV-1+maturation+inhibitor+with+broad+spectrum+antiviral+activity&doi=10.1021%2Facsmedchemlett.6b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity</span></div><div class="casAuthors">Regueiro-Ren, Alicia; Liu, Zheng; Chen, Yan; Sin, Ny; Sit, Sing-Yuen; Swidorski, Jacob J.; Chen, Jie; Venables, Brian L.; Zhu, Juliang; Nowicka-Sans, Beata; Protack, Tricia; Lin, Zeyu; Terry, Brian; Samanta, Himadri; Zhang, Sharon; Li, Zhufang; Beno, Brett R.; Huang, Xiaohua S.; Rahematpura, Sandhya; Parker, Dawn D.; Haskell, Roy; Jenkins, Susan; Santone, Kenneth S.; Cockett, Mark I.; Krystal, Mark; Meanwell, Nicholas A.; Hanumegowda, Umesh; Dicker, Ira B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">568-572</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 maturation inhibition (MI) has been clin. validated as an approach to the control of HIV-1 infection.  However, identifying an MI with both broad polymorphic spectrum coverage and good oral exposure has been challenging.  Herein, we describe the design, synthesis, and preclin. characterization of a potent, orally active, second generation HIV-1 MI, BMS-955176 (2)(I), which is currently in Phase IIb clin. trials as part of a combination antiretroviral regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvDTuPfUkgArVg90H21EOLACvtfcHk0lgwl6fAd9wxnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVOhsLw%253D&md5=d6bb9ad5b3d3ea7e4884401ff882d7a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00010%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DSit%26aufirst%3DS.%2BY.%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DSamanta%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%2BF.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DHaskell%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DCockett%26aufirst%3DM.%2BI.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26atitle%3DDiscovery%2520of%2520BMS-955176%252C%2520a%2520second%2520generation%2520HIV-1%2520maturation%2520inhibitor%2520with%2520broad%2520spectrum%2520antiviral%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D568%26epage%3D572%26doi%3D10.1021%2Facsmedchemlett.6b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogundele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span> <span> </span><span class="NLM_article-title">Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3′3-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3574</span>– <span class="NLM_lpage">3581</span>, <span class="refDoi"> DOI: 10.1128/AAC.00152-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.00152-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=3574-3581&author=P.+F.+Smithauthor=A.+Ogundeleauthor=J.+W.+Forrestauthor=J.+Wiltonauthor=K.+Salzwedelauthor=J.+Dotoauthor=G.+P.+Allawayauthor=D.+E.+Martin&title=Phase+I+and+II+study+of+the+safety%2C+virologic+effect%2C+and+pharmacokinetics%2Fpharmacodynamics+of+single-dose+3-O-%283%E2%80%B23-dimethylsuccinyl%29betulinic+acid+%28bevirimat%29+against+human+immunodeficiency+virus+infection&doi=10.1128%2FAAC.00152-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.00152-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00152-07%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DOgundele%26aufirst%3DA.%26aulast%3DForrest%26aufirst%3DJ.%2BW.%26aulast%3DWilton%26aufirst%3DJ.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DDoto%26aufirst%3DJ.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26atitle%3DPhase%2520I%2520and%2520II%2520study%2520of%2520the%2520safety%252C%2520virologic%2520effect%252C%2520and%2520pharmacokinetics%252Fpharmacodynamics%2520of%2520single-dose%25203-O-%25283%25E2%2580%25B23-dimethylsuccinyl%2529betulinic%2520acid%2520%2528bevirimat%2529%2520against%2520human%2520immunodeficiency%2520virus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D3574%26epage%3D3581%26doi%3D10.1128%2FAAC.00152-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCallister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrigan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G.</span></span> <span> </span><span class="NLM_article-title">HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457)</span>. <i>Antiviral Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">A10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=A10&author=S.+McCallisterauthor=J.+Lalezariauthor=G.+Richmondauthor=M.+Thompsonauthor=R.+Harriganauthor=D.+Martinauthor=K.+Salzwedelauthor=G.+Allaway&title=HIV-1+Gag+polymorphisms+determine+treatment+response+to+bevirimat+%28PA-457%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCallister%26aufirst%3DS.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DHarrigan%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DAllaway%26aufirst%3DG.%26atitle%3DHIV-1%2520Gag%2520polymorphisms%2520determine%2520treatment%2520response%2520to%2520bevirimat%2520%2528PA-457%2529%26jtitle%3DAntiviral%2520Ther.%26date%3D2008%26volume%3D13%26spage%3DA10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Baelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondelez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eygen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steegen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verlinden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuyver, L. J.</span></span> <span> </span><span class="NLM_article-title">Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1128/AAC.01650-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.01650-08" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=2185-2188&author=K.+Van%0ABaelenauthor=K.+Salzwedelauthor=E.+Rondelezauthor=V.+Van+Eygenauthor=S.+De+Vosauthor=A.+Verheyenauthor=K.+Steegenauthor=Y.+Verlindenauthor=G.+P.+Allawayauthor=L.+J.+Stuyver&title=Susceptibility+of+human+immunodeficiency+virus+type+1+to+the+maturation+inhibitor+bevirimat+is+modulated+by+baseline+polymorphisms+in+Gag+spacer+peptide+1&doi=10.1128%2FAAC.01650-08"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.01650-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01650-08%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBaelen%26aufirst%3DK.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DRondelez%26aufirst%3DE.%26aulast%3DVan%2BEygen%26aufirst%3DV.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DVerheyen%26aufirst%3DA.%26aulast%3DSteegen%26aufirst%3DK.%26aulast%3DVerlinden%26aufirst%3DY.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26aulast%3DStuyver%26aufirst%3DL.%2BJ.%26atitle%3DSusceptibility%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520to%2520the%2520maturation%2520inhibitor%2520bevirimat%2520is%2520modulated%2520by%2520baseline%2520polymorphisms%2520in%2520Gag%2520spacer%2520peptide%25201%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D2185%26epage%3D2188%26doi%3D10.1128%2FAAC.01650-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margot, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic susceptibility to bevirimat among HIV-1 infected patient isolates without prior exposure to bevirimat</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2345</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1128/AAC.01784-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.01784-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2345-2353&author=N.+A.+Margotauthor=C.+S.+Gibbsauthor=M.+D.+Miller&title=Phenotypic+susceptibility+to+bevirimat+among+HIV-1+infected+patient+isolates+without+prior+exposure+to+bevirimat&doi=10.1128%2FAAC.01784-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.01784-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01784-09%26sid%3Dliteratum%253Aachs%26aulast%3DMargot%26aufirst%3DN.%2BA.%26aulast%3DGibbs%26aufirst%3DC.%2BS.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DPhenotypic%2520susceptibility%2520to%2520bevirimat%2520among%2520HIV-1%2520infected%2520patient%2520isolates%2520without%2520prior%2520exposure%2520to%2520bevirimat%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2345%26epage%3D2353%26doi%3D10.1128%2FAAC.01784-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span>; <span class="NLM_string-name">Richards, J.</span>; <span class="NLM_string-name">Augustine, J. G.</span>; <span class="NLM_string-name">Milea, J. S.</span></span> <span> </span><span class="NLM_article-title">Liquid Bevirimat Dosage Forms for Oral Administration</span>. U.S. Patent <span class="NLM_patent">US20100216751A1</span>, August 26, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Jacob&author=J.+Richards&author=J.+G.+Augustine&author=J.+S.+Milea&title=Liquid+Bevirimat+Dosage+Forms+for+Oral+Administration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%26aufirst%3DJ.%26atitle%3DLiquid%2520Bevirimat%2520Dosage%2520Forms%2520for%2520Oral%2520Administration%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span> <span> </span><span class="NLM_article-title">An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1177/0091270009333488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1177%2F0091270009333488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=19304891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=606-612&author=A.+Connorauthor=P.+Evansauthor=J.+Dotoauthor=C.+Ellisauthor=D.+E.+Martin&title=An+oral+human+drug+absorption+study+to+assess+the+impact+of+site+of+delivery+on+the+bioavailability+of+bevirimat&doi=10.1177%2F0091270009333488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat</span></div><div class="casAuthors">Connor, Alyson; Evans, Phil; Doto, Judy; Ellis, Corey; Martin, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">606-612</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bevirimat is a first in class, orally active, potent and selective inhibitor of HIV-1.  It may have utility for the treatment of HIV-1-infected patients who are failing current regimens because of the development of drug resistance.  In earlier studies in HIV-1-infected patients, an immediate-release tablet formulation exhibited a relative bioavailability (Frel) of 50% or greater and a higher intersubject variability than an oral soln.  The purpose of this study was to det. whether this pharmacokinetic profile is attributable to a narrow permeability-dependent absorption window within the gastrointestinal tract.  Three groups of subjects completed an open-label, 2-way crossover, randomized pharmacoscintigraphic study.  Subjects received a 25-mg bevirimat oral immediate-release soln. plus 25 mg bevirimat soln. delivered to the proximal small bowel, distal small bowel, or colon via the Enterion capsule.  The results indicate that the permeability of bevirimat throughout the small intestine was excellent and suggest that the variability obsd. for the immediate release tablet was not related to the presence of an absorption window in the small intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6fZ-OhBjwObVg90H21EOLACvtfcHk0ljHCx3fuvCjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWlsr4%253D&md5=a8b69f57e94bd403112bf0f917127063</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F0091270009333488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333488%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DP.%26aulast%3DDoto%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26atitle%3DAn%2520oral%2520human%2520drug%2520absorption%2520study%2520to%2520assess%2520the%2520impact%2520of%2520site%2520of%2520delivery%2520on%2520the%2520bioavailability%2520of%2520bevirimat%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D606%26epage%3D612%26doi%3D10.1177%2F0091270009333488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, J.</span></span> <span> </span><span class="NLM_article-title">Can the further clinical development of bevirimat be justified?</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1097/QAD.0b013e328331c83b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1097%2FQAD.0b013e328331c83b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=773-774&author=M.+A.+Wainbergauthor=J.+Albert&title=Can+the+further+clinical+development+of+bevirimat+be+justified%3F&doi=10.1097%2FQAD.0b013e328331c83b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1097%2FQAD.0b013e328331c83b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0b013e328331c83b%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26aulast%3DAlbert%26aufirst%3DJ.%26atitle%3DCan%2520the%2520further%2520clinical%2520development%2520of%2520bevirimat%2520be%2520justified%253F%26jtitle%3DAIDS%26date%3D2010%26volume%3D24%26spage%3D773%26epage%3D774%26doi%3D10.1097%2FQAD.0b013e328331c83b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1770</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmc.2016.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=26968652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvV2hsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1757-1770&author=Z.+Liuauthor=J.+J.+Swidorskiauthor=B.+Nowicka-Sansauthor=B.+Terryauthor=T.+Protackauthor=Z.+Linauthor=H.+Samantaauthor=S.+Zhangauthor=Z.+Liauthor=S.+Rahematpuraauthor=D.+D.+Parkerauthor=S.+Jenkinsauthor=B.+R.+Benoauthor=M.+Krystalauthor=N.+A.+Meanwellauthor=I.+B.+Dickerauthor=A.+Regueiro-Ren&title=C-3+benzoic+acid+derivatives+of+C-3+deoxybetulinic+acid+and+deoxybetulin+as+HIV-1+maturation+inhibitors&doi=10.1016%2Fj.bmc.2016.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors</span></div><div class="casAuthors">Liu, Zheng; Swidorski, Jacob J.; Nowicka-Sans, Beata; Terry, Brian; Protack, Tricia; Lin, Zeyu; Samanta, Himadri; Zhang, Sharon; Li, Zhufang; Parker, Dawn D.; Rahematpura, Sandhya; Jenkins, Susan; Beno, Brett R.; Krystal, Mark; Meanwell, Nicholas A.; Dicker, Ira B.; Regueiro-Ren, Alicia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1757-1770</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of C-3 phenyl- and heterocycle-substituted derivs. of C-3 deoxybetulinic acid and C-3 deoxybetulin was designed and synthesized as HIV-1 maturation inhibitors (MIs) and evaluated for their antiviral activity and cytotoxicity in cell culture.  A 4-subsituted benzoic acid moiety was identified as an advantageous replacement for the 3'3'-dimethylsuccinate moiety present in previously disclosed MIs that illuminates new aspects of the topog. of the pharmacophore.  The new analogs exhibit excellent in vitro antiviral activity against wild-type (wt) virus and a lower serum shift when compared with the prototypical HIV-1 MI bevirimat (1, BVM), the first MI to be evaluated in clin. studies.  Compd. 9a exhibits comparable cell culture potency toward wt virus as 1 (WT EC50 = 16 nM for 9a compared to 10 nM for 1).  However, the potency of 9a is less affected by the presence of human serum, while the compd. displays a similar pharmacokinetic profile in rats to 1.  Hence 9a, the 4-benzoic acid deriv. of deoxybetulinic acid, represents a new starting point from which to explore the design of a 2nd generation MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo6JzDEZTpIrVg90H21EOLACvtfcHk0ljHCx3fuvCjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvV2hsLk%253D&md5=bbcabfc972def3487a7144765fe8ac20</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSamanta%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DC-3%2520benzoic%2520acid%2520derivatives%2520of%2520C-3%2520deoxybetulinic%2520acid%2520and%2520deoxybetulin%2520as%2520HIV-1%2520maturation%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1757%26epage%3D1770%26doi%3D10.1016%2Fj.bmc.2016.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of HIV-1 maturation: development of structure-activity relationships for C-28 amide derivatives of C-3 benzoic acid-modified triterpenoids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmcl.2016.03.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1925-1930&author=J.+J.+Swidorskiauthor=Z.+Liuauthor=S.-Y.+Sitauthor=J.+Chenauthor=Y.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=D.+D.+Parkerauthor=B.+Nowicka-Sansauthor=B.+J.+Terryauthor=T.+Protackauthor=S.+Rahematpuraauthor=U.+Hanumegowdaauthor=S.+Jenkinsauthor=M.+Krystalauthor=I.+B.+Dickerauthor=N.+A.+Meanwellauthor=A.+Regueiro-Ren&title=Inhibitors+of+HIV-1+maturation%3A+development+of+structure-activity+relationships+for+C-28+amide+derivatives+of+C-3+benzoic+acid-modified+triterpenoids&doi=10.1016%2Fj.bmcl.2016.03.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DTerry%26aufirst%3DB.%2BJ.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520HIV-1%2520maturation%253A%2520development%2520of%2520structure-activity%2520relationships%2520for%2520C-28%2520amide%2520derivatives%2520of%2520C-3%2520benzoic%2520acid-modified%2520triterpenoids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1925%26epage%3D1930%26doi%3D10.1016%2Fj.bmcl.2016.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Venables, B. L.</span>; <span class="NLM_string-name">Sit, S.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">C-17 and C-3 Modified Triterpenoids with HIV Maturation Inhibitory Activity</span>. U.S. Patent <span class="NLM_patent">US8846647</span>, September 30, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Regueiro-Ren&author=Z.+Liu&author=J.+Swidorski&author=N.+Sin&author=B.+L.+Venables&author=S.+Sit&author=Y.+Chen&author=J.+Chen&author=N.+A.+Meanwell&title=C-17+and+C-3+Modified+Triterpenoids+with+HIV+Maturation+Inhibitory+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DC-17%2520and%2520C-3%2520Modified%2520Triterpenoids%2520with%2520HIV%2520Maturation%2520Inhibitory%2520Activity%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and structure-activity-relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1557</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmcl.2018.03.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1550-1557&author=Y.+Chenauthor=S.-Y.+Sitauthor=J.+Chenauthor=J.+J.+Swidorskiauthor=Z.+Liuauthor=N.+Sinauthor=B.+L.+Venablesauthor=D.+D.+Parkerauthor=B.+Nowicka-Sansauthor=Z.+Linauthor=Z.+Liauthor=B.+Terryauthor=T.+Protackauthor=S.+Rahematpuraauthor=U.+Hanumegowdaauthor=S.+Jenkinsauthor=M.+Krystalauthor=I.+B.+Dickerauthor=N.+A.+Meanwellauthor=A.+Regueiro-Ren&title=The+design%2C+synthesis+and+structure-activity-relationships+associated+with+C28+amine-based+betulinic+acid+derivatives+as+inhibitors+of+HIV-1+maturation&doi=10.1016%2Fj.bmcl.2018.03.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520structure-activity-relationships%2520associated%2520with%2520C28%2520amine-based%2520betulinic%2520acid%2520derivatives%2520as%2520inhibitors%2520of%2520HIV-1%2520maturation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1550%26epage%3D1557%26doi%3D10.1016%2Fj.bmcl.2018.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcombe, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. D.</span></span> <span> </span><span class="NLM_article-title">Preparation and use of tetra-n-butylammonium per-ruthenate (TBAP reagent) and tetra-n-propylammonium per-ruthenate (TPAP reagent) as new catalytic oxidants for alcohols</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1627</span>, <span class="refDoi"> DOI: 10.1039/c39870001625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1039%2Fc39870001625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=1625-1627&author=W.+P.+Griffithauthor=S.+V.+Leyauthor=G.+P.+Whitcombeauthor=A.+D.+White&title=Preparation+and+use+of+tetra-n-butylammonium+per-ruthenate+%28TBAP+reagent%29+and+tetra-n-propylammonium+per-ruthenate+%28TPAP+reagent%29+as+new+catalytic+oxidants+for+alcohols&doi=10.1039%2Fc39870001625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and use of tetrabutylammonium perruthenate (TBAP reagent) and tetrapropylammonium perruthenate (TPAP reagent) as new catalytic oxidants for alcohols</span></div><div class="casAuthors">Griffith, William P.; Ley, Steven V.; Whitcombe, Gwynne P.; White, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1625-7</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Bu4NRuO4 or Pr4NRuO4 in combination with N-methylmorpholine N-oxide are mild catalytic oxidants for the high yield conversion of alcs. to aldehyde and ketones and are competitive with more conventional reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxf2jCOWaVh7Vg90H21EOLACvtfcHk0lhA9G3N0d3HNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D&md5=19a661844cadf93bad8dc9ae9ba18477</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fc39870001625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39870001625%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DWhitcombe%26aufirst%3DG.%2BP.%26aulast%3DWhite%26aufirst%3DA.%2BD.%26atitle%3DPreparation%2520and%2520use%2520of%2520tetra-n-butylammonium%2520per-ruthenate%2520%2528TBAP%2520reagent%2529%2520and%2520tetra-n-propylammonium%2520per-ruthenate%2520%2528TPAP%2520reagent%2529%2520as%2520new%2520catalytic%2520oxidants%2520for%2520alcohols%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1987%26spage%3D1625%26epage%3D1627%26doi%3D10.1039%2Fc39870001625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lindgren, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of carboxylic acids from aldehydes (including hydroxylated benzaldehydes) by oxidation with chlorite</span>. <i>Acta Chem. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">888</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.3891/acta.chem.scand.27-0888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.3891%2Facta.chem.scand.27-0888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaE3sXksVaju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1973&pages=888-890&author=B.+O.+Lindgrenauthor=T.+Nilsson&title=Preparation+of+carboxylic+acids+from+aldehydes+%28including+hydroxylated+benzaldehydes%29+by+oxidation+with+chlorite&doi=10.3891%2Facta.chem.scand.27-0888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of carboxylic acids from aldehydes (including hydroxylated benzaldehydes) by oxidation with chlorite</span></div><div class="casAuthors">Lindgren, Bengt O.; Nilsson, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chemica Scandinavica (1947-1973)</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">888-90</span>CODEN:
                <span class="NLM_cas:coden">ACSAA4</span>;
        ISSN:<span class="NLM_cas:issn">0001-5393</span>.
    </div><div class="casAbstract">Addn. of H2NSO3Hj or m-(%hO)2C6H4 to a title oxidn. mixt. contg. vanilline prevented the formation of ClO2, which reacted with vanillin or vanillic acid to form undesirable side products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ZVjX2rhlvrVg90H21EOLACvtfcHk0lhA9G3N0d3HNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXksVaju7k%253D&md5=459f307094848ba957093e19ba9de0d2</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.3891%2Facta.chem.scand.27-0888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3891%252Facta.chem.scand.27-0888%26sid%3Dliteratum%253Aachs%26aulast%3DLindgren%26aufirst%3DB.%2BO.%26aulast%3DNilsson%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520carboxylic%2520acids%2520from%2520aldehydes%2520%2528including%2520hydroxylated%2520benzaldehydes%2529%2520by%2520oxidation%2520with%2520chlorite%26jtitle%3DActa%2520Chem.%2520Scand.%26date%3D1973%26volume%3D27%26spage%3D888%26epage%3D890%26doi%3D10.3891%2Facta.chem.scand.27-0888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinnick, H. W.</span></span> <span> </span><span class="NLM_article-title">Oxidation of α,β-unsaturated aldehydes</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2096</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(01)97963-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4020%2801%2997963-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL3MXlsFSjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1981&pages=2091-2096&author=B.+S.+Balauthor=W.+E.+Childersauthor=H.+W.+Pinnick&title=Oxidation+of+%CE%B1%2C%CE%B2-unsaturated+aldehydes&doi=10.1016%2FS0040-4020%2801%2997963-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of α,β-unsaturated aldehydes</span></div><div class="casAuthors">Bal, Balkrishna S.; Childers, Wayne E., Jr.; Pinnick, Harold W.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2091-6</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">Three methods for the oxidn. of α,β-unsatd. aldehydes to the corresponding acids were studied.  These were MnO2 oxidn. of the cyanohydrin deriv., treatment with Caro's acid, and reaction with NaClO2.  The last was the best method, giving pure acid in high yield.  E.g., propenal I (R = H) with NaClO2 (Me3COH, MeCH:CMe2, aq. NaH2PO4, room temp., overnight) gave 90% I (R = OH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy3LIBi4Dq7LVg90H21EOLACvtfcHk0litg4K3Ed1g1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXlsFSjs74%253D&md5=1cea4c957f6032c660027bcd98e35e19</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2997963-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252997963-3%26sid%3Dliteratum%253Aachs%26aulast%3DBal%26aufirst%3DB.%2BS.%26aulast%3DChilders%26aufirst%3DW.%2BE.%26aulast%3DPinnick%26aufirst%3DH.%2BW.%26atitle%3DOxidation%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520aldehydes%26jtitle%3DTetrahedron%26date%3D1981%26volume%3D37%26spage%3D2091%26epage%3D2096%26doi%3D10.1016%2FS0040-4020%2801%2997963-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span> <span> </span><span class="NLM_article-title">Synthetic studies toward verrucarol. 2. Synthesis of the AB ring system</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">4825</span>– <span class="NLM_lpage">4830</span>, <span class="refDoi"> DOI: 10.1021/jo01312a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01312a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL3MXhsF2jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=4825-4830&author=G.+A.+Krausauthor=B.+Roth&title=Synthetic+studies+toward+verrucarol.+2.+Synthesis+of+the+AB+ring+system&doi=10.1021%2Fjo01312a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic studies toward verrucarol.  2.  Synthesis of the AB ring system</span></div><div class="casAuthors">Kraus, George A.; Roth, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4825-30</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">A route to the AB ring system of verrucarol is described.  The successful scheme involved the formation of the A ring by a boron triacetate-catalyzed Diels-Alder reaction.  The second ring can be appended by an intramol. Knoevenagel reaction to afford lactone I.  This lactone could be converted into the desired keto alc. II by redn. of the lactone and nitrile followed by an oxidn. and Curtius degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiD9e02uy7u7Vg90H21EOLACvtfcHk0litg4K3Ed1g1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhsF2jtQ%253D%253D&md5=d93d7efb2bcf8c61fb811de83be424db</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Fjo01312a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01312a004%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DRoth%26aufirst%3DB.%26atitle%3DSynthetic%2520studies%2520toward%2520verrucarol.%25202.%2520Synthesis%2520of%2520the%2520AB%2520ring%2520system%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D4825%26epage%3D4830%26doi%3D10.1021%2Fjo01312a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taschner, M. J.</span></span> <span> </span><span class="NLM_article-title">Model studies for the synthesis of quassinoids. 1. Construction of the BCE ring system</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1021/jo01294a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01294a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL3cXhs1Cis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=1175-1176&author=G.+A.+Krausauthor=M.+J.+Taschner&title=Model+studies+for+the+synthesis+of+quassinoids.+1.+Construction+of+the+BCE+ring+system&doi=10.1021%2Fjo01294a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22dR"><div class="casContent"><span class="casTitleNuber">22d</span><div class="casTitle"><span class="NLM_cas:atitle">Model studies for the synthesis of quassinoids.  1.  Construction of the BCE ring system</span></div><div class="casAuthors">Kraus, George A.; Taschner, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1175-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The synthesis of a key intermediate I for the prepn. of quassimarin (II) is described.  The BC ring system is constructed using a Diels-Alder reaction involving the in situ generated carbomethoxybenzoquinone.  The E ring is introduced by a selenoetherification reaction.  The trans diaxial diol unit can be constructed by intramol. epoxide opening.  Attempts to open the epoxide with external nucleophiles failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXJGvgihSziLVg90H21EOLACvtfcHk0litg4K3Ed1g1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhs1Cis70%253D&md5=9202fa3b893c40e56d1700545f3a3a3d</span></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fjo01294a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01294a058%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DTaschner%26aufirst%3DM.%2BJ.%26atitle%3DModel%2520studies%2520for%2520the%2520synthesis%2520of%2520quassinoids.%25201.%2520Construction%2520of%2520the%2520BCE%2520ring%2520system%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D1175%26epage%3D1176%26doi%3D10.1021%2Fjo01294a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Sit, S.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Liu, Z.</span></span>; <span> </span><span class="NLM_article-title">C-28 Amines of C-3 Modified Betulinic Acid Derivatives as HIV Maturation Inhibitors</span>. U.S. Patent <span class="NLM_patent">US8748415</span>, June 10, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Regueiro-Ren&author=J.+Swidorski&author=S.+Sit&author=Y.+Chen&author=J.+Chen&author=N.+A.+Meanwell&author=Z.+Liu&title=C-28+Amines+of+C-3+Modified+Betulinic+Acid+Derivatives+as+HIV+Maturation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DC-28%2520Amines%2520of%2520C-3%2520Modified%2520Betulinic%2520Acid%2520Derivatives%2520as%2520HIV%2520Maturation%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Sit, S.-Y.</span>; <span class="NLM_string-name">Chen, J.</span>, <span class="NLM_string-name">Sin, N.</span></span> <span> </span><span class="NLM_article-title">Modified C-3 Betulinic Acid Derivatives as HIV Maturation Inhibitors</span>. <span class="NLM_patent">US 8754068</span>, June 17, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Regueiro-Ren&author=J.+Swidorski&author=Z.+Liu&author=N.+A.+Meanwell&author=S.-Y.+Sit&author=J.+Chen&author=N.+Sin&title=Modified+C-3+Betulinic+Acid+Derivatives+as+HIV+Maturation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DModified%2520C-3%2520Betulinic%2520Acid%2520Derivatives%2520as%2520HIV%2520Maturation%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioiri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorus in organic synthesis-VII. Diphenyl phosphorazidate (DPPA). A new convenient reagent for a modified Curtius Reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2151</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(01)97352-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4020%2801%2997352-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1974&pages=2151-2157&author=K.+Ninomiyaauthor=T.+Shioiriauthor=S.+Yamada&title=Phosphorus+in+organic+synthesis-VII.+Diphenyl+phosphorazidate+%28DPPA%29.+A+new+convenient+reagent+for+a+modified+Curtius+Reaction&doi=10.1016%2FS0040-4020%2801%2997352-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2997352-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252997352-1%26sid%3Dliteratum%253Aachs%26aulast%3DNinomiya%26aufirst%3DK.%26aulast%3DShioiri%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DPhosphorus%2520in%2520organic%2520synthesis-VII.%2520Diphenyl%2520phosphorazidate%2520%2528DPPA%2529.%2520A%2520new%2520convenient%2520reagent%2520for%2520a%2520modified%2520Curtius%2520Reaction%26jtitle%3DTetrahedron%26date%3D1974%26volume%3D30%26spage%3D2151%26epage%3D2157%26doi%3D10.1016%2FS0040-4020%2801%2997352-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baltina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flekhter, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigmatullina, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boreko, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaeva, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstikov, G. A.</span></span> <span> </span><span class="NLM_article-title">Lupane triterpenes and derivatives with antiviral activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3549</span>– <span class="NLM_lpage">3552</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00714-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0960-894X%2803%2900714-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3549-3552&author=L.+A.+Baltinaauthor=O.+B.+Flekhterauthor=L.+R.+Nigmatullinaauthor=E.+I.+Borekoauthor=N.+I.+Pavlovaauthor=S.+N.+Nikolaevaauthor=O.+V.+Savinovaauthor=G.+A.+Tolstikov&title=Lupane+triterpenes+and+derivatives+with+antiviral+activity&doi=10.1016%2FS0960-894X%2803%2900714-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900714-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900714-5%26sid%3Dliteratum%253Aachs%26aulast%3DBaltina%26aufirst%3DL.%2BA.%26aulast%3DFlekhter%26aufirst%3DO.%2BB.%26aulast%3DNigmatullina%26aufirst%3DL.%2BR.%26aulast%3DBoreko%26aufirst%3DE.%2BI.%26aulast%3DPavlova%26aufirst%3DN.%2BI.%26aulast%3DNikolaeva%26aufirst%3DS.%2BN.%26aulast%3DSavinova%26aufirst%3DO.%2BV.%26aulast%3DTolstikov%26aufirst%3DG.%2BA.%26atitle%3DLupane%2520triterpenes%2520and%2520derivatives%2520with%2520antiviral%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D3549%26epage%3D3552%26doi%3D10.1016%2FS0960-894X%2803%2900714-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Sit, S.-Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">C-17 Bicyclic Amines of Triterpenoids with HIV Maturation Inhibitory Activity and Their Preparation</span>. World Patent <span class="NLM_patent">WO 2013169578</span>, November 14, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Sin&author=Z.+Liu&author=J.+Swidorski&author=S.-Y.+Sit&author=J.+Chen&author=Y.+Chen&author=N.+A.+Meanwell&author=A.+Regueiro-Ren&title=C-17+Bicyclic+Amines+of+Triterpenoids+with+HIV+Maturation+Inhibitory+Activity+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSin%26aufirst%3DN.%26atitle%3DC-17%2520Bicyclic%2520Amines%2520of%2520Triterpenoids%2520with%2520HIV%2520Maturation%2520Inhibitory%2520Activity%2520and%2520Their%2520Preparation%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.
F. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P.</span></span> <span> </span><span class="NLM_article-title">Cu(I)-catalyzed sulfoximination</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">4805</span>– <span class="NLM_lpage">4806</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(98)00925-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4039%2898%2900925-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=4805-4806&author=J.%0AF.+K+Mullerauthor=P.+Vogt&title=Cu%28I%29-catalyzed+sulfoximination&doi=10.1016%2FS0040-4039%2898%2900925-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2900925-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252900925-3%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DJ.%2BF.%2BK%26aulast%3DVogt%26aufirst%3DP.%26atitle%3DCu%2528I%2529-catalyzed%2520sulfoximination%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D4805%26epage%3D4806%26doi%3D10.1016%2FS0040-4039%2898%2900925-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strege, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, T. R.</span></span> <span> </span><span class="NLM_article-title">Desulfonylation of aryl alkyl sulfones</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3477</span>– <span class="NLM_lpage">3478</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)71334-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4039%2800%2971334-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1976&pages=3477-3478&author=B.+M.+Trostauthor=H.+C.+Arndtauthor=P.+E.+Stregeauthor=T.+R.+Verhoeven&title=Desulfonylation+of+aryl+alkyl+sulfones&doi=10.1016%2FS0040-4039%2800%2971334-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2971334-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252971334-7%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DArndt%26aufirst%3DH.%2BC.%26aulast%3DStrege%26aufirst%3DP.%2BE.%26aulast%3DVerhoeven%26aufirst%3DT.%2BR.%26atitle%3DDesulfonylation%2520of%2520aryl%2520alkyl%2520sulfones%26jtitle%3DTetrahedron%2520Lett.%26date%3D1976%26volume%3D17%26spage%3D3477%26epage%3D3478%26doi%3D10.1016%2FS0040-4039%2800%2971334-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikugawa, Y.</span></span> <span> </span><span class="NLM_article-title">One-pot reductive amination of aldehydes and ketones with α-picoline-borane in methanol, in water, and in neat conditions</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7899</span>– <span class="NLM_lpage">7906</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.06.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.tet.2004.06.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=7899-7906&author=S.+Satoauthor=T.+Sakamotoauthor=E.+Miyazawaauthor=Y.+Kikugawa&title=One-pot+reductive+amination+of+aldehydes+and+ketones+with+%CE%B1-picoline-borane+in+methanol%2C+in+water%2C+and+in+neat+conditions&doi=10.1016%2Fj.tet.2004.06.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot reductive amination of aldehydes and ketones with α-picoline-borane in methanol, in water, and in neat conditions</span></div><div class="casAuthors">Sato, Shinya; Sakamoto, Takeshi; Miyazawa, Etsuko; Kikugawa, Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">7899-7906</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A one-pot reductive amination of aldehydes and ketones with amines using α-picoline-borane as a reducing agent is described.  The reaction has been carried out in MeOH, in H2O, and under neat conditions in the presence of small amts. of AcOH.  This was a highly efficient and mild procedure that was applicable for a wide variety of substrates.  In particular, this was a successful demonstration that the reaction can be carried out in water and under neat conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboH8FKbO3_rVg90H21EOLACvtfcHk0lgrisr9SZbWAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVajtrY%253D&md5=1f8369a5a0dc0b51bdceb2cba6f4f792</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.06.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.06.045%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DS.%26aulast%3DSakamoto%26aufirst%3DT.%26aulast%3DMiyazawa%26aufirst%3DE.%26aulast%3DKikugawa%26aufirst%3DY.%26atitle%3DOne-pot%2520reductive%2520amination%2520of%2520aldehydes%2520and%2520ketones%2520with%2520%25CE%25B1-picoline-borane%2520in%2520methanol%252C%2520in%2520water%252C%2520and%2520in%2520neat%2520conditions%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26spage%3D7899%26epage%3D7906%26doi%3D10.1016%2Fj.tet.2004.06.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plancq, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavelle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Remote modulation of amine basicity by a phenylsulfone and a phenylthio group</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">287</span>, The p<i>K</i><sub>a</sub> value for the TMD moiety in <b>1</b> could not be obtained experimentally due to the low aqueous solubility of the compound. Potentiometric analysis was performed to obtain an approximated value with the p<i>K</i><sub>a</sub> estimated to be 4.5. <span class="refDoi"> DOI: 10.1002/cmdc.200600265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.200600265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=17200999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVWqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=285-287&author=R.+E.+Martinauthor=B.+Plancqauthor=O.+Gavelleauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=K.+M%C3%BCller&title=Remote+modulation+of+amine+basicity+by+a+phenylsulfone+and+a+phenylthio+group&doi=10.1002%2Fcmdc.200600265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Remote modulation of amine basicity by a phenylsulfone and a phenylthio group</span></div><div class="casAuthors">Martin, Rainer E.; Plancq, Baptiste; Gavelle, Olivier; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-287</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of Ph sulfones and phenylthioamines was studied with respect to their pKa values in water under std. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPxZKU1NhH-rVg90H21EOLACvtfcHk0lgrvmoygqdm_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVWqtLk%253D&md5=1e5681e5549ca7fc205493c7db96262b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600265%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DPlancq%26aufirst%3DB.%26aulast%3DGavelle%26aufirst%3DO.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DRemote%2520modulation%2520of%2520amine%2520basicity%2520by%2520a%2520phenylsulfone%2520and%2520a%2520phenylthio%2520group%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D285%26epage%3D287%26doi%3D10.1002%2Fcmdc.200600265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kleeb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zihlmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abgottspon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiesko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüdin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezençon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwardt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, B.</span></span> <span> </span><span class="NLM_article-title">FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2221</span>– <span class="NLM_lpage">2239</span>, <span class="refDoi"> DOI: 10.1021/jm501524q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501524q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2221-2239&author=S.+Kleebauthor=L.+Pangauthor=K.+Mayerauthor=D.+Erisauthor=A.+Siglauthor=R.+C.+Prestonauthor=P.+Zihlmannauthor=T.+Sharpeauthor=R.+P.+Jakobauthor=D.+Abgottsponauthor=A.+S.+Hutterauthor=M.+Scharenbergauthor=X.+Jiangauthor=G.+Navarraauthor=S.+Rabbaniauthor=M.+Smieskoauthor=N.+L%C3%BCdinauthor=J.+Bezen%C3%A7onauthor=O.+Schwardtauthor=T.+Maierauthor=B.+Ernst&title=FimH+antagonists%3A+bioisosteres+to+improve+the+in+vitro+and+in+vivo+PK%2FPD+profile&doi=10.1021%2Fjm501524q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1021%2Fjm501524q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501524q%26sid%3Dliteratum%253Aachs%26aulast%3DKleeb%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DL.%26aulast%3DMayer%26aufirst%3DK.%26aulast%3DEris%26aufirst%3DD.%26aulast%3DSigl%26aufirst%3DA.%26aulast%3DPreston%26aufirst%3DR.%2BC.%26aulast%3DZihlmann%26aufirst%3DP.%26aulast%3DSharpe%26aufirst%3DT.%26aulast%3DJakob%26aufirst%3DR.%2BP.%26aulast%3DAbgottspon%26aufirst%3DD.%26aulast%3DHutter%26aufirst%3DA.%2BS.%26aulast%3DScharenberg%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DNavarra%26aufirst%3DG.%26aulast%3DRabbani%26aufirst%3DS.%26aulast%3DSmiesko%26aufirst%3DM.%26aulast%3DL%25C3%25BCdin%26aufirst%3DN.%26aulast%3DBezen%25C3%25A7on%26aufirst%3DJ.%26aulast%3DSchwardt%26aufirst%3DO.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DErnst%26aufirst%3DB.%26atitle%3DFimH%2520antagonists%253A%2520bioisosteres%2520to%2520improve%2520the%2520in%2520vitro%2520and%2520in%2520vivo%2520PK%252FPD%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2221%26epage%3D2239%26doi%3D10.1021%2Fjm501524q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lgrvmoygqdm_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oukoloff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayendran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunden, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span> <span> </span><span class="NLM_article-title">Evaluation of oxetan-3-ol, thietan-3-ol, and derivatives thereof as bioisosteres of the carboxylic acid functional group</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFagu7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=864-868&author=P.+Lassalasauthor=K.+Oukoloffauthor=V.+Makaniauthor=M.+Jamesauthor=V.+Tranauthor=Y.+Yaoauthor=L.+Huangauthor=K.+Vijayendranauthor=L.+Montiauthor=J.+Q.+Trojanowskiauthor=V.+M.-Y.+Leeauthor=M.+C.+Kozlowskiauthor=A.+B.+Smithauthor=K.+R.+Brundenauthor=C.+Ballatore&title=Evaluation+of+oxetan-3-ol%2C+thietan-3-ol%2C+and+derivatives+thereof+as+bioisosteres+of+the+carboxylic+acid+functional+group&doi=10.1021%2Facsmedchemlett.7b00212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30cR"><div class="casContent"><span class="casTitleNuber">30c</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group</span></div><div class="casAuthors">Lassalas, Pierrik; Oukoloff, Killian; Makani, Vishruti; James, Michael; Tran, Van; Yao, Yuemang; Huang, Longchuan; Vijayendran, Krishna; Monti, Ludovica; Trojanowski, John Q.; Lee, Virginia M.-Y.; Kozlowski, Marisa C.; Smith, Amos B.; Brunden, Kurt R.; Ballatore, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">864-868</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxetane ring serves as an isostere of the carbonyl moiety, suggesting that oxetan-3-ol may be considered as a potential surrogate of the carboxylic acid functional group.  To investigate this structural unit, as well as thietan-3-ol and the corresponding sulfoxide and sulfone derivs., as potential carboxylic acid bioisosteres, a set of model compds. has been designed, synthesized, and evaluated for physicochem. properties.  Similar derivs. of the cyclooxygenase inhibitor, ibuprofen, were also synthesized and evaluated for inhibition of eicosanoid biosynthesis in vitro.  Collectively, the data suggest that oxetan-3-ol, thietan-3-ol, and related structures hold promise as isosteric replacements of the carboxylic acid moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1ZLULOrc2bVg90H21EOLACvtfcHk0lgrvmoygqdm_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFagu7zK&md5=bb7c7a383ccc3c4c275d550a863a5330</span></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00212%26sid%3Dliteratum%253Aachs%26aulast%3DLassalas%26aufirst%3DP.%26aulast%3DOukoloff%26aufirst%3DK.%26aulast%3DMakani%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DV.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DVijayendran%26aufirst%3DK.%26aulast%3DMonti%26aufirst%3DL.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.-Y.%26aulast%3DKozlowski%26aufirst%3DM.%2BC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DEvaluation%2520of%2520oxetan-3-ol%252C%2520thietan-3-ol%252C%2520and%2520derivatives%2520thereof%2520as%2520bioisosteres%2520of%2520the%2520carboxylic%2520acid%2520functional%2520group%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D864%26epage%3D868%26doi%3D10.1021%2Facsmedchemlett.7b00212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murafuji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imajo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muto, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5272</span>– <span class="NLM_lpage">5276</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmcl.2017.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=29102227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslejtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5272-5276&author=H.+Murafujiauthor=H.+Sakaiauthor=M.+Gotoauthor=S.+Imajoauthor=H.+Sugawaraauthor=T.+Muto&title=Discovery+and+structure-activity+relationship+study+of+1%2C3%2C6-trisubstituted+1%2C4-diazepane-7-ones+as+novel+human+kallikrein+7+inhibitors&doi=10.1016%2Fj.bmcl.2017.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30dR"><div class="casContent"><span class="casTitleNuber">30d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors</span></div><div class="casAuthors">Murafuji, Hidenobu; Sakai, Hiroki; Goto, Megumi; Imajo, Seiichi; Sugawara, Hajime; Muto, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5272-5276</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. I, composed of a 1,3,6-trisubstituted 1,4-diazepane-7-one, was discovered as a novel human kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme, SCCE) inhibitor, and its derivs. were synthesized and evaluated.  Structure-activity relationship studies of the amidoxime unit and benzoic acid part of this new scaffold led to the identification of compds. II (R = CO2H and R = Ms), which were more potent than the hit compd., I.  The X-ray co-crystal structure of compd. II (R = CO2H) and human KLK7 revealed the characteristic interactions and enabled explanations of the structure-activity relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK1C4HsV46o7Vg90H21EOLACvtfcHk0lj0DyeZf4cKBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslejtr3M&md5=25aa9fa4add2001cfca7897e56f710ef</span></div><a href="/servlet/linkout?suffix=cit30d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DMurafuji%26aufirst%3DH.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DImajo%26aufirst%3DS.%26aulast%3DSugawara%26aufirst%3DH.%26aulast%3DMuto%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520structure-activity%2520relationship%2520study%2520of%25201%252C3%252C6-trisubstituted%25201%252C4-diazepane-7-ones%2520as%2520novel%2520human%2520kallikrein%25207%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D5272%26epage%3D5276%26doi%3D10.1016%2Fj.bmcl.2017.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi-Parmar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisneros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimmer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Optimization of pyrazoles as phenol surrogates to yield potent inhibitors of macrophage migration inhibitory factor</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1092</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.201800158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=29575754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1092-1097&author=V.+Trivedi-Parmarauthor=M.+J.+Robertsonauthor=J.+A.+Cisnerosauthor=S.+G.+Krimmerauthor=W.+L.+Jorgensen&title=Optimization+of+pyrazoles+as+phenol+surrogates+to+yield+potent+inhibitors+of+macrophage+migration+inhibitory+factor&doi=10.1002%2Fcmdc.201800158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30eR"><div class="casContent"><span class="casTitleNuber">30e</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Pyrazoles as Phenol Surrogates to Yield Potent Inhibitors of Macrophage Migration Inhibitory Factor</span></div><div class="casAuthors">Trivedi-Parmar, Vinay; Robertson, Michael J.; Cisneros, Jose A.; Krimmer, Stefan G.; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1092-1097</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that is implicated in the regulation of inflammation, cell proliferation, and neurol. disorders.  MIF is also an enzyme that functions as a keto-enol tautomerase.  Most potent MIF tautomerase inhibitors incorporate a phenol, which hydrogen bonds to Asn97 in the active site.  Starting from a 113-μm docking hit, we report results of structure-based and computer-aided design that have provided substituted pyrazoles as phenol alternatives with potencies of 60-70 nm.  Crystal structures of complexes of MIF with the pyrazoles highlight the contributions of hydrogen bonding with Lys32 and Asn97, and aryl-aryl interactions with Tyr36, Tyr95, and Phe113 to the binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBNIBiGpnG57Vg90H21EOLACvtfcHk0lj0DyeZf4cKBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFWjt78%253D&md5=f9e8fa5897bb763c5a36333e01eb69c4</span></div><a href="/servlet/linkout?suffix=cit30e&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800158%26sid%3Dliteratum%253Aachs%26aulast%3DTrivedi-Parmar%26aufirst%3DV.%26aulast%3DRobertson%26aufirst%3DM.%2BJ.%26aulast%3DCisneros%26aufirst%3DJ.%2BA.%26aulast%3DKrimmer%26aufirst%3DS.%2BG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DOptimization%2520of%2520pyrazoles%2520as%2520phenol%2520surrogates%2520to%2520yield%2520potent%2520inhibitors%2520of%2520macrophage%2520migration%2520inhibitory%2520factor%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D1092%26epage%3D1097%26doi%3D10.1002%2Fcmdc.201800158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Röder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lj0DyeZf4cKBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lgzsiVL9XuNLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: a neglected opportunity in medicinal chemistry</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9399</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1002/anie.201302209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fanie.201302209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9399-9408&author=U.+L%C3%BCcking&title=Sulfoximines%3A+a+neglected+opportunity+in+medicinal+chemistry&doi=10.1002%2Fanie.201302209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines: A Neglected Opportunity in Medicinal Chemistry</span></div><div class="casAuthors">Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9399-9408</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Innovation has frequently been described as the key to drug discovery.  However, in the daily routine, medicinal chemists often tend to stick to the functional groups and structural elements they know and love.  Blockbuster cancer drug Velcade (bortezomib), for example, was rejected by more than 50 companies, supposedly because of its unusual boronic acid function (as often repeated: "only a moron would put boron in a drug!").  Similarly, in the discovery process of the pan-CDK inhibitor BAY 1000394, the unconventional proposal to introduce a sulfoximine group into the lead series also led to sneers and raised eyebrows, since sulfoximines have seldom been used in medicinal chem.  However, it was the introduction of the sulfoximine group that finally allowed the fundamental issues of the project to be overcome, culminating in the identification of the clin. sulfoximine pan-CDK inhibitor BAY 1000394.  This Minireview provides an overview of a widely neglected opportunity in medicinal chem.-the sulfoximine group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcpeepAANfbVg90H21EOLACvtfcHk0lgzsiVL9XuNLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI&md5=6850d8d77b1141d9d9344410822c00c3</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302209%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DSulfoximines%253A%2520a%2520neglected%2520opportunity%2520in%2520medicinal%2520chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9399%26epage%3D9408%26doi%3D10.1002%2Fanie.201302209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines from a medicinal chemist’s perspective: physicochemical and in vitro parameters relevant for drug discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.ejmech.2016.09.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=27821325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=225-245&author=M.+Fringsauthor=C.+Bolmauthor=A.+Blumauthor=C.+Gnamm&title=Sulfoximines+from+a+medicinal+chemist%E2%80%99s+perspective%3A+physicochemical+and+in+vitro+parameters+relevant+for+drug+discovery&doi=10.1016%2Fj.ejmech.2016.09.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery</span></div><div class="casAuthors">Frings, Marcus; Bolm, Carsten; Blum, Andreas; Gnamm, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sulfoximines, sulfondiimides and sulfonimidamides are fascinating but not yet fully explored variants of the common sulfone or sulfonamide motif.  In this study, we report the physicochem. and in vitro properties of sulfoximines and compare them with related analogs and isosteres.  Furthermore, we present a matched mol. pair anal. of compds. from drug discovery projects within Boehringer Ingelheim.  We demonstrate that the sulfoximine moiety is a chem. stable, comparatively polar and weakly basic functional group, often leading to favorable aq. soly., permeability and metabolic stability.  Moreover, their addnl. vectors at nitrogen enable simple chem. modifications and thus facilitate exploration and fine-tuning of the mol. properties.  We conclude that sulfoximines and their congeners do not exhibit any intrinsic flaw but significantly enrich the toolbox of medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu0FlXXURKybVg90H21EOLACvtfcHk0lgzsiVL9XuNLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK&md5=8a7939f22425f46ad9eb87fcddd29099</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.091%26sid%3Dliteratum%253Aachs%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DBolm%26aufirst%3DC.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DGnamm%26aufirst%3DC.%26atitle%3DSulfoximines%2520from%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%253A%2520physicochemical%2520and%2520in%2520vitro%2520parameters%2520relevant%2520for%2520drug%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D225%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.09.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sirvent, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Novel pieces for the emerging picture of sulfoximines in drug discovery: synthesis and evaluation of sulfoximine analogues of marketed drugs and advanced clinical candidates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.201700044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=28221724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=487-501&author=J.+A.+Sirventauthor=U.+L%C3%BCcking&title=Novel+pieces+for+the+emerging+picture+of+sulfoximines+in+drug+discovery%3A+synthesis+and+evaluation+of+sulfoximine+analogues+of+marketed+drugs+and+advanced+clinical+candidates&doi=10.1002%2Fcmdc.201700044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates</span></div><div class="casAuthors">Sirvent, Juan Alberto; Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-501</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sulfoximines have gained considerable recognition as an important structural motif in drug discovery of late.  In particular, the clin. kinase inhibitors for the treatment of cancer, roniciclib (pan-CDK inhibitor), BAY 1143572 (P-TEFb inhibitor), and AZD 6738 (ATR inhibitor), have recently drawn considerable attention.  While the interest in this underrepresented functional group in drug discovery is clearly on the rise, there remains an incomplete understanding of the medicinal-chem.-relevant properties of sulfoximines.  Herein we report the synthesis and in vitro characterization of a variety of sulfoximine analogs of marketed drugs and advanced clin. candidates to gain a better understanding of this neglected functional group and its potential in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5kfVM3I45LVg90H21EOLACvtfcHk0ljdd4dWJFgBig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D&md5=5b4589d7af32c8984d4fd3027c31c168</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700044%26sid%3Dliteratum%253Aachs%26aulast%3DSirvent%26aufirst%3DJ.%2BA.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DNovel%2520pieces%2520for%2520the%2520emerging%2520picture%2520of%2520sulfoximines%2520in%2520drug%2520discovery%253A%2520synthesis%2520and%2520evaluation%2520of%2520sulfoximine%2520analogues%2520of%2520marketed%2520drugs%2520and%2520advanced%2520clinical%2520candidates%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D487%26epage%3D501%26doi%3D10.1002%2Fcmdc.201700044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span> <span> </span><span class="NLM_article-title">Organic synthesis provides opportunities to transform drug discovery</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1038/s41557-018-0021-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1038%2Fs41557-018-0021-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=29568051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Sktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=383-394&author=D.+C.+Blakemoreauthor=L.+Castroauthor=I.+Churcherauthor=D.+C.+Reesauthor=A.+W.+Thomasauthor=D.+M.+Wilsonauthor=A.+Wood&title=Organic+synthesis+provides+opportunities+to+transform+drug+discovery&doi=10.1038%2Fs41557-018-0021-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">Organic synthesis provides opportunities to transform drug discovery</span></div><div class="casAuthors">Blakemore, David C.; Castro, Luis; Churcher, Ian; Rees, David C.; Thomas, Andrew W.; Wilson, David M.; Wood, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-394</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Despite decades of ground-breaking research in academia, org. synthesis is still a rate-limiting factor in drug-discovery projects.  Here we present some current challenges in synthetic org. chem. from the perspective of the pharmaceutical industry and highlight problematic steps that, if overcome, would find extensive application in the discovery of transformational medicines.  Significant synthesis challenges arise from the fact that drug mols. typically contain amines and N-heterocycles, as well as unprotected polar groups.  There is also a need for new reactions that enable non-traditional disconnections, more C-H bond activation and late-stage functionalization, as well as stereoselectively substituted aliph. heterocyclic ring synthesis, C-X or C-C bond formation.  We also emphasize that syntheses compatible with biomacromols. will find increasing use, while new technologies such as machine-assisted approaches and artificial intelligence for synthesis planning have the potential to dramatically accelerate the drug-discovery process.  We believe that increasing collaboration between academic and industrial chemists is crucial to address the challenges outlined here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonqR_RxjClS7Vg90H21EOLACvtfcHk0ljdd4dWJFgBig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Sktrk%253D&md5=f6269ea8193e28416fd86fe8afbcea3f</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1038%2Fs41557-018-0021-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41557-018-0021-z%26sid%3Dliteratum%253Aachs%26aulast%3DBlakemore%26aufirst%3DD.%2BC.%26aulast%3DCastro%26aufirst%3DL.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DThomas%26aufirst%3DA.%2BW.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DWood%26aufirst%3DA.%26atitle%3DOrganic%2520synthesis%2520provides%2520opportunities%2520to%2520transform%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%26date%3D2018%26volume%3D10%26spage%3D383%26epage%3D394%26doi%3D10.1038%2Fs41557-018-0021-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickl, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dressman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfefferle, M. L.</span></span> <span> </span><span class="NLM_article-title">Instant FaSSIF and FeSSIF-biorelevance meets practicality</span>. <i>Dissolution Technol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.14227/DT160309P41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.14227%2FDT160309P41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OhtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=41-45&author=J.+E.+Boniauthor=R.+S.+Bricklauthor=J.+Dressmanauthor=M.+L.+Pfefferle&title=Instant+FaSSIF+and+FeSSIF-biorelevance+meets+practicality&doi=10.14227%2FDT160309P41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Instant FaSSIF and FeSSIF - biorelevance meets practicality</span></div><div class="casAuthors">Boni, Julia Elisabeth; Brickl, Rolf Stefan; Dressman, Jennifer; Pfefferle, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Dissolution Technologies</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">41-45</span>CODEN:
                <span class="NLM_cas:coden">DITEFX</span>;
        ISSN:<span class="NLM_cas:issn">1521-298X</span>.
    
            (<span class="NLM_cas:orgname">Dissolution Technologies, Inc.</span>)
        </div><div class="casAbstract">The objective of this study was to prep. an "instant" form of FaSSIF and FeSSIF that could be implemented easily and reproducibly in the lab. setting.  Concd. solns. contg. bile salts and lecithin were freeze-dried and further processed into bulk packs, blisters, or tablets, or sealed in powder form under nitrogen in vials.  Phys. properties as well as soly. and dissoln. data for two poorly sol. compds., danazol and a Boehringer-Ingelheim development compd. (BIXX), were compared with data for freshly prepd. FaSSIF and FeSSIF and a com. available "instant" product.  After the freeze-dried FaSSIF and FeSSIF media were reconstituted with appropriate buffers, their properties were close to those of freshly prepd. media and a com. available product for reconstitution, SIF Powder.  Addnl., the soly. and dissoln. profiles of danazol and BIXX in media prepd. by all three methods were similar.  Reconstitution of freeze-dried "instant" FaSSIF and FeSSIF appears to be an accurate, reproducible, and efficient way of prepg. biorelevant dissoln. media.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPVO8h4DmoprVg90H21EOLACvtfcHk0ljdd4dWJFgBig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OhtL3L&md5=2a37a984ee108f50504e372b39da4019</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.14227%2FDT160309P41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14227%252FDT160309P41%26sid%3Dliteratum%253Aachs%26aulast%3DBoni%26aufirst%3DJ.%2BE.%26aulast%3DBrickl%26aufirst%3DR.%2BS.%26aulast%3DDressman%26aufirst%3DJ.%26aulast%3DPfefferle%26aufirst%3DM.%2BL.%26atitle%3DInstant%2520FaSSIF%2520and%2520FeSSIF-biorelevance%2520meets%2520practicality%26jtitle%3DDissolution%2520Technol.%26date%3D2009%26volume%3D16%26spage%3D41%26epage%3D45%26doi%3D10.14227%2FDT160309P41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yordanova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S. P.</span></span> <span> </span><span class="NLM_article-title">Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1021/tx9003825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9003825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVeqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=749-755&author=U.+M.+Hanumegowdaauthor=G.+Wenkeauthor=A.+Regueiro-Renauthor=R.+Yordanovaauthor=J.+P.+Corradiauthor=S.+P.+Adams&title=Phospholipidosis+as+a+function+of+basicity%2C+lipophilicity%2C+and+volume+of+distribution+of+compounds&doi=10.1021%2Ftx9003825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Phospholipidosis as a Function of Basicity, Lipophilicity, and Volume of Distribution of Compounds</span></div><div class="casAuthors">Hanumegowda, Umesh M.; Wenke, Gottfried; Regueiro-Ren, Alicia; Yordanova, Roumyana; Corradi, John P.; Adams, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-755</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced phospholipidosis (PLD) is an adaptive histol. alteration that is seen with various marketed drugs and often encountered during drug development.  Various in silico and in vitro cell-based methods have been developed to predict the PLD-inducing potential of compds.  These methods rely on the inherent physicochem. properties of the mol. and, as such, tend to overpredict compds. as PLD inducers.  Recognizing that the distribution of compds. into tissues or tissue accumulation is likely a key factor in PLD induction, in addn. to key physicochem. properties, we developed a model to predict PLD in vivo using the measures of basicity (pKa), lipophilicity (ClogP), and vol. of distribution (Vd).  Using sets of PLD inducers and noninducers, we demonstrate improved concordance with this method.  Furthermore, we propose a screening paradigm that includes a combination of various methods to predict the in vivo PLD-inducing potential of compds., which may be esp. useful in lead identification and optimization processes in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJNq2nVkAysrVg90H21EOLACvtfcHk0ljdd4dWJFgBig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVeqtLw%253D&md5=471380f65644ba0db549660acf6b4d8d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Ftx9003825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9003825%26sid%3Dliteratum%253Aachs%26aulast%3DHanumegowda%26aufirst%3DU.%2BM.%26aulast%3DWenke%26aufirst%3DG.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DYordanova%26aufirst%3DR.%26aulast%3DCorradi%26aufirst%3DJ.%2BP.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26atitle%3DPhospholipidosis%2520as%2520a%2520function%2520of%2520basicity%252C%2520lipophilicity%252C%2520and%2520volume%2520of%2520distribution%2520of%2520compounds%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D749%26epage%3D755%26doi%3D10.1021%2Ftx9003825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeras, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goila-Gaur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soheilian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakalian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span> <span> </span><span class="NLM_article-title">In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat)</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">10957</span>– <span class="NLM_lpage">10971</span>, <span class="refDoi"> DOI: 10.1128/JVI.01369-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FJVI.01369-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=16956950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Khur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=10957-10971&author=C.+S.+Adamsonauthor=S.+D.+Ablanauthor=I.+Boerasauthor=R.+Goila-Gaurauthor=F.+Soheilianauthor=K.+Nagashimaauthor=F.+Liauthor=K.+Salzwedelauthor=M.+Sakalianauthor=C.+T.+Wildauthor=E.+O.+Freed&title=In+vitro+resistance+to+the+human+immunodeficiency+virus+type+1+maturation+inhibitor+PA-457+%28bevirimat%29&doi=10.1128%2FJVI.01369-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat)</span></div><div class="casAuthors">Adamson, Catherine S.; Ablan, Sherimay D.; Boeras, Ioana; Goila-Gaur, Ritu; Soheilian, Ferri; Nagashima, Kunio; Li, Feng; Salzwedel, Karl; Sakalian, Michael; Wild, Carl T.; Freed, Eric O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10957-10971</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">3-O-(3',3'-dimethylsuccinyl)betulinic acid (PA-457 or bevirimat) potently inhibits human immunodeficiency virus type 1 (HIV-1) maturation by blocking a late step in the Gag processing pathway, specifically the cleavage of SP1 from the C terminus of capsid (CA).  To gain insights into the mechanism(s) by which HIV-1 could evolve resistance to PA-457 and to evaluate the likelihood of such resistance arising in PA-457-treated patients, we sought to identify and characterize a broad spectrum of HIV-1 variants capable of conferring resistance to this compd.  Numerous independent rounds of selection repeatedly identified six single-amino-acid substitutions that independently confer PA-457 resistance: three at or near the C terminus of CA (CA-H226Y, -L231F, and -L231M) and three at the first and third residues of SP1 (SP1-A1V, -A3T, and -A3V).  We detd. that mutations CA-H226Y, CA-L231F, CA-L231M, and SP1-A1V do not impose a significant replication defect on HIV-1 in culture.  In contrast, mutations SP1-A3V and -A3T severely impaired virus replication and inhibited virion core condensation.  The replication defect imposed by SP1-A3V was reversed by a second-site compensatory mutation in CA (CA-G225S).  Intriguingly, high concns. of PA-457 enhanced the maturation of SP1 residue 3 mutants.  The different phenotypes assocd. with mutations that confer PA-457 resistance suggest the existence of multiple mechanisms by which HIV-1 can evolve resistance to this maturation inhibitor.  These findings have implications for the ongoing development of PA-457 to treat HIV-1 infection in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRpEKRcJysSbVg90H21EOLACvtfcHk0ljyxp-oEXXBlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Khur3K&md5=423f3bec176afb60e598780749f47050</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FJVI.01369-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01369-06%26sid%3Dliteratum%253Aachs%26aulast%3DAdamson%26aufirst%3DC.%2BS.%26aulast%3DAblan%26aufirst%3DS.%2BD.%26aulast%3DBoeras%26aufirst%3DI.%26aulast%3DGoila-Gaur%26aufirst%3DR.%26aulast%3DSoheilian%26aufirst%3DF.%26aulast%3DNagashima%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DSakalian%26aufirst%3DM.%26aulast%3DWild%26aufirst%3DC.%2BT.%26aulast%3DFreed%26aufirst%3DE.%2BO.%26atitle%3DIn%2520vitro%2520resistance%2520to%2520the%2520human%2520immunodeficiency%2520virus%2520type%25201%2520maturation%2520inhibitor%2520PA-457%2520%2528bevirimat%2529%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D10957%26epage%3D10971%26doi%3D10.1128%2FJVI.01369-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoumplis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matallana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgore, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunus, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span> <span> </span><span class="NLM_article-title">Determinants of activity of the HIV-1 maturation inhibitor PA-457</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2006.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.virol.2006.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=16930665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1CgsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2006&pages=217-224&author=F.+Liauthor=D.+Zoumplisauthor=C.+Matallanaauthor=N.+R.+Kilgoreauthor=M.+Reddickauthor=A.+S.+Yunusauthor=C.+S.+Adamsonauthor=K.+Salzwedelauthor=D.+E.+Martinauthor=G.+P.+Allawayauthor=E.+O.+Freedauthor=C.+T.+Wild&title=Determinants+of+activity+of+the+HIV-1+maturation+inhibitor+PA-457&doi=10.1016%2Fj.virol.2006.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of activity of the HIV-1 maturation inhibitor PA-457</span></div><div class="casAuthors">Li, Feng; Zoumplis, Dorian; Matallana, Claudia; Kilgore, Nicole R.; Reddick, Mary; Yunus, Abdul S.; Adamson, Catherine S.; Salzwedel, Karl; Martin, David E.; Allaway, Graham P.; Freed, Eric O.; Wild, Carl T.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1 and 2</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">3-O-(3',3'-dimethylsuccinyl) betulinic acid, also termed PA-457 or DSB, is a novel HIV-1 inhibitor that blocks virus maturation by disrupting cleavage of the capsid precursor, CA-SP1.  To better define the mol. target for PA-457, we prepd. a panel of mutant viruses with point deletions spanning the CA-SP1 cleavage domain and characterized each of these viruses for PA-457 sensitivity.  Our results indicate that amino acid residues in the N-terminal half of SP1 serve as determinants of PA-457 activity, while residues in the C-terminal half of SP1 were not involved in compd. activity.  These findings support and extend previous observations that PA-457 is a specific inhibitor of CA-SP1 cleavage and identify the CA-SP1 domain as the primary viral determinant for this novel inhibitor of HIV-1 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLD2a0C9ozC7Vg90H21EOLACvtfcHk0ljyxp-oEXXBlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1CgsL7K&md5=9bf789f30b2787e482d38b8b2baa10e0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2006.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2006.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DZoumplis%26aufirst%3DD.%26aulast%3DMatallana%26aufirst%3DC.%26aulast%3DKilgore%26aufirst%3DN.%2BR.%26aulast%3DReddick%26aufirst%3DM.%26aulast%3DYunus%26aufirst%3DA.%2BS.%26aulast%3DAdamson%26aufirst%3DC.%2BS.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26aulast%3DFreed%26aufirst%3DE.%2BO.%26aulast%3DWild%26aufirst%3DC.%2BT.%26atitle%3DDeterminants%2520of%2520activity%2520of%2520the%2520HIV-1%2520maturation%2520inhibitor%2520PA-457%26jtitle%3DVirology%26date%3D2006%26volume%3D356%26spage%3D217%26epage%3D224%26doi%3D10.1016%2Fj.virol.2006.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span> <span> </span><span class="NLM_article-title">Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">4884</span>– <span class="NLM_lpage">4894</span>, <span class="refDoi"> DOI: 10.1128/JVI.02659-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FJVI.02659-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=19279107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVGhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=4884-4894&author=C.+S.+Adamsonauthor=K.+Wakiauthor=S.+D.+Ablanauthor=K.+Salzwedelauthor=E.+O.+Freed&title=Impact+of+human+immunodeficiency+virus+type+1+resistance+to+protease+inhibitors+on+evolution+of+resistance+to+the+maturation+inhibitor+bevirimat+%28PA-457%29&doi=10.1128%2FJVI.02659-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)</span></div><div class="casAuthors">Adamson, Catherine S.; Waki, Kayoko; Ablan, Sherimay D.; Salzwedel, Karl; Freed, Eric O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4884-4894</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The maturation inhibitor bevirimat [3-O-(3',3'dimethysuccinyl)betulinic acid; BVM; also known as PA-457 or DSB] potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking protease (PR)-mediated cleavage at the junction between capsid (CA) and spacer peptide 1 (SP1) in Gag.  We previously isolated a panel of single-amino-acid substitutions that confer resistance to BVM in vitro.  The BVM resistance mutations cluster at or near the CA-SP1 cleavage site.  Because BVM likely will be used clin. in patients harboring viruses resistant to PR inhibitors (PIs), in this study we evaluated the interplay between a PI-resistant (PIR) PR and the BVM resistance mutations in Gag.  As expected, the PIR mutations had no effect on inhibition by BVM; however, we obsd. general processing defects and a slight delay in viral replication in Jurkat T cells assocd. with the PIR mutations, even in the absence of compd.  When combined, most BVM resistance and PIR mutations acted additively to impair viral replication, particularly in the presence of BVM.  The BVM-resistant mutant SP1-A1V was an exception, as it supported robust replication in the context of either wild-type (WT) or PIR PR, even at high BVM concns.  Significantly, the emergence of BVM resistance was delayed in the context of the PIR PR, and the SP1-A1V mutation was acquired most frequently with either WT or PIR PR.  These results suggest that resistance to BVM is less likely to emerge in patients who have failed PIs than in patients who are PI naive.  We predict that the SP1-A1V substitution is the most likely to emerge in vivo, as this mutant replicates robustly independently of PR mutations or BVM.  These findings offer insights into the effect of PIR mutations on the evolution of BVM resistance in PI-experienced patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBxrMI6pkqe7Vg90H21EOLACvtfcHk0ljyxp-oEXXBlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVGhtr8%253D&md5=be66b5fec3d34d4f27333a55fcf74c2c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FJVI.02659-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02659-08%26sid%3Dliteratum%253Aachs%26aulast%3DAdamson%26aufirst%3DC.%2BS.%26aulast%3DWaki%26aufirst%3DK.%26aulast%3DAblan%26aufirst%3DS.%2BD.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DFreed%26aufirst%3DE.%2BO.%26atitle%3DImpact%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520resistance%2520to%2520protease%2520inhibitors%2520on%2520evolution%2520of%2520resistance%2520to%2520the%2520maturation%2520inhibitor%2520bevirimat%2520%2528PA-457%2529%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D4884%26epage%3D4894%26doi%3D10.1128%2FJVI.02659-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lataillade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies and modeling reveal the origin of differential inhibition of Gag polymorphic viruses by HIV-1 maturation inhibitors</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e1005990</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1371%2Fjournal.ppat.1005990" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1005990&author=Z.+Linauthor=J.+Cantoneauthor=H.+Luauthor=B.+Nowicka-Sansauthor=T.+Protackauthor=T.+Yuanauthor=H.+Yangauthor=Z.+Liuauthor=D.+Drexlerauthor=A.+Regueiro-Renauthor=N.+A.+Meanwellauthor=M.+Cockettauthor=M.+Krystalauthor=M.+Latailladeauthor=I.+B.+Dicker&title=Mechanistic+studies+and+modeling+reveal+the+origin+of+differential+inhibition+of+Gag+polymorphic+viruses+by+HIV-1+maturation+inhibitors&doi=10.1371%2Fjournal.ppat.1005990"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005990%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DCantone%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDrexler%26aufirst%3DD.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DLataillade%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26atitle%3DMechanistic%2520studies%2520and%2520modeling%2520reveal%2520the%2520origin%2520of%2520differential%2520inhibition%2520of%2520Gag%2520polymorphic%2520viruses%2520by%2520HIV-1%2520maturation%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26spage%3De1005990%26doi%3D10.1371%2Fjournal.ppat.1005990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokui, T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1002/jps.20012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fjps.20012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=847-854&author=D.+Nakaiauthor=K.+Kumamotoauthor=C.+Sakikawaauthor=T.+Kosakaauthor=T.+Tokui&title=Evaluation+of+the+protein+binding+ratio+of+drugs+by+a+micro-scale+ultracentrifugation+method&doi=10.1002%2Fjps.20012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fjps.20012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20012%26sid%3Dliteratum%253Aachs%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DKumamoto%26aufirst%3DK.%26aulast%3DSakikawa%26aufirst%3DC.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DTokui%26aufirst%3DT.%26atitle%3DEvaluation%2520of%2520the%2520protein%2520binding%2520ratio%2520of%2520drugs%2520by%2520a%2520micro-scale%2520ultracentrifugation%2520method%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D847%26epage%3D854%26doi%3D10.1002%2Fjps.20012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardelmeijer, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tellingen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span> <span> </span><span class="NLM_article-title">The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1023/A:1006469621561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1023%2FA%3A1006469621561" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=231-241&author=H.+A.+Bardelmeijerauthor=O.+van+Tellingenauthor=J.+H.+M+Schellensauthor=J.+H.+Beijnen&title=The+oral+route+for+the+administration+of+cytotoxic+drugs%3A+strategies+to+increase+the+efficiency+and+consistency+of+drug+delivery&doi=10.1023%2FA%3A1006469621561"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006469621561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006469621561%26sid%3Dliteratum%253Aachs%26aulast%3DBardelmeijer%26aufirst%3DH.%2BA.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520oral%2520route%2520for%2520the%2520administration%2520of%2520cytotoxic%2520drugs%253A%2520strategies%2520to%2520increase%2520the%2520efficiency%2520and%2520consistency%2520of%2520drug%2520delivery%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2000%26volume%3D18%26spage%3D231%26epage%3D241%26doi%3D10.1023%2FA%3A1006469621561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span> <span> </span><span class="NLM_article-title">Utility of Mdr-1 gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.2174/1389200033489415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.2174%2F1389200033489415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=12871045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1GhsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=272-291&author=C.+Chenauthor=X.+Liuauthor=B.+J.+Smith&title=Utility+of+Mdr-1+gene+deficient+mice+in+assessing+the+impact+of+P-glycoprotein+on+pharmacokinetics+and+pharmacodynamics+in+drug+discovery+and+development&doi=10.2174%2F1389200033489415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development</span></div><div class="casAuthors">Chen, Cuiping; Liu, Xingrong; Smith, Bill J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">272-291</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the generation of the multi-drug resistance 1 (mdr1) gene knockout (KO) mice in the early 90's, these animals have been instrumental to our understanding of the physiol. roles of mdr1 gene product P-glycoprotein.  Located in crucial organs such as brain, intestine, liver, and kidney, P-glycoprotein-mediated transport has been shown to affect both the pharmacokinetics and pharmacodynamics of endogenous compds. and xenobiotics.  It appears that P-glycoprotein may not be essential for the maintenance of normal body function as suggested by the similarity in life span and serum chem. values of mdr1 gene KO mice compared to their genetically competent littermates.  However, numerous studies have demonstrated that P-glycoprotein limits the brain penetration of many drug substrates.  The reduced central nervous system (CNS) access of these compds. has been linked to decreased pharmacol. or toxicol. effects.  In contrast to the crit. role that P-glycoprotein plays in the brain, the extent of P-glycoprotein involvement in oral absorption and hepatobiliary or renal excretion of xenobiotics appears more variable.  In addn. to the mdr1 gene KO model, in vitro cell lines that over-express P-glycoprotein, and clin. trials using P-glycoprotein modulators have allowed for the comparison of in vitro-in vivo and species related difference in P-glycoprotein activity.  For the most part, studies have shown reasonable in vitro-in vivo correlations, modest species-related differences, and comparable human-mouse in vivo P-glycoprotein effects on systemic drug disposition.  Therefore, the mdr1 gene KO mouse model, when used appropriately, may allow for prediction of CNS drug access and certain drug-drug interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxT1JuNSYiVrVg90H21EOLACvtfcHk0liwJEm5oiv4jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1GhsrY%253D&md5=41360c60c25393d0cfe564b2f14cb2b5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F1389200033489415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200033489415%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26atitle%3DUtility%2520of%2520Mdr-1%2520gene%2520deficient%2520mice%2520in%2520assessing%2520the%2520impact%2520of%2520P-glycoprotein%2520on%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2003%26volume%3D4%26spage%3D272%26epage%3D291%26doi%3D10.2174%2F1389200033489415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzarano, L. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.068288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1124%2Fjpet.104.068288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=15056727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVyktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2004&pages=703-709&author=K.+W.+Wardauthor=L.+M.+Azzarano&title=Preclinical+pharmacokinetic+properties+of+the+P-glycoprotein+inhibitor+GF120918A+%28HCl+salt+of+GF120918%2C+9%2C10-dihydro-5-methoxy-9-oxo-N-%5B4-%5B2-%281%2C2%2C3%2C4-tetrahydro-6%2C7-dimethoxy-2-isoquinolinyl%29ethyl%5Dphenyl%5D-4-acridine-carboxamide%29+in+the+mouse%2C+rat%2C+dog%2C+and+monkey&doi=10.1124%2Fjpet.104.068288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridinecarboxamide) in the mouse, rat, dog, and monkey</span></div><div class="casAuthors">Ward, Keith W.; Azzarano, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">703-709</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GF120918A, the HCl salt of GF120918, has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test mols.  However, to date, a detailed description of the preclin. pharmacokinetic properties of GF120918A has not been published.  This investigation was performed to evaluate in vitro and in vivo pharmacokinetic properties of GF120918A in the mouse, rat, dog, and monkey and to evaluate the in vivo efficacy of GF120918A in modulating absorption and systemic exposure in the monkey.  GF120918A demonstrated reasonable absorption and systemic exposure in each of the species studied, however, in rodents, administration of 300 mg/kg afforded a substantially less than linear increase in systemic exposure compared with 30 mg/kg.  In accordance with its intestinal and hepatic exposure and potency against P-glycoprotein, GF120918A demonstrated marked modulation of erythromycin systemic exposure in the monkey, with no effect on propranolol, a neg. control mol.  In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma.  GF120918A did not demonstrate potent inhibition of several human cytochrome P 450 enzymes evaluated in vitro, with IC50 values well above concns. anticipated to be achieved in vivo.  Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclin. species and offer addnl. guidance on preclin. dose regimens likely to produce P-glycoprotein-mediated effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuAYdnFmpH7Vg90H21EOLACvtfcHk0lid4YY6q4seWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVyktr4%253D&md5=36cd74ecc6d47027f3cfb4223ee6ac6b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068288%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DAzzarano%26aufirst%3DL.%2BM.%26atitle%3DPreclinical%2520pharmacokinetic%2520properties%2520of%2520the%2520P-glycoprotein%2520inhibitor%2520GF120918A%2520%2528HCl%2520salt%2520of%2520GF120918%252C%25209%252C10-dihydro-5-methoxy-9-oxo-N-%255B4-%255B2-%25281%252C2%252C3%252C4-tetrahydro-6%252C7-dimethoxy-2-isoquinolinyl%2529ethyl%255Dphenyl%255D-4-acridine-carboxamide%2529%2520in%2520the%2520mouse%252C%2520rat%252C%2520dog%252C%2520and%2520monkey%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D310%26spage%3D703%26epage%3D709%26doi%3D10.1124%2Fjpet.104.068288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moench, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faria, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent dissolution in vitro and absorption in vivo of weakly basic drugs; development of a canine model</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s11095-004-1185-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1007%2Fs11095-004-1185-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=188-192&author=R.+Zhouauthor=P.+Moenchauthor=C.+Heranauthor=X.+Luauthor=N.+Mathiasauthor=T.+N.+Fariaauthor=D.+A.+Wallauthor=M.+A.+Hussainauthor=R.+L.+Smithauthor=D.+Sun&title=pH-Dependent+dissolution+in+vitro+and+absorption+in+vivo+of+weakly+basic+drugs%3B+development+of+a+canine+model&doi=10.1007%2Fs11095-004-1185-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs11095-004-1185-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-004-1185-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DMoench%26aufirst%3DP.%26aulast%3DHeran%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DMathias%26aufirst%3DN.%26aulast%3DFaria%26aufirst%3DT.%2BN.%26aulast%3DWall%26aufirst%3DD.%2BA.%26aulast%3DHussain%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DR.%2BL.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DpH-Dependent%2520dissolution%2520in%2520vitro%2520and%2520absorption%2520in%2520vivo%2520of%2520weakly%2520basic%2520drugs%253B%2520development%2520of%2520a%2520canine%2520model%26jtitle%3DPharm.%2520Res.%26date%3D2005%26volume%3D22%26spage%3D188%26epage%3D192%26doi%3D10.1007%2Fs11095-004-1185-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quitko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span> <span> </span><span class="NLM_article-title">Development and validation of a preclinical food effect model</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1002/jps.20767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fjps.20767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=459-472&author=K.+Lentzauthor=M.+Quitkoauthor=D.+Morganauthor=J.+Graceauthor=C.+Gleasonauthor=P.+Marathe&title=Development+and+validation+of+a+preclinical+food+effect+model&doi=10.1002%2Fjps.20767"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjps.20767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20767%26sid%3Dliteratum%253Aachs%26aulast%3DLentz%26aufirst%3DK.%26aulast%3DQuitko%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DD.%26aulast%3DGrace%26aufirst%3DJ.%26aulast%3DGleason%26aufirst%3DC.%26aulast%3DMarathe%26aufirst%3DP.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520preclinical%2520food%2520effect%2520model%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2007%26volume%3D96%26spage%3D459%26epage%3D472%26doi%3D10.1002%2Fjps.20767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1890</span>– <span class="NLM_lpage">1900</span>, <span class="refDoi"> DOI: 10.1002/jps.20099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fjps.20099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=1890-1900&author=T.+Wajimaauthor=Y.+Yanoauthor=K.+Fukumuraauthor=T.+Oguma&title=Prediction+of+human+pharmacokinetic+profile+in+animal+scale+up+based+on+normalizing+time+course+profiles&doi=10.1002%2Fjps.20099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjps.20099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20099%26sid%3Dliteratum%253Aachs%26aulast%3DWajima%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DY.%26aulast%3DFukumura%26aufirst%3DK.%26aulast%3DOguma%26aufirst%3DT.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetic%2520profile%2520in%2520animal%2520scale%2520up%2520based%2520on%2520normalizing%2520time%2520course%2520profiles%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D1890%26epage%3D1900%26doi%3D10.1002%2Fjps.20099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schürmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobotha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevinsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keicher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lataillade, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity, safety, and exposure-response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002)</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1093/cid/cix239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1093%2Fcid%2Fcix239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=28369211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFGks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=442-452&author=C.+Hwangauthor=D.+Sch%C3%BCrmannauthor=C.+Sobothaauthor=M.+Boffitoauthor=H.+Sevinskyauthor=N.+Rayauthor=P.+Ravindranauthor=H.+Xiaoauthor=C.+Keicherauthor=A.+H%C3%BCserauthor=M.+Krystalauthor=I.+B.+Dickerauthor=D.+Graselaauthor=M.+Lataillade&title=Antiviral+activity%2C+safety%2C+and+exposure-response+relationships+of+GSK3532795%2C+a+second-generation+human+immunodeficiency+virus+type+1+maturation+inhibitor%2C+administered+as+monotherapy+or+in+combination+with+atazanavir+with+or+without+ritonavir+in+a+phase+2a+randomized%2C+dose-ranging%2C+controlled+trial+%28AI468002%29&doi=10.1093%2Fcid%2Fcix239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46aR"><div class="casContent"><span class="casTitleNuber">46a</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity, safety, and exposure-response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002)</span></div><div class="casAuthors">Hwang, Carey; Schurmann, Dirk; Sobotha, Christian; Boffito, Marta; Sevinsky, Heather; Ray, Neelanjana; Ravindran, Palanikumar; Xiao, Hong; Keicher, Christian; Huser, Andreas; Krystal, Mark; Dicker, Ira B.; Grasela, Dennis; Lataillade, Max</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">442-452</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor that targets HIV-1 Gag, inhibiting the final protease cleavage between capsid protein p24 and spacer protein-1, producing immature, noninfectious virions.  Methods.  This was a phase 2a, randomized, dose-ranging multipart trial.  In part A, subtype B-infected subjects received 5-120 mg GSK3532795 (or placebo) once daily for 10 days.  In part B, subtype B-infected subjects received 40 mg or 80 mg GSK3532795 once daily with atazanavir (ATV) with or without (±) ritonavir (RTV) or std. of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28 days.  In part C, subtype C-infected subjects received 40 mg or 120 mg GSK3532795 once daily (or placebo) for 10 days.  Endpoints included change in HIV-1 RNA from baseline on day 11 (parts A/C) or day 29 (part B).  Results.  A >1 log10 median decline in HIV-1 RNA was achieved by day 11 in parts A and C and day 29 in part B at GSK3532795 doses ≥40 mg; part B subjects receiving GSK3532795 and ATV ± RTV achieved similar declines to those receiving SOC.  Median of the max. declines in HIV-1 RNA were similar for the 40-120 mg once-daily dose groups regardless of baseline Gag polymorphisms.  There were no deaths, adverse events leading to discontinuation, or serious adverse events.  Conclusions.  GSK3532795 demonstrated potent antiviral activity against subtype B (monotherapy or with ATV ± RTV) and subtype C, and was generally well tolerated, which supported continued development of GSK3532795 in subjects with HIV-1 subtype B or subtype C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1x-uS8V4fSrVg90H21EOLACvtfcHk0lid4YY6q4seWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFGks77I&md5=dfaac445cd480ef649d0a95f0dc6f6e4</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcix239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcix239%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DC.%26aulast%3DSch%25C3%25BCrmann%26aufirst%3DD.%26aulast%3DSobotha%26aufirst%3DC.%26aulast%3DBoffito%26aufirst%3DM.%26aulast%3DSevinsky%26aufirst%3DH.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DRavindran%26aufirst%3DP.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKeicher%26aufirst%3DC.%26aulast%3DH%25C3%25BCser%26aufirst%3DA.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DGrasela%26aufirst%3DD.%26aulast%3DLataillade%26aufirst%3DM.%26atitle%3DAntiviral%2520activity%252C%2520safety%252C%2520and%2520exposure-response%2520relationships%2520of%2520GSK3532795%252C%2520a%2520second-generation%2520human%2520immunodeficiency%2520virus%2520type%25201%2520maturation%2520inhibitor%252C%2520administered%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520atazanavir%2520with%2520or%2520without%2520ritonavir%2520in%2520a%2520phase%25202a%2520randomized%252C%2520dose-ranging%252C%2520controlled%2520trial%2520%2528AI468002%2529%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D65%26spage%3D442%26epage%3D452%26doi%3D10.1093%2Fcid%2Fcix239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit46b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I.</span>; <span class="NLM_string-name">Nowicka-Sans, B.</span>; <span class="NLM_string-name">Zhang, S.</span>; <span class="NLM_string-name">Ray, N.</span>; <span class="NLM_string-name">Beno, B.</span>; <span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Joshi, S.</span>; <span class="NLM_string-name">Krystal, M.</span>; <span class="NLM_string-name">Lataillade, M.</span></span> <span> </span><span class="NLM_article-title">Resistance Profile of GSK3532795</span>.  <i>26th International Workshop on HIV Drug Resistance and Treatment Strategies, November 6–8, 2017, Johannesburg, South Africa</i>, <span class="NLM_year">2017</span>; Poster  <span class="NLM_fpage">60</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=60&author=I.+Dicker&author=B.+Nowicka-Sans&author=S.+Zhang&author=N.+Ray&author=B.+Beno&author=A.+Regueiro-Ren&author=S.+Joshi&author=M.+Krystal&author=M.+Lataillade&title=Resistance+Profile+of+GSK3532795"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDicker%26aufirst%3DI.%26atitle%3DResistance%2520Profile%2520of%2520GSK3532795%26jtitle%3D26th%2520International%2520Workshop%2520on%2520HIV%2520Drug%2520Resistance%2520and%2520Treatment%2520Strategies%252C%2520November%25206%25E2%2580%25938%252C%25202017%252C%2520Johannesburg%252C%2520South%2520Africa%26date%3D2017%26spage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, S.</span></span> <span> </span><span class="NLM_article-title">GSK Drops a Pair of Late-Stage Candidates in COPD, HIV</span>.  <i>FierceBiotech</i>; <span class="NLM_publisher-name">Questex</span>: <span class="NLM_publisher-loc">Newton, MA</span>, October 26, <span class="NLM_year">2018</span>; <a href="https://www.fiercebiotech.com/biotech/gsk-drops-a-pair-late-stage-candidates-copd-hiv" class="extLink">https://www.fiercebiotech.com/biotech/gsk-drops-a-pair-late-stage-candidates-copd-hiv</a> (accessed April 28, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Lawrence&title=GSK+Drops+a+Pair+of+Late-Stage+Candidates+in+COPD%2C+HIV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DS.%26atitle%3DGSK%2520Drops%2520a%2520Pair%2520of%2520Late-Stage%2520Candidates%2520in%2520COPD%252C%2520HIV%26jtitle%3DFierceBiotech%26pub%3DQuestex%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.-Y.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Swidorsk, J.</span>; <span class="NLM_string-name">Venables, B. L.</span>; <span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Hartz, R.</span>; <span class="NLM_string-name">Xu, L.</span>; <span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Preparation of Triterpenoids with HIV Maturation Inhibitory Activity, Substituted in Position 3 by a Non-aromatic Ring Carrying a Haloalkyl Substituent</span>. World Patent <span class="NLM_patent">WO2015157483</span>, October 15, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.-Y.+Sit&author=Y.+Chen&author=J.+Chen&author=J.+Swidorsk&author=B.+L.+Venables&author=N.+Sin&author=N.+A.+Meanwell&author=A.+Regueiro-Ren&author=R.+Hartz&author=L.+Xu&author=Z.+Liu&title=Preparation+of+Triterpenoids+with+HIV+Maturation+Inhibitory+Activity%2C+Substituted+in+Position+3+by+a+Non-aromatic+Ring+Carrying+a+Haloalkyl+Substituent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSit%26aufirst%3DS.-Y.%26atitle%3DPreparation%2520of%2520Triterpenoids%2520with%2520HIV%2520Maturation%2520Inhibitory%2520Activity%252C%2520Substituted%2520in%2520Position%25203%2520by%2520a%2520Non-aromatic%2520Ring%2520Carrying%2520a%2520Haloalkyl%2520Substituent%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c','cit7d'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b','cit22c','cit22d'],'ref23':['cit23a','cit23b'],'ref24':['cit24a','cit24b'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30a','cit30b','cit30c','cit30d','cit30e'],'ref31':['cit31a','cit31b'],'ref32':['cit32a','cit32b','cit32c','cit32d'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46a','cit46b'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Haiwei Li, Jiaqi Sun, Sulong Xiao, Lihe Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Demin Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Triterpenoid-Mediated Inhibition of Virus–Host Interaction: Is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15371-15388. <a href="https://doi.org/10.1021/acs.jmedchem.0c01348" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01348%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTriterpenoid-Mediated%252BInhibition%252Bof%252BVirus%2525E2%252580%252593Host%252BInteraction%25253A%252BIs%252BNow%252Bthe%252BTime%252Bfor%252BDiscovering%252BViral%252BEntry%25252FRelease%252BInhibitors%252Bfrom%252BNature%25253F%26aulast%3DLi%26aufirst%3DHaiwei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D02082020%26date%3D17112020%26volume%3D63%26issue%3D24%26spage%3D15371%26epage%3D15388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Somin Park, Jihee Cho, Hongjun Jeon, Sang Hyun Sung, Seunghee Lee, <span class="NLM_string-name hlFld-ContribAuthor">Sanghee Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Expedient Synthesis of Alphitolic Acid and Its Naturally Occurring 2-O-Ester Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2019,</strong> <em>82 </em>
                                    (4)
                                     , 895-902. <a href="https://doi.org/10.1021/acs.jnatprod.8b00986" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.8b00986</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.8b00986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.8b00986%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DExpedient%252BSynthesis%252Bof%252BAlphitolic%252BAcid%252Band%252BIts%252BNaturally%252BOccurring%252B2-O-Ester%252BDerivatives%26aulast%3DPark%26aufirst%3DSomin%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D22112018%26date%3D15022019%26volume%3D82%26issue%3D4%26spage%3D895%26epage%3D902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alicia Regueiro-Ren, Ira B. Dicker, Umesh Hanumegowda, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Second Generation Inhibitors of HIV-1 Maturation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 287-294. <a href="https://doi.org/10.1021/acsmedchemlett.8b00656" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00656%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSecond%252BGeneration%252BInhibitors%252Bof%252BHIV-1%252BMaturation%26aulast%3DRegueiro-Ren%26aufirst%3DAlicia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D29122018%26date%3D28012019%26date%3D08022019%26volume%3D10%26issue%3D3%26spage%3D287%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Bailly</span>. </span><span class="cited-content_cbyCitation_article-title">Acankoreagenin and acankoreosides, a family of lupane triterpenoids with anti‐inflammatory properties: an overview. </span><span class="cited-content_cbyCitation_journal-name">Annals of the New York Academy of Sciences</span><span> <strong>2021,</strong> <em>104 </em><a href="https://doi.org/10.1111/nyas.14623" title="DOI URL">https://doi.org/10.1111/nyas.14623</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/nyas.14623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fnyas.14623%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520the%2520New%2520York%2520Academy%2520of%2520Sciences%26atitle%3DAcankoreagenin%252Band%252Bacankoreosides%25252C%252Ba%252Bfamily%252Bof%252Blupane%252Btriterpenoids%252Bwith%252Banti%2525E2%252580%252590inflammatory%252Bproperties%25253A%252Ban%252Boverview%26aulast%3DBailly%26aufirst%3DChristian%26date%3D2021%26date%3D2021%26volume%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob J.  Swidorski</span>, <span class="hlFld-ContribAuthor ">Susan  Jenkins</span>, <span class="hlFld-ContribAuthor ">Umesh  Hanumegowda</span>, <span class="hlFld-ContribAuthor ">Dawn D.  Parker</span>, <span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Tricia  Protack</span>, <span class="hlFld-ContribAuthor ">Alicia  Ng</span>, <span class="hlFld-ContribAuthor ">Anuradha  Gupta</span>, <span class="hlFld-ContribAuthor ">Yoganand  Shanmugam</span>, <span class="hlFld-ContribAuthor ">Ira B.  Dicker</span>, <span class="hlFld-ContribAuthor ">Mark  Krystal</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Alicia  Regueiro-Ren</span>. </span><span class="cited-content_cbyCitation_article-title">Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>36 </em>, 127823. <a href="https://doi.org/10.1016/j.bmcl.2021.127823" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127823%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bexploration%252Bof%252BC-3%252Bbenzoic%252Bacid%252Bbioisosteres%252Band%252Balkyl%252Breplacements%252Bin%252Bthe%252Bcontext%252Bof%252BGSK3532795%252B%252528BMS-955176%252529%252Bthat%252Bexhibit%252Bbroad%252Bspectrum%252BHIV-1%252Bmaturation%252Binhibition%26aulast%3DSwidorski%26aufirst%3DJacob%2BJ.%26date%3D2021%26volume%3D36%26spage%3D127823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicia  Regueiro-Ren</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic sulfoxides and sulfones in drug design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-30. <a href="https://doi.org/10.1016/bs.aihch.2020.10.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2020.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2020.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2020.10.003%26sid%3Dliteratum%253Aachs%26atitle%3DCyclic%252Bsulfoxides%252Band%252Bsulfones%252Bin%252Bdrug%252Bdesign%26aulast%3DRegueiro-Ren%26aufirst%3DAlicia%26date%3D2021%26spage%3D1%26epage%3D30%26pub%3DElsevier%26atitle%3DApplications%252Bof%252BHeterocycles%252Bin%252Bthe%252BDesign%252Bof%252BDrugs%252Band%252BAgricultural%252BProducts%26date%3D2021%26volume%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai‐Feng  Wu</span>, <span class="hlFld-ContribAuthor ">Susan L.  Morris‐Natschke</span>, <span class="hlFld-ContribAuthor ">Xu‐Dong  Xu</span>, <span class="hlFld-ContribAuthor ">Mei‐Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Yung‐Yi  Cheng</span>, <span class="hlFld-ContribAuthor ">Shi‐Shan  Yu</span>, <span class="hlFld-ContribAuthor ">Kuo‐Hsiung  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in natural anti‐HIV triterpenoids and analogs. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (6)
                                     , 2339-2385. <a href="https://doi.org/10.1002/med.21708" title="DOI URL">https://doi.org/10.1002/med.21708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21708%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bnatural%252Banti%2525E2%252580%252590HIV%252Btriterpenoids%252Band%252Banalogs%26aulast%3DWu%26aufirst%3DHai%25E2%2580%2590Feng%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D6%26spage%3D2339%26epage%3D2385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Man  Li</span>, <span class="hlFld-ContribAuthor ">Lan  Yuan</span>, <span class="hlFld-ContribAuthor ">Yingying  Chen</span>, <span class="hlFld-ContribAuthor ">Wenxiao  Ma</span>, <span class="hlFld-ContribAuthor ">Fuxiang  Ran</span>, <span class="hlFld-ContribAuthor ">Lihe  Zhang</span>, <span class="hlFld-ContribAuthor ">Demin  Zhou</span>, <span class="hlFld-ContribAuthor ">Sulong  Xiao</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodamine B-based fluorescent probes for molecular mechanism study of the anti-influenza activity of pentacyclic triterpenes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112664. <a href="https://doi.org/10.1016/j.ejmech.2020.112664" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112664</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112664%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRhodamine%252BB-based%252Bfluorescent%252Bprobes%252Bfor%252Bmolecular%252Bmechanism%252Bstudy%252Bof%252Bthe%252Banti-influenza%252Bactivity%252Bof%252Bpentacyclic%252Btriterpenes%26aulast%3DLi%26aufirst%3DMan%26date%3D2020%26volume%3D205%26spage%3D112664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure–activity relationship (SAR) evolution of HIV-1 maturation inhibitors from betulinic acid to GSK3532795 (BMS-955176, <b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of C-17 Amine Derivatives of Triterpenoid MIs <b>23</b>–<b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TPAP, NMO, CH<sub>3</sub>CN/CH<sub>2</sub>Cl<sub>2</sub>, rt, 24 h 89%; (b) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 2-methyl-2-butene, <sup>t</sup>BuOH, H<sub>2</sub>O, rt, 1 h, quant; (c) K<sub>2</sub>CO<sub>3</sub>, BnBr, DMF, 60 °C, 3.5 h, 99%; (d) KHMDS, PhNTf<sub>2</sub>, THF, −78 °C, 4 h, 90%; (e) (4-(methoxycarbonyl)phenyl)boronic acid, Na<sub>2</sub>CO<sub>3</sub>, Pd(Ph<sub>3</sub>P)<sub>4</sub>, 1,4-dioxane/<i>i</i>-PrOH/H<sub>2</sub>O, reflux, 14.5 h, 68%; (f) TBDMSH, Pd(OAc)<sub>2</sub>, TEA, DCE, 60 °C, 2 h, 97%; (g) TBAF, H<sub>2</sub>O/1,4-dioxane, rt, 4 h, 99%; (h) DPPA, TEA, 1,4-dioxane, 100 °C, 5 h, 93%; (i) 4-(2-hydroxyethyl)thiomorpholine-1,1-dioxide, NaH, THF, rt, 18; (j) LiOH, THF/H<sub>2</sub>O, 18 h, 75 °C or NaOH, 1,4-dioxane, 78 °C, 3 h; (k) 4-(2-aminoethyl)thiomorpholine 1,1-dioxide, DIEA, THF, rt, 18 h; (l) HCl, THF, rt, 4 h, 95%; (m) RCOOH, HATU, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 18 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of C-17 Alkylamino Triterpenoid MIs Prepared via Direct Alkylation of <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RCl, K<sub>3</sub>PO<sub>4</sub>, KI, CH<sub>3</sub>CN, 115–125 °C, 48 h; (b) LiOH, THF/H<sub>2</sub>O, 18 h, 75 °C or NaOH, 1,4-dioxane, 78 °C, 3 h; (c) oxone, MeOH/H<sub>2</sub>O/acetone, 0 °C, 2 h; (d) Hg(Na), NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, MeOH, reflux, 4.5 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of C-17 Alkylamino Triterpenoid MIs Prepared via Reductive Amination of <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RCHO, Ti(<sup>i</sup>PrO)<sub>4</sub>, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>ClCH<sub>2</sub>Cl, rt, 18–48 h or RCHO, NaBH(OAc)<sub>3</sub>, AcOH, EtOH/1,4-dioxane, rt, 2 h; (b) TBAF, THF, rt, 3 h; (c) LiOH, THF/H<sub>2</sub>O, 18 h, 75 °C or NaOH, 1,4-dioxane, 78 °C, 3 h; (d) HCl, 1,4-dioxane, rt, 4–17 h; (e) vinylsulfonylethene, TEA, 100 °C, 3 h; (f) <i>tert</i>-butyl-3-oxopyrrolidine-1-carboxylate, Pic-BH<sub>3</sub>, MeOH/AcOH, rt, 17 h; (g) ClSO<sub>2</sub>Me, TEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of C-17 Alkylamino Triterpenoid MIs Prepared via Alkylchloride <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) BrCH<sub>2</sub>CH<sub>2</sub>OH, K<sub>3</sub>PO<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, KI, CH<sub>3</sub>CN, 120 °C, 15 h, 86%; (b) SOCl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 90%; (c) 4,4-difluoropyridine, K<sub>3</sub>PO<sub>4</sub>, NaI, CH<sub>3</sub>CN, 120 °C, 19 h; (d) NaOH, 1,4-dioxane, 78–80 °C, 1–4 h; (e) R<sub>1</sub>R<sub>2</sub>NH, DIPEA, DMSO, 120 °C, 1 h; (f) <i>t</i>-butyl piperazine-1-carboxylate, DIPEA, DMSO, 120 °C, 1 h, 52%; (g) HCl, THF, rt, 18 h, 39%; (h) <sup>i</sup>PrSO<sub>2</sub>Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of C-17 Alkylamine Triterpenoid MIs Prepared via Aziridine <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) BrCH<sub>2</sub>CH<sub>2</sub>Cl, K<sub>3</sub>PO<sub>4</sub>, KI, CH<sub>3</sub>CN, 120 °C, 24 h, 98%; (b) mono-Boc protected diamine, DIPEA, THF, 100 °C, 14–67 h; (c) TFA/HCl, CH<sub>2</sub>Cl<sub>2</sub>/ClCH<sub>2</sub>CH<sub>2</sub>Cl, rt; 1–3 h; (d) ClSO<sub>2</sub>Me, TEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1.5–2 h; (e) LiOH, THF/MeOH, 75 °C, 1–2 h.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro metabolic profiling of <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>1</b> IV/PO PK profile in animal species and predicted human PK properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. P-glycoprotein (P-gp) substrate potential determination studies with <b>1</b>. (a) Plasma concentrations of <b>1</b> following IV administration (1 mg/kg) to P-gp knockout mice. (b) Plasma concentrations of <b>1</b> following PO administration (5 mg/kg) to P-gp knockout mice. (c) Plasma concentrations of <b>1</b> following PO administration (5 mpk) to elacridar-treated rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/medium/jm-2018-00854d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma concentrations following PO administration of <b>1</b> (5 mpk) to dogs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00854/20180816/images/large/jm-2018-00854d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00854&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54241" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54241" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taiwo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J.</span></span> <span> </span><span class="NLM_article-title">Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1093/jac/dkq096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1093%2Fjac%2Fdkq096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=20348088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFOhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=1100-1107&author=B.+Taiwoauthor=C.+Hicksauthor=J.+Eron&title=Unmet+therapeutic+needs+in+the+new+era+of+combination+antiretroviral+therapy+for+HIV-1&doi=10.1093%2Fjac%2Fdkq096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1</span></div><div class="casAuthors">Taiwo, Babafemi; Hicks, Charles; Eron, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1100-1107</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Significant advances in outcomes were achieved with combination antiretroviral therapy (cART) in patients living with HIV.  However, several ongoing needs remain with respect to the development of new treatments.  The need for new or enhanced cART may become increasingly apparent as patients live longer with HIV and a greater proportion die from non-AIDS-related illnesses.  Immunol. response to cART is variable and immune failure occurs, despite virol. control.  Moreover, viral suppression can be incomplete due to insufficient antiviral efficacy, acquired or transmitted drug resistance, suboptimal pharmacokinetics/pharmacodynamics and lack of adherence.  Chronic immune activation may continue even when viral replication is relatively restrained.  Patients continue to experience cardiovascular and metabolic complications, due to disease, treatment and aging.  In addn., neurocognitive impairment and malignancy are important sources of ongoing morbidity despite cART.  HIV also affects immune system senescence and bone turnover.  This review discusses potential unmet needs with respect to these issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Au0uaJt3ZbVg90H21EOLACvtfcHk0ljQ051RAfcPIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFOhtrY%253D&md5=c338501700cf75a10602f178252c67ff</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkq096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkq096%26sid%3Dliteratum%253Aachs%26aulast%3DTaiwo%26aufirst%3DB.%26aulast%3DHicks%26aufirst%3DC.%26aulast%3DEron%26aufirst%3DJ.%26atitle%3DUnmet%2520therapeutic%2520needs%2520in%2520the%2520new%2520era%2520of%2520combination%2520antiretroviral%2520therapy%2520for%2520HIV-1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2010%26volume%3D65%26spage%3D1100%26epage%3D1107%26doi%3D10.1093%2Fjac%2Fdkq096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pau, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. M.</span></span> <span> </span><span class="NLM_article-title">Antiretroviral therapy</span>. <i>Infect. Dis. Clin. N. Am.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/j.idc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.idc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=25151562" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=371-402&author=A.+K.+Pauauthor=J.+M.+George&title=Antiretroviral+therapy&doi=10.1016%2Fj.idc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.idc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.idc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DPau%26aufirst%3DA.%2BK.%26aulast%3DGeorge%26aufirst%3DJ.%2BM.%26atitle%3DAntiretroviral%2520therapy%26jtitle%3DInfect.%2520Dis.%2520Clin.%2520N.%2520Am.%26date%3D2014%26volume%3D28%26spage%3D371%26epage%3D402%26doi%3D10.1016%2Fj.idc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensing, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijhuis, M.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus gag and protease: partners in resistance</span>. <i>Retrovirology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">63</span>, <span class="refDoi"> DOI: 10.1186/1742-4690-9-63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1186%2F1742-4690-9-63" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=63&author=A.+Funauthor=A.+J.+Wensingauthor=J.+Verheyenauthor=M.+Nijhuis&title=Human+immunodeficiency+virus+gag+and+protease%3A+partners+in+resistance&doi=10.1186%2F1742-4690-9-63"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1186%2F1742-4690-9-63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4690-9-63%26sid%3Dliteratum%253Aachs%26aulast%3DFun%26aufirst%3DA.%26aulast%3DWensing%26aufirst%3DA.%2BJ.%26aulast%3DVerheyen%26aufirst%3DJ.%26aulast%3DNijhuis%26aufirst%3DM.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520gag%2520and%2520protease%253A%2520partners%2520in%2520resistance%26jtitle%3DRetrovirology%26date%3D2012%26volume%3D9%26spage%3D63%26doi%3D10.1186%2F1742-4690-9-63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Le, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, F. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the HIV RNA genome: high hanging fruit only needs a longer ladder</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1007/82_2015_434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1007%2F82_2015_434" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2015&pages=147-169&author=G.+Leauthor=F.+J.+Stuart&title=Targeting+the+HIV+RNA+genome%3A+high+hanging+fruit+only+needs+a+longer+ladder&doi=10.1007%2F82_2015_434"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1007%2F82_2015_434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F82_2015_434%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DG.%26aulast%3DStuart%26aufirst%3DF.%2BJ.%26atitle%3DTargeting%2520the%2520HIV%2520RNA%2520genome%253A%2520high%2520hanging%2520fruit%2520only%2520needs%2520a%2520longer%2520ladder%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2015%26volume%3D389%26spage%3D147%26epage%3D169%26doi%3D10.1007%2F82_2015_434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span> For a comprehensive
review on HIV-1 protease inhibitors see:<span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span>; <span class="NLM_string-name">Anderson, D. D.</span>; <span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">The FDA-approved HIV-1 protease inhibitors for treatment of HIV/AIDS</span>. In  <i>Burger’s Medicinal Chemistry and Drug Discovery</i>, <span class="NLM_edition">7th</span> ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D. J.</span>, <span class="NLM_string-name">Rotella, D. P.</span></span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">7</span>, pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">74</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2F0471266949.bmc224" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=1-74&author=A.+K.+Ghosh&author=D.+D.+Anderson&author=H.+Mitsuyaauthor=D.+J.+Abraham&author=D.+P.+Rotella&title=Burger%E2%80%99s+Medicinal+Chemistry+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1002%2F0471266949.bmc224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471266949.bmc224%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DThe%2520FDA-approved%2520HIV-1%2520protease%2520inhibitors%2520for%2520treatment%2520of%2520HIV%252FAIDS%26btitle%3DBurger%25E2%2580%2599s%2520Medicinal%2520Chemistry%2520and%2520Drug%2520Discovery%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2010%26volume%3D7%26spage%3D1%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prato, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5172</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5172-5208&author=A.+K.+Ghoshauthor=H.+L.+Osswaldauthor=G.+Prato&title=Recent+progress+in+the+development+of+HIV-1+protease+inhibitors+for+the+treatment+of+HIV%2FAIDS&doi=10.1021%2Facs.jmedchem.5b01697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.; Prato, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5172-5208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 protease inhibitors continue to play an important role in the treatment of HIV/AIDS, transforming this deadly ailment into a more manageable chronic infection.  Over the years, intensive research has led to a variety of approved protease inhibitors for the treatment of HIV/AIDS.  In this review, we outline current drug design and medicinal chem. efforts toward the development of next-generation protease inhibitors beyond the currently approved drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4DisuSRbQXbVg90H21EOLACvtfcHk0ljQ051RAfcPIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D&md5=e0994f3d84ab627d3ac3f757e8d11725</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01697%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26aulast%3DPrato%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520in%2520the%2520development%2520of%2520HIV-1%2520protease%2520inhibitors%2520for%2520the%2520treatment%2520of%2520HIV%252FAIDS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5172%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.5b01697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dismuke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forshey, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of HIV-1 replication by a novel mechanism: specific interference with the final step of virion maturation</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.2.922-929.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FJVI.78.2.922-929.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=14694123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=922-929&author=J.+Zhouauthor=X.+Yuanauthor=D.+Dismukeauthor=B.+M.+Forsheyauthor=C.+Lundquistauthor=K.+H.+Leeauthor=C.+Aikenauthor=C.+H.+Chen&title=Pharmacologic+inhibition+of+HIV-1+replication+by+a+novel+mechanism%3A+specific+interference+with+the+final+step+of+virion+maturation&doi=10.1128%2FJVI.78.2.922-929.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation</span></div><div class="casAuthors">Zhou, Jing; Yuan, Xiong; Dismuke, David; Forshey, Brett M.; Lundquist, Christopher; Lee, Kuo-hsiung; Aiken, Christopher; Chen, Chin Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">922-929</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Despite the effectiveness of currently available human immunodeficiency virus type 1 (HIV-1) therapies, a continuing need exists for new drugs to treat HIV-1 infection.  We investigated the mechanism by which 3-O-{3',3'-dimethylsuccinyl}betulinic acid (DSB) inhibits HIV-1 replication.  DSB functions at a late stage of the virus life cycle but does not inhibit the HIV-1 protease in vitro or interfere with virus assembly or release.  DSB specifically delays the cleavage of Gag between the capsid (CA) and p2, resulting in delayed formation of the mature viral core and reduced HIV-1 infectivity.  Replication of simian immunodeficiency virus (SIV) was resistant to DSB; however, a chimeric SIV carrying CA-p2 sequences from HIV-1 was inhibited by the drug, indicating that susceptibility to DSB maps to the CA-p2 region of the HIV-1 Gag protein.  A single point mutation at the CA-p2 cleavage site of HIV-1 conferred strong resistance to DSB, confirming the target of the drug.  HIV-1 strains that are resistant to a variety of protease inhibitors were sensitive to DSB.  These findings indicate that DSB specifically protects the CA-p2 cleavage site from processing by the viral protease during virion maturation, thereby revealing a novel mechanism for pharmacol. inhibition of HIV-1 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqINzh_nRQEVLVg90H21EOLACvtfcHk0lhpTA_BlYpXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFeiug%253D%253D&md5=00be1aa7c70e20a1855418a784089da6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.2.922-929.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.2.922-929.2004%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DDismuke%26aufirst%3DD.%26aulast%3DForshey%26aufirst%3DB.%2BM.%26aulast%3DLundquist%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DAiken%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DPharmacologic%2520inhibition%2520of%2520HIV-1%2520replication%2520by%2520a%2520novel%2520mechanism%253A%2520specific%2520interference%2520with%2520the%2520final%2520step%2520of%2520virion%2520maturation%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D922%26epage%3D929%26doi%3D10.1128%2FJVI.78.2.922-929.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundquist, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kräusslich, H. G.</span></span> <span> </span><span class="NLM_article-title">HIV-1 assembly, budding, and maturation</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">a006924</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a006924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1101%2Fcshperspect.a006924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=22762019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a006924&author=W.+I.+Sundquistauthor=H.+G.+Kr%C3%A4usslich&title=HIV-1+assembly%2C+budding%2C+and+maturation&doi=10.1101%2Fcshperspect.a006924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 assembly, budding, and maturation</span></div><div class="casAuthors">Sundquist, Wesley I.; Krausslich, Hans-Georg</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">a006924/1-a006924/24</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  A defining property of retroviruses is their ability to assemble into particles that can leave producer cells and spread infection to susceptible cells and hosts.  Virion morphogenesis can be divided into three stages: assembly, wherein the virion is created and essential components are packaged; budding, wherein the virion crosses the plasma membrane and obtains its lipid envelope; and maturation, wherein the virion changes structure and becomes infectious.  All of these stages are coordinated by the Gag polyprotein and its proteolytic maturation products, which function as the major structural proteins of the virus.  Here, we review our current understanding of the mechanisms of HIV-1 assembly, budding, and maturation, starting with a general overview and then providing detailed descriptions of each of the different stages of virion morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH1Quq8ytnBrVg90H21EOLACvtfcHk0lhpTA_BlYpXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemtbs%253D&md5=91c7bf7383d85be14ef6f5200990f451</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a006924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a006924%26sid%3Dliteratum%253Aachs%26aulast%3DSundquist%26aufirst%3DW.%2BI.%26aulast%3DKr%25C3%25A4usslich%26aufirst%3DH.%2BG.%26atitle%3DHIV-1%2520assembly%252C%2520budding%252C%2520and%2520maturation%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26spage%3Da006924%26doi%3D10.1101%2Fcshperspect.a006924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span> <span> </span><span class="NLM_article-title">HIV-1 assembly, release and maturation</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1038/nrmicro3490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1038%2Fnrmicro3490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=26119571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFaitr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=484-496&author=E.+O.+Freed&title=HIV-1+assembly%2C+release+and+maturation&doi=10.1038%2Fnrmicro3490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 assembly, release and maturation</span></div><div class="casAuthors">Freed, Eric O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">484-496</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Major advances occurred in recent years in the authors' understanding of HIV-1 assembly, release and maturation, as work in this field has been propelled forwards by developments in imaging technol., structural biol., and cell and mol. biol.  This increase in basic knowledge is being applied to the development of novel inhibitors designed to target various aspects of virus assembly and maturation.  This Review highlights recent progress in elucidating the late stages of the HIV-1 replication cycle and the related interplay between virol., cell and mol. biol., and drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPfA3gjWasqbVg90H21EOLACvtfcHk0lhpTA_BlYpXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFaitr3I&md5=6eeb09143263c9ef53e385d3243323ff</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro3490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro3490%26sid%3Dliteratum%253Aachs%26aulast%3DFreed%26aufirst%3DE.%2BO.%26atitle%3DHIV-1%2520assembly%252C%2520release%2520and%2520maturation%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2015%26volume%3D13%26spage%3D484%26epage%3D496%26doi%3D10.1038%2Fnrmicro3490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">HIV protease inhibitors: a review of molecular selectivity and toxicity</span>. <i>HIV/AIDS</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.2147/HIV.S79956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.2147%2FHIV.S79956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=25897264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFChtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=95-104&author=Z.+Lvauthor=Y.+Chuauthor=Y.+Wang&title=HIV+protease+inhibitors%3A+a+review+of+molecular+selectivity+and+toxicity&doi=10.2147%2FHIV.S79956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HIV protease inhibitors: a review of molecular selectivity and toxicity</span></div><div class="casAuthors">Lv, Zhengtong; Chu, Yuan; Wang, Yong</div><div class="citationInfo"><span class="NLM_cas:title">HIV/AIDS</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-104</span>CODEN:
                <span class="NLM_cas:coden">HIVAA2</span>;
        ISSN:<span class="NLM_cas:issn">1179-1373</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Highly active antiretroviral therapy (HAART) is recognized as the most effective treatment method for AIDS, and protease inhibitors play a very important role in HAART.  However, poor bioavailability and unbearable toxicity are their common disadvantages.  Thus, the development of safer and potentially promising protease inhibitors is eagerly needed.  In this review, we introduced the chem. characteristics and assocd. side effects of HIV protease inhibitors, as well as the possible off-target mechanisms causing the side effects.  From the chem. structures of HIV protease inhibitors and their possible off-target mols., we could obtain hints for optimizing the mol. selectivity of the inhibitors, to provide help in the design of new compds. with enhanced bioavailability and reduced side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAkmF3LC4h4rVg90H21EOLACvtfcHk0lj8mLqAY-u6YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFChtrk%253D&md5=2a28e6df087fcf50f52aa3f217c57ffe</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FHIV.S79956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHIV.S79956%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DHIV%2520protease%2520inhibitors%253A%2520a%2520review%2520of%2520molecular%2520selectivity%2520and%2520toxicity%26jtitle%3DHIV%252FAIDS%26date%3D2015%26volume%3D7%26spage%3D95%26epage%3D104%26doi%3D10.2147%2FHIV.S79956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span> <span> </span><span class="NLM_article-title">Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1177/095632020801900301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1177%2F095632020801900301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=19024627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlChur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=107-113&author=D.+E.+Martinauthor=K.+Salzwedelauthor=G.+P.+Allaway&title=Bevirimat%3A+a+novel+maturation+inhibitor+for+the+treatment+of+HIV-1+infection&doi=10.1177%2F095632020801900301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection</span></div><div class="casAuthors">Martin, David E.; Salzwedel, Karl; Allaway, Graham P.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">107-113</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  Existing antiretroviral treatments for HIV type-1 (HIV-1) disease are limited by problems of resistance and drug-drug interactions.  Bevirimat is a novel HIV-1 maturation inhibitor with a mechanism of action that is distinct from other antiretroviral agents.  Specific inhibition of the final rate-limiting step in Gag processing by bevirimat prevents release of mature capsid protein from its precursor (CA-SP1), resulting in the prodn. of immature, non-infectious virus particles.  Bevirimat inhibits replication of both wild-type and drug-resistant HIV-1 isolates in vitro, achieving similar 50% inhibitory concn. values with both categories.  Serial drug passage studies have identified six single amino acid substitutions that independently confer bevirimat resistance.  These resistance mutations occur at or near the CA-SP1 cleavage site, which is not a known target for resistance to other antiretroviral drugs.  Bevirimat has demonstrated a consistent pharmacokinetic profile in healthy volunteers and HIV-infected patients, with peak plasma concns. attained approx. 1-3 h after dosing.  Plasma concns. decrease in a log-linear manner with a mean plasma elimination half-life of 58-80 h, supporting once-daily dosing.  Animal studies suggest that elimination of bevirimat is primarily by hepatic glucuronidation and hepatobiliary excretion.  There is minimal renal elimination, with <1% of the administered dose appearing in the urine.  In responsive patients, bevirimat has demonstrated a robust dose-dependent redn. in viral load (>1.5 log10 copies/mL).  Short-term administration (≤14 days) of bevirimat is well tolerated, even when used in combination with other antiretroviral agents.  Further studies to evaluate the long-term efficacy and tolerability of bevirimat are currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGralYiuCP9_FrVg90H21EOLACvtfcHk0lj8mLqAY-u6YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlChur3L&md5=9e6c7573626ce746ef6c26b25efea756</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1177%2F095632020801900301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020801900301%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DD.%2BE.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26atitle%3DBevirimat%253A%2520a%2520novel%2520maturation%2520inhibitor%2520for%2520the%2520treatment%2520of%2520HIV-1%2520infection%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2008%26volume%3D19%26spage%3D107%26epage%3D113%26doi%3D10.1177%2F095632020801900301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilgore, N.</span>; <span class="NLM_string-name">Reddick, M.</span>; <span class="NLM_string-name">Zuiderhof, M.</span>; <span class="NLM_string-name">Stanley, D.</span>; <span class="NLM_string-name">Nitz, T.</span>; <span class="NLM_string-name">Bullock, P.</span>; <span class="NLM_string-name">Allaway, G.</span>; <span class="NLM_string-name">Martin, D.</span></span> <span> </span><span class="NLM_article-title">Characterization of PA1050040, a second generation HIV-1 maturation inhibitor</span>. In  <i>4th IAS Conference on HIV Pathogenesis, Treatment and Prevention,  July 22–25, 2007, Sydney, Australia</i>, <span class="NLM_year">2007</span>; abstract  <span class="NLM_fpage">MOPDX05</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=MOPDX05&author=N.+Kilgore&author=M.+Reddick&author=M.+Zuiderhof&author=D.+Stanley&author=T.+Nitz&author=P.+Bullock&author=G.+Allaway&author=D.+Martin&title=Characterization+of+PA1050040%2C+a+second+generation+HIV-1+maturation+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKilgore%26aufirst%3DN.%26atitle%3DCharacterization%2520of%2520PA1050040%252C%2520a%2520second%2520generation%2520HIV-1%2520maturation%2520inhibitor%26jtitle%3D4th%2520IAS%2520Conference%2520on%2520HIV%2520Pathogenesis%252C%2520Treatment%2520and%2520Prevention%252C%2520%2520July%252022%25E2%2580%259325%252C%25202007%252C%2520Sydney%252C%2520Australia%26date%3D2007%26spage%3DMOPDX05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baichwal, V.</span>; <span class="NLM_string-name">Austin, H.</span>; <span class="NLM_string-name">Brown, B.</span>; <span class="NLM_string-name">McKinnon, R.</span>; <span class="NLM_string-name">Yager, K.</span>; <span class="NLM_string-name">Kumar, V.</span>; <span class="NLM_string-name">Gerrish, D.</span>; <span class="NLM_string-name">Anderson, M.</span>; <span class="NLM_string-name">Carlson, R.</span></span> <span> </span><span class="NLM_article-title">Anti-viral characterization in vitro of a novel maturation inhibitor, MPC-9055</span>.  <i>16th Conference on Retroviruses and Opportunistic Infections, February 8–11, 2009, Montreal, Canada</i>, <span class="NLM_year">2009</span>; abstract  <span class="NLM_fpage">J-105</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=J-105&author=V.+Baichwal&author=H.+Austin&author=B.+Brown&author=R.+McKinnon&author=K.+Yager&author=V.+Kumar&author=D.+Gerrish&author=M.+Anderson&author=R.+Carlson&title=Anti-viral+characterization+in+vitro+of+a+novel+maturation+inhibitor%2C+MPC-9055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBaichwal%26aufirst%3DV.%26atitle%3DAnti-viral%2520characterization%2520in%2520vitro%2520of%2520a%2520novel%2520maturation%2520inhibitor%252C%2520MPC-9055%26jtitle%3D16th%2520Conference%2520on%2520Retroviruses%2520and%2520Opportunistic%2520Infections%252C%2520February%25208%25E2%2580%259311%252C%25202009%252C%2520Montreal%252C%2520Canada%26date%3D2009%26spage%3DJ-105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span> <span> </span><span class="NLM_article-title">A repeat dose pharmacokinetic (PK) and safety study of GSK2838232
with and without ritonavir (RTV) conducted in healthy subjects</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>; <a href="https://www.clinicaltrials.gov/ct2/show/NCT02289495?term=GSK2838232&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02289495?term=GSK2838232&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+repeat+dose+pharmacokinetic+%28PK%29+and+safety+study+of+GSK2838232%0Awith+and+without+ritonavir+%28RTV%29+conducted+in+healthy+subjects.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02289495%3Fterm%3DGSK2838232%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520repeat%2520dose%2520pharmacokinetic%2520%2528PK%2529%2520and%2520safety%2520study%2520of%2520GSK2838232%250Awith%2520and%2520without%2520ritonavir%2520%2528RTV%2529%2520conducted%2520in%2520healthy%2520subjects%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and gag polymorphic coverage</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3956</span>– <span class="NLM_lpage">3969</span>, <span class="refDoi"> DOI: 10.1128/AAC.02560-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.02560-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=27090171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=3956-3969&author=B.+Nowicka-Sansauthor=T.+Protackauthor=Z.+Linauthor=Z.+Liauthor=S.+Zhangauthor=Y.+Sunauthor=H.+Samantaauthor=B.+Terryauthor=Z.+Liuauthor=Y.+Chenauthor=N.+Sinauthor=S.+Sitauthor=J.+Swidorskiauthor=J.+Chenauthor=B.+L.+Venablesauthor=M.+Healyauthor=N.+A.+Meanwellauthor=M.+Cockettauthor=U.+Hanumegowdaauthor=A.+Regueiro-Renauthor=M.+Krystalauthor=I.+B.+Dicker&title=Identification+and+characterization+of+BMS-955176%2C+a+second-generation+HIV-1+maturation+inhibitor+with+improved+potency%2C+antiviral+spectrum%2C+and+gag+polymorphic+coverage&doi=10.1128%2FAAC.02560-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of BMS-955176, a second- generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and Gag polymorphic coverage</span></div><div class="casAuthors">Nowicka-Sans, Beata; Protack, Tricia; Lin, Zeyu; Li, Zhufang; Zhang, Sharon; Sun, Yongnian; Samanta, Himadri; Terry, Brian; Liu, Zheng; Chen, Yan; Sin, Ny; Sit, Sing-Yuen; Swidorski, Jacob J.; Chen, Jie; Venables, Brian L.; Healy, Matthew; Meanwell, Nicholas A.; Cockett, Mark; Hanumegowda, Umesh; Regueiro-Ren, Alicia; Krystal, Mark; Dicker, Ira B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3956-3969</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-955176 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor (MI).  A first-generation MI, bevirimat, showed clin. efficacy in early-phase studies, but ∼50% of subjects had viruses with reduced susceptibility assocd. with naturally occurring polymorphisms in Gag near the site of MI action.  MI potency was optimized using a panel of engineered reporter viruses contg. site-directed polymorphic changes in Gag that reduce susceptibility to bevirimat (including V362I, V370A/M/Δ, and T371A/Δ), leading incrementally to the identification of BMS-955176.  BMS-955176 exhibits potent activity (50% effective concn. [EC50], 3.9 ± 3.4 nM [mean ± std. deviation]) toward a library (n = 87) of gag/pr recombinant viruses representing 96.5% of subtype B polymorphic Gag diversity near the CA/SP1 cleavage site.  BMS-955176 exhibited a median EC50 of 21 nM toward a library of subtype B clin. isolates assayed in peripheral blood mononuclear cells (PBMCs).  Potent activity was maintained against a panel of reverse transcriptase, protease, and integrase inhibitor-resistant viruses, with EC50s similar to those for the wild-type virus.  A 5.4-fold redn. in EC50 occurred in the presence of 40% human serum plus 27 mg/mL of human serum albumin (HSA), which corresponded well to an in vitro measurement of 86% human serum binding.  Time-of-addn. and pseudotype reporter virus studies confirm a mechanism of action for the compd. that occurs late in the virus replication cycle.  BMS-955176 inhibits HIV-1 protease cleavage at the CA/SP1 junction within Gag in virus-like particles (VLPs) and in HIV-1-infected cells, and it binds reversibly and with high affinity to assembled Gag in purified HIV-1 VLPs.  Finally, in vitro combination studies showed no antagonistic interactions with representative antiretrovirals (ARVs) of other mechanistic classes.  In conclusion, BMS-955176 is a second-generation MI with potent in vitro anti-HIV-1 activity and a greatly improved preclin. profile compared to that of bevirimat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOlEXzA0wovbVg90H21EOLACvtfcHk0lgubThfhxqNdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyksbY%253D&md5=3a2d50795078357c62d002d2293c1852</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.02560-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02560-15%26sid%3Dliteratum%253Aachs%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSamanta%26aufirst%3DH.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DSit%26aufirst%3DS.%26aulast%3DSwidorski%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DHealy%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520BMS-955176%252C%2520a%2520second-generation%2520HIV-1%2520maturation%2520inhibitor%2520with%2520improved%2520potency%252C%2520antiviral%2520spectrum%252C%2520and%2520gag%2520polymorphic%2520coverage%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D3956%26epage%3D3969%26doi%3D10.1128%2FAAC.02560-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockett, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of BMS-955176, a second generation HIV-1 maturation inhibitor with broad spectrum antiviral activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVOhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=568-572&author=A.+Regueiro-Renauthor=Z.+Liuauthor=Y.+Chenauthor=N.+Sinauthor=S.+Y.+Sitauthor=J.+J.+Swidorskiauthor=J.+Chenauthor=B.+L.+Venablesauthor=J.+L.+Zhuauthor=B.+Nowicka-Sansauthor=T.+Protackauthor=Z.+Linauthor=B.+Terryauthor=H.+Samantaauthor=S.+Zhangauthor=Z.+F.+Liauthor=B.+R.+Benoauthor=X.+S.+Huangauthor=S.+Rahematpuraauthor=D.+D.+Parkerauthor=R.+Haskellauthor=S.+Jenkinsauthor=K.+S.+Santoneauthor=M.+I.+Cockettauthor=M.+Krystalauthor=N.+A.+Meanwellauthor=U.+Hanumegowdaauthor=I.+B.+Dicker&title=Discovery+of+BMS-955176%2C+a+second+generation+HIV-1+maturation+inhibitor+with+broad+spectrum+antiviral+activity&doi=10.1021%2Facsmedchemlett.6b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity</span></div><div class="casAuthors">Regueiro-Ren, Alicia; Liu, Zheng; Chen, Yan; Sin, Ny; Sit, Sing-Yuen; Swidorski, Jacob J.; Chen, Jie; Venables, Brian L.; Zhu, Juliang; Nowicka-Sans, Beata; Protack, Tricia; Lin, Zeyu; Terry, Brian; Samanta, Himadri; Zhang, Sharon; Li, Zhufang; Beno, Brett R.; Huang, Xiaohua S.; Rahematpura, Sandhya; Parker, Dawn D.; Haskell, Roy; Jenkins, Susan; Santone, Kenneth S.; Cockett, Mark I.; Krystal, Mark; Meanwell, Nicholas A.; Hanumegowda, Umesh; Dicker, Ira B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">568-572</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 maturation inhibition (MI) has been clin. validated as an approach to the control of HIV-1 infection.  However, identifying an MI with both broad polymorphic spectrum coverage and good oral exposure has been challenging.  Herein, we describe the design, synthesis, and preclin. characterization of a potent, orally active, second generation HIV-1 MI, BMS-955176 (2)(I), which is currently in Phase IIb clin. trials as part of a combination antiretroviral regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvDTuPfUkgArVg90H21EOLACvtfcHk0ljqDZGL2JGuDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVOhsLw%253D&md5=d6bb9ad5b3d3ea7e4884401ff882d7a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00010%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DSit%26aufirst%3DS.%2BY.%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DSamanta%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%2BF.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DHaskell%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DCockett%26aufirst%3DM.%2BI.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26atitle%3DDiscovery%2520of%2520BMS-955176%252C%2520a%2520second%2520generation%2520HIV-1%2520maturation%2520inhibitor%2520with%2520broad%2520spectrum%2520antiviral%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D568%26epage%3D572%26doi%3D10.1021%2Facsmedchemlett.6b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogundele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span> <span> </span><span class="NLM_article-title">Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3′3-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3574</span>– <span class="NLM_lpage">3581</span>, <span class="refDoi"> DOI: 10.1128/AAC.00152-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.00152-07" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=3574-3581&author=P.+F.+Smithauthor=A.+Ogundeleauthor=J.+W.+Forrestauthor=J.+Wiltonauthor=K.+Salzwedelauthor=J.+Dotoauthor=G.+P.+Allawayauthor=D.+E.+Martin&title=Phase+I+and+II+study+of+the+safety%2C+virologic+effect%2C+and+pharmacokinetics%2Fpharmacodynamics+of+single-dose+3-O-%283%E2%80%B23-dimethylsuccinyl%29betulinic+acid+%28bevirimat%29+against+human+immunodeficiency+virus+infection&doi=10.1128%2FAAC.00152-07"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.00152-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00152-07%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DOgundele%26aufirst%3DA.%26aulast%3DForrest%26aufirst%3DJ.%2BW.%26aulast%3DWilton%26aufirst%3DJ.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DDoto%26aufirst%3DJ.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26atitle%3DPhase%2520I%2520and%2520II%2520study%2520of%2520the%2520safety%252C%2520virologic%2520effect%252C%2520and%2520pharmacokinetics%252Fpharmacodynamics%2520of%2520single-dose%25203-O-%25283%25E2%2580%25B23-dimethylsuccinyl%2529betulinic%2520acid%2520%2528bevirimat%2529%2520against%2520human%2520immunodeficiency%2520virus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D3574%26epage%3D3581%26doi%3D10.1128%2FAAC.00152-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCallister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrigan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G.</span></span> <span> </span><span class="NLM_article-title">HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457)</span>. <i>Antiviral Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">A10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=A10&author=S.+McCallisterauthor=J.+Lalezariauthor=G.+Richmondauthor=M.+Thompsonauthor=R.+Harriganauthor=D.+Martinauthor=K.+Salzwedelauthor=G.+Allaway&title=HIV-1+Gag+polymorphisms+determine+treatment+response+to+bevirimat+%28PA-457%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCallister%26aufirst%3DS.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DHarrigan%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DAllaway%26aufirst%3DG.%26atitle%3DHIV-1%2520Gag%2520polymorphisms%2520determine%2520treatment%2520response%2520to%2520bevirimat%2520%2528PA-457%2529%26jtitle%3DAntiviral%2520Ther.%26date%3D2008%26volume%3D13%26spage%3DA10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Baelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondelez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eygen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steegen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verlinden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuyver, L. J.</span></span> <span> </span><span class="NLM_article-title">Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1128/AAC.01650-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.01650-08" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=2185-2188&author=K.+Van%0ABaelenauthor=K.+Salzwedelauthor=E.+Rondelezauthor=V.+Van+Eygenauthor=S.+De+Vosauthor=A.+Verheyenauthor=K.+Steegenauthor=Y.+Verlindenauthor=G.+P.+Allawayauthor=L.+J.+Stuyver&title=Susceptibility+of+human+immunodeficiency+virus+type+1+to+the+maturation+inhibitor+bevirimat+is+modulated+by+baseline+polymorphisms+in+Gag+spacer+peptide+1&doi=10.1128%2FAAC.01650-08"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.01650-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01650-08%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBaelen%26aufirst%3DK.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DRondelez%26aufirst%3DE.%26aulast%3DVan%2BEygen%26aufirst%3DV.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DVerheyen%26aufirst%3DA.%26aulast%3DSteegen%26aufirst%3DK.%26aulast%3DVerlinden%26aufirst%3DY.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26aulast%3DStuyver%26aufirst%3DL.%2BJ.%26atitle%3DSusceptibility%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520to%2520the%2520maturation%2520inhibitor%2520bevirimat%2520is%2520modulated%2520by%2520baseline%2520polymorphisms%2520in%2520Gag%2520spacer%2520peptide%25201%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D2185%26epage%3D2188%26doi%3D10.1128%2FAAC.01650-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margot, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic susceptibility to bevirimat among HIV-1 infected patient isolates without prior exposure to bevirimat</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2345</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1128/AAC.01784-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FAAC.01784-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2345-2353&author=N.+A.+Margotauthor=C.+S.+Gibbsauthor=M.+D.+Miller&title=Phenotypic+susceptibility+to+bevirimat+among+HIV-1+infected+patient+isolates+without+prior+exposure+to+bevirimat&doi=10.1128%2FAAC.01784-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.01784-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01784-09%26sid%3Dliteratum%253Aachs%26aulast%3DMargot%26aufirst%3DN.%2BA.%26aulast%3DGibbs%26aufirst%3DC.%2BS.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DPhenotypic%2520susceptibility%2520to%2520bevirimat%2520among%2520HIV-1%2520infected%2520patient%2520isolates%2520without%2520prior%2520exposure%2520to%2520bevirimat%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2345%26epage%3D2353%26doi%3D10.1128%2FAAC.01784-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span>; <span class="NLM_string-name">Richards, J.</span>; <span class="NLM_string-name">Augustine, J. G.</span>; <span class="NLM_string-name">Milea, J. S.</span></span> <span> </span><span class="NLM_article-title">Liquid Bevirimat Dosage Forms for Oral Administration</span>. U.S. Patent <span class="NLM_patent">US20100216751A1</span>, August 26, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Jacob&author=J.+Richards&author=J.+G.+Augustine&author=J.+S.+Milea&title=Liquid+Bevirimat+Dosage+Forms+for+Oral+Administration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%26aufirst%3DJ.%26atitle%3DLiquid%2520Bevirimat%2520Dosage%2520Forms%2520for%2520Oral%2520Administration%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span> <span> </span><span class="NLM_article-title">An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1177/0091270009333488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1177%2F0091270009333488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=19304891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=606-612&author=A.+Connorauthor=P.+Evansauthor=J.+Dotoauthor=C.+Ellisauthor=D.+E.+Martin&title=An+oral+human+drug+absorption+study+to+assess+the+impact+of+site+of+delivery+on+the+bioavailability+of+bevirimat&doi=10.1177%2F0091270009333488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat</span></div><div class="casAuthors">Connor, Alyson; Evans, Phil; Doto, Judy; Ellis, Corey; Martin, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">606-612</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Bevirimat is a first in class, orally active, potent and selective inhibitor of HIV-1.  It may have utility for the treatment of HIV-1-infected patients who are failing current regimens because of the development of drug resistance.  In earlier studies in HIV-1-infected patients, an immediate-release tablet formulation exhibited a relative bioavailability (Frel) of 50% or greater and a higher intersubject variability than an oral soln.  The purpose of this study was to det. whether this pharmacokinetic profile is attributable to a narrow permeability-dependent absorption window within the gastrointestinal tract.  Three groups of subjects completed an open-label, 2-way crossover, randomized pharmacoscintigraphic study.  Subjects received a 25-mg bevirimat oral immediate-release soln. plus 25 mg bevirimat soln. delivered to the proximal small bowel, distal small bowel, or colon via the Enterion capsule.  The results indicate that the permeability of bevirimat throughout the small intestine was excellent and suggest that the variability obsd. for the immediate release tablet was not related to the presence of an absorption window in the small intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6fZ-OhBjwObVg90H21EOLACvtfcHk0lj7oYc2ilYyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWlsr4%253D&md5=a8b69f57e94bd403112bf0f917127063</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F0091270009333488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333488%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DP.%26aulast%3DDoto%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26atitle%3DAn%2520oral%2520human%2520drug%2520absorption%2520study%2520to%2520assess%2520the%2520impact%2520of%2520site%2520of%2520delivery%2520on%2520the%2520bioavailability%2520of%2520bevirimat%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D606%26epage%3D612%26doi%3D10.1177%2F0091270009333488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, J.</span></span> <span> </span><span class="NLM_article-title">Can the further clinical development of bevirimat be justified?</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1097/QAD.0b013e328331c83b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1097%2FQAD.0b013e328331c83b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=773-774&author=M.+A.+Wainbergauthor=J.+Albert&title=Can+the+further+clinical+development+of+bevirimat+be+justified%3F&doi=10.1097%2FQAD.0b013e328331c83b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1097%2FQAD.0b013e328331c83b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0b013e328331c83b%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26aulast%3DAlbert%26aufirst%3DJ.%26atitle%3DCan%2520the%2520further%2520clinical%2520development%2520of%2520bevirimat%2520be%2520justified%253F%26jtitle%3DAIDS%26date%3D2010%26volume%3D24%26spage%3D773%26epage%3D774%26doi%3D10.1097%2FQAD.0b013e328331c83b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1770</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmc.2016.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=26968652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvV2hsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1757-1770&author=Z.+Liuauthor=J.+J.+Swidorskiauthor=B.+Nowicka-Sansauthor=B.+Terryauthor=T.+Protackauthor=Z.+Linauthor=H.+Samantaauthor=S.+Zhangauthor=Z.+Liauthor=S.+Rahematpuraauthor=D.+D.+Parkerauthor=S.+Jenkinsauthor=B.+R.+Benoauthor=M.+Krystalauthor=N.+A.+Meanwellauthor=I.+B.+Dickerauthor=A.+Regueiro-Ren&title=C-3+benzoic+acid+derivatives+of+C-3+deoxybetulinic+acid+and+deoxybetulin+as+HIV-1+maturation+inhibitors&doi=10.1016%2Fj.bmc.2016.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors</span></div><div class="casAuthors">Liu, Zheng; Swidorski, Jacob J.; Nowicka-Sans, Beata; Terry, Brian; Protack, Tricia; Lin, Zeyu; Samanta, Himadri; Zhang, Sharon; Li, Zhufang; Parker, Dawn D.; Rahematpura, Sandhya; Jenkins, Susan; Beno, Brett R.; Krystal, Mark; Meanwell, Nicholas A.; Dicker, Ira B.; Regueiro-Ren, Alicia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1757-1770</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of C-3 phenyl- and heterocycle-substituted derivs. of C-3 deoxybetulinic acid and C-3 deoxybetulin was designed and synthesized as HIV-1 maturation inhibitors (MIs) and evaluated for their antiviral activity and cytotoxicity in cell culture.  A 4-subsituted benzoic acid moiety was identified as an advantageous replacement for the 3'3'-dimethylsuccinate moiety present in previously disclosed MIs that illuminates new aspects of the topog. of the pharmacophore.  The new analogs exhibit excellent in vitro antiviral activity against wild-type (wt) virus and a lower serum shift when compared with the prototypical HIV-1 MI bevirimat (1, BVM), the first MI to be evaluated in clin. studies.  Compd. 9a exhibits comparable cell culture potency toward wt virus as 1 (WT EC50 = 16 nM for 9a compared to 10 nM for 1).  However, the potency of 9a is less affected by the presence of human serum, while the compd. displays a similar pharmacokinetic profile in rats to 1.  Hence 9a, the 4-benzoic acid deriv. of deoxybetulinic acid, represents a new starting point from which to explore the design of a 2nd generation MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo6JzDEZTpIrVg90H21EOLACvtfcHk0ljrmanl6R8BAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvV2hsLk%253D&md5=bbcabfc972def3487a7144765fe8ac20</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSamanta%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DC-3%2520benzoic%2520acid%2520derivatives%2520of%2520C-3%2520deoxybetulinic%2520acid%2520and%2520deoxybetulin%2520as%2520HIV-1%2520maturation%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1757%26epage%3D1770%26doi%3D10.1016%2Fj.bmc.2016.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of HIV-1 maturation: development of structure-activity relationships for C-28 amide derivatives of C-3 benzoic acid-modified triterpenoids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmcl.2016.03.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1925-1930&author=J.+J.+Swidorskiauthor=Z.+Liuauthor=S.-Y.+Sitauthor=J.+Chenauthor=Y.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=D.+D.+Parkerauthor=B.+Nowicka-Sansauthor=B.+J.+Terryauthor=T.+Protackauthor=S.+Rahematpuraauthor=U.+Hanumegowdaauthor=S.+Jenkinsauthor=M.+Krystalauthor=I.+B.+Dickerauthor=N.+A.+Meanwellauthor=A.+Regueiro-Ren&title=Inhibitors+of+HIV-1+maturation%3A+development+of+structure-activity+relationships+for+C-28+amide+derivatives+of+C-3+benzoic+acid-modified+triterpenoids&doi=10.1016%2Fj.bmcl.2016.03.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DTerry%26aufirst%3DB.%2BJ.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520HIV-1%2520maturation%253A%2520development%2520of%2520structure-activity%2520relationships%2520for%2520C-28%2520amide%2520derivatives%2520of%2520C-3%2520benzoic%2520acid-modified%2520triterpenoids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1925%26epage%3D1930%26doi%3D10.1016%2Fj.bmcl.2016.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Venables, B. L.</span>; <span class="NLM_string-name">Sit, S.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">C-17 and C-3 Modified Triterpenoids with HIV Maturation Inhibitory Activity</span>. U.S. Patent <span class="NLM_patent">US8846647</span>, September 30, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Regueiro-Ren&author=Z.+Liu&author=J.+Swidorski&author=N.+Sin&author=B.+L.+Venables&author=S.+Sit&author=Y.+Chen&author=J.+Chen&author=N.+A.+Meanwell&title=C-17+and+C-3+Modified+Triterpenoids+with+HIV+Maturation+Inhibitory+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DC-17%2520and%2520C-3%2520Modified%2520Triterpenoids%2520with%2520HIV%2520Maturation%2520Inhibitory%2520Activity%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swidorski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and structure-activity-relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1557</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmcl.2018.03.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1550-1557&author=Y.+Chenauthor=S.-Y.+Sitauthor=J.+Chenauthor=J.+J.+Swidorskiauthor=Z.+Liuauthor=N.+Sinauthor=B.+L.+Venablesauthor=D.+D.+Parkerauthor=B.+Nowicka-Sansauthor=Z.+Linauthor=Z.+Liauthor=B.+Terryauthor=T.+Protackauthor=S.+Rahematpuraauthor=U.+Hanumegowdaauthor=S.+Jenkinsauthor=M.+Krystalauthor=I.+B.+Dickerauthor=N.+A.+Meanwellauthor=A.+Regueiro-Ren&title=The+design%2C+synthesis+and+structure-activity-relationships+associated+with+C28+amine-based+betulinic+acid+derivatives+as+inhibitors+of+HIV-1+maturation&doi=10.1016%2Fj.bmcl.2018.03.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSwidorski%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTerry%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520structure-activity-relationships%2520associated%2520with%2520C28%2520amine-based%2520betulinic%2520acid%2520derivatives%2520as%2520inhibitors%2520of%2520HIV-1%2520maturation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1550%26epage%3D1557%26doi%3D10.1016%2Fj.bmcl.2018.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcombe, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. D.</span></span> <span> </span><span class="NLM_article-title">Preparation and use of tetra-n-butylammonium per-ruthenate (TBAP reagent) and tetra-n-propylammonium per-ruthenate (TPAP reagent) as new catalytic oxidants for alcohols</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1627</span>, <span class="refDoi"> DOI: 10.1039/c39870001625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1039%2Fc39870001625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=1625-1627&author=W.+P.+Griffithauthor=S.+V.+Leyauthor=G.+P.+Whitcombeauthor=A.+D.+White&title=Preparation+and+use+of+tetra-n-butylammonium+per-ruthenate+%28TBAP+reagent%29+and+tetra-n-propylammonium+per-ruthenate+%28TPAP+reagent%29+as+new+catalytic+oxidants+for+alcohols&doi=10.1039%2Fc39870001625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and use of tetrabutylammonium perruthenate (TBAP reagent) and tetrapropylammonium perruthenate (TPAP reagent) as new catalytic oxidants for alcohols</span></div><div class="casAuthors">Griffith, William P.; Ley, Steven V.; Whitcombe, Gwynne P.; White, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1625-7</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Bu4NRuO4 or Pr4NRuO4 in combination with N-methylmorpholine N-oxide are mild catalytic oxidants for the high yield conversion of alcs. to aldehyde and ketones and are competitive with more conventional reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxf2jCOWaVh7Vg90H21EOLACvtfcHk0lh0-9DaRFKiew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktlOhuro%253D&md5=19a661844cadf93bad8dc9ae9ba18477</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fc39870001625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39870001625%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DW.%2BP.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DWhitcombe%26aufirst%3DG.%2BP.%26aulast%3DWhite%26aufirst%3DA.%2BD.%26atitle%3DPreparation%2520and%2520use%2520of%2520tetra-n-butylammonium%2520per-ruthenate%2520%2528TBAP%2520reagent%2529%2520and%2520tetra-n-propylammonium%2520per-ruthenate%2520%2528TPAP%2520reagent%2529%2520as%2520new%2520catalytic%2520oxidants%2520for%2520alcohols%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1987%26spage%3D1625%26epage%3D1627%26doi%3D10.1039%2Fc39870001625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lindgren, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of carboxylic acids from aldehydes (including hydroxylated benzaldehydes) by oxidation with chlorite</span>. <i>Acta Chem. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">888</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.3891/acta.chem.scand.27-0888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.3891%2Facta.chem.scand.27-0888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaE3sXksVaju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1973&pages=888-890&author=B.+O.+Lindgrenauthor=T.+Nilsson&title=Preparation+of+carboxylic+acids+from+aldehydes+%28including+hydroxylated+benzaldehydes%29+by+oxidation+with+chlorite&doi=10.3891%2Facta.chem.scand.27-0888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of carboxylic acids from aldehydes (including hydroxylated benzaldehydes) by oxidation with chlorite</span></div><div class="casAuthors">Lindgren, Bengt O.; Nilsson, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chemica Scandinavica (1947-1973)</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">888-90</span>CODEN:
                <span class="NLM_cas:coden">ACSAA4</span>;
        ISSN:<span class="NLM_cas:issn">0001-5393</span>.
    </div><div class="casAbstract">Addn. of H2NSO3Hj or m-(%hO)2C6H4 to a title oxidn. mixt. contg. vanilline prevented the formation of ClO2, which reacted with vanillin or vanillic acid to form undesirable side products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ZVjX2rhlvrVg90H21EOLACvtfcHk0lh0-9DaRFKiew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXksVaju7k%253D&md5=459f307094848ba957093e19ba9de0d2</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.3891%2Facta.chem.scand.27-0888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3891%252Facta.chem.scand.27-0888%26sid%3Dliteratum%253Aachs%26aulast%3DLindgren%26aufirst%3DB.%2BO.%26aulast%3DNilsson%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520carboxylic%2520acids%2520from%2520aldehydes%2520%2528including%2520hydroxylated%2520benzaldehydes%2529%2520by%2520oxidation%2520with%2520chlorite%26jtitle%3DActa%2520Chem.%2520Scand.%26date%3D1973%26volume%3D27%26spage%3D888%26epage%3D890%26doi%3D10.3891%2Facta.chem.scand.27-0888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinnick, H. W.</span></span> <span> </span><span class="NLM_article-title">Oxidation of α,β-unsaturated aldehydes</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2096</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(01)97963-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4020%2801%2997963-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL3MXlsFSjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1981&pages=2091-2096&author=B.+S.+Balauthor=W.+E.+Childersauthor=H.+W.+Pinnick&title=Oxidation+of+%CE%B1%2C%CE%B2-unsaturated+aldehydes&doi=10.1016%2FS0040-4020%2801%2997963-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of α,β-unsaturated aldehydes</span></div><div class="casAuthors">Bal, Balkrishna S.; Childers, Wayne E., Jr.; Pinnick, Harold W.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2091-6</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">Three methods for the oxidn. of α,β-unsatd. aldehydes to the corresponding acids were studied.  These were MnO2 oxidn. of the cyanohydrin deriv., treatment with Caro's acid, and reaction with NaClO2.  The last was the best method, giving pure acid in high yield.  E.g., propenal I (R = H) with NaClO2 (Me3COH, MeCH:CMe2, aq. NaH2PO4, room temp., overnight) gave 90% I (R = OH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy3LIBi4Dq7LVg90H21EOLACvtfcHk0ljO9CBS9klFIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXlsFSjs74%253D&md5=1cea4c957f6032c660027bcd98e35e19</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2997963-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252997963-3%26sid%3Dliteratum%253Aachs%26aulast%3DBal%26aufirst%3DB.%2BS.%26aulast%3DChilders%26aufirst%3DW.%2BE.%26aulast%3DPinnick%26aufirst%3DH.%2BW.%26atitle%3DOxidation%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520aldehydes%26jtitle%3DTetrahedron%26date%3D1981%26volume%3D37%26spage%3D2091%26epage%3D2096%26doi%3D10.1016%2FS0040-4020%2801%2997963-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B.</span></span> <span> </span><span class="NLM_article-title">Synthetic studies toward verrucarol. 2. Synthesis of the AB ring system</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">4825</span>– <span class="NLM_lpage">4830</span>, <span class="refDoi"> DOI: 10.1021/jo01312a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01312a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL3MXhsF2jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=4825-4830&author=G.+A.+Krausauthor=B.+Roth&title=Synthetic+studies+toward+verrucarol.+2.+Synthesis+of+the+AB+ring+system&doi=10.1021%2Fjo01312a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic studies toward verrucarol.  2.  Synthesis of the AB ring system</span></div><div class="casAuthors">Kraus, George A.; Roth, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4825-30</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">A route to the AB ring system of verrucarol is described.  The successful scheme involved the formation of the A ring by a boron triacetate-catalyzed Diels-Alder reaction.  The second ring can be appended by an intramol. Knoevenagel reaction to afford lactone I.  This lactone could be converted into the desired keto alc. II by redn. of the lactone and nitrile followed by an oxidn. and Curtius degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiD9e02uy7u7Vg90H21EOLACvtfcHk0ljO9CBS9klFIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhsF2jtQ%253D%253D&md5=d93d7efb2bcf8c61fb811de83be424db</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Fjo01312a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01312a004%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DRoth%26aufirst%3DB.%26atitle%3DSynthetic%2520studies%2520toward%2520verrucarol.%25202.%2520Synthesis%2520of%2520the%2520AB%2520ring%2520system%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D4825%26epage%3D4830%26doi%3D10.1021%2Fjo01312a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taschner, M. J.</span></span> <span> </span><span class="NLM_article-title">Model studies for the synthesis of quassinoids. 1. Construction of the BCE ring system</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1021/jo01294a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01294a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADyaL3cXhs1Cis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=1175-1176&author=G.+A.+Krausauthor=M.+J.+Taschner&title=Model+studies+for+the+synthesis+of+quassinoids.+1.+Construction+of+the+BCE+ring+system&doi=10.1021%2Fjo01294a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22dR"><div class="casContent"><span class="casTitleNuber">22d</span><div class="casTitle"><span class="NLM_cas:atitle">Model studies for the synthesis of quassinoids.  1.  Construction of the BCE ring system</span></div><div class="casAuthors">Kraus, George A.; Taschner, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1175-6</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The synthesis of a key intermediate I for the prepn. of quassimarin (II) is described.  The BC ring system is constructed using a Diels-Alder reaction involving the in situ generated carbomethoxybenzoquinone.  The E ring is introduced by a selenoetherification reaction.  The trans diaxial diol unit can be constructed by intramol. epoxide opening.  Attempts to open the epoxide with external nucleophiles failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXJGvgihSziLVg90H21EOLACvtfcHk0ljOkQyacRhe7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhs1Cis70%253D&md5=9202fa3b893c40e56d1700545f3a3a3d</span></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fjo01294a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01294a058%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DTaschner%26aufirst%3DM.%2BJ.%26atitle%3DModel%2520studies%2520for%2520the%2520synthesis%2520of%2520quassinoids.%25201.%2520Construction%2520of%2520the%2520BCE%2520ring%2520system%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D1175%26epage%3D1176%26doi%3D10.1021%2Fjo01294a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Sit, S.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Liu, Z.</span></span>; <span> </span><span class="NLM_article-title">C-28 Amines of C-3 Modified Betulinic Acid Derivatives as HIV Maturation Inhibitors</span>. U.S. Patent <span class="NLM_patent">US8748415</span>, June 10, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Regueiro-Ren&author=J.+Swidorski&author=S.+Sit&author=Y.+Chen&author=J.+Chen&author=N.+A.+Meanwell&author=Z.+Liu&title=C-28+Amines+of+C-3+Modified+Betulinic+Acid+Derivatives+as+HIV+Maturation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DC-28%2520Amines%2520of%2520C-3%2520Modified%2520Betulinic%2520Acid%2520Derivatives%2520as%2520HIV%2520Maturation%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Sit, S.-Y.</span>; <span class="NLM_string-name">Chen, J.</span>, <span class="NLM_string-name">Sin, N.</span></span> <span> </span><span class="NLM_article-title">Modified C-3 Betulinic Acid Derivatives as HIV Maturation Inhibitors</span>. <span class="NLM_patent">US 8754068</span>, June 17, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Regueiro-Ren&author=J.+Swidorski&author=Z.+Liu&author=N.+A.+Meanwell&author=S.-Y.+Sit&author=J.+Chen&author=N.+Sin&title=Modified+C-3+Betulinic+Acid+Derivatives+as+HIV+Maturation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26atitle%3DModified%2520C-3%2520Betulinic%2520Acid%2520Derivatives%2520as%2520HIV%2520Maturation%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioiri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorus in organic synthesis-VII. Diphenyl phosphorazidate (DPPA). A new convenient reagent for a modified Curtius Reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2151</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(01)97352-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4020%2801%2997352-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1974&pages=2151-2157&author=K.+Ninomiyaauthor=T.+Shioiriauthor=S.+Yamada&title=Phosphorus+in+organic+synthesis-VII.+Diphenyl+phosphorazidate+%28DPPA%29.+A+new+convenient+reagent+for+a+modified+Curtius+Reaction&doi=10.1016%2FS0040-4020%2801%2997352-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2997352-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252997352-1%26sid%3Dliteratum%253Aachs%26aulast%3DNinomiya%26aufirst%3DK.%26aulast%3DShioiri%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DPhosphorus%2520in%2520organic%2520synthesis-VII.%2520Diphenyl%2520phosphorazidate%2520%2528DPPA%2529.%2520A%2520new%2520convenient%2520reagent%2520for%2520a%2520modified%2520Curtius%2520Reaction%26jtitle%3DTetrahedron%26date%3D1974%26volume%3D30%26spage%3D2151%26epage%3D2157%26doi%3D10.1016%2FS0040-4020%2801%2997352-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baltina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flekhter, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigmatullina, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boreko, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaeva, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstikov, G. A.</span></span> <span> </span><span class="NLM_article-title">Lupane triterpenes and derivatives with antiviral activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3549</span>– <span class="NLM_lpage">3552</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00714-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0960-894X%2803%2900714-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3549-3552&author=L.+A.+Baltinaauthor=O.+B.+Flekhterauthor=L.+R.+Nigmatullinaauthor=E.+I.+Borekoauthor=N.+I.+Pavlovaauthor=S.+N.+Nikolaevaauthor=O.+V.+Savinovaauthor=G.+A.+Tolstikov&title=Lupane+triterpenes+and+derivatives+with+antiviral+activity&doi=10.1016%2FS0960-894X%2803%2900714-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900714-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900714-5%26sid%3Dliteratum%253Aachs%26aulast%3DBaltina%26aufirst%3DL.%2BA.%26aulast%3DFlekhter%26aufirst%3DO.%2BB.%26aulast%3DNigmatullina%26aufirst%3DL.%2BR.%26aulast%3DBoreko%26aufirst%3DE.%2BI.%26aulast%3DPavlova%26aufirst%3DN.%2BI.%26aulast%3DNikolaeva%26aufirst%3DS.%2BN.%26aulast%3DSavinova%26aufirst%3DO.%2BV.%26aulast%3DTolstikov%26aufirst%3DG.%2BA.%26atitle%3DLupane%2520triterpenes%2520and%2520derivatives%2520with%2520antiviral%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D3549%26epage%3D3552%26doi%3D10.1016%2FS0960-894X%2803%2900714-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Swidorski, J.</span>; <span class="NLM_string-name">Sit, S.-Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Regueiro-Ren, A.</span></span> <span> </span><span class="NLM_article-title">C-17 Bicyclic Amines of Triterpenoids with HIV Maturation Inhibitory Activity and Their Preparation</span>. World Patent <span class="NLM_patent">WO 2013169578</span>, November 14, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Sin&author=Z.+Liu&author=J.+Swidorski&author=S.-Y.+Sit&author=J.+Chen&author=Y.+Chen&author=N.+A.+Meanwell&author=A.+Regueiro-Ren&title=C-17+Bicyclic+Amines+of+Triterpenoids+with+HIV+Maturation+Inhibitory+Activity+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSin%26aufirst%3DN.%26atitle%3DC-17%2520Bicyclic%2520Amines%2520of%2520Triterpenoids%2520with%2520HIV%2520Maturation%2520Inhibitory%2520Activity%2520and%2520Their%2520Preparation%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J.
F. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P.</span></span> <span> </span><span class="NLM_article-title">Cu(I)-catalyzed sulfoximination</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">4805</span>– <span class="NLM_lpage">4806</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(98)00925-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4039%2898%2900925-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=4805-4806&author=J.%0AF.+K+Mullerauthor=P.+Vogt&title=Cu%28I%29-catalyzed+sulfoximination&doi=10.1016%2FS0040-4039%2898%2900925-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2900925-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252900925-3%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DJ.%2BF.%2BK%26aulast%3DVogt%26aufirst%3DP.%26atitle%3DCu%2528I%2529-catalyzed%2520sulfoximination%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D4805%26epage%3D4806%26doi%3D10.1016%2FS0040-4039%2898%2900925-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strege, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, T. R.</span></span> <span> </span><span class="NLM_article-title">Desulfonylation of aryl alkyl sulfones</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3477</span>– <span class="NLM_lpage">3478</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)71334-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2FS0040-4039%2800%2971334-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1976&pages=3477-3478&author=B.+M.+Trostauthor=H.+C.+Arndtauthor=P.+E.+Stregeauthor=T.+R.+Verhoeven&title=Desulfonylation+of+aryl+alkyl+sulfones&doi=10.1016%2FS0040-4039%2800%2971334-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2971334-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252971334-7%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DArndt%26aufirst%3DH.%2BC.%26aulast%3DStrege%26aufirst%3DP.%2BE.%26aulast%3DVerhoeven%26aufirst%3DT.%2BR.%26atitle%3DDesulfonylation%2520of%2520aryl%2520alkyl%2520sulfones%26jtitle%3DTetrahedron%2520Lett.%26date%3D1976%26volume%3D17%26spage%3D3477%26epage%3D3478%26doi%3D10.1016%2FS0040-4039%2800%2971334-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikugawa, Y.</span></span> <span> </span><span class="NLM_article-title">One-pot reductive amination of aldehydes and ketones with α-picoline-borane in methanol, in water, and in neat conditions</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7899</span>– <span class="NLM_lpage">7906</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.06.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.tet.2004.06.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVajtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=7899-7906&author=S.+Satoauthor=T.+Sakamotoauthor=E.+Miyazawaauthor=Y.+Kikugawa&title=One-pot+reductive+amination+of+aldehydes+and+ketones+with+%CE%B1-picoline-borane+in+methanol%2C+in+water%2C+and+in+neat+conditions&doi=10.1016%2Fj.tet.2004.06.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot reductive amination of aldehydes and ketones with α-picoline-borane in methanol, in water, and in neat conditions</span></div><div class="casAuthors">Sato, Shinya; Sakamoto, Takeshi; Miyazawa, Etsuko; Kikugawa, Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">7899-7906</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A one-pot reductive amination of aldehydes and ketones with amines using α-picoline-borane as a reducing agent is described.  The reaction has been carried out in MeOH, in H2O, and under neat conditions in the presence of small amts. of AcOH.  This was a highly efficient and mild procedure that was applicable for a wide variety of substrates.  In particular, this was a successful demonstration that the reaction can be carried out in water and under neat conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboH8FKbO3_rVg90H21EOLACvtfcHk0ljpt9dN_vA6dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVajtrY%253D&md5=1f8369a5a0dc0b51bdceb2cba6f4f792</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.06.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.06.045%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DS.%26aulast%3DSakamoto%26aufirst%3DT.%26aulast%3DMiyazawa%26aufirst%3DE.%26aulast%3DKikugawa%26aufirst%3DY.%26atitle%3DOne-pot%2520reductive%2520amination%2520of%2520aldehydes%2520and%2520ketones%2520with%2520%25CE%25B1-picoline-borane%2520in%2520methanol%252C%2520in%2520water%252C%2520and%2520in%2520neat%2520conditions%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26spage%3D7899%26epage%3D7906%26doi%3D10.1016%2Fj.tet.2004.06.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plancq, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavelle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Remote modulation of amine basicity by a phenylsulfone and a phenylthio group</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">287</span>, The p<i>K</i><sub>a</sub> value for the TMD moiety in <b>1</b> could not be obtained experimentally due to the low aqueous solubility of the compound. Potentiometric analysis was performed to obtain an approximated value with the p<i>K</i><sub>a</sub> estimated to be 4.5. <span class="refDoi"> DOI: 10.1002/cmdc.200600265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.200600265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=17200999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVWqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=285-287&author=R.+E.+Martinauthor=B.+Plancqauthor=O.+Gavelleauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=K.+M%C3%BCller&title=Remote+modulation+of+amine+basicity+by+a+phenylsulfone+and+a+phenylthio+group&doi=10.1002%2Fcmdc.200600265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Remote modulation of amine basicity by a phenylsulfone and a phenylthio group</span></div><div class="casAuthors">Martin, Rainer E.; Plancq, Baptiste; Gavelle, Olivier; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-287</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of Ph sulfones and phenylthioamines was studied with respect to their pKa values in water under std. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPxZKU1NhH-rVg90H21EOLACvtfcHk0ljpt9dN_vA6dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVWqtLk%253D&md5=1e5681e5549ca7fc205493c7db96262b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600265%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DPlancq%26aufirst%3DB.%26aulast%3DGavelle%26aufirst%3DO.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DRemote%2520modulation%2520of%2520amine%2520basicity%2520by%2520a%2520phenylsulfone%2520and%2520a%2520phenylthio%2520group%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D285%26epage%3D287%26doi%3D10.1002%2Fcmdc.200600265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kleeb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zihlmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abgottspon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiesko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüdin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezençon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwardt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, B.</span></span> <span> </span><span class="NLM_article-title">FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2221</span>– <span class="NLM_lpage">2239</span>, <span class="refDoi"> DOI: 10.1021/jm501524q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501524q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2221-2239&author=S.+Kleebauthor=L.+Pangauthor=K.+Mayerauthor=D.+Erisauthor=A.+Siglauthor=R.+C.+Prestonauthor=P.+Zihlmannauthor=T.+Sharpeauthor=R.+P.+Jakobauthor=D.+Abgottsponauthor=A.+S.+Hutterauthor=M.+Scharenbergauthor=X.+Jiangauthor=G.+Navarraauthor=S.+Rabbaniauthor=M.+Smieskoauthor=N.+L%C3%BCdinauthor=J.+Bezen%C3%A7onauthor=O.+Schwardtauthor=T.+Maierauthor=B.+Ernst&title=FimH+antagonists%3A+bioisosteres+to+improve+the+in+vitro+and+in+vivo+PK%2FPD+profile&doi=10.1021%2Fjm501524q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1021%2Fjm501524q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501524q%26sid%3Dliteratum%253Aachs%26aulast%3DKleeb%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DL.%26aulast%3DMayer%26aufirst%3DK.%26aulast%3DEris%26aufirst%3DD.%26aulast%3DSigl%26aufirst%3DA.%26aulast%3DPreston%26aufirst%3DR.%2BC.%26aulast%3DZihlmann%26aufirst%3DP.%26aulast%3DSharpe%26aufirst%3DT.%26aulast%3DJakob%26aufirst%3DR.%2BP.%26aulast%3DAbgottspon%26aufirst%3DD.%26aulast%3DHutter%26aufirst%3DA.%2BS.%26aulast%3DScharenberg%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DNavarra%26aufirst%3DG.%26aulast%3DRabbani%26aufirst%3DS.%26aulast%3DSmiesko%26aufirst%3DM.%26aulast%3DL%25C3%25BCdin%26aufirst%3DN.%26aulast%3DBezen%25C3%25A7on%26aufirst%3DJ.%26aulast%3DSchwardt%26aufirst%3DO.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DErnst%26aufirst%3DB.%26atitle%3DFimH%2520antagonists%253A%2520bioisosteres%2520to%2520improve%2520the%2520in%2520vitro%2520and%2520in%2520vivo%2520PK%252FPD%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2221%26epage%3D2239%26doi%3D10.1021%2Fjm501524q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0liMxn-XCC1PPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oukoloff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayendran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunden, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span> <span> </span><span class="NLM_article-title">Evaluation of oxetan-3-ol, thietan-3-ol, and derivatives thereof as bioisosteres of the carboxylic acid functional group</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFagu7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=864-868&author=P.+Lassalasauthor=K.+Oukoloffauthor=V.+Makaniauthor=M.+Jamesauthor=V.+Tranauthor=Y.+Yaoauthor=L.+Huangauthor=K.+Vijayendranauthor=L.+Montiauthor=J.+Q.+Trojanowskiauthor=V.+M.-Y.+Leeauthor=M.+C.+Kozlowskiauthor=A.+B.+Smithauthor=K.+R.+Brundenauthor=C.+Ballatore&title=Evaluation+of+oxetan-3-ol%2C+thietan-3-ol%2C+and+derivatives+thereof+as+bioisosteres+of+the+carboxylic+acid+functional+group&doi=10.1021%2Facsmedchemlett.7b00212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30cR"><div class="casContent"><span class="casTitleNuber">30c</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group</span></div><div class="casAuthors">Lassalas, Pierrik; Oukoloff, Killian; Makani, Vishruti; James, Michael; Tran, Van; Yao, Yuemang; Huang, Longchuan; Vijayendran, Krishna; Monti, Ludovica; Trojanowski, John Q.; Lee, Virginia M.-Y.; Kozlowski, Marisa C.; Smith, Amos B.; Brunden, Kurt R.; Ballatore, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">864-868</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxetane ring serves as an isostere of the carbonyl moiety, suggesting that oxetan-3-ol may be considered as a potential surrogate of the carboxylic acid functional group.  To investigate this structural unit, as well as thietan-3-ol and the corresponding sulfoxide and sulfone derivs., as potential carboxylic acid bioisosteres, a set of model compds. has been designed, synthesized, and evaluated for physicochem. properties.  Similar derivs. of the cyclooxygenase inhibitor, ibuprofen, were also synthesized and evaluated for inhibition of eicosanoid biosynthesis in vitro.  Collectively, the data suggest that oxetan-3-ol, thietan-3-ol, and related structures hold promise as isosteric replacements of the carboxylic acid moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1ZLULOrc2bVg90H21EOLACvtfcHk0lhOVGoX9vwHpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFagu7zK&md5=bb7c7a383ccc3c4c275d550a863a5330</span></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00212%26sid%3Dliteratum%253Aachs%26aulast%3DLassalas%26aufirst%3DP.%26aulast%3DOukoloff%26aufirst%3DK.%26aulast%3DMakani%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DV.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DVijayendran%26aufirst%3DK.%26aulast%3DMonti%26aufirst%3DL.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.-Y.%26aulast%3DKozlowski%26aufirst%3DM.%2BC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DEvaluation%2520of%2520oxetan-3-ol%252C%2520thietan-3-ol%252C%2520and%2520derivatives%2520thereof%2520as%2520bioisosteres%2520of%2520the%2520carboxylic%2520acid%2520functional%2520group%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D864%26epage%3D868%26doi%3D10.1021%2Facsmedchemlett.7b00212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murafuji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imajo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muto, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5272</span>– <span class="NLM_lpage">5276</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.bmcl.2017.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=29102227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslejtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5272-5276&author=H.+Murafujiauthor=H.+Sakaiauthor=M.+Gotoauthor=S.+Imajoauthor=H.+Sugawaraauthor=T.+Muto&title=Discovery+and+structure-activity+relationship+study+of+1%2C3%2C6-trisubstituted+1%2C4-diazepane-7-ones+as+novel+human+kallikrein+7+inhibitors&doi=10.1016%2Fj.bmcl.2017.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30dR"><div class="casContent"><span class="casTitleNuber">30d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors</span></div><div class="casAuthors">Murafuji, Hidenobu; Sakai, Hiroki; Goto, Megumi; Imajo, Seiichi; Sugawara, Hajime; Muto, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5272-5276</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. I, composed of a 1,3,6-trisubstituted 1,4-diazepane-7-one, was discovered as a novel human kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme, SCCE) inhibitor, and its derivs. were synthesized and evaluated.  Structure-activity relationship studies of the amidoxime unit and benzoic acid part of this new scaffold led to the identification of compds. II (R = CO2H and R = Ms), which were more potent than the hit compd., I.  The X-ray co-crystal structure of compd. II (R = CO2H) and human KLK7 revealed the characteristic interactions and enabled explanations of the structure-activity relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK1C4HsV46o7Vg90H21EOLACvtfcHk0lhOVGoX9vwHpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslejtr3M&md5=25aa9fa4add2001cfca7897e56f710ef</span></div><a href="/servlet/linkout?suffix=cit30d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DMurafuji%26aufirst%3DH.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DImajo%26aufirst%3DS.%26aulast%3DSugawara%26aufirst%3DH.%26aulast%3DMuto%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520structure-activity%2520relationship%2520study%2520of%25201%252C3%252C6-trisubstituted%25201%252C4-diazepane-7-ones%2520as%2520novel%2520human%2520kallikrein%25207%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D5272%26epage%3D5276%26doi%3D10.1016%2Fj.bmcl.2017.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi-Parmar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisneros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimmer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Optimization of pyrazoles as phenol surrogates to yield potent inhibitors of macrophage migration inhibitory factor</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1092</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.201800158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=29575754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1092-1097&author=V.+Trivedi-Parmarauthor=M.+J.+Robertsonauthor=J.+A.+Cisnerosauthor=S.+G.+Krimmerauthor=W.+L.+Jorgensen&title=Optimization+of+pyrazoles+as+phenol+surrogates+to+yield+potent+inhibitors+of+macrophage+migration+inhibitory+factor&doi=10.1002%2Fcmdc.201800158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30eR"><div class="casContent"><span class="casTitleNuber">30e</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Pyrazoles as Phenol Surrogates to Yield Potent Inhibitors of Macrophage Migration Inhibitory Factor</span></div><div class="casAuthors">Trivedi-Parmar, Vinay; Robertson, Michael J.; Cisneros, Jose A.; Krimmer, Stefan G.; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1092-1097</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that is implicated in the regulation of inflammation, cell proliferation, and neurol. disorders.  MIF is also an enzyme that functions as a keto-enol tautomerase.  Most potent MIF tautomerase inhibitors incorporate a phenol, which hydrogen bonds to Asn97 in the active site.  Starting from a 113-μm docking hit, we report results of structure-based and computer-aided design that have provided substituted pyrazoles as phenol alternatives with potencies of 60-70 nm.  Crystal structures of complexes of MIF with the pyrazoles highlight the contributions of hydrogen bonding with Lys32 and Asn97, and aryl-aryl interactions with Tyr36, Tyr95, and Phe113 to the binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBNIBiGpnG57Vg90H21EOLACvtfcHk0lhOVGoX9vwHpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFWjt78%253D&md5=f9e8fa5897bb763c5a36333e01eb69c4</span></div><a href="/servlet/linkout?suffix=cit30e&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800158%26sid%3Dliteratum%253Aachs%26aulast%3DTrivedi-Parmar%26aufirst%3DV.%26aulast%3DRobertson%26aufirst%3DM.%2BJ.%26aulast%3DCisneros%26aufirst%3DJ.%2BA.%26aulast%3DKrimmer%26aufirst%3DS.%2BG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DOptimization%2520of%2520pyrazoles%2520as%2520phenol%2520surrogates%2520to%2520yield%2520potent%2520inhibitors%2520of%2520macrophage%2520migration%2520inhibitory%2520factor%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D1092%26epage%3D1097%26doi%3D10.1002%2Fcmdc.201800158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Röder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0ljINvlru7AiiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0ljgBJfbCEe4sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: a neglected opportunity in medicinal chemistry</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9399</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1002/anie.201302209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fanie.201302209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9399-9408&author=U.+L%C3%BCcking&title=Sulfoximines%3A+a+neglected+opportunity+in+medicinal+chemistry&doi=10.1002%2Fanie.201302209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines: A Neglected Opportunity in Medicinal Chemistry</span></div><div class="casAuthors">Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9399-9408</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Innovation has frequently been described as the key to drug discovery.  However, in the daily routine, medicinal chemists often tend to stick to the functional groups and structural elements they know and love.  Blockbuster cancer drug Velcade (bortezomib), for example, was rejected by more than 50 companies, supposedly because of its unusual boronic acid function (as often repeated: "only a moron would put boron in a drug!").  Similarly, in the discovery process of the pan-CDK inhibitor BAY 1000394, the unconventional proposal to introduce a sulfoximine group into the lead series also led to sneers and raised eyebrows, since sulfoximines have seldom been used in medicinal chem.  However, it was the introduction of the sulfoximine group that finally allowed the fundamental issues of the project to be overcome, culminating in the identification of the clin. sulfoximine pan-CDK inhibitor BAY 1000394.  This Minireview provides an overview of a widely neglected opportunity in medicinal chem.-the sulfoximine group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcpeepAANfbVg90H21EOLACvtfcHk0ljgBJfbCEe4sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI&md5=6850d8d77b1141d9d9344410822c00c3</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302209%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DSulfoximines%253A%2520a%2520neglected%2520opportunity%2520in%2520medicinal%2520chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9399%26epage%3D9408%26doi%3D10.1002%2Fanie.201302209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines from a medicinal chemist’s perspective: physicochemical and in vitro parameters relevant for drug discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.ejmech.2016.09.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=27821325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=225-245&author=M.+Fringsauthor=C.+Bolmauthor=A.+Blumauthor=C.+Gnamm&title=Sulfoximines+from+a+medicinal+chemist%E2%80%99s+perspective%3A+physicochemical+and+in+vitro+parameters+relevant+for+drug+discovery&doi=10.1016%2Fj.ejmech.2016.09.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery</span></div><div class="casAuthors">Frings, Marcus; Bolm, Carsten; Blum, Andreas; Gnamm, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sulfoximines, sulfondiimides and sulfonimidamides are fascinating but not yet fully explored variants of the common sulfone or sulfonamide motif.  In this study, we report the physicochem. and in vitro properties of sulfoximines and compare them with related analogs and isosteres.  Furthermore, we present a matched mol. pair anal. of compds. from drug discovery projects within Boehringer Ingelheim.  We demonstrate that the sulfoximine moiety is a chem. stable, comparatively polar and weakly basic functional group, often leading to favorable aq. soly., permeability and metabolic stability.  Moreover, their addnl. vectors at nitrogen enable simple chem. modifications and thus facilitate exploration and fine-tuning of the mol. properties.  We conclude that sulfoximines and their congeners do not exhibit any intrinsic flaw but significantly enrich the toolbox of medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu0FlXXURKybVg90H21EOLACvtfcHk0ljgBJfbCEe4sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK&md5=8a7939f22425f46ad9eb87fcddd29099</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.091%26sid%3Dliteratum%253Aachs%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DBolm%26aufirst%3DC.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DGnamm%26aufirst%3DC.%26atitle%3DSulfoximines%2520from%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%253A%2520physicochemical%2520and%2520in%2520vitro%2520parameters%2520relevant%2520for%2520drug%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D225%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.09.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sirvent, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Novel pieces for the emerging picture of sulfoximines in drug discovery: synthesis and evaluation of sulfoximine analogues of marketed drugs and advanced clinical candidates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fcmdc.201700044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=28221724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=487-501&author=J.+A.+Sirventauthor=U.+L%C3%BCcking&title=Novel+pieces+for+the+emerging+picture+of+sulfoximines+in+drug+discovery%3A+synthesis+and+evaluation+of+sulfoximine+analogues+of+marketed+drugs+and+advanced+clinical+candidates&doi=10.1002%2Fcmdc.201700044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates</span></div><div class="casAuthors">Sirvent, Juan Alberto; Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-501</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sulfoximines have gained considerable recognition as an important structural motif in drug discovery of late.  In particular, the clin. kinase inhibitors for the treatment of cancer, roniciclib (pan-CDK inhibitor), BAY 1143572 (P-TEFb inhibitor), and AZD 6738 (ATR inhibitor), have recently drawn considerable attention.  While the interest in this underrepresented functional group in drug discovery is clearly on the rise, there remains an incomplete understanding of the medicinal-chem.-relevant properties of sulfoximines.  Herein we report the synthesis and in vitro characterization of a variety of sulfoximine analogs of marketed drugs and advanced clin. candidates to gain a better understanding of this neglected functional group and its potential in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5kfVM3I45LVg90H21EOLACvtfcHk0lja7zPBtNsK_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D&md5=5b4589d7af32c8984d4fd3027c31c168</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700044%26sid%3Dliteratum%253Aachs%26aulast%3DSirvent%26aufirst%3DJ.%2BA.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DNovel%2520pieces%2520for%2520the%2520emerging%2520picture%2520of%2520sulfoximines%2520in%2520drug%2520discovery%253A%2520synthesis%2520and%2520evaluation%2520of%2520sulfoximine%2520analogues%2520of%2520marketed%2520drugs%2520and%2520advanced%2520clinical%2520candidates%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D487%26epage%3D501%26doi%3D10.1002%2Fcmdc.201700044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span> <span> </span><span class="NLM_article-title">Organic synthesis provides opportunities to transform drug discovery</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1038/s41557-018-0021-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1038%2Fs41557-018-0021-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=29568051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Sktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=383-394&author=D.+C.+Blakemoreauthor=L.+Castroauthor=I.+Churcherauthor=D.+C.+Reesauthor=A.+W.+Thomasauthor=D.+M.+Wilsonauthor=A.+Wood&title=Organic+synthesis+provides+opportunities+to+transform+drug+discovery&doi=10.1038%2Fs41557-018-0021-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">Organic synthesis provides opportunities to transform drug discovery</span></div><div class="casAuthors">Blakemore, David C.; Castro, Luis; Churcher, Ian; Rees, David C.; Thomas, Andrew W.; Wilson, David M.; Wood, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-394</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Despite decades of ground-breaking research in academia, org. synthesis is still a rate-limiting factor in drug-discovery projects.  Here we present some current challenges in synthetic org. chem. from the perspective of the pharmaceutical industry and highlight problematic steps that, if overcome, would find extensive application in the discovery of transformational medicines.  Significant synthesis challenges arise from the fact that drug mols. typically contain amines and N-heterocycles, as well as unprotected polar groups.  There is also a need for new reactions that enable non-traditional disconnections, more C-H bond activation and late-stage functionalization, as well as stereoselectively substituted aliph. heterocyclic ring synthesis, C-X or C-C bond formation.  We also emphasize that syntheses compatible with biomacromols. will find increasing use, while new technologies such as machine-assisted approaches and artificial intelligence for synthesis planning have the potential to dramatically accelerate the drug-discovery process.  We believe that increasing collaboration between academic and industrial chemists is crucial to address the challenges outlined here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonqR_RxjClS7Vg90H21EOLACvtfcHk0lja7zPBtNsK_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Sktrk%253D&md5=f6269ea8193e28416fd86fe8afbcea3f</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1038%2Fs41557-018-0021-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41557-018-0021-z%26sid%3Dliteratum%253Aachs%26aulast%3DBlakemore%26aufirst%3DD.%2BC.%26aulast%3DCastro%26aufirst%3DL.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DThomas%26aufirst%3DA.%2BW.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DWood%26aufirst%3DA.%26atitle%3DOrganic%2520synthesis%2520provides%2520opportunities%2520to%2520transform%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%26date%3D2018%26volume%3D10%26spage%3D383%26epage%3D394%26doi%3D10.1038%2Fs41557-018-0021-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickl, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dressman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfefferle, M. L.</span></span> <span> </span><span class="NLM_article-title">Instant FaSSIF and FeSSIF-biorelevance meets practicality</span>. <i>Dissolution Technol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.14227/DT160309P41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.14227%2FDT160309P41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OhtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=41-45&author=J.+E.+Boniauthor=R.+S.+Bricklauthor=J.+Dressmanauthor=M.+L.+Pfefferle&title=Instant+FaSSIF+and+FeSSIF-biorelevance+meets+practicality&doi=10.14227%2FDT160309P41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Instant FaSSIF and FeSSIF - biorelevance meets practicality</span></div><div class="casAuthors">Boni, Julia Elisabeth; Brickl, Rolf Stefan; Dressman, Jennifer; Pfefferle, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Dissolution Technologies</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">41-45</span>CODEN:
                <span class="NLM_cas:coden">DITEFX</span>;
        ISSN:<span class="NLM_cas:issn">1521-298X</span>.
    
            (<span class="NLM_cas:orgname">Dissolution Technologies, Inc.</span>)
        </div><div class="casAbstract">The objective of this study was to prep. an "instant" form of FaSSIF and FeSSIF that could be implemented easily and reproducibly in the lab. setting.  Concd. solns. contg. bile salts and lecithin were freeze-dried and further processed into bulk packs, blisters, or tablets, or sealed in powder form under nitrogen in vials.  Phys. properties as well as soly. and dissoln. data for two poorly sol. compds., danazol and a Boehringer-Ingelheim development compd. (BIXX), were compared with data for freshly prepd. FaSSIF and FeSSIF and a com. available "instant" product.  After the freeze-dried FaSSIF and FeSSIF media were reconstituted with appropriate buffers, their properties were close to those of freshly prepd. media and a com. available product for reconstitution, SIF Powder.  Addnl., the soly. and dissoln. profiles of danazol and BIXX in media prepd. by all three methods were similar.  Reconstitution of freeze-dried "instant" FaSSIF and FeSSIF appears to be an accurate, reproducible, and efficient way of prepg. biorelevant dissoln. media.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPVO8h4DmoprVg90H21EOLACvtfcHk0lj12GBTarHcNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OhtL3L&md5=2a37a984ee108f50504e372b39da4019</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.14227%2FDT160309P41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14227%252FDT160309P41%26sid%3Dliteratum%253Aachs%26aulast%3DBoni%26aufirst%3DJ.%2BE.%26aulast%3DBrickl%26aufirst%3DR.%2BS.%26aulast%3DDressman%26aufirst%3DJ.%26aulast%3DPfefferle%26aufirst%3DM.%2BL.%26atitle%3DInstant%2520FaSSIF%2520and%2520FeSSIF-biorelevance%2520meets%2520practicality%26jtitle%3DDissolution%2520Technol.%26date%3D2009%26volume%3D16%26spage%3D41%26epage%3D45%26doi%3D10.14227%2FDT160309P41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yordanova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S. P.</span></span> <span> </span><span class="NLM_article-title">Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1021/tx9003825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9003825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVeqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=749-755&author=U.+M.+Hanumegowdaauthor=G.+Wenkeauthor=A.+Regueiro-Renauthor=R.+Yordanovaauthor=J.+P.+Corradiauthor=S.+P.+Adams&title=Phospholipidosis+as+a+function+of+basicity%2C+lipophilicity%2C+and+volume+of+distribution+of+compounds&doi=10.1021%2Ftx9003825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Phospholipidosis as a Function of Basicity, Lipophilicity, and Volume of Distribution of Compounds</span></div><div class="casAuthors">Hanumegowda, Umesh M.; Wenke, Gottfried; Regueiro-Ren, Alicia; Yordanova, Roumyana; Corradi, John P.; Adams, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-755</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced phospholipidosis (PLD) is an adaptive histol. alteration that is seen with various marketed drugs and often encountered during drug development.  Various in silico and in vitro cell-based methods have been developed to predict the PLD-inducing potential of compds.  These methods rely on the inherent physicochem. properties of the mol. and, as such, tend to overpredict compds. as PLD inducers.  Recognizing that the distribution of compds. into tissues or tissue accumulation is likely a key factor in PLD induction, in addn. to key physicochem. properties, we developed a model to predict PLD in vivo using the measures of basicity (pKa), lipophilicity (ClogP), and vol. of distribution (Vd).  Using sets of PLD inducers and noninducers, we demonstrate improved concordance with this method.  Furthermore, we propose a screening paradigm that includes a combination of various methods to predict the in vivo PLD-inducing potential of compds., which may be esp. useful in lead identification and optimization processes in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJNq2nVkAysrVg90H21EOLACvtfcHk0lj12GBTarHcNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVeqtLw%253D&md5=471380f65644ba0db549660acf6b4d8d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Ftx9003825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9003825%26sid%3Dliteratum%253Aachs%26aulast%3DHanumegowda%26aufirst%3DU.%2BM.%26aulast%3DWenke%26aufirst%3DG.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DYordanova%26aufirst%3DR.%26aulast%3DCorradi%26aufirst%3DJ.%2BP.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26atitle%3DPhospholipidosis%2520as%2520a%2520function%2520of%2520basicity%252C%2520lipophilicity%252C%2520and%2520volume%2520of%2520distribution%2520of%2520compounds%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D749%26epage%3D755%26doi%3D10.1021%2Ftx9003825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeras, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goila-Gaur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soheilian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakalian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span> <span> </span><span class="NLM_article-title">In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat)</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">10957</span>– <span class="NLM_lpage">10971</span>, <span class="refDoi"> DOI: 10.1128/JVI.01369-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FJVI.01369-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=16956950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Khur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=10957-10971&author=C.+S.+Adamsonauthor=S.+D.+Ablanauthor=I.+Boerasauthor=R.+Goila-Gaurauthor=F.+Soheilianauthor=K.+Nagashimaauthor=F.+Liauthor=K.+Salzwedelauthor=M.+Sakalianauthor=C.+T.+Wildauthor=E.+O.+Freed&title=In+vitro+resistance+to+the+human+immunodeficiency+virus+type+1+maturation+inhibitor+PA-457+%28bevirimat%29&doi=10.1128%2FJVI.01369-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat)</span></div><div class="casAuthors">Adamson, Catherine S.; Ablan, Sherimay D.; Boeras, Ioana; Goila-Gaur, Ritu; Soheilian, Ferri; Nagashima, Kunio; Li, Feng; Salzwedel, Karl; Sakalian, Michael; Wild, Carl T.; Freed, Eric O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10957-10971</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">3-O-(3',3'-dimethylsuccinyl)betulinic acid (PA-457 or bevirimat) potently inhibits human immunodeficiency virus type 1 (HIV-1) maturation by blocking a late step in the Gag processing pathway, specifically the cleavage of SP1 from the C terminus of capsid (CA).  To gain insights into the mechanism(s) by which HIV-1 could evolve resistance to PA-457 and to evaluate the likelihood of such resistance arising in PA-457-treated patients, we sought to identify and characterize a broad spectrum of HIV-1 variants capable of conferring resistance to this compd.  Numerous independent rounds of selection repeatedly identified six single-amino-acid substitutions that independently confer PA-457 resistance: three at or near the C terminus of CA (CA-H226Y, -L231F, and -L231M) and three at the first and third residues of SP1 (SP1-A1V, -A3T, and -A3V).  We detd. that mutations CA-H226Y, CA-L231F, CA-L231M, and SP1-A1V do not impose a significant replication defect on HIV-1 in culture.  In contrast, mutations SP1-A3V and -A3T severely impaired virus replication and inhibited virion core condensation.  The replication defect imposed by SP1-A3V was reversed by a second-site compensatory mutation in CA (CA-G225S).  Intriguingly, high concns. of PA-457 enhanced the maturation of SP1 residue 3 mutants.  The different phenotypes assocd. with mutations that confer PA-457 resistance suggest the existence of multiple mechanisms by which HIV-1 can evolve resistance to this maturation inhibitor.  These findings have implications for the ongoing development of PA-457 to treat HIV-1 infection in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRpEKRcJysSbVg90H21EOLACvtfcHk0ljt_BRNrEInVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Khur3K&md5=423f3bec176afb60e598780749f47050</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FJVI.01369-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01369-06%26sid%3Dliteratum%253Aachs%26aulast%3DAdamson%26aufirst%3DC.%2BS.%26aulast%3DAblan%26aufirst%3DS.%2BD.%26aulast%3DBoeras%26aufirst%3DI.%26aulast%3DGoila-Gaur%26aufirst%3DR.%26aulast%3DSoheilian%26aufirst%3DF.%26aulast%3DNagashima%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DSakalian%26aufirst%3DM.%26aulast%3DWild%26aufirst%3DC.%2BT.%26aulast%3DFreed%26aufirst%3DE.%2BO.%26atitle%3DIn%2520vitro%2520resistance%2520to%2520the%2520human%2520immunodeficiency%2520virus%2520type%25201%2520maturation%2520inhibitor%2520PA-457%2520%2528bevirimat%2529%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D10957%26epage%3D10971%26doi%3D10.1128%2FJVI.01369-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoumplis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matallana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgore, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunus, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaway, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span> <span> </span><span class="NLM_article-title">Determinants of activity of the HIV-1 maturation inhibitor PA-457</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2006.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1016%2Fj.virol.2006.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=16930665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1CgsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2006&pages=217-224&author=F.+Liauthor=D.+Zoumplisauthor=C.+Matallanaauthor=N.+R.+Kilgoreauthor=M.+Reddickauthor=A.+S.+Yunusauthor=C.+S.+Adamsonauthor=K.+Salzwedelauthor=D.+E.+Martinauthor=G.+P.+Allawayauthor=E.+O.+Freedauthor=C.+T.+Wild&title=Determinants+of+activity+of+the+HIV-1+maturation+inhibitor+PA-457&doi=10.1016%2Fj.virol.2006.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of activity of the HIV-1 maturation inhibitor PA-457</span></div><div class="casAuthors">Li, Feng; Zoumplis, Dorian; Matallana, Claudia; Kilgore, Nicole R.; Reddick, Mary; Yunus, Abdul S.; Adamson, Catherine S.; Salzwedel, Karl; Martin, David E.; Allaway, Graham P.; Freed, Eric O.; Wild, Carl T.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1 and 2</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">3-O-(3',3'-dimethylsuccinyl) betulinic acid, also termed PA-457 or DSB, is a novel HIV-1 inhibitor that blocks virus maturation by disrupting cleavage of the capsid precursor, CA-SP1.  To better define the mol. target for PA-457, we prepd. a panel of mutant viruses with point deletions spanning the CA-SP1 cleavage domain and characterized each of these viruses for PA-457 sensitivity.  Our results indicate that amino acid residues in the N-terminal half of SP1 serve as determinants of PA-457 activity, while residues in the C-terminal half of SP1 were not involved in compd. activity.  These findings support and extend previous observations that PA-457 is a specific inhibitor of CA-SP1 cleavage and identify the CA-SP1 domain as the primary viral determinant for this novel inhibitor of HIV-1 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLD2a0C9ozC7Vg90H21EOLACvtfcHk0ljt_BRNrEInVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1CgsL7K&md5=9bf789f30b2787e482d38b8b2baa10e0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2006.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2006.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DZoumplis%26aufirst%3DD.%26aulast%3DMatallana%26aufirst%3DC.%26aulast%3DKilgore%26aufirst%3DN.%2BR.%26aulast%3DReddick%26aufirst%3DM.%26aulast%3DYunus%26aufirst%3DA.%2BS.%26aulast%3DAdamson%26aufirst%3DC.%2BS.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26aulast%3DAllaway%26aufirst%3DG.%2BP.%26aulast%3DFreed%26aufirst%3DE.%2BO.%26aulast%3DWild%26aufirst%3DC.%2BT.%26atitle%3DDeterminants%2520of%2520activity%2520of%2520the%2520HIV-1%2520maturation%2520inhibitor%2520PA-457%26jtitle%3DVirology%26date%3D2006%26volume%3D356%26spage%3D217%26epage%3D224%26doi%3D10.1016%2Fj.virol.2006.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzwedel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, E. O.</span></span> <span> </span><span class="NLM_article-title">Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">4884</span>– <span class="NLM_lpage">4894</span>, <span class="refDoi"> DOI: 10.1128/JVI.02659-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1128%2FJVI.02659-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=19279107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVGhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=4884-4894&author=C.+S.+Adamsonauthor=K.+Wakiauthor=S.+D.+Ablanauthor=K.+Salzwedelauthor=E.+O.+Freed&title=Impact+of+human+immunodeficiency+virus+type+1+resistance+to+protease+inhibitors+on+evolution+of+resistance+to+the+maturation+inhibitor+bevirimat+%28PA-457%29&doi=10.1128%2FJVI.02659-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)</span></div><div class="casAuthors">Adamson, Catherine S.; Waki, Kayoko; Ablan, Sherimay D.; Salzwedel, Karl; Freed, Eric O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4884-4894</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The maturation inhibitor bevirimat [3-O-(3',3'dimethysuccinyl)betulinic acid; BVM; also known as PA-457 or DSB] potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking protease (PR)-mediated cleavage at the junction between capsid (CA) and spacer peptide 1 (SP1) in Gag.  We previously isolated a panel of single-amino-acid substitutions that confer resistance to BVM in vitro.  The BVM resistance mutations cluster at or near the CA-SP1 cleavage site.  Because BVM likely will be used clin. in patients harboring viruses resistant to PR inhibitors (PIs), in this study we evaluated the interplay between a PI-resistant (PIR) PR and the BVM resistance mutations in Gag.  As expected, the PIR mutations had no effect on inhibition by BVM; however, we obsd. general processing defects and a slight delay in viral replication in Jurkat T cells assocd. with the PIR mutations, even in the absence of compd.  When combined, most BVM resistance and PIR mutations acted additively to impair viral replication, particularly in the presence of BVM.  The BVM-resistant mutant SP1-A1V was an exception, as it supported robust replication in the context of either wild-type (WT) or PIR PR, even at high BVM concns.  Significantly, the emergence of BVM resistance was delayed in the context of the PIR PR, and the SP1-A1V mutation was acquired most frequently with either WT or PIR PR.  These results suggest that resistance to BVM is less likely to emerge in patients who have failed PIs than in patients who are PI naive.  We predict that the SP1-A1V substitution is the most likely to emerge in vivo, as this mutant replicates robustly independently of PR mutations or BVM.  These findings offer insights into the effect of PIR mutations on the evolution of BVM resistance in PI-experienced patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBxrMI6pkqe7Vg90H21EOLACvtfcHk0lgfq-i-ZvPGPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVGhtr8%253D&md5=be66b5fec3d34d4f27333a55fcf74c2c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FJVI.02659-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02659-08%26sid%3Dliteratum%253Aachs%26aulast%3DAdamson%26aufirst%3DC.%2BS.%26aulast%3DWaki%26aufirst%3DK.%26aulast%3DAblan%26aufirst%3DS.%2BD.%26aulast%3DSalzwedel%26aufirst%3DK.%26aulast%3DFreed%26aufirst%3DE.%2BO.%26atitle%3DImpact%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520resistance%2520to%2520protease%2520inhibitors%2520on%2520evolution%2520of%2520resistance%2520to%2520the%2520maturation%2520inhibitor%2520bevirimat%2520%2528PA-457%2529%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D4884%26epage%3D4894%26doi%3D10.1128%2FJVI.02659-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lataillade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies and modeling reveal the origin of differential inhibition of Gag polymorphic viruses by HIV-1 maturation inhibitors</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e1005990</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1371%2Fjournal.ppat.1005990" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1005990&author=Z.+Linauthor=J.+Cantoneauthor=H.+Luauthor=B.+Nowicka-Sansauthor=T.+Protackauthor=T.+Yuanauthor=H.+Yangauthor=Z.+Liuauthor=D.+Drexlerauthor=A.+Regueiro-Renauthor=N.+A.+Meanwellauthor=M.+Cockettauthor=M.+Krystalauthor=M.+Latailladeauthor=I.+B.+Dicker&title=Mechanistic+studies+and+modeling+reveal+the+origin+of+differential+inhibition+of+Gag+polymorphic+viruses+by+HIV-1+maturation+inhibitors&doi=10.1371%2Fjournal.ppat.1005990"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005990%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DCantone%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DProtack%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDrexler%26aufirst%3DD.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DLataillade%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26atitle%3DMechanistic%2520studies%2520and%2520modeling%2520reveal%2520the%2520origin%2520of%2520differential%2520inhibition%2520of%2520Gag%2520polymorphic%2520viruses%2520by%2520HIV-1%2520maturation%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26spage%3De1005990%26doi%3D10.1371%2Fjournal.ppat.1005990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokui, T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.1002/jps.20012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fjps.20012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=847-854&author=D.+Nakaiauthor=K.+Kumamotoauthor=C.+Sakikawaauthor=T.+Kosakaauthor=T.+Tokui&title=Evaluation+of+the+protein+binding+ratio+of+drugs+by+a+micro-scale+ultracentrifugation+method&doi=10.1002%2Fjps.20012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fjps.20012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20012%26sid%3Dliteratum%253Aachs%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DKumamoto%26aufirst%3DK.%26aulast%3DSakikawa%26aufirst%3DC.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DTokui%26aufirst%3DT.%26atitle%3DEvaluation%2520of%2520the%2520protein%2520binding%2520ratio%2520of%2520drugs%2520by%2520a%2520micro-scale%2520ultracentrifugation%2520method%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D847%26epage%3D854%26doi%3D10.1002%2Fjps.20012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardelmeijer, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tellingen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span> <span> </span><span class="NLM_article-title">The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1023/A:1006469621561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1023%2FA%3A1006469621561" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=231-241&author=H.+A.+Bardelmeijerauthor=O.+van+Tellingenauthor=J.+H.+M+Schellensauthor=J.+H.+Beijnen&title=The+oral+route+for+the+administration+of+cytotoxic+drugs%3A+strategies+to+increase+the+efficiency+and+consistency+of+drug+delivery&doi=10.1023%2FA%3A1006469621561"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006469621561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006469621561%26sid%3Dliteratum%253Aachs%26aulast%3DBardelmeijer%26aufirst%3DH.%2BA.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520oral%2520route%2520for%2520the%2520administration%2520of%2520cytotoxic%2520drugs%253A%2520strategies%2520to%2520increase%2520the%2520efficiency%2520and%2520consistency%2520of%2520drug%2520delivery%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2000%26volume%3D18%26spage%3D231%26epage%3D241%26doi%3D10.1023%2FA%3A1006469621561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span> <span> </span><span class="NLM_article-title">Utility of Mdr-1 gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.2174/1389200033489415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.2174%2F1389200033489415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=12871045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1GhsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=272-291&author=C.+Chenauthor=X.+Liuauthor=B.+J.+Smith&title=Utility+of+Mdr-1+gene+deficient+mice+in+assessing+the+impact+of+P-glycoprotein+on+pharmacokinetics+and+pharmacodynamics+in+drug+discovery+and+development&doi=10.2174%2F1389200033489415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development</span></div><div class="casAuthors">Chen, Cuiping; Liu, Xingrong; Smith, Bill J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">272-291</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the generation of the multi-drug resistance 1 (mdr1) gene knockout (KO) mice in the early 90's, these animals have been instrumental to our understanding of the physiol. roles of mdr1 gene product P-glycoprotein.  Located in crucial organs such as brain, intestine, liver, and kidney, P-glycoprotein-mediated transport has been shown to affect both the pharmacokinetics and pharmacodynamics of endogenous compds. and xenobiotics.  It appears that P-glycoprotein may not be essential for the maintenance of normal body function as suggested by the similarity in life span and serum chem. values of mdr1 gene KO mice compared to their genetically competent littermates.  However, numerous studies have demonstrated that P-glycoprotein limits the brain penetration of many drug substrates.  The reduced central nervous system (CNS) access of these compds. has been linked to decreased pharmacol. or toxicol. effects.  In contrast to the crit. role that P-glycoprotein plays in the brain, the extent of P-glycoprotein involvement in oral absorption and hepatobiliary or renal excretion of xenobiotics appears more variable.  In addn. to the mdr1 gene KO model, in vitro cell lines that over-express P-glycoprotein, and clin. trials using P-glycoprotein modulators have allowed for the comparison of in vitro-in vivo and species related difference in P-glycoprotein activity.  For the most part, studies have shown reasonable in vitro-in vivo correlations, modest species-related differences, and comparable human-mouse in vivo P-glycoprotein effects on systemic drug disposition.  Therefore, the mdr1 gene KO mouse model, when used appropriately, may allow for prediction of CNS drug access and certain drug-drug interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxT1JuNSYiVrVg90H21EOLACvtfcHk0lgeeZ6fZ9S6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1GhsrY%253D&md5=41360c60c25393d0cfe564b2f14cb2b5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F1389200033489415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200033489415%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26atitle%3DUtility%2520of%2520Mdr-1%2520gene%2520deficient%2520mice%2520in%2520assessing%2520the%2520impact%2520of%2520P-glycoprotein%2520on%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2003%26volume%3D4%26spage%3D272%26epage%3D291%26doi%3D10.2174%2F1389200033489415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzarano, L. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.068288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1124%2Fjpet.104.068288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=15056727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVyktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2004&pages=703-709&author=K.+W.+Wardauthor=L.+M.+Azzarano&title=Preclinical+pharmacokinetic+properties+of+the+P-glycoprotein+inhibitor+GF120918A+%28HCl+salt+of+GF120918%2C+9%2C10-dihydro-5-methoxy-9-oxo-N-%5B4-%5B2-%281%2C2%2C3%2C4-tetrahydro-6%2C7-dimethoxy-2-isoquinolinyl%29ethyl%5Dphenyl%5D-4-acridine-carboxamide%29+in+the+mouse%2C+rat%2C+dog%2C+and+monkey&doi=10.1124%2Fjpet.104.068288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridinecarboxamide) in the mouse, rat, dog, and monkey</span></div><div class="casAuthors">Ward, Keith W.; Azzarano, Leonard M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">703-709</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GF120918A, the HCl salt of GF120918, has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test mols.  However, to date, a detailed description of the preclin. pharmacokinetic properties of GF120918A has not been published.  This investigation was performed to evaluate in vitro and in vivo pharmacokinetic properties of GF120918A in the mouse, rat, dog, and monkey and to evaluate the in vivo efficacy of GF120918A in modulating absorption and systemic exposure in the monkey.  GF120918A demonstrated reasonable absorption and systemic exposure in each of the species studied, however, in rodents, administration of 300 mg/kg afforded a substantially less than linear increase in systemic exposure compared with 30 mg/kg.  In accordance with its intestinal and hepatic exposure and potency against P-glycoprotein, GF120918A demonstrated marked modulation of erythromycin systemic exposure in the monkey, with no effect on propranolol, a neg. control mol.  In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma.  GF120918A did not demonstrate potent inhibition of several human cytochrome P 450 enzymes evaluated in vitro, with IC50 values well above concns. anticipated to be achieved in vivo.  Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclin. species and offer addnl. guidance on preclin. dose regimens likely to produce P-glycoprotein-mediated effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuAYdnFmpH7Vg90H21EOLACvtfcHk0liOimB4HJLLWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVyktr4%253D&md5=36cd74ecc6d47027f3cfb4223ee6ac6b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068288%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DAzzarano%26aufirst%3DL.%2BM.%26atitle%3DPreclinical%2520pharmacokinetic%2520properties%2520of%2520the%2520P-glycoprotein%2520inhibitor%2520GF120918A%2520%2528HCl%2520salt%2520of%2520GF120918%252C%25209%252C10-dihydro-5-methoxy-9-oxo-N-%255B4-%255B2-%25281%252C2%252C3%252C4-tetrahydro-6%252C7-dimethoxy-2-isoquinolinyl%2529ethyl%255Dphenyl%255D-4-acridine-carboxamide%2529%2520in%2520the%2520mouse%252C%2520rat%252C%2520dog%252C%2520and%2520monkey%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D310%26spage%3D703%26epage%3D709%26doi%3D10.1124%2Fjpet.104.068288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moench, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faria, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent dissolution in vitro and absorption in vivo of weakly basic drugs; development of a canine model</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s11095-004-1185-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1007%2Fs11095-004-1185-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=188-192&author=R.+Zhouauthor=P.+Moenchauthor=C.+Heranauthor=X.+Luauthor=N.+Mathiasauthor=T.+N.+Fariaauthor=D.+A.+Wallauthor=M.+A.+Hussainauthor=R.+L.+Smithauthor=D.+Sun&title=pH-Dependent+dissolution+in+vitro+and+absorption+in+vivo+of+weakly+basic+drugs%3B+development+of+a+canine+model&doi=10.1007%2Fs11095-004-1185-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs11095-004-1185-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-004-1185-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DMoench%26aufirst%3DP.%26aulast%3DHeran%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DMathias%26aufirst%3DN.%26aulast%3DFaria%26aufirst%3DT.%2BN.%26aulast%3DWall%26aufirst%3DD.%2BA.%26aulast%3DHussain%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DR.%2BL.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DpH-Dependent%2520dissolution%2520in%2520vitro%2520and%2520absorption%2520in%2520vivo%2520of%2520weakly%2520basic%2520drugs%253B%2520development%2520of%2520a%2520canine%2520model%26jtitle%3DPharm.%2520Res.%26date%3D2005%26volume%3D22%26spage%3D188%26epage%3D192%26doi%3D10.1007%2Fs11095-004-1185-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quitko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span> <span> </span><span class="NLM_article-title">Development and validation of a preclinical food effect model</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1002/jps.20767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fjps.20767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=459-472&author=K.+Lentzauthor=M.+Quitkoauthor=D.+Morganauthor=J.+Graceauthor=C.+Gleasonauthor=P.+Marathe&title=Development+and+validation+of+a+preclinical+food+effect+model&doi=10.1002%2Fjps.20767"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjps.20767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20767%26sid%3Dliteratum%253Aachs%26aulast%3DLentz%26aufirst%3DK.%26aulast%3DQuitko%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DD.%26aulast%3DGrace%26aufirst%3DJ.%26aulast%3DGleason%26aufirst%3DC.%26aulast%3DMarathe%26aufirst%3DP.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520preclinical%2520food%2520effect%2520model%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2007%26volume%3D96%26spage%3D459%26epage%3D472%26doi%3D10.1002%2Fjps.20767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1890</span>– <span class="NLM_lpage">1900</span>, <span class="refDoi"> DOI: 10.1002/jps.20099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1002%2Fjps.20099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=1890-1900&author=T.+Wajimaauthor=Y.+Yanoauthor=K.+Fukumuraauthor=T.+Oguma&title=Prediction+of+human+pharmacokinetic+profile+in+animal+scale+up+based+on+normalizing+time+course+profiles&doi=10.1002%2Fjps.20099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjps.20099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20099%26sid%3Dliteratum%253Aachs%26aulast%3DWajima%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DY.%26aulast%3DFukumura%26aufirst%3DK.%26aulast%3DOguma%26aufirst%3DT.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetic%2520profile%2520in%2520animal%2520scale%2520up%2520based%2520on%2520normalizing%2520time%2520course%2520profiles%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D1890%26epage%3D1900%26doi%3D10.1002%2Fjps.20099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schürmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobotha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevinsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keicher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lataillade, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity, safety, and exposure-response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002)</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1093/cid/cix239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=10.1093%2Fcid%2Fcix239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=28369211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFGks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=442-452&author=C.+Hwangauthor=D.+Sch%C3%BCrmannauthor=C.+Sobothaauthor=M.+Boffitoauthor=H.+Sevinskyauthor=N.+Rayauthor=P.+Ravindranauthor=H.+Xiaoauthor=C.+Keicherauthor=A.+H%C3%BCserauthor=M.+Krystalauthor=I.+B.+Dickerauthor=D.+Graselaauthor=M.+Lataillade&title=Antiviral+activity%2C+safety%2C+and+exposure-response+relationships+of+GSK3532795%2C+a+second-generation+human+immunodeficiency+virus+type+1+maturation+inhibitor%2C+administered+as+monotherapy+or+in+combination+with+atazanavir+with+or+without+ritonavir+in+a+phase+2a+randomized%2C+dose-ranging%2C+controlled+trial+%28AI468002%29&doi=10.1093%2Fcid%2Fcix239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46aR"><div class="casContent"><span class="casTitleNuber">46a</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity, safety, and exposure-response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002)</span></div><div class="casAuthors">Hwang, Carey; Schurmann, Dirk; Sobotha, Christian; Boffito, Marta; Sevinsky, Heather; Ray, Neelanjana; Ravindran, Palanikumar; Xiao, Hong; Keicher, Christian; Huser, Andreas; Krystal, Mark; Dicker, Ira B.; Grasela, Dennis; Lataillade, Max</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">442-452</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor that targets HIV-1 Gag, inhibiting the final protease cleavage between capsid protein p24 and spacer protein-1, producing immature, noninfectious virions.  Methods.  This was a phase 2a, randomized, dose-ranging multipart trial.  In part A, subtype B-infected subjects received 5-120 mg GSK3532795 (or placebo) once daily for 10 days.  In part B, subtype B-infected subjects received 40 mg or 80 mg GSK3532795 once daily with atazanavir (ATV) with or without (±) ritonavir (RTV) or std. of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28 days.  In part C, subtype C-infected subjects received 40 mg or 120 mg GSK3532795 once daily (or placebo) for 10 days.  Endpoints included change in HIV-1 RNA from baseline on day 11 (parts A/C) or day 29 (part B).  Results.  A >1 log10 median decline in HIV-1 RNA was achieved by day 11 in parts A and C and day 29 in part B at GSK3532795 doses ≥40 mg; part B subjects receiving GSK3532795 and ATV ± RTV achieved similar declines to those receiving SOC.  Median of the max. declines in HIV-1 RNA were similar for the 40-120 mg once-daily dose groups regardless of baseline Gag polymorphisms.  There were no deaths, adverse events leading to discontinuation, or serious adverse events.  Conclusions.  GSK3532795 demonstrated potent antiviral activity against subtype B (monotherapy or with ATV ± RTV) and subtype C, and was generally well tolerated, which supported continued development of GSK3532795 in subjects with HIV-1 subtype B or subtype C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1x-uS8V4fSrVg90H21EOLACvtfcHk0lg13OzJiUkDCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFGks77I&md5=dfaac445cd480ef649d0a95f0dc6f6e4</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcix239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcix239%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DC.%26aulast%3DSch%25C3%25BCrmann%26aufirst%3DD.%26aulast%3DSobotha%26aufirst%3DC.%26aulast%3DBoffito%26aufirst%3DM.%26aulast%3DSevinsky%26aufirst%3DH.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DRavindran%26aufirst%3DP.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKeicher%26aufirst%3DC.%26aulast%3DH%25C3%25BCser%26aufirst%3DA.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DGrasela%26aufirst%3DD.%26aulast%3DLataillade%26aufirst%3DM.%26atitle%3DAntiviral%2520activity%252C%2520safety%252C%2520and%2520exposure-response%2520relationships%2520of%2520GSK3532795%252C%2520a%2520second-generation%2520human%2520immunodeficiency%2520virus%2520type%25201%2520maturation%2520inhibitor%252C%2520administered%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520atazanavir%2520with%2520or%2520without%2520ritonavir%2520in%2520a%2520phase%25202a%2520randomized%252C%2520dose-ranging%252C%2520controlled%2520trial%2520%2528AI468002%2529%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D65%26spage%3D442%26epage%3D452%26doi%3D10.1093%2Fcid%2Fcix239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit46b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I.</span>; <span class="NLM_string-name">Nowicka-Sans, B.</span>; <span class="NLM_string-name">Zhang, S.</span>; <span class="NLM_string-name">Ray, N.</span>; <span class="NLM_string-name">Beno, B.</span>; <span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Joshi, S.</span>; <span class="NLM_string-name">Krystal, M.</span>; <span class="NLM_string-name">Lataillade, M.</span></span> <span> </span><span class="NLM_article-title">Resistance Profile of GSK3532795</span>.  <i>26th International Workshop on HIV Drug Resistance and Treatment Strategies, November 6–8, 2017, Johannesburg, South Africa</i>, <span class="NLM_year">2017</span>; Poster  <span class="NLM_fpage">60</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=60&author=I.+Dicker&author=B.+Nowicka-Sans&author=S.+Zhang&author=N.+Ray&author=B.+Beno&author=A.+Regueiro-Ren&author=S.+Joshi&author=M.+Krystal&author=M.+Lataillade&title=Resistance+Profile+of+GSK3532795"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DDicker%26aufirst%3DI.%26atitle%3DResistance%2520Profile%2520of%2520GSK3532795%26jtitle%3D26th%2520International%2520Workshop%2520on%2520HIV%2520Drug%2520Resistance%2520and%2520Treatment%2520Strategies%252C%2520November%25206%25E2%2580%25938%252C%25202017%252C%2520Johannesburg%252C%2520South%2520Africa%26date%3D2017%26spage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, S.</span></span> <span> </span><span class="NLM_article-title">GSK Drops a Pair of Late-Stage Candidates in COPD, HIV</span>.  <i>FierceBiotech</i>; <span class="NLM_publisher-name">Questex</span>: <span class="NLM_publisher-loc">Newton, MA</span>, October 26, <span class="NLM_year">2018</span>; <a href="https://www.fiercebiotech.com/biotech/gsk-drops-a-pair-late-stage-candidates-copd-hiv" class="extLink">https://www.fiercebiotech.com/biotech/gsk-drops-a-pair-late-stage-candidates-copd-hiv</a> (accessed April 28, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Lawrence&title=GSK+Drops+a+Pair+of+Late-Stage+Candidates+in+COPD%2C+HIV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DS.%26atitle%3DGSK%2520Drops%2520a%2520Pair%2520of%2520Late-Stage%2520Candidates%2520in%2520COPD%252C%2520HIV%26jtitle%3DFierceBiotech%26pub%3DQuestex%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sit, S.-Y.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Swidorsk, J.</span>; <span class="NLM_string-name">Venables, B. L.</span>; <span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Meanwell, N. A.</span>; <span class="NLM_string-name">Regueiro-Ren, A.</span>; <span class="NLM_string-name">Hartz, R.</span>; <span class="NLM_string-name">Xu, L.</span>; <span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Preparation of Triterpenoids with HIV Maturation Inhibitory Activity, Substituted in Position 3 by a Non-aromatic Ring Carrying a Haloalkyl Substituent</span>. World Patent <span class="NLM_patent">WO2015157483</span>, October 15, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.-Y.+Sit&author=Y.+Chen&author=J.+Chen&author=J.+Swidorsk&author=B.+L.+Venables&author=N.+Sin&author=N.+A.+Meanwell&author=A.+Regueiro-Ren&author=R.+Hartz&author=L.+Xu&author=Z.+Liu&title=Preparation+of+Triterpenoids+with+HIV+Maturation+Inhibitory+Activity%2C+Substituted+in+Position+3+by+a+Non-aromatic+Ring+Carrying+a+Haloalkyl+Substituent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSit%26aufirst%3DS.-Y.%26atitle%3DPreparation%2520of%2520Triterpenoids%2520with%2520HIV%2520Maturation%2520Inhibitory%2520Activity%252C%2520Substituted%2520in%2520Position%25203%2520by%2520a%2520Non-aromatic%2520Ring%2520Carrying%2520a%2520Haloalkyl%2520Substituent%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00854">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_67570"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00854">10.1021/acs.jmedchem.8b00854</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures and characterization data for <b>[</b><sup><b>14</b></sup><b>C]-1</b>, WT EC<sub>50</sub>, V370A EC<sub>50</sub>, and ΔV370 EC<sub>50</sub> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_002.pdf">PDF</a>)</p></li><li><p class="inline">SMILE strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_001.csv">jm8b00854_si_001.csv (5.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00854/suppl_file/jm8b00854_si_002.pdf">jm8b00854_si_002.pdf (165.19 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00854&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00854%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-16%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00854" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799de10e95c3d48","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
